Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out

PubMed Search - BioMed Central

VIEWS: 147 PAGES: 305

									Costs and cost-effectiveness of malaria control interventions - a systematic revie

Michael T White1, Lesong Conteh2, Richard Cibulskis3, Azra C Ghani1

1MRC Centre for Outbreak Analysis & Modelling, Department of Infectious Disease Epidemiology, Imperial College Lond
2Centre for Health Policy, Institute of Global Health Innovation, Imperial College London, UK
3Global Malaria Programme, World Health Organization, Geneva, Switzerland




All of the results contained in this document are free to use and disseminate by any interested
individual studies please also cite the original source as documented in this spreadsheet.

Any mistakes or transcription errors that may have arisen during the review process are entire
original documented source.

Michael White
m.white08@imperial.ac.uk
       a systematic review


idemiology, Imperial College London, UK




seminate by any interested parties. Please cite accordingly and if quoting results or figures from
d in this spreadsheet.

e review process are entirely my own. If in doubt of any figures please contact me or check the
or figures from


 or check the
Title
Reproduction-longevity trade-off in Anopheles gambiae (Diptera: Culicidae).
Cost effectiveness of OptiMal(R) rapid diagnostic test for malaria in remote areas of the Amazon Region, Brazil.
Improving educational achievement and anaemia of school children: design of a cluster randomised trial of school-based mal
Past, present and future research directions with Pichia anomala.
Predicting the unmet need for biologically targeted coverage of insecticide-treated nets in Kenya.
A mathematical model for antimalarial drug resistance.
Mosquito-borne illnesses in travelers: a review of risk and prevention.
Drug combinations for visceral leishmaniasis.
Achieving the health MDGs: country ownership in four steps.
Long synthetic peptides for the production of vaccines and drugs: a technological platform coming of age.
Cost-effectiveness analysis of malaria chemoprophylaxis for travellers to West-Africa.
Who gets prompt access to artemisinin-based combination therapy? A prospective community-based study in children from r
Countdown to 2015: assessment of official development assistance to maternal, newborn, and child health, 2003-08.
Treating uncomplicated malaria in children: comparing artemisinin-based combination therapies.
Evaluating the relevance of disability weights for adjusting disease-cost and comorbidity calculations at the Kigali University T
Clustering of under-five mortality in Rufiji Health and Demographic Surveillance System in rural Tanzania.
Spatio-temporal clustering of mortality in Butajira HDSS, Ethiopia, from 1987 to 2008.
Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases.
Rethinking breast cancer screening strategies in resource-limited settings.
Cost effectiveness of seasonal intermittent preventive treatment using amodiaquine & artesunate or sulphadoxine-pyrimetha
An economic evaluation of home management of malaria in Uganda: an interactive Markov model.
Social marketing and the fight against malaria in Africa: population services international (PSI) and insecticide treated nets (IT
Asking people directly about preferred health-seeking behaviour yields invalid response: an experiment in south-east Nigeria.
Community directed approach beyond ivermectin in Tanzania: a promising mechanism for the delivery of complex health inte
[Operation to promote use of long-lasting insecticidal nets (LLIN) in French Guiana in 2006: design, implementation and resul
The President's Global Health Initiative.
Examining appropriate diagnosis and treatment of malaria: availability and use of rapid diagnostic tests and artemisinin-based
Donors lose faith in Zambian Health Ministry.
Correlation of hepatitis C RNA and serum alanine aminotransferase in hepatitis B and C seronegative healthy blood donors.
Perceptions on the use of insecticide treated nets in parts of the Imo River Basin, Nigeria: implications for preventing malaria
The Global Fund: replenishment and redefinition.
The price of success.
What would PCR assessment change in the management of fevers in a malaria endemic area? A school-based study in Benin i
Demand for malaria drug soars.
Ownership and usage of insecticide-treated bed nets after free distribution via a voucher system in two provinces of Mozamb
Economic evaluation of point-of-care diagnostic technologies for infectious diseases.
Which family members use the best nets? An analysis of the condition of mosquito nets and their distribution within househo
Household demand for insecticide-treated bednets in Tanzania and policy options for increasing uptake.
Refractive-index-based screening of membrane-protein-mediated transfer across biological membranes.
Burden of non-sexually transmitted infections on adolescent growth and development in the developing world.
A progressive declining in the burden of malaria in north-eastern Tanzania.
Potential benefits, limitations and target product-profiles of odor-baited mosquito traps for malaria control in Africa.
Integrated surveys of neglected tropical diseases in southern Sudan: how much do they cost and can they be refined?
Knowledge and treatment practices of malaria among mothers and caregivers of children in an urban slum in Jos, Nigeria.
Type 2 diabetes mellitus and obesity in sub-Saharan Africa.
Changes in the burden of malaria in sub-Saharan Africa.
[Delocalized meeting of the Société de pathologie exotique: "The Global Fund to Fight AIDS, Tuberculosis and Malaria: issues
CRIMALDDI: a co-ordinated, rational, and integrated effort to set logical priorities in anti-malarial drug discovery initiatives.
Principal component analysis of socioeconomic factors and their association with malaria in children from the Ashanti Region
A pharmacy too far? Equity and spatial distribution of outcomes in the delivery of subsidized artemisinin-based combination t
Estimating the number of paediatric fevers associated with malaria infection presenting to Africa's public health sector in 200
Soft targets or partners in health? Retail pharmacies and their role in Tanzania's malaria control program.
Community-directed interventions for priority health problems in Africa: results of a multicountry study.
Battling a scourge. Malaria has plagued us for centuries but a new model for global aid could change the game.
Treatment of visceral leishmaniasis.
Cost savings with rapid diagnostic tests for malaria in low-transmission areas: evidence from Dar es Salaam, Tanzania.
Control of malaria.
Primaquine administration after falciparum malaria treatment in malaria hypoendemic areas with high incidence of falciparum
Effect of incentives on insecticide-treated bed net use in sub-Saharan Africa: a cluster randomized trial in Madagascar.
The effect of protest zeros on estimates of willingness to pay in healthcare contingent valuation analysis.
The development of artemisinin resistance in malaria: reasons and solutions.
WHO policy development processes for a new vaccine: case study of malaria vaccines.
Effect of repeated exposure to Plasmodium relictum (lineage SGS1) on infection dynamics in domestic canaries.
System effectiveness of a targeted free mass distribution of long lasting insecticidal nets in Zanzibar, Tanzania.
The cost-effectiveness of intermittent preventive treatment for malaria in infants in Sub-Saharan Africa.
Comparison of the novel Partec rapid malaria test to the conventional Giemsa stain and the gold standard real-time PCR.
Determinants of anemia among young children in rural India.
Knowledge and reported practices of men and women on maternal and child health in rural Guinea Bissau: a cross sectional s
Novel ellipsoid spatial analysis for determining malaria risk at the village level.
Use of HRP-2-based rapid diagnostic test for Plasmodium falciparum malaria: assessing accuracy and cost-effectiveness in the
The economic costs of malaria in four Kenyan districts: do household costs differ by disease endemicity?
Artemisinin combination therapy for vivax malaria.
A situational analysis of pharmacovigilance plans in the Global Fund Malaria and U.S. President's Malaria Initiative proposals.
New perspectives of malaria control in India under World Bank Project.
Barriers to prompt and effective malaria treatment among the poorest population in Kenya.
The death of bioethics (as we once knew it).
What will it take to stop the needless deaths of millions of women and children each year?
Use of insecticide treated bed nets among pregnant women in Kilifi District, Kenya.
Disappearance of drugs undermines Uganda's fight against malaria.
The selection landscape of malaria parasites.
Shrinking the malaria map from the outside in.
Support for global health.
Towards malaria risk prediction in Afghanistan using remote sensing.
Zimbabwean diabetics' beliefs about health and illness: an interview study.
Where did all the aid go? An in-depth analysis of increased health aid flows over the past 10 years.
African Burkitt's lymphoma: could collaboration with HIV-1 and malaria programmes reduce the high mortality rate?
Production of the 42-kDa fragment of Plasmodium falciparum merozoite surface protein 1, a leading malaria vaccine antigen,
Anti-malarial market and policy surveys in sub-Saharan Africa.
Bridging the gaps between research, policy and practice in low- and middle-income countries: a survey of health care provide
Bayesian modelling of the effect of climate on malaria in Burundi.
Lack of awareness of problems with treatments threatens malaria control efforts.
Alternative strategies to reduce maternal mortality in India: a cost-effectiveness analysis.
Adulticidal activity of essential oil of Lantana camara leaves against mosquitoes.
Malaria in children.
Malaria 2010: more ambition and accountability please.
Malaria and primary education in Mali: a longitudinal study in the village of Donéguébougou.
Costs and effects of two public sector delivery channels for long-lasting insecticidal nets in Uganda.
Rural health centres, communities and malaria case detection in Zambia using mobile telephones: a means to detect potentia
Organizational integrity of entities that are implementing programs and activities under the Leadership Act. Final rule.
Ethnopharmacological use of herbal remedies for the treatment of malaria in the Dangme West District of Ghana.
Should new antimalarial drugs be subsidized?
Determining utility values related to malaria and malaria chemoprophylaxis.
[The Global Fund to fight HIV/AIDS, TB and Malaria 5-y: evaluation policy issues]
Biological cost of tolerance to heavy metals in the mosquito Anopheles gambiae.
Syndromic diagnosis of malaria in rural Sierra Leone and proposed additions to the national integrated management of childh
[The Global Fund to fight HIV/AIDS, TB and malaria policy issues]
The molecular mechanism of action of artemisinin--the debate continues.
Wildlife service plans for a warmer world.
Malaria vaccine: the pros and cons.
The Global Fund: replenishment and redefinition in 2010.
Moving toward hematological predictors of disease severity in malaria: going with the flow.
Strategies for diagnosis and treatment of suspected leptospirosis: a cost-benefit analysis.
Policy development in malaria vector management in Mozambique, South Africa and Zimbabwe.
Route transition interventions: potential public health gains from reducing or preventing injecting.
Assessment of in vivo antimalarial activity of rifampicin, isoniazide, and ethambutol combination therapy.
Women's experiences and views about costs of seeking malaria chemoprevention and other antenatal services: a qualitative
Increased financial accessibility and targeted education messages could increase ownership and use of mosquito nets in Puru
Retail sector distribution chains for malaria treatment in the developing world: a review of the literature.
Willingness to pay for rapid diagnostic tests for the diagnosis and treatment of malaria in southeast Nigeria: ex post and ex an
Control of pyrethroid and DDT-resistant Anopheles gambiae by application of indoor residual spraying or mosquito nets treat
An assessment of Lot Quality Assurance Sampling to evaluate malaria outcome indicators: extending malaria indicator survey
The global health system: lessons for a stronger institutional framework.
Informal payments for healthcare: differences in expenditures from consumers and providers perspectives for treatment of m
Aid fund faces cash crunch.
Integration of control of neglected tropical diseases into health-care systems: challenges and opportunities.
Implementing intermittent preventive treatment in infants.
Affordable medicines facility for malaria: reasonable or rash?
Countdown to 2015: comparing progress towards the achievement of the health Millennium Development Goals in Ethiopia a
The Multilateral Initiative on Malaria: looking back and looking ahead.
Low-technology cooling box for storage of malaria RDTs and other medical supplies in remote areas.
Treatment of asymptomatic carriers with artemether-lumefantrine: an opportunity to reduce the burden of malaria?
Cost implications of improving malaria diagnosis: findings from north-eastern Tanzania.
The global health system: linking knowledge with action--learning from malaria.
Costs of insensitive acetylcholinesterase insecticide resistance for the malaria vector Anopheles gambiae homozygous for the
Comparative field trial of alternative vector control strategies for non-domiciliated Triatoma dimidiata.
Evolutionary forces on Anopheles: what makes a malaria vector?
Chloroplast-derived vaccine antigens confer dual immunity against cholera and malaria by oral or injectable delivery.
Fever of unknown origin in an infant with an unexpected blood film report: a case report.
A summary of the literature on global hearing impairment: current status and priorities for action.
Global status of DDT and its alternatives for use in vector control to prevent disease.
Use and limitations of malaria rapid diagnostic testing by community health workers in war-torn Democratic Republic of Cong
Drug procurement, the Global Fund and misguided competition policies.
WHO reports progress in malaria control.
[Assessment of a rapid diagnostic test for malaria in rural health care facilities in Senegal]
Modeling the risk of malaria for travelers to areas with stable malaria transmission.
Evaluation of the performance of CareStart Malaria Pf/Pv Combo rapid diagnostic test for the diagnosis of malaria in Jimma, s
A rapid malaria appraisal in the Venezuelan Amazon.
A microarray-based system for the simultaneous analysis of single nucleotide polymorphisms in human genes involved in the
Multiplex real-time quantitative PCR, microscopy and rapid diagnostic immuno-chromatographic tests for the detection of Pla
Development of multiplex real-time PCR assays for identification of members of the Anopheles funestus species group.
Community health seeking practices for the management of malaria of the under-five in Bugiri District, Uganda.
Tuberculosis: a new vision for the 21st century.
SIT for African malaria vectors: epilogue.
Health seeking behavior after fever onset in a malaria-endemic area of Malawi.
Hidden burden of malaria in Indian women.
Cost-effectiveness of a successful schistosomiasis control programme in Cambodia (1995-2006).
Down-regulation of hypusine biosynthesis in Plasmodium by inhibition of S-adenosyl-methionine-decarboxylase.
High-throughput pooling and real-time PCR-based strategy for malaria detection.
ART in rural Uganda--efficient scale-up with home-based care?
Cost-effectiveness analysis of rapid diagnostic test, microscopy and syndromic approach in the diagnosis of malaria in Nigeria
Antimalarial drug development: past to present scenario.
Estimating unreported malaria cases in England: a capture-recapture study.
Health systems strengthening through insurance subsidies: the GFATM experience in Rwanda.
Dynamics of socioeconomic risk factors for neglected tropical diseases and malaria in an armed conflict.
Reduction of malaria: one insecticide treated bednet at a time.
Implications of the global financial crisis for the response to diseases of poverty within overall health sector development: the
Are malaria treatment expenditures catastrophic to different socio-economic and geographic groups and how do they cope w
Turning neglected tropical diseases into forgotten maladies.
Promoting country ownership and stewardship of health programs: The global fund experience.
Health systems exist for real people. Introduction.
Synthesis of 9-anilinoacridine triazines as new class of hybrid antimalarial agents.
Malaria control, elimination, and eradication: the role of the evolving biomedical research agenda.
Malaria's primate links.
Malaria treatment perceptions, practices and influences on provider behaviour: comparing hospitals and non-hospitals in sou
A simplified, low-cost method for polarized light microscopy.
Malaria diagnosis by a polymerase chain reaction-based assay using a pooling strategy.
HLA-DR: molecular insights and vaccine design.
The anti-malaria agent artesunate inhibits expression of vascular endothelial growth factor and hypoxia-inducible factor-1alp
Integrated mapping of neglected tropical diseases: epidemiological findings and control implications for northern Bahr-el-Gha
Molecular identification of T. brucei s.l. in tsetse flies after long-term permanence in field traps.
A simple cost-effective high performance liquid chromatographic assay of sulphadoxine in whole blood spotted on filter pape
Habitat stability and occurrences of malaria vector larvae in western Kenya highlands.
Ongoing challenges in the management of malaria.
FlexiChip package: an universal microarray with a dedicated analysis software for high-thoughput SNPs detection linked to an
Cost is killing patients: subsidising effective antimalarials.
Insecticide-treated nets usage and malaria episodes among boarding students in Zaria, northern Nigeria.
Analysis of the direct and indirect costs of treatment of imported malaria in the Slovak Republic.
Obstetric ultrasound scanning by local health workers in a refugee camp on the Thai-Burmese border.
Malaria preventive measures, health care seeking behaviour and malaria burden in different epidemiological settings in Suda
Window screening, ceilings and closed eaves as sustainable ways to control malaria in Dar es Salaam, Tanzania.
Utilisation of laboratory services by health workers in a district hospital in Malawi.
Vaccination with recombinant Plasmodium vivax MSP-10 formulated in different adjuvants induces strong immunogenicity bu
Priorities in research and development of vaccines against Plasmodium vivax malaria.
Traditional antimalarial phytotherapy remedies in herbal markets in southern Ghana.
Malaria vaccine: latest update and challenges ahead.
Misdiagnosis of an imported case of malaria caused by Plasmodium falciparum.
Hybrid drugs for malaria.
Malaria management: past, present, and future.
Comparative cost analysis of insecticide-treated net delivery strategies: sales supported by social marketing and free distribu
Genetics and the general physician: insights, applications and future challenges.
Innovating for impact: the Affordable Medicines Facility-malaria (AMFm).
Inequities in incidence, morbidity and expenditures on prevention and treatment of malaria in southeast Nigeria.
The blood donor in sub-Saharan Africa: a review.
Imported malaria in United Arab Emirates: evaluation of a new DNA extraction technique using nested PCR.
Piloting the global subsidy: the impact of subsidized artemisinin-based combination therapies distributed through private dru
12th Annual Conference on Vaccine Research.
Cost-effectiveness of adding bed net distribution for malaria prevention to antenatal services in Kinshasa, Democratic Republ
A unique 45-amino-acid region in the toprim domain of Plasmodium falciparum gyrase B is essential for its activity.
Health research oversight in Africa.
The 10/90 gap in sub-Saharan Africa: resolving inequities in health research.
[Cost-effectiveness ratio of using rapid tests for malaria diagnosis in the Peruvian Amazon]
From research to control: Translating research findings into health policies, operational guidelines and health products.
The ethics of improving African traditional medical practice: scientific or African traditional research methods?
Addressing the malaria drug resistance challenge using flow cytometry to discover new antimalarials.
Professional ethics: an overview from health research ethics point of view.
Defining the relationship between Plasmodium falciparum parasite rate and clinical disease: statistical models for disease bur
Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databases.
Economic crisis threatens AIDS fight.
Treatment of malaria from monotherapy to artemisinin-based combination therapy by health professionals in rural health fac
Sustainable developments. Good news on malaria control.
Maintaining momentum for malaria elimination.
Seasonal fluctuation of drug-resistant malaria parasites: a sign of fitness cost.
Acceptability, willing to purchase and use long lasting insecticide treated mosquito nets in Orissa State, India.
The Schistosomiasis Control Initiative (SCI): rationale, development and implementation from 2002-2008.
Immunophoretic rapid diagnostic tests as a source of immunoglobulins for estimating malaria sero-prevalence and transmissi
Mobile phone based clinical microscopy for global health applications.
Focusing on quality patient care in the new global subsidy for malaria medicines.
An informatics model for guiding assembly of telemicrobiology workstations for malaria collaborative diagnostics using comm
Complexity, cofactors, and the failure of AIDS policy in Africa.
Household ownership and use of insecticide treated nets among target groups after implementation of a national voucher pr
2La chromosomal inversion enhances thermal tolerance of Anopheles gambiae larvae.
Tracking and decomposing health and disease inequality in Thailand.
Affordable medicines facility for malaria.
US is now "past the rhetoric" in fighting malaria worldwide.
[Evaluation of vector control techniques: an economic approach]
Indoor residual spraying of DDT for malaria control.
Expert group calls for more funding to tackle malaria.
Towards a global fund for the health MDGs?
Towards a global fund for the health MDGs?
Delivering new malaria drugs through grassroots private sector.
Comparison of deltamethrin as indoor residual spray or on insecticide treated nets for mosquito control in Lake Chilwa.
Use of drugs, perceived drug efficacy and preferred providers for febrile children: implications for home management of feve
Simulation of the cost-effectiveness of malaria vaccines.
Multi-locus assortment (MLA) for transgene dispersal and elimination in mosquito populations.
Larvicidal activity of neem oil (Azadirachta indica) formulation against mosquitoes.
From malaria control to eradication: The WHO perspective.
Integration of insecticide-treated net distribution into routine immunization services in Malawi: a pilot study.
Factors influencing adherence to referral advice following pre-referral treatment with artesunate suppositories in children in
Prizes and parasites: incentive models for addressing Chagas disease.
The effects of global health initiatives on country health systems: a review of the evidence from HIV/AIDS control.
Impaired fitness of drug-resistant malaria parasites: evidence and implication on drug-deployment policies.
Potential of integrated continuous surveys and quality management to support monitoring, evaluation, and the scale-up of h
Effect of malaria rapid diagnostic tests on the management of uncomplicated malaria with artemether-lumefantrine in Kenya
Impact of ministry of health interventions on private medicine retailer knowledge and practices on anti-malarial treatment in
Marked increase in child survival after four years of intensive malaria control.
Good news in malaria control... now what?
Requirements for diagnosis of malaria at different levels of the laboratory network in Africa.
Laboratory challenges in the scaling up of HIV, TB, and malaria programs: The interaction of health and laboratory systems, cl
The global fight against HIV/AIDS, tuberculosis, and malaria: current status and future perspectives.
How equitable is bed net ownership and utilisation in Tanzania? A practical application of the principles of horizontal and vert
Identification of malaria hot spots for focused intervention in tribal state of India: a GIS based approach.
Malaria control in the municipality of San Esteban, Honduras.
Rapid mapping of schistosomiasis and other neglected tropical diseases in the context of integrated control programmes in A
Valuing climate change impacts on human health: empirical evidence from the literature.
Moving candidate vaccines into development from research: lessons from HIV.
The Bill & Melinda Gates Foundation's grant-making programme for global health.
Low efficacy of chloroquine: time to switchover to artemisinin-based combination therapy for falciparum malaria in India.
Malaria prevention in north-eastern Tanzania: patterns of expenditure and determinants of demand at the household level.
Early rectal artesunate administration: a life-saver in remote areas?
Efficacy of Aquatain, a monomolecular surface film, against the malaria vectors Anopheles stephensi and An. gambiae s.s. in t
The global portfolio of new antimalarial medicines under development.
Community directed interventions for malaria, tuberculosis and vitamin A in onchocerciasis endemic districts of Tanzania.
A retrospective analysis of the change in anti-malarial treatment policy: Peru.
The role of rapid diagnostic tests in managing malaria.
Influence of rapid malaria diagnostic tests on treatment and health outcome in fever patients, Zanzibar: a crossover validatio
Resistance to the Affordable Medicines Facility for malaria?
High retention and appropriate use of insecticide-treated nets distributed to HIV-affected households in Rakai, Uganda: resul
New funding mechanism is launched to combat malaria.
Ace-1 duplication in Anopheles gambiae: a challenge for malaria control.
Equity and coverage of insecticide-treated bed nets in an area of intense transmission of Plasmodium falciparum in Tanzania.
Bed net use and associated factors in a rice farming community in Central Kenya.
Home management of malaria with artemether-lumefantrine compared with standard care in urban Ugandan children: a ran
Malaria overdiagnosis and burden of malaria misdiagnosis in the suburbs of central Sudan: special emphasis on artemisinin-b
Enhanced antimalarial effects of chloroquine by aqueous Vernonia amygdalina leaf extract in mice infected with chloroquine
Community-based environmental management for malaria control: evidence from a small-scale intervention in Dar es Salaam
Cost-effectiveness analysis of the available strategies for diagnosing malaria in outpatient clinics in Zambia.
A comparative study of blood smear, QBC and antigen detection for diagnosis of malaria.
Costs and cost-effectiveness of vector control in Eritrea using insecticide-treated bed nets.
Pathways to malaria persistence in remote central Vietnam: a mixed-method study of health care and the community.
Concentration and drug prices in the retail market for malaria treatment in rural Tanzania.
Eliminating neglected diseases in poor countries: a conversation with Andrew Witty. Interview by Susan Dentzer.
Application of pharmacogenomics to malaria: a holistic approach for successful chemotherapy.
Utilization of public or private health care providers by febrile children after user fee removal in Uganda.
Caspar controls resistance to Plasmodium falciparum in diverse anopheline species.
Albumin is a blood product too - is it safe for all patients?
The role of mathematical modelling in malaria elimination and eradication (Comment on: Can malaria be eliminated?).
Parasitic lung infections.
Current treatment and drug discovery against Leishmania spp. and Plasmodium spp.: a review.
Cost-effectiveness of malaria intermittent preventive treatment in infants (IPTi) in Mozambique and the United Republic of T
[Fake malaria drugs]
Availability, affordability, and prescribing pattern of medicines in Sudan.
Physical and chemical stability of expired fixed dose combination artemether-lumefantrine in uncontrolled tropical condition
Health policy in interwar Greece: the intervention by the League of Nations Health Organisation.
Deployment of ACT antimalarials for treatment of malaria: challenges and opportunities.
Working without a blindfold: the critical role of diagnostics in malaria control.
Malaria eradication: the economic, financial and institutional challenge.
Development and climate change: a mainstreaming approach for assessing economic, social, and environmental impacts of a
Estimating inequalities in ownership of insecticide treated nets: does the choice of socio-economic status measure matter?
Estimating the burden of malaria in pregnancy: a case study from rural Madhya Pradesh, India.
The progress of Roll Back Malaria in the Eastern Mediterranean Region over the past decade.
Mebendazole in parasitic infections other than those caused by soil-transmitted helminths.
[Molecular diagnosis of parasitic and fungal infections]
Gates foundation pledges new funds to fight neglected diseases.
Cost-effectiveness of artesunate for the treatment of severe malaria.
The effect of interrupted 5-day training on Integrated Management of Neonatal and Childhood Illness on the knowledge and
Rapid diagnostic tests for the home-based management of malaria, in a high-transmission area.
Disability adjusted life years lost to dengue in Brazil.
Splenic enlargement and abdominal scarification in childhood malaria. Beliefs, practices and their possible roles in manageme
Neglected tropical diseases and the Global Fund.
The economic burden of inpatient paediatric care in Kenya: household and provider costs for treatment of pneumonia, malar
[Evaluation indices of social burden caused by advanced schistosomiasis]
Poverty, inequality and health: the challenge of the double burden of disease in a non-profit hospital in rural Ethiopia.
On the trail of disease in Southeast Asia.
The emergence of global health partnerships as facilitators of access to medication in Africa: a narrative policy analysis.
Costs of early detection systems for epidemic malaria in highland areas of Kenya and Uganda.
Simultaneous liquid chromatographic analysis of ritonavir, quinine and 3-hydroxyquinine in human plasma.
Artemisinin-based combinations versus amodiaquine plus sulphadoxine-pyrimethamine for the treatment of uncomplicated m
Abolishing user fees in Africa.
Effect of removing direct payment for health care on utilisation and health outcomes in Ghanaian children: a randomised con
Development, malaria and adaptation to climate change: a case study from India.
Multiplex real-time PCR detection of P. falciparum, P. vivax and P. malariae in human blood samples.
Free distribution of insecticide treated bed nets to pregnant women in Kinshasa: an effective way to achieve 80% use by wom
Antimalarial prescribing patterns in state hospitals and selected parastatal hospitals in Lagos, Nigeria.
Prevalence of malaria from peripheral blood smears examination: a 1-year retrospective study from the Serbo Health Center,
Perspectives on strategies for establishing cancer on the global health agenda: possibilities of creating infrastructure for canc
Combining 4-aminoquinoline- and clotrimazole-based pharmacophores toward innovative and potent hybrid antimalarials.
Improving the cost-effectiveness of IRS with climate informed health surveillance systems.
The burden of human African trypanosomiasis.
Rolling back malaria--the next 10 years.
Costs and consequences of large-scale vector control for malaria.
The evolution of drug-resistant malaria.
The Burden of Early Exposure to Malaria in the United States, 1850-1860: Malnutrition and Immune Disorders.
Disposal of obsolete pesticides, the case of Ethiopia.
Acceptance of ACTs by patients in private healthcare facilities in Surulere, Lagos State.
Disease emergence from global climate and land use change.
FDA launches priority vouchers for neglected-disease drugs.
Human vaccine research in the European Union.
The content of African diets is adequate to achieve optimal efficacy with fixed-dose artemether-lumefantrine: a review of the
[Mortality and morbidity worldwide, now and tomorrow: what is known?]
Cervical cancer: the sub-Saharan African perspective.
A field-adapted sampling and HPLC quantification method for lumefantrine and its desbutyl metabolite in whole blood spotte
Global health. Malaria drugs, the Coca-Cola way.
Research needed to strengthen science and programs for the control of iron deficiency and its consequences in young childre
Insecticide-treated net coverage in Africa: mapping progress in 2000-07.
Out with the old, in with the new: the utility of rapid diagnostic tests for malaria diagnosis in Africa.
Novel therapies for the prevention of malaria.
The elimination of child poverty and the pivotal significance of the mother.
New malaria drugs need subsidy, study finds.
Recent advances in artemisinin production through heterologous expression.
Malaria battle boost.
A randomized trial of artesunate-mefloquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium fa
Willingness and ability to pay for artemisinin-based combination therapy in rural Tanzania.
[Evaluation of usefulness of the panel test composed of malaria non-specific tests as a surrogate marker]
A general SNP-based molecular barcode for Plasmodium falciparum identification and tracking.
The long march: a sample preparation technique that enhances contig length and coverage by high-throughput short-read se
Reflections on a century of malaria biochemistry.
Clonal diversity within infections and the virulence of a malaria parasite, Plasmodium mexicanum.
Use of insecticide treated nets by pregnant women and associated factors in a pre-dominantly rural population in northern E
Misfinancing global health: a case for transparency in disbursements and decision making.
Assessing the impact of the trauma team training program in Tanzania.
An efficient fluorimetric method to measure the viability of intraerythrocytic Plasmodium falciparum.
Malaria's watershed.
Burden of cerebral malaria in central India (2004-2007).
Determinants of the accuracy of rapid diagnostic tests in malaria case management: evidence from low and moderate transm
Infectious disease. New malaria plan called ambitious by some, unrealistic by others.
Predicting Global Fund grant disbursements for procurement of artemisinin-based combination therapies.
Heterologous expression of plasmodial proteins for structural studies and functional annotation.
World leaders pledge extra $3bn to combat malaria.
Costs and cost-effectiveness of delivering intermittent preventive treatment through schools in western Kenya.
The neglected tropical diseases of Latin America and the Caribbean: a review of disease burden and distribution and a roadm
Bed net ownership, use and perceptions among women seeking antenatal care in Kinshasa, Democratic Republic of the Congo
The burden of stroke in Nigeria.
The stem cell transplant program in Pakistan--the first decade.
Obstacles to prompt and effective malaria treatment lead to low community-coverage in two rural districts of Tanzania.
Should countries implementing an artemisinin-based combination malaria treatment policy also introduce rapid diagnostic te
The Global Fund and tuberculosis in Nicaragua: building sustainable capacity?
A modern African perspective on the role of the clinical nurse specialist.
The economic burden of malaria on the household in south-central Vietnam.
Host control of malaria infections: constraints on immune and erythropoeitic response kinetics.
[Concordance between thick blood smear, immunochromatography and polymerase chain reaction for malaria diagnosis]
Tackling malaria today.
Utilization of monoclonal antibodies for detection of Plasmodium falciparum antigen in cerebrospinal fluid of cerebral malari
Pre-departure and post-arrival management of P. falciparum malaria in refugees relocating from sub-Saharan Africa to the Un
Indicators of anaemia in under-fives with malaria at a hospital in northern Cameroon.
Using climate information for improved health in Africa: relevance, constraints and opportunities.
Injuries in developing countries--how can we help? The role of orthopaedic surgeons.
Paracheck Pf compared with microscopy for diagnosis of Plasmodium falciparum malaria among children in Tanga City, north
From strategy development to routine implementation: the cost of Intermittent Preventive Treatment in Infants for malaria c
[Drug access in poor countries]
Oral vaccine delivery: can it protect against non-mucosal pathogens?
Tropical anemia: one of Africa's great killers and a rationale for linking malaria and neglected tropical disease control to achie
Assessing debt-to-health swaps: a case study on the Global Fund Debt2Health Conversion Scheme.
Efficacy of local neem extracts for sustainable malaria vector control in an African village.
Divergent goals and commitments in global malaria intervention.
International funding for malaria control in relation to populations at risk of stable Plasmodium falciparum transmission.
The importance of "throwing money at" the problem of global health.
Genistein-supplemented diet decreases malaria liver infection in mice and constitutes a potential prophylactic strategy.
A deadline on malaria.
Development of pilot scale production process and characterization of a recombinant multiepitope malarial vaccine candidat
Availability and choice of antimalarials at medicine outlets in Ghana: the question of access to effective medicines for malaria
The challenges of diagnosis and treatment of malaria in pregnancy in low resource settings.
Elimination of visceral leishmaniasis in Nepal: pipe-dreams and possibilities.
Adherence and effectiveness of drug combination in curative treatment among children suffering uncomplicated malaria in ru
The persistent problem of malaria: addressing the fundamental causes of a global killer.
Malaria and poverty.
Diseases of poverty with high mortality in infants and children: malaria, measles, lower respiratory infections, and diarrheal il
Splenic enlargement and abdominal scarifications in childhood malaria: beliefs, practices and their possible roles in managem
Perceptions and home management practices of malaria in some rural communities in Abeokuta, Nigeria.
Delayed care seeking for fatal pneumonia in children aged under five years in Uganda: a case-series study.
Spatial and multidimensional visualization of Indonesia's village health statistics.
Vouchers for scaling up insecticide-treated nets in Tanzania: methods for monitoring and evaluation of a national health syste
Modeling the financial and clinical implications of malaria rapid diagnostic tests in the case-management of older children and
Determinants of provider choice for malaria treatment: experiences from The Gambia.
DNA microarrays in the clinic: infectious diseases.
Comparison of male reproductive success in malaria-refractory and susceptible strains of Anopheles gambiae.
A new attack on malaria.
The tip of the iceberg: evidence of seasonality in institutional maternal mortality and implications for health resources manag
Seeing (RED).
Point-of-care testing for malaria outbreak management.
Intermittent preventive treatment of malaria in pregnancy: the incremental cost-effectiveness of a new delivery system in Ug
Crystal structure of the aquaglyceroporin PfAQP from the malarial parasite Plasmodium falciparum.
Funding scrutiny could help set priorities for malaria.
Artemisinin-based combination therapy for uncomplicated malaria in sub-Saharan Africa: the efficacy, safety, resistance and p
Cost of increasing access to artemisinin combination therapy: the Cambodian experience.
WHO position statement on integrated vector management.
Costs and effectiveness of application of Poecilia reticulata (guppy) and temephos in anopheline mosquito control in river bas
[Visceral leishmaniasis: clinical sensitivity and resistance to various therapeutic agents]
Traditional birth home attendance and its implications for malaria control during pregnancy in Nigeria.
Benefiting from the Gates' billions: where next for malaria?
Effects of malaria double infection in birds: one plus one is not two.
The use of mosquito nets and the prevalence of Plasmodium falciparum infection in rural South Central Somalia.
Detection of Plasmodium falciparum histidine-rich protein II in saliva of malaria patients.
Comparison of Anopheles gambiae and Culex pipiens acetycholinesterase 1 biochemical properties.
Cofactor infections and HIV epidemics in developing countries: implications for treatment.
Experimental manipulation of immune-mediated disease and its fitness costs for rodent malaria parasites.
[Treatment of malaria: outlook]
Drug subsidy could help Tanzania tackle malaria.
Cost-effectiveness analysis of insecticide-treated net distribution as part of the Togo Integrated Child Health Campaign.
Determination of nitric oxide metabolites, nitrate and nitrite, in Anopheles culicifacies mosquito midgut and haemolymph by
Reimbursement of malaria chemoprophylaxis for travellers from Europe to Sub-Saharan Africa: Cost-effectiveness analysis fro
Responding to the challenge to end malaria deaths in Africa.
[Tuberculosis and malaria global prophylaxis in the light of decisions of the Big Eight]
DNA vaccines and their applications in veterinary practice: current perspectives.
India takes an open source approach to drug discovery.
Malaria programmes need informed advocacy.
Malaria: efforts starting to show widespread results.
Qinghaosu (artemisinin): the price of success.
Studies in haemoglobin E beta-thalassaemia.
Assessing the validity of health facility-based data on insecticide-treated bednet possession and use: comparison of data colle
Use of proxy measures in estimating socioeconomic inequalities in malaria prevalence.
Insecticide treated mosquito nets for malaria control in India-experience from a tribal area on operational feasibility and upta
Growth generates health care challenges in booming India.
Malaria vector management: where have we come from and where are we headed?
[Fight with HIV/AIDS, tuberculosis, and malaria in African continent in the light of G8 decisions]
A novel semi-automatic image processing approach to determine Plasmodium falciparum parasitemia in Giemsa-stained thin
The health impact of polyparasitism in humans: are we under-estimating the burden of parasitic diseases?
Estimating the burden of rhodesiense sleeping sickness during an outbreak in Serere, eastern Uganda.
Corporate Champions: doing good more effectively.
Malaria eradication in India: a failure?
Expression of a mutated phospholipase A2 in transgenic Aedes fluviatilis mosquitoes impacts Plasmodium gallinaceum develo
Single-day, three-dose treatment with fixed dose combination artesunate/sulfamethoxypyrazine/pyrimethamine to cure Plas
Economic cost of malaria on households during a transmission season in Khartoum State, Sudan.
Treatment seeking behaviour of malaria patients in desert part of Rajasthan, India.
Diagnostics in the shadow of HIV epidemics.
Rural-urban differences in maternal responses to childhood fever in South East Nigeria.
When to seek health care: a duration analysis for malaria patients in Nepal.
Households willingness to pay for long-lasting insecticide treated nets in three urban communities of Assosa Zone, western E
Reduced mortality with home-based HIV treatment in Uganda.
A review of the current state of malaria among pregnant women in Papua New Guinea.
The billion-dollar malaria moment.
Malaria: the end of the beginning.
Time to take control.
What is the significance of the HPV epidemic?
Effectiveness of malaria control during changing climate conditions in Eritrea, 1998-2003.
Iron supplementation of young children: learning from the new evidence.
Cost-effectiveness of malaria diagnostic methods in sub-Saharan Africa in an era of combination therapy.
Civil society organisations and global health initiatives: problems of legitimacy.
The Global Fund: growing pains.
Household burden of malaria in South Africa and Mozambique: is there a catastrophic impact?
Translation of artemether-lumefantrine treatment policy into paediatric clinical practice: an early experience from Kenya.
Household cost of malaria overdiagnosis in rural Mozambique.
Costs and effects of the Tanzanian national voucher scheme for insecticide-treated nets.
Clotrimazole scaffold as an innovative pharmacophore towards potent antimalarial agents: design, synthesis, and biological a
The untapped potential of bed nets.
Households' perceptions and prioritization of tropical endemic diseases in Nigeria: implications for priority setting for resourc
Global and regional child mortality and burden of disease attributable to zinc deficiency.
Construct validity of the bidding game, binary with follow-up, and a novel structured haggling question format in determining
Mycotoxin problem in Africa: current status, implications to food safety and health and possible management strategies.
Identification and geographic distribution of the ACE-1R mutation in the malaria vector Anopheles gambiae in south-western
Participatory involvement of farming communities and public sectors in determining malaria control strategies in Mvomero D
Building to collective impact: the Global Fund support for measuring reduction in the burden of malaria.
Advocacy for malaria prevention, control, and research in the twenty-first century.
Research themes and advances in malaria research capacity made by the Multilateral Initiative on Malaria.
Multilateral initiative on malaria: justification, evolution, achievements, challenges, opportunities, and future plans.
Dichlorodiphenyltrichloroethane (DDT) for indoor residual spraying in Africa: how can it be used for malaria control?
Broken promise? Taxes and tariffs on insecticide treated mosquito nets.
Quick wins versus sustainability: options for the upscaling of insecticide-treated nets.
A global subsidy for antimalarial drugs.
Medicine sellers and malaria treatment in sub-Saharan Africa: what do they do and how can their practice be improved?
A major transition in malaria treatment: the adoption and deployment of artemisinin-based combination therapies.
Artemisinin-based combination treatment of falciparum malaria.
Responding to the challenge of antimalarial drug resistance by routine monitoring to update national malaria treatment polic
Scaling up malaria control in Africa: an economic and epidemiological assessment.
Estimating trends in the burden of malaria at country level.
The cost-effectiveness of parasitologic diagnosis for malaria-suspected patients in an era of combination therapy.
A review of malaria diagnostic tools: microscopy and rapid diagnostic test (RDT).
Uncertainty in malaria control in Tanzania: crossroads and challenges for future interventions.
Priority setting on malaria interventions in Tanzania: strategies and challenges to mitigate against the intolerable burden.
Vivax malaria: neglected and not benign.
Burden of malaria in India: retrospective and prospective view.
Malaria burden among pregnant women living in the rural district of Boromo, Burkina Faso.
When is "malaria" malaria? The different burdens of malaria infection, malaria disease, and malaria-like illnesses.
Killer applications: toward affordable rapid cell-based diagnostics for malaria and tuberculosis.
Simplified cytometry for routine monitoring of infectious diseases.
An interactive model for the assessment of the economic costs and benefits of different rapid diagnostic tests for malaria.
[1986-2006: 20 years of failed international policy to control AIDS in Africa]
A tool box for operational mosquito larval control: preliminary results and early lessons from the Urban Malaria Control Prog
Using evolutionary costs to enhance the efficacy of malaria control via genetically manipulated mosquitoes.
The impact of response to the results of diagnostic tests for malaria: cost-benefit analysis.
Costs of treating malaria according to test results.
Of oxford bags and twirling canes: the state, popular responses, and Zulu antimalaria assistants in the early-twentieth-centur
Novel paradigms for drug discovery: computational multitarget screening.
Habitat-based larval interventions: a new perspective for malaria control.
Improving equity in malaria treatment: relationship of socio-economic status with health seeking as well as with perceptions
The costs of introducing artemisinin-based combination therapy: evidence from district-wide implementation in rural Tanzan
Is there evidence for dual causation between malaria and socioeconomic status? Findings from rural Tanzania.
Malaria chemoprophylaxis: what do the travelers choose, and how does pretravel consultation influence their final decision.
Can transgenic mosquitoes afford the fitness cost?
Sex and the global fund: how sex workers, lesbians, gays, bisexuals, transgender people, and men who have sex with men are
Implementing Intermittent Preventive Treatment for Malaria in Pregnancy: Review of Prospects, Achievements, Challenges a
Cost implication of irrational prescribing of chloroquine in Lagos State general hospitals.
Malaria: an eradicable threat?
The Global Burden of Disease assessments--WHO is responsible?
Development and death: reinterpreting malaria, economics and ecology in British India.
DDT reintroduction for malaria control: the cost-benefit debate for public health.
Estimated financial and human resources requirements for the treatment of malaria in Malawi.
Knowledge on malaria transmission and its prevention among schoolchildren in Kyela District, south-western Tanzania.
DEET microencapsulation: a slow-release formulation enhancing the residual efficacy of bed nets against malaria vectors.
The US President's Malaria Initiative: 2 years on.
Antagonistic effects of a Mhc class I allele on malaria-infected house sparrows.
Proceedings of a Consensus Conference: pathogen inactivation-making decisions about new technologies.
Neglected tropical diseases, neglected data sources, and neglected issues.
A quantitative synthesis of the medicinal ethnobotany of the Malinké of Mali and the Asháninka of Peru, with a new theoretic
Equity in access to ARV drugs in Malawi.
Global Fund-supported programmes contribution to international targets and the Millennium Development Goals: an initial a
The Global Fund expands its role. Interview by the Bulletin.
Trip into the unknown.
VIOLIN: vaccine investigation and online information network.
Towards sustainable malaria control.
Progress and challenges towards the development of malaria vaccines.
Seasonal carriage of pfcrt and pfmdr1 alleles in Gambian Plasmodium falciparum imply reduced fitness of chloroquine-resista
Global public health problem of sudden cardiac death.
Global theme issue on poverty and human development.
Monitoring the operational impact of insecticide usage for malaria control on Anopheles funestus from Mozambique.
Combating malaria. Malaria treatment: ACT two.
Combating malaria. Battling over bed nets.
The Global Fund: growing pains.
Cost-sharing strategies combining targeted public subsidies with private-sector delivery achieve high bednet coverage and re
Economic costs of epidemic malaria to households in rural Ethiopia.
Economic burden of malaria in rural Tanzania: variations by socioeconomic status and season.
Oral drug therapy for multiple neglected tropical diseases: a systematic review.
Estimating the burden of disease attributable to vitamin A deficiency in South Africa in 2000.
Estimating the burden of disease attributable to childhood and maternal undernutrition in South Africa in 2000.
Making medical devices accessible: a drug-resistant malaria detection system.
Financing the fight against AIDS, tuberculosis, and malaria.
Varying efficacy of intermittent preventive treatment for malaria in infants in two similar trials: public health implications.
Brazilian policy of universal access to AIDS treatment: sustainability challenges and perspectives.
Are West African plants a source of future antimalarial drugs?
Malaria research should go 'back to basics'.
Personal-protection measures against mosquitoes: a study of practices and costs in a district, in the Indian state of Orissa, wh
Ensuring sustained ACT production and reliable artemisinin supply.
Comparison of three molecular methods for the detection and speciation of Plasmodium vivax and Plasmodium falciparum.
Developing recombinant bacteria for control of mosquito larvae.
Financial implications of refugee malaria: the impact of pre-departure presumptive treatment with anti-malarial drugs.
Neglected tropical diseases in Uganda: the prospect and challenge of integrated control.
[Population's behaviour and expectations concerning malaria control in Ouidah, Benin, April 2006)]
Rapid microarray-based method for monitoring of all currently known single-nucleotide polymorphisms associated with para
Estimated global resources needed to attain international malaria control goals.
Increasing coverage and decreasing inequity in insecticide-treated bed net use among rural Kenyan children.
Making performance-based funding work for health.
rDNA-ITS2-PCR assay for grouping the cryptic species of Anopheles culicifacies complex (Diptera: Culicidae).
[Achievements and failure of WHO during realization of the control programmes of the communicable diseases during twenti
Detection of knockdown resistance (kdr) mutations in Anopheles gambiae: a comparison of two new high-throughput assays
Preliminary field testing of a long-lasting insecticide-treated hammock against Anopheles gambiae and Mansonia spp. (Dipter
Field evaluation of traditionally used plant-based insect repellents and fumigants against the malaria vector Anopheles darlin
[Molecular markers for malaria drug resistance: necessary but not sufficient criteria to decide change in treatment policy]
[ASAQ, a breakthrough in the fight against malaria]
Eliminating human tuberculosis in the twenty-first century.
Consumer response and satisfaction to prepackaged antimalarial drugs for children in Aba, Nigeria.
Social marketing of insecticide-treated bednets: the case for Pakistan.
Battling the malaria iceberg with chloroquine in India.
A low-cost repellent for malaria vectors in the Americas: results of two field trials in Guatemala and Peru.
The Global Fund: 5 years on.
Prospects for the treatment of drug-resistant malaria parasites.
Comparison of serological methods (ELISA, DAT and IFA) for diagnosis of visceral leishmaniasis utilizing an endemic strain.
Modelling the effect of malaria endemicity on spatial variations in childhood fever, diarrhoea and pneumonia in Malawi.
Blood schizontocidal activity of methylene blue in combination with antimalarials against Plasmodium falciparum.
Superiority of DAT over ELISA as a diagnostic and seroepidemiological tool for the diagnosis of Indian Kala-azar.
Community coverage of an antimalarial combination of artesunate and amodiaquine in Makamba Province, Burundi, nine mo
Exploring the contributions of bed nets, cattle, insecticides and excitorepellency to malaria control: a deterministic model of m
Estimating antimalarial drugs consumption in Africa before the switch to artemisinin-based combination therapies (ACTs).
Monitoring of larval habitats and mosquito densities in the Sudan savanna of Mali: implications for malaria vector control.
An update on anemia in less developed countries.
Inequities in valuation of benefits, choice of drugs, and mode of payment for malaria treatment services provided by commun
Quinine substitutes in the confederate army.
Antimalarial cation-dimers synthesized in two steps from an inexpensive starting material, isonicotinic acid.
Delivery systems for insecticide treated and untreated mosquito nets in Africa: categorization and outcomes achieved.
Malaria control needs mass distribution of insecticidal bednets.
Sustained high coverage of insecticide-treated bednets through combined Catch-up and Keep-up strategies.
Achieving child survival goals: potential contribution of community health workers.
Microbial larvicides for malaria control in The Gambia.
Gates of opportunity.
[A new, cheaper and simpler anti-malaria preparation]
A financial road map to scaling up essential child health interventions in 75 countries.
The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya.
Computational modeling tools for the design of potent antimalarial bisbenzamidines: overcoming the antimalarial potential o
Global Fund grant programmes: an analysis of evaluation scores.
The performance of the Global Fund.
The framework of international health research--secondary publication.
Malaria 2007--progressing research, persisting challenges.
Burden, features, and outcome of neurological involvement in acute falciparum malaria in Kenyan children.
Deletion mutagenesis of large areas in Plasmodium falciparum genes: a comparative study.
Age-related changes in adaptation to severe anemia in childhood in developing countries.
Quantifying the economic burden of malaria in Nigeria using the willingness to pay approach.
Twenty years of human immunodeficiency virus infection in Croatia--an epidemic that is still in an early stage.
Biomedical philanthropy: the giving machine. Tadataka Yamada interviewed by Lucy Odling-Smee.
Determinants of bed net use in the Gambia: implications for malaria control.
Community views on health sector reform and their participation in health priority setting: case of Lushoto and Muheza distr
Canada's fevered failure on malaria.
Micro-epidemiology of Plasmodium falciparum malaria: Is there any difference in transmission risk between neighbouring vill
[Against malaria: ASAQ, one dollar per box]
Equity, empowerment and choice: from theory to practice in public health.
Introducing desirable transgenes into insect populations using Y-linked meiotic drive - a theoretical assessment.
Choice of treatment for fever at household level in Malawi: examining spatial patterns.
Erythrocyte remodeling by malaria parasites.
Synthetic vaccine update: applying lessons learned from recent SPf66 malarial vaccine physicochemical, structural and immun
Comparison of the diagnosis of malaria by microscopy, immunochromatography and PCR in endemic areas of Venezuela.
Functional genomics and the biosynthesis of artemisinin.
Counterfeit artemisinin derivatives and Africa: update from authors.
Millennium development holes.
Population genomics of the immune evasion (var) genes of Plasmodium falciparum.
Investigating mosquito-net coverage in Nigeria. How useful are consumer marketing surveys?
Accessibility and affordability of malaria intervention, treatment and prevention in Africa.
Changing funding patterns in tuberculosis.
Malaria in pregnancy, risk perceptions and care seeking practices among adolescents in Mukono district Uganda.
Ethical challenges in voluntary blood donation in Kerala, India.
Paediatric health economic evaluations: a world view.
The hospital on Bushenyi Hill.
A cost-effectiveness analysis of artemether lumefantrine for treatment of uncomplicated malaria in Zambia.
The role of communication between clients and health care providers: implications for adherence to malaria treatment in rur
Traditional use of indigenous mosquito-repellents to protect humans against mosquitoes and other insect bites in a rural com
[Links and effects of globalization on social and economic organization and malaria prevalence in the Coastal Region of Living
The health and economic impact of dengue in Latin America.
[Knowledge, attitudes and practices of populations towards mosquitoes in urban and rural area (Côte d'Ivoire--West Africa)]
The clinical spectrum of severe malaria in children in the east provincial hospital of Bertoua, Cameroon.
A community-based feasibility study of National Health Insurance Scheme in Ghana.
Reformed US malaria program garners critics' approval.
Increasing burden of childhood severe malaria in a Nigerian tertiary hospital: implication for control.
[Extraction of artemisinin and synthesis of its derivates artesunate and artemether]
[Control of malaria: market for artemisinin and its derivatives]
Combination vaccines: synergistic simultaneous induction of antibody and T-cell immunity.
Feasibility of a community health worker strategy for providing near and appropriate treatment of malaria in southeast Niger
Design and synthesis of potent antimalarial agents based on clotrimazole scaffold: exploring an innovative pharmacophore.
Global Fund pulls grants from mismanaging countries.
The impact of a hybrid social marketing intervention on inequities in access, ownership and use of insecticide-treated nets.
DDT for malaria control: the issue of trade.
Effect of artemisinin-based treatment policy on consumption pattern of antimalarials.
The economics of malaria in pregnancy--a review of the evidence and research priorities.
Reducing the burden of malaria in pregnancy by preventive strategies.
Sickle cell disease in Africa: burden and research priorities.
Commentary: improving the health of neglected populations in Latin America.
Preventing vertical transmission of HIV in Kinshasa, Democratic Republic of the Congo: a baseline survey of 18 antenatal clinic
[Development of antituberculous drugs: current status and future prospects]
Strategies to avoid the loss of developmental potential in more than 200 million children in the developing world.
Treatment of malaria restricted to laboratory-confirmed cases: a prospective cohort study in Ugandan children.
Comparison of a SYBR green I-based assay with a histidine-rich protein II enzyme-linked immunosorbent assay for in vitro ant
Herbal remedy in the treatment of malaria: cross sectional survey of residents of Lagos State, Nigeria.
Delivery of insecticide-treated net services through employer and community-based approaches in Kenya.
Practical malaria tests promise results in remote regions.
Solutions to nutrition-related health problems of preschool children: education and nutritional policies for children.
Footbath acaricide treatment to control cattle infestation by the tick Amblyomma variegatum.
USAID's health challenge: improving US foreign assistance.
The cost of uncomplicated childhood fevers to Kenyan households: implications for reaching international access targets.
Changing faces: A review of infectious disease screening of refugees by the Migrant Health Unit, Western Australia in 2003 an
[Cost-effectiveness analysis of two strategies for malaria control in the urban area of Buenaventura, Colombia]
Monitoring chloroquine resistance using Plasmodium falciparum parasites isolated from wild mosquitoes in Tanzania.
GFATM-WHO partnership: a win for TB-HIV.
Baculovirus-based vaccination vectors allow for efficient induction of immune responses against plasmodium falciparum circu
Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria.
Reducing the burden of childhood malaria in Africa: the role of improved.
Intrahost selection of Plasmodium falciparum pfmdr1 alleles after antimalarial treatment on the northwestern border of Thai
Consumers stated and revealed preferences for community health workers and other strategies for the provision of timely an
Getting global funds to those most in need: the Thai Drug Users' Network.
Optimized Malaria-antigens delivered by immunostimulating reconstituted influenza virosomes.
High-throughput Plasmodium falciparum growth assay for malaria drug discovery.
[Malaria: knowledge, behaviour and practices among a rural population of Gossas, Senegal]
Malaria: anti malarial resistance and policy ramifications and challenges.
Quantifying behavioural interactions between humans and mosquitoes: evaluating the protective efficacy of insecticidal nets
Sixth Africa Malaria Day in 2006: how far have we come after the Abuja Declaration?
[What is the cost of health in low income countries]
Innovative lead discovery strategies for tropical diseases.
Maternal health in poor countries: the broader context and a call for action.
Insecticide-treated bed-nets for malaria mosquito control.
[Causes of neuropaediatric morbidity in Africa]
Suppression of exposure to malaria vectors by an order of magnitude using microbial larvicides in rural Kenya.
Development of an automated malaria discriminant factor using VCS technology.
Successful integration of insecticide-treated bed net distribution with mass drug administration in Central Nigeria.
A randomized trial of artesunate-sulfamethoxypyrazine-pyrimethamine versus artemether-lumefantrine for the treatment of
Burden of malaria at community level in children less than 5 years of age in Togo.
Responding to AIDS, tuberculosis, malaria, and emerging infectious diseases in Burma: dilemmas of policy and practice.
Cost-effectiveness study of three antimalarial drug combinations in Tanzania.
The Global Fund at five: what next for universal access for HIV/AIDS, TB and malaria?
Innate immune responses to human malaria: heterogeneous cytokine responses to blood-stage Plasmodium falciparum corre
An edible vaccine for malaria using transgenic tomatoes of varying sizes, shapes and colors to carry different antigens.
Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness.
Ensuring quality and access for malaria diagnosis: how can it be achieved?
[International health research: priorities and commitment]
Economic and practical challenges to the formulation of vaccines against endemic infectious diseases such as malaria.
Donor funding priorities for communicable disease control in the developing world.
Accuracy of the health information system on malaria surveillance in Vietnam.
How much disease burden can be prevented by environmental interventions?
Malaria hotspot areas in a highland Kenya site are consistent in epidemic and non-epidemic years and are associated with eco
Laboratory use in Ghana: physician perception and practice.
Socio-economic differences in preferences and willingness to pay for different providers of malaria treatment in southeast Ni
Cost considerations of malaria chemoprophylaxis including use of primaquine for primary or terminal chemoprophylaxis.
Utility of alkylaminoquinolinyl methanols as new antimalarial drugs.
Pyrosequencing, a high-throughput method for detecting single nucleotide polymorphisms in the dihydrofolate reductase and
Burden of diseases in poor resource countries: meeting the challenges of combating HIV/AIDS, tuberculosis and malaria.
Rethinking the economic costs of malaria at the household level: evidence from applying a new analytical framework in rural
A fixed-dose 24-hour regimen of artesunate plus sulfamethoxypyrazine-pyrimethamine for the treatment of uncomplicated P
Predicting the cost-effectiveness of introducing a pre-erythrocytic malaria vaccine into the expanded program on immunizati
The costs of introducing a malaria vaccine through the expanded program on immunization in Tanzania.
An approach to model the costs and effects of case management of Plasmodium falciparum malaria in sub-saharan Africa.
Mathematical modeling of the impact of malaria vaccines on the clinical epidemiology and natural history of Plasmodium falc
[Impact of a new parasitologic laboratory for malaria diagnosis on diagnosis and cost of malaria in a company setting: experie
A versatile denaturing HPLC approach for human beta-globin gene mutation screening.
Analytical chemistry and developing nations. Challenges for clinical diagnostic devices. Lack of healthcare personnel, few reag
Ensuring quality and access for malaria diagnosis: how can it be achieved?
The financial and clinical implications of adult malaria diagnosis using microscopy in Kenya.
Burden of diseases in Amhara region, Ethiopia.
Developing an evidence-based decision support system for rational insecticide choice in the control of African malaria vectors
Profile: Amir Attaran.
Move against malaria.
An examination of the Global Fund at 5 years.
Absorptive capacity and disbursements by the Global Fund to Fight AIDS, Tuberculosis and Malaria: analysis of grant impleme
Exemption policies and community preferences for tropical endemic diseases in the Bamako initiative programme in Nigeria.
Applying the concepts of financial options to stimulate vaccine development.
From chloroquine to artemisinin-based combination therapy: the Sudanese experience.
The Global Fund Secretariat's suspension of funding to Uganda: how could this have been avoided?
Use of insecticide-treated clothes for personal protection against malaria: a community trial.
Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda.
Zinc in human health.
[Antimalarial drug resistance]
The Booster Program for Malaria Control: putting knowledge and money to work.
The World Bank: false financial and statistical accounts and medical malpractice in malaria treatment.
The World Bank and malaria treatment.
Impact of opportunistic diseases on chronic mortality in HIV-infected adults in Côte d'Ivoire.
Uganda's successful Guinea Worm Eradication Program.
[Burden of hospitalizations attributable to malaria in Spain during 1999-2002]
[Anaemia in a school of rural Cambodia: detection, prevalence, and links with intestinal worms and malnutrition]
Melinda Moree.
Occurrence of the leucine-to-phenylalanine knockdown resistance (kdr) mutation in Anopheles arabiensis populations in Tanz
A clinical drug library screen identifies astemizole as an antimalarial agent.
The US President's Malaria Initiative.
Cost and cost-effectiveness of PPM-DOTS for tuberculosis control: evidence from India.
Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-la
Artemisinin combination therapies.
[Knowledge of the risks of smoking in patients admitted to a respiratory clinic in Senegal]
Rolling out insecticide treated nets in Eritrea: examining the determinants of possession and use in malarious zones during th
Perspectives on polio and immunization in Northern Nigeria.
Comparative analysis of two alternative models for epidemiological surveillance in the Mexican Malaria Control Program.
Manslaughter by fake artesunate in Asia--will Africa be next?
Insecticide-treated nets.
Control of human parasitic diseases: Context and overview.
Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data.
Meeting of the immunization Strategic Advisory Group of Experts, Geneva, 10-11 April 2006: conclusions and recommendatio
Capacity strengthening in malaria research: the Gates Malaria Partnership.
The renaissance in global health.
Can the ubiquitous power of mobile phones be used to improve health outcomes in developing countries?
The Innovative Vector Control Consortium: improved control of mosquito-borne diseases.
Comparison of coverage with insecticide-treated nets in a Tanzanian town and villages where nets and insecticide are either m
The pricing and procurement of antiretroviral drugs: an observational study of data from the Global Fund.
Supporting the use of artemisinin in combination.
Progress towards the development of malaria vaccines.
An act to provide assistance to foreign countries to combat HIV/AIDS, tuberculosis, and malaria, and for other purposes. Unit
Field-based evidence for linkage of mutations associated with chloroquine (pfcrt/pfmdr1) and sulfadoxine-pyrimethamine (pf
Niger welcomes largest bednet distribution in history.
The cost-effectiveness of improving malaria home management: shopkeeper training in rural Kenya.
Costing the distribution of insecticide-treated nets: a review of cost and cost-effectiveness studies to provide guidance on sta
Vaccination for vivax malaria: targeting the invaders.
Determinants of household health expenditure on western institutional health care.
Time for the World Bank to act on malaria.
Bioefficacy of Olyset nets against mosquitoes in India.
World Bank defends efforts to curb malaria.
[Influence of social perceptions and practices on the use of bednets in the malaria control programme in Ivory Coast (West Af
[Malaria: a medical and economic problem]
Production of the antimalarial drug precursor artemisinic acid in engineered yeast.
Malaria breakthrough raises spectre of drug resistance.
Habitat targeting for controlling aquatic stages of malaria vectors in Africa.
Modelling malaria control.
Putting the genie back in the bottle? Availability and presentation of oral artemisinin compounds at retail pharmacies in urba
Antiplasmodial marine natural products in the perspective of current chemotherapy and prevention of malaria: a review.
Mosquito transgenesis: what is the fitness cost?
Prevention of malaria during pregnancy in West Africa: policy change and the power of subregional action.
The costs of changing national policy: lessons from malaria treatment policy guidelines in Tanzania.
Malaria prevention in The Gambia: patterns of expenditure and determinants of demand at the household level.
Reaching the Abuja target for intermittent preventive treatment of malaria in pregnancy in African women: a review of progr
Operational response to malaria epidemics: are rapid diagnostic tests cost-effective?
Fever treatment and household wealth: the challenge posed for rolling out combination therapy for malaria.
Fighting tropical diseases.
Diagnosing infection levels of four human malaria parasite species by a polymerase chain reaction/ligase detection reaction f
Will a global subsidy of new antimalarials delay the emergence of resistance and save lives?
Evaluation of a rapid immunochromatographic test for diagnosis of kala-azar & post kala-azar dermal leishmaniasis at a tertia
Prevention of malaria using ITNs: potential for achieving the millennium development goals.
Malaria: burden of disease.
Household decision-making process and childhood cerebral malaria in The Gambia.
The G8 and global health: What now? What next?
The burden of malaria mortality among African children in the year 2000.
Evaluation of different methods for diagnosis of P. falciparum malaria.
New type of R and D cooperation spawns malaria drugs.
Thinking big about global health.
Comparison of the Paracheck-Pf test with microscopy, for the confirmation of Plasmodium falciparum malaria in Tanzania.
Treatment-seeking practices for malaria in pregnancy among rural women in Mukono district, Uganda.
Recco: recombination analysis using cost optimization.
Analysis of cost and effectiveness of pre-transfusion screening of donor blood and anti-malarial prophylaxis for recipients.
Exploiting the potential of vector control for disease prevention.
Ecologists can enable communities to implement malaria vector control in Africa.
Canada's doing a lot...but is it soon enough?
Infectious diseases. Tackling neglected diseases could offer more bang for the buck.
Therapeutic efficacy of chloroquine or amodiaquine in combination with sulfadoxine-pyrimethamine for uncomplicated falcip
Malaria quagmire.
Housing conditions and Plasmodium falciparum infection: protective effect of iron-sheet roofed houses.
Modelling distances travelled to government health services in Kenya.
Maternal use of insecticide-treated nets in the prevention of malaria among children under five years in Nyamira district, Ken
Insecticide-treated nets in the prevention of malaria.
Plasmodium falciparum infection and exoerythrocytic development in mice with chimeric human livers.
User charges in public health facilities in Tanzania: effect on revenues, quality of services and people's health-seeking behavio
Immune effector mechanisms in malaria.
Optimizing malarial epidemiological studies in areas of low transmission.
Wealth, mother's education and physical access as determinants of retail sector net use in rural Kenya.
Control of neglected tropical diseases: integrated chemotherapy and beyond.
Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria.
Real-time quantitative PCR with SYBR Green I detection for estimating copy numbers of nine drug resistance candidate genes
Taking away the sting of malaria.
Impact of imported malaria on the burden of disease in northeastern Venezuela.
Global Fund suspends grants to Burma.
Four malaria success stories: how malaria burden was successfully reduced in Brazil, Eritrea, India, and Vietnam.
"I thought it was only ordinary fever!" cultural knowledge and the micropolitics of therapy seeking for childhood febrile illnes
Beyond registration--measuring the public-health potential of new treatments for malaria in Africa.
Biotechnology may help thwart malaria.
Socio-economic inequity in demand for insecticide-treated nets, in-door residual house spraying, larviciding and fogging in Su
The economic value of an improved malaria treatment programme in Zambia: results from a contingent valuation survey.
Issues of measuring and improving the treatment of malaria in sub-Saharan Africa.
Culturally compelling strategies for behaviour change: a social ecology model and case study in malaria prevention.
Infectious diseases. Cracks in the first line of defense.
Sensitive and inexpensive molecular test for falciparum malaria: detecting Plasmodium falciparum DNA directly from heat-tre
Tackling malaria.
Preventing malaria in pregnancy: a study of perceptions and policy implications in Mukono district, Uganda.
Uganda is learning from its Global Fund grant suspension.
The use of biodiversity as source of new chemical entities against defined molecular targets for treatment of malaria, tubercu
Differences in willingness to pay for artemisinin-based combinations or monotherapy: experiences from the United Republic
Human CD4+ T cells induced by synthetic peptide malaria vaccine are comparable to cells elicited by attenuated Plasmodium
Do malaria preventive interventions reach the poor? Socioeconomic inequities in expenditure on and use of mosquito contro
Use and misuse of a discount voucher scheme as a subsidy for insecticide-treated nets for malaria control in southern Tanzan
Chloroquine-treatment failure in northern Ghana: roles of pfcrt T76 and pfmdr1 Y86.
Epidemiology, therapeutic agents and cost of management of paediatric malaria in a Nigerian tertiary hospital.
Global Fund withdraws grants to Myanmar.
Cost effectiveness analysis of strategies to combat malaria in developing countries.
The double burden of communicable and non-communicable diseases in developing countries.
Gates leads on malaria funding.
Betting on a malaria vaccine.
Integrating insecticide-treated bednets into a measles vaccination campaign achieves high, rapid and equitable coverage with
Malaria prevention practices in Mopti region, Mali.
Artemisinin-based combinations.
Reducing the burden of malaria in different eco-epidemiological settings with environmental management: a systematic revie
Haemoglobin E beta thalassaemia in Sri Lanka.
Research influence on antimalarial drug policy change in Tanzania: case study of replacing chloroquine with sulfadoxine-pyrim
[Malaria prophylaxis for long-term travellers and expatriates]
Adherence to travel health guidelines: the experience of Nigerian immigrants in Houston, Texas.
Diagnosis of invasive pneumococcal disease among children in Kenya with enzyme-linked immunosorbent assay for immunog
Carriage of chloroquine-resistant parasites and delay of effective treatment increase the risk of severe malaria in Gambian ch
Stroke in Latin America.
Barriers to uptake and adherence with malaria prophylaxis by the African community in London, England: focus group study.
[The state of research in French-speaking Africa]
Ascribing quantitative value to community participation: a case study of the Roll Back Malaria (RBM) initiative in five African c
Is malaria a disease of poverty? A review of the literature.
Advanced purchase commitments for a malaria vaccine.
Opinion: do we have the architecture for health aid right? Increasing global aid effectiveness.
Malaria: new diagnostics for an old problem.
How can we achieve and maintain high-quality performance of health workers in low-resource settings?
Transposable element insertion location bias and the dynamics of gene drive in mosquito populations.
Artemisinin-based combination treatment for malaria in Africa: no perfect solutions.
Rapid urban malaria appraisal (RUMA) in sub-Saharan Africa.
Global Fund pulls grants to Myanmar and Uganda.
A comparison of case-control and family-based association methods: the example of sickle-cell and malaria.
Molecular diagnosis of inherited disorders: lessons from hemoglobinopathies.
Economic evaluation of a policy change from single-agent treatment for suspected malaria to artesunate-amodiaquine for mi
Optimal life stage for radiation sterilization of Anopheles males and their fitness for release.
Infectious diseases. Global fund pulls Myanmar grants.
Magnitude of malaria admissions and deaths at hospitals and health centers in Oromia, Ethiopia.
First global report on effort to Roll Back Malaria highlights progress and challenges.
Evaluation of the polymerase chain reaction analysis for diagnosis of falciparum malaria in Delhi, India.
Artemisinin-based combination therapies (ACTs): best hope for malaria treatment but inaccessible to the needy!
Africa focus raises malaria funds.
Public-private partnership: from there to here.
Who needs drug prophylaxis against malaria? My personal view.
Current drug development portfolio for antimalarial therapies.
Real-time quantitative PCR for determining the burden of Plasmodium falciparum parasites during pregnancy and infancy.
Simultaneous detection of microsatellite repeats and SNPs in the macrophage migration inhibitory factor (MIF) gene by thin-f
Untangling the debate surrounding strategies for achieving sustainable high coverage of insecticide-treated nets.
[Evaluation of prescriptions for inpatient treatment of malaria and gastroenteritis: Bondeko and St Joseph hospitals in Kinsha
Malaria dogs African hopes.
Should chloroquine be laid to rest?
Biology-based mapping of vector-borne parasites by Geographic Information Systems and Remote Sensing.
Proteome composition in Plasmodium falciparum: higher usage of GC-rich nonsynonymous codons in highly expressed genes
Brands, costs and registration status of antimalarial drugs in the Kenyan retail sector.
Creating an "enabling environment" for taking insecticide treated nets to national scale: the Tanzanian experience.
Live attenuated measles vaccine as a potential multivalent pediatric vaccination vector.
Drug resistance hampers our capacity to roll back malaria.
Increasing coverage of insecticide-treated nets in rural Nigeria: implications of consumer knowledge, preferences and expend
Rapid increase in resistance of Plasmodium falciparum to chloroquine-Fansidar in Uganda and the potential of amodiaquine-F
Critically ill obstetric patients in an American and an Indian public hospital: comparison of case-mix, organ dysfunction, intens
Social science research in malaria prevention, management and control in the last two decades: an overview.
Anopheles infection responses; laboratory models versus field malaria transmission systems.
The current status and potential role of laboratory testing to prevent transfusion-transmitted malaria.
Making antimalarial agents available in Africa.
[Malaria chemoprophylaxis in 2005: new policy, new drugs]
Child health in Africa: 2005 a year of hope?
Financial costs of deworming children in all primary schools in Cambodia.
Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
Economic impact of dengue fever/dengue hemorrhagic fever in Thailand at the family and population levels.
Rapid malaria screening and targeted treatment of United States-bound Montagnard refugees from Cambodia in 2002.
Community-based surveillance: a pilot study from rural Cambodia.
Malaria infection among pregnant women attending antenatal clinics in six Rwandan districts.
The Global Fund at three years--flying in crowded air space.
Malaria vaccines. Evaluation and implementation.
Gaps in policy-relevant information on burden of disease in children: a systematic review.
A randomized, placebo-controlled, double-blind trial on sulfadoxine-pyrimethamine alone or combined with artesunate or am
[Treating malaria for less than one dollar]
New malaria combination cheaper and easier to take.
The impact of antimalarial drug resistance mutations on parasite fitness, and its implications for the evolution of resistance.
Zambia to wage 'scientific' war on malaria.
Uncovering the molecular mode of action of the antimalarial drug atovaquone using a bacterial system.
Evaluation of malaria parasite screening procedures among Sudanese blood donors.
The epidemiology of patients with severe malaria who died at the Hospital for Tropical Diseases, 1991-2004.
US aid agency grilled over malaria funds.
Drug resistance models for malaria.
New combination drug to treat malaria.
The costs and effects of a nationwide insecticide-treated net programme: the case of Malawi.
Cost effective treatment of acute, uncomplicated Plasmodium falciparum malaria.
Gender and willingness to pay for insecticides treated bed nets in a poor rural area in Tanzania.
Malaria.
Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for o
Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodiu
Altitude-dependent and -independent variations in Plasmodium falciparum prevalence in northeastern Tanzania.
Prophylaxis against rabies.
Emerging infectious diseases: a 10-year perspective from the National Institute of Allergy and Infectious Diseases.
Efficacy comparison between anti-malarial drugs in Africans presenting with mild malaria in the Central Republic of Africa: a p
[Italian state's quinine laws: the role of Giustino Fortunato and Angelo Celli. An introduction to the paper by Anna Celli "La lot
The Rockefeller Foundation and the prevention of malaria in Corsica, 1923-1951: support given to the French parasitologist E
Willingness to pay for hypothetical malaria vaccines in rural Burkina Faso.
Moving towards true integration.
The financial burden of malaria in Tanzania: implications for future government policy.
Distributing insecticide-treated bednets during measles vaccination: a low-cost means of achieving high and equitable covera
Deficiencies in disaster funding: malaria epidemics are predicted in tsunami regions from El Niño conditions.
A piece of my mind. Jambo, Jahi.
Evaluating a malaria intervention strategy using knowledge, practices and coverage surveys in rural Bolifamba, southwest Cam
Severe malaria: still counting the costs.
Short report: Rapid DNA extraction from archive blood spots on filter paper for genotyping of Plasmodium falciparum.
The global distribution of clinical episodes of Plasmodium falciparum malaria.
Direct health costs of occupationally acquired malaria in a military population in Europe.
Evidence base for interventions in complex emergencies.
Comparison of three larviciding options for malaria vector control.
Household survey of treatment of malaria in Hajjah, Yemen.
Recent advances in research and control of malaria, leishmaniasis, trypanosomiasis and schistosomiasis.
[Evaluation of direct costs of child severe malaria management at the general hospital of Bonoua, Côte-d'Ivoire]
Artemisinin-based combination therapies for uncomplicated malaria.
Economic access to effective drugs for falciparum malaria.
Combination drug policy for malaria.
Combination drug policy for malaria.
From the core to the peripheries: multilateral governance of malaria in a multi-cultural world.
Mefloquine increases the risk of serious psychiatric events during travel abroad: a nationwide case-control study in the Nethe
Shortfall in front-line antimalarial drug likely in 2005.
Socio-economic and geographic differentials in costs and payment strategies for primary healthcare services in Southeast Nig
Costs of scaling up health interventions: a systematic review.
pfmdr1 mutations associated with chloroquine resistance incur a fitness cost in Plasmodium falciparum.
Malaria control through municipalities in the Philippines: struggling with the mandate of decentralized health programme ma
Political analysis of rapid change in Uganda's health financing policy and consequences on service delivery for malaria control
Inequity in the Bamako Initiative programme--implications for the treatment of malaria in south-east Nigeria.
The impact of user fee exemption on service utilization and treatment seeking behaviour: the case of malaria in Sudan.
Evidence basis for antimalarial policy change in Sierra Leone: five in vivo efficacy studies of chloroquine, sulphadoxine-pyrime
A new model for child survival in Africa.
Follow-up studies after withdrawal of deltamethrin spraying against Anopheles culicifacies and malaria incidence.
Health and poverty: a new Marshall plan?
An online operational rainfall-monitoring resource for epidemic malaria early warning systems in Africa.
[The PAL+ program, an incentive concerted action about malaria and associated infectious diseases, for developing countries
[Malaria in the emergency room. Results of the emergency treatment of 137 patients with symptomatic malaria]
Experience of targeting subsidies on insecticide-treated nets: what do we know and what are the knowledge gaps?
The disease profile of poverty: morbidity and mortality in northern Uganda in the context of war, population displacement an
Ethnomedicine in malaria treatment.
Global Fund gives go-ahead for new grants.
Filling the vaccine gap.
HIV, malaria and beyond: reducing the disease burden of female adolescents.
Drive to produce more long-lasting insecticidal mosquito nets for malaria.
Infectious diseases. Source of new hope against malaria is in short supply.
Rapid and inexpensive method of diluting Giemsa stain for diagnosis of malaria and other infestations by blood parasites.
Preferences for hospital quality in Zambia: results from a discrete choice experiment.
Piperaquine: a resurgent antimalarial drug.
A systems approach to malaria control: an institutional perspective.
Costs to the patient for seeking malaria care in Myanmar.
Prevalence of pfcrt mutations in Congolese and Malawian Plasmodium falciparum isolates as determined by a new Taqman a
World Bank reducing funds to fight malaria.
Participation of African social scientists in malaria control: identifying enabling and constraining factors.
Malaria misdiagnosis: effects on the poor and vulnerable.
Aggressive active case detection: a malaria control strategy based on the Brazilian model.
Do divergences between stated and actual willingness to pay signify the existence of bias in contingent valuation surveys?
Globalization and infectious diseases in women.
Inulin-derived adjuvants efficiently promote both Th1 and Th2 immune responses.
Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate.
To prevent, react, and rebuild: health research and the prevention of genocide.
Expression of an immunologically reactive merozoite surface protein (MSP-1(42)) in E. coli.
The European and developing countries clinical trails partnership.
The economics of social marketing: the case of mosquito nets in Tanzania.
HIV/AIDS, hunger and malaria are the world's most urgent problems, say economists.
Malaria. A complex new vaccine shows promise.
[European region program--"Roll Back Malaria": its results and prospects for its control]
Mosquito nets and the poor: can social marketing redress inequities in access?
Synthetic antimalaria drug enters clinical trials.
Orally delivered malaria vaccines: not too hard to swallow.
The process of changing national malaria treatment policy: lessons from country-level studies.
Pediatric acute renal failure in southwestern Nigeria.
A method for cross-sector priority setting. Gaps and hypotheses in malaria research: Tanzania.
Prevention of mosquito nuisance among urban populations in Burkina Faso.
Accounting for the cost of scaling-up health interventions.
Inter-rater and test-retest reliability of three contingent valuation question formats in south-east Nigeria.
The Global Fund's principal recipients... or neglected partners.
Evaluation of the rapid diagnostic test OptiMAL for diagnosis of malaria due to Plasmodium vivax.
Artemisinin-based combination therapy reduces expenditure on malaria treatment in KwaZulu Natal, South Africa.
Thalassemia in Sri Lanka: a progress report.
The intolerable burden of malaria: what's new, what's needed. Proceedings of the Third Pan-African MIM Conference. Novem
Tying up lions: multilateral initiative on malaria communications: the first chapter of a malaria research network in Africa.
Policy challenges in malaria vaccine introduction.
Monitoring future impact on malaria burden in sub-saharan Africa.
A threshold analysis of the cost-effectiveness of artemisinin-based combination therapies in sub-saharan Africa.
Act now or later? Economics of malaria resistance.
Antimalarial drug resistance, artemisinin-based combination therapy, and the contribution of modeling to elucidating policy c
Public and private roles in malaria control: the contributions of economic analysis.
Providing practical estimates of malaria burden for health planners in resource-poor countries.
The social burden of malaria: what are we measuring?
The economic burden of illness for households in developing countries: a review of studies focusing on malaria, tuberculosis,
The malaria gap.
The burden of malaria epidemics and cost-effectiveness of interventions in epidemic situations in Africa.
A review of the clinical and epidemiologic burdens of epidemic malaria.
Describing the burden of malaria on child development: what should we be measuring and how should we be measuring it?
The burden of the neurocognitive impairment associated with Plasmodium falciparum malaria in sub-saharan Africa.
Undernutrition as an underlying cause of malaria morbidity and mortality in children less than five years old.
Reducing the burden of anemia in infants and young children in malaria-endemic countries of Africa: from evidence to action
Pediatric mortality in Africa: plasmodium falciparum malaria as a cause or risk?
Conquering the intolerable burden of malaria: what's new, what's needed: a summary.
Chloroquine and hydroxychloroquine as inhibitors of human immunodeficiency virus (HIV-1) activity.
Winning the drugs war.
Strength in unity.
The long and winding road.
Struggling to make an impact.
Where did it all go wrong?
An attack on all fronts.
Power to the people.
Between hope and a hard place.
Plague of my people.
Identification of an antimalarial synthetic trioxolane drug development candidate.
Virulence in malaria: an evolutionary viewpoint.
[Combined antimalarial therapy using artemisinin]
[New drugs for the treatment of human parasitic protozoa]
Averting a malaria disaster in Africa--where does the buck stop?
Global fund switches to artemisinin.
Severe malaria in the under-fives--clinical featrues, management and outcome in a district hospital.
"Cellular astronomy"--a foreseeable future in cytometry.
Why the world needs another malaria initiative.
The educative impact of health care treatment on malarial prevention behavior for the poor in Guinea, West Africa.
A study of malaria care provider choice in Ghana.
Goat serum: an alternative to fetal bovine serum in biomedical research.
Measuring urbanization pattern and extent for malaria research: a review of remote sensing approaches.
The operation, quality and costs of a district hospital laboratory service in Malawi.
Predictors of the quality of health worker treatment practices for uncomplicated malaria at government health facilities in Ke
Profile of and control measures for paediatric discharges against medical advice.
Aid agencies predict victory for HIV unless cash crisis is solved.
Community chloroquine distribution for malaria control in Bushenyi district of Uganda.
Mosquito--malaria interactions: a reappraisal of the concepts of susceptibility and refractoriness.
Impact of increasing consultation fees on malaria in Africa.
Malaria and money.
The Global Fund: managing great expectations.
The Global Fund to Fight AIDS, Tuberculosis and Malaria: funding for unpopular public-health programmes.
Is combination therapy for malaria based on user-fees worthwhile and equitable to consumers? Assessment of costs and will
Determinants of health-seeking behaviour for schistosomiasis-related symptoms in the context of integrating schistosomiasis
Evaluation of Olyset insecticide-treated nets distributed seven years previously in Tanzania.
Newer drug combinations for malaria.
Description of the transcriptomes of immune response-activated hemocytes from the mosquito vectors Aedes aegypti and Ar
Estimating resource needs for HIV/AIDS health care services in low-income and middle-income countries.
Approaches to treating malarial anaemia.
Aging and infectious diseases in the developing world.
Socio-economic differences and health seeking behaviour for the diagnosis and treatment of malaria: a case study of four loc
Clinton Foundation negotiates $140/Year HIV treatment, but U.S. won't buy.
Assessment of inpatient paediatric care in first referral level hospitals in 13 districts in Kenya.
Subsidized sales of insecticide-treated nets in Afghan refugee camps demonstrate the feasibility of a transition from humanit
Fighting AIDS is best use of money, says cost-benefit analysis.
Global fund changes tack on malaria therapy.
Global fund signs major new AIDS and TB grants for India.
Osteoporosis and the global competition for health care resources.
Community based trials and informed consent in rural north India.
Mosquito appetite for blood is stimulated by Plasmodium chabaudi infections in themselves and their vertebrate hosts.
Cost-effectiveness of malaria control interventions when malaria mortality is low: insecticide-treated nets versus in-house res
Mass use of insecticide-treated bednets in malaria endemic poor countries: public health concerns and remedies.
Parallel synthesis and antimalarial screening of a 4-aminoquinoline library.
WHO uses Malaria Day to promote ACTs.
Linking disease control programmes in rural Africa: a pro-poor strategy to reach Abuja targets and millennium development g
Health agencies end in-fighting on malaria.
Roll Back Malaria: a failing global health campaign.
Stated and actual altruistic willingness to pay for insecticide-treated nets in Nigeria: validity of open-ended and binary with fo
A comparison of prescribing practices between public and private sector physicians in Uganda.
[Post-transfusion malaria: is the risk irreconciliable with biological silence?]
Insecticide treated nets: impact on vector populations and relevance of initial intensity of transmission and pyrethroid resista
The Global Fund and effective malaria treatment.
Novel, rapid, and inexpensive cell-based quantification of antimalarial drug efficacy.
Microsample preparation by dielectrophoresis: isolation of malaria.
Valuing the benefits of a health intervention using three different approaches to contingent valuation: re-treatment of mosqu
Rethinking medical ethics: a view from below.
Fitness of anopheline mosquitoes expressing transgenes that inhibit Plasmodium development.
Response to accusations of medical malpractice by WHO and the Global Fund.
Response to accusations of medical malpractice by WHO and the Global Fund.
WHO, the Global Fund, and medical malpractice in malaria treatment.
WHO, the Global Fund, and medical malpractice in malaria treatment.
WHO, the Global Fund, and medical malpractice in malaria treatment.
WHO, the Global Fund, and medical malpractice in malaria treatment.
Coupling ecology and evolution: malaria and the S-gene across time scales.
Does reducing malaria improve household living standards?
Efficacy of sulphadoxine-pyrimethamine alone or combined with amodiaquine or chloroquine for the treatment of uncomplic
Malaria incidence in rural Benin: does economics matter in endemic area?
Molecular epidemiology of malaria in Cameroon. XIX. Quality of antimalarial drugs used for self-medication.
Epidemiology of malaria in a hypoendemic Brazilian Amazon migrant population: a cohort study.
Inequalities in purchase of mosquito nets and willingness to pay for insecticide-treated nets in Nigeria: challenges for malaria
A heterogeneous enzymatic assay for quantification of Plasmepsin II activity and the evaluation of its inhibitors.
Artesunate combinations for malaria.
A cost analysis of the use of the rapid, whole-blood, immunochromatographic P.f/P.v assay for the diagnosis of Plasmodium v
Combating tropical infectious diseases: report of the Disease Control Priorities in Developing Countries Project.
Australia's contribution to global health fund provokes dismay.
[Intervention against malaria requires international solidarity. Institutions and drug industry should find new forms of collabo
A cost analysis of the employer-based bednet programme in Coastal and Western Kenya.
Antimalarial activity of phenazines from lapachol, beta-lapachone and its derivatives against Plasmodium falciparum in vitro a
The Global TB Drug Facility: innovative global procurement.
Comparative field evaluation of the Mbita trap, the Centers for Disease Control light trap, and the human landing catch for sa
Evolutionary relationships, cospeciation, and host switching in avian malaria parasites.
Financing to Global Fund slashed by the Bush administration.
The cost-effectiveness of screening blood donors for malaria by PCR.
[Management of children with sickle cell disease in Africa: experience in a cohort of children at the Royal Albert Hospital in Da
[Malaria during pregnancy: consequences and interventional perspectives]
The burden of malaria in Ahmedabad city, India: a retrospective analysis of reported cases and deaths.
WHO, the Global Fund, and medical malpractice in malaria treatment.
Childhood morbidity and treatment pattern at the multipurpose health centre, Ilesa, Nigeria.
A malaria risk analysis in an irrigated area in Sri Lanka.
Does irrigated urban agriculture influence the transmission of malaria in the city of Kumasi, Ghana?
Opportunities and limiting factors of intensive vegetable farming in malaria endemic Côte d'Ivoire.
Engineering and malaria control: learning from the past 100 years.
The cost and cost-effectiveness of malaria vector control by residual insecticide house-spraying in southern Mozambique: a r
Burden and cost of imported infections admitted to infectious diseases units in England and Wales in 1998 and 1999.
Antimalarial drug toxicity: a review.
Military aviators, special operations forces, and causal malaria prophylaxis.
Hopes that Novartis deal on tuberculosis will spur donations for HIV and malaria.
An affordable antimalarial.
A cost-effectiveness analysis of three antimalarial treatments for acute, uncomplicated Plasmodium falciparum malaria in Mu
Efficacy of mosquito nets treated with insecticide mixtures or mosaics against insecticide resistant Anopheles gambiae and Cu
Ethiopia faces severe malaria epidemic. WHO predicts 15 million people could be infected.
Operational feasibility and bio-efficacy of alphacypermethrin (Fendona) treated jute curtains to control urban malaria in a slu
Developing-world health: the fightback starts here.
Virtual drug discovery and development for neglected diseases through public-private partnerships.
Gates Foundation takes "reality-driven" vision to the field.
District health systems in a neoliberal world: a review of five key policy areas.
Criterion and content validity of a novel structured haggling contingent valuation question format versus the bidding game an
The use of formal and informal curative services in the management of paediatric fevers in four districts in Kenya.
Socio-economic factors associated with the purchasing of insecticide-treated nets in Afghanistan and their implications for so
Malaria researchers say global fund is buying "useless drug".
Field efficacy of thermally expelled or live potted repellent plants against African malaria vectors in western Kenya.
Use of bednets given free to pregnant women in Kenya.
Is it feasible to give insecticide-treated bednets free to pregnant women?
Struggling Global Fund approves grants for HIV, TB, and malaria. But board meeting is marred by warnings about shortfalls an
The relationship between prevention of mother to child transmission of HIV and stakeholder decision making in Uganda: imp
Isoquine and related amodiaquine analogues: a new generation of improved 4-aminoquinoline antimalarials.
Common themes in changing vector-borne disease scenarios.
The silent burden of anaemia in Tanzanian children: a community-based study.
Philanthropic gifts for health: the stage is set.
In praise of Gates.
Home treatment of 'malaria' in children in rural Gambia is uncommon.
Rapid diagnostic testing for malaria.
The Pediatric Economic Database Evaluation (PEDE) Project: establishing a database to study trends in pediatric economic eva
Household expenditure on malaria case management in Wad-Medani, Sudan.
Real-time quantitative PCR for analysis of genetically mixed infections of malaria parasites: technique validation and applicati
Evaluation of a rapid immunochromatographic card test for Plasmodium falciparum in Ibadan, Nigeria.
Gates steps up war on malaria with donation of 168 million dollars.
Recombinant bacteria for mosquito control.
Antimalarial drug discovery: old and new approaches.
Estimating HIV prevalence and the impact of HIV/AIDS on a Ugandan hospital by combining serosurvey data and hospital disc
Progress in the development of a recombinant vaccine for human hookworm disease: the Human Hookworm Vaccine Initiativ
Cooperative actions to achieve malaria control without the use of DDT.
Determining cost-effectiveness and cost component of three malaria diagnostic models being used in remote non-microscop
Trends in malaria chemoprophylaxis prescription in South Africa 1994 to 2000.
World Trade Organization finally agrees cheap drugs deal.
Performance of forecasting, warning and detection of malaria epidemics in the highlands of western Kenya.
New malaria drug to be unveiled in Africa.
Malaria control in a forest camp in an oil exploration area of Upper Assam.
Despite boost from U.S., Global Fund faces a struggle.
Infectious diseases, non-zero-sum thinking, and the developing world.
Drug company to offer new malaria drug cheaply in Africa.
Who buys insecticide-treated nets? Implications for increasing coverage in Nigeria.
Estimating the needs for artesunate-based combination therapy for malaria case-management in Africa.
Scaling-up and sustaining insecticide-treated net coverage.
Scaling-up and sustaining insecticide-treated net coverage.
Tropical disease vaccines.
Emerging issues in vaccine economics: perspectives from the USA.
Exoerythrocytic malaria vaccine development: understanding host-parasite immunobiology underscores strategic success.
Health and equity impacts of a large oil project in Africa.
EU commits $1bn to global fund.
Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indon
Vaccine news, March 2, 2000.
A model for the coevolution of immunity and immune evasion in vector-borne diseases with implications for the epidemiolog
Evidence on the use of paracetamol in febrile children.
A rapid assessment approach for public health decision-making related to the prevention of malaria during pregnancy.
Current strategies to avoid misdiagnosis of malaria.
[DNA vaccines]
Wait of the world falls on Bush's ambitious AIDS plan.
Vendor-to-vendor education to improve malaria treatment by private drug outlets in Bungoma District, Kenya.
Malaria dipsticks beneficial for IMCI in Cambodia.
Safety, efficacy and determinants of effectiveness of antimalarial drugs during pregnancy: implications for prevention program
Roll back malaria? The scarcity of international aid for malaria control.
A single agenda needed for malaria.
Beliefs and traditional treatment of malaria in Kishe settlement area, southwest Ethiopia.
No deal in sight on cheap drugs for poor countries.
Cost-effectiveness of social marketing of insecticide-treated nets for malaria control in the United Republic of Tanzania.
Are statistical contributions to medicine undervalued?
Avoiding misdiagnosis of imported malaria: screening of emergency department samples with thrombocytopenia detects clin
The contribution of clinical pharmacology to antimalarial drug discovery and development.
Willingness to pay and determinants of choice for improved malaria treatment in rural Nepal.
Malaria and property accumulation in rice production systems in the savannah zone of Côte d'Ivoire.
Quality and comparison of antenatal care in public and private providers in the United Republic of Tanzania.
The cost-effectiveness of permethrin-treated bed nets in an area of intense malaria transmission in western Kenya.
The household-level economics of using permethrin-treated bed nets to prevent malaria in children less than five years of age
Targeted subsidy for malaria control with treated nets using a discount voucher system in Tanzania.
Money being wasted in fight against malaria, says MSF.
Roll Back Malaria campaign still has a long way to go.
Scaling-up coverage with insecticide-treated nets against malaria in Africa: who should pay?
[Malaria]
Developing drugs for parasitic diseases.
[Iron supplementation associated with malaria prevention among pregnant women in Abidjan]
Problems in prescribing malaria chemoprophylaxis for travelers.
The new drug combinations: their place in the treatment of uncomplicated Plasmodium falciparum malaria.
The mechanisms of resistance to antimalarial drugs in Plasmodium falciparum.
The effect on haemoglobin of the use of iron cooking pots in rural Malawian households in an area with high malaria prevalen
Metalloantimalarials: targeting of P. falciparum strains with novel iron(III) and gallium(III) complexes of an amine phenol ligan
Euro MPs vote on research fund for neglected diseases.
Epidemiological models for the spread of anti-malarial resistance.
Comparative efficacy of aminoquinoline-antifolate combinations for the treatment of uncomplicated falciparum malaria in Ka
Social and health determinants of the efficiency of cotton farmers in Northern Côte d'Ivoire.
Immunity to liver stage malaria: considerations for vaccine design.
Hospital costs of high-burden diseases: malaria and pulmonary tuberculosis in a high HIV prevalence context in Zimbabwe.
The influence of healthcare facilities on malarial mortality in and around Rourkela, India.
Perspectives. Bush health agenda: less than meets the eye.
The development of Lapdap, an affordable new treatment for malaria.
[Association between reported annual gold mining extraction and incidence of malaria in Mato Grosso-Brazil, 1985-1996]
[Vaccines against poverty]
What can be done about the private health sector in low-income countries?
Current and emerging infectious risks of blood transfusions.
Impact of genetic manipulation on the fitness of Anopheles stephensi mosquitoes.
Involving the general public in priority setting: experiences from Australia.
Early treatment of childhood fevers with pre-packaged antimalarial drugs in the home reduces severe malaria morbidity in Bu
[Cost-effectiveness analysis of the current measures for malaria prevention in Yuanjiang valley, Yunnan province]
The contribution of health-care services to a sound and sustainable malaria-control policy.
Rapid assessment procedures of malaria in low endemic countries: community perceptions in Jepara district, Indonesia.
Gates ploughs millions into plan for assault on killer diseases.
Acridine Orange for malaria diagnosis: its diagnostic performance, its promotion and implementation in Tanzania, and the im
Malaria control in complex emergencies: the example of East Timor.
Therapeutic efficacy of chloroquine plus sulphadoxine/ pyrimethamine compared with monotherapy with either chloroquine
Gates, GAVI, the glorious global funds and more: all you ever wanted to know.
Feasibility and limitations of acridine orange fluorescence technique using a Malaria Diagnosis Microscope in Myanmar.
Malaria after the genome.
The global impact of drug resistance.
[GlaxoSmithKline again lowers prices of drugs for HIV/AIDS and malaria]
Joint European plan will tackle Africa's killer diseases.
A new method for culturing Plasmodium falciparum shows replication at the highest erythrocyte densities.
Bridging sectors. Medicon Valley.
Examining the determinants of mosquito-avoidance practices in two Kenyan cities.
Evolutionary ideas about genetically manipulated mosquitoes and malaria control.
How will the reduction of tariffs and taxes on insecticide- treated bednets affect household purchases?
Malaria vaccines: orphans in transition.
How the research-based industry approaches vaccine development and establishes priorities.
Evaluation of the Integrated Management of Childhood Illness guidelines for treatment of intestinal helminth infections amon
[Aetiologic factors and clinical features associated with thrombocytopenia in Cameroonese adults: the importance of Plasmo
Community cooperatives and insecticide-treated materials for malaria control: a new experience in Latin America.
The economic impact of malaria in Africa: a critical review of the evidence.
Malaria vaccines: where are we and where are we going?
Rejuvenating health systems for aging communities.
Novel cost-effective method of screening soils for the presence of mosquito-pathogenic bacilli.
Malaria control: constraints and opportunities.
Increasing antimalarial drug resistance in Uganda and revision of the national drug policy.
Editorial: Malaria investments and activities: it is now! or never?
Malaria initiative cries out for action in Africa.
Fighting malaria from the front.
Report of the WHO Commission on Macroeconomics and Health: a critique.
New strategies for the diagnosis and screening of malaria.
Willingness to pay for treated mosquito nets in Surat, India: the design and descriptive analysis of a household survey.
Towards a malaria vaccine for Papua New Guinea.
Investigating starting-point bias: a survey of willingness to pay for insecticide-treated nets.
Mosquito-net makers forced to renege on zero-VAT policy.
Visiting the virus veteran. Interview by Philip Siekman.
Global Fund faces uncertain future as cash runs low.
Effects of early cerebral malaria on cognitive ability in Senegalese children.
Malaria after the genomes.
HHS details leading HIV/AIDS physician to Gates foundation.
Atovaquone + proguanil: new preparation. Second-line antimalarial combination.
Interdisciplinary malaria vector research and training for Africa.
How useful is PCR in the diagnosis of malaria?
The impact of 9/11 on HIV/AIDS care in Africa and the Global Fund to Fight AIDS, Tuberculosis, and Malaria.
The grand assault.
What difference does a genome make?
A new global effort to control malaria.
An elegant but imperfect tool.
Evolutionary and historical aspects of the burden of malaria.
Too poor to pay: charging for insecticide-treated bednets in highland Kenya.
Prevention of malaria in Afghanistan through social marketing of insecticide-treated nets: evaluation of coverage and effectiv
Will the Global Fund help roll back malaria in Africa?
WHO outlines three-pronged attack against AIDS epidemic.
Roll Back Malaria: spotlight on Africa.
TDR at the interface of research and control.
Personal protection against mosquitoes in Dar es Salaam, Tanzania, by using a kerosene oil lamp to vaporize transfluthrin.
Hemofiltration and peritoneal dialysis in infection-associated acute renal failure in Vietnam.
WHO awarded US$ 1.5 million to test new treatment for malaria.
U.S. to withhold $34 million in funds for U.N. AIDS, population control.
A cost comparison of two malaria control methods in Kyunggi Province, Republic of Korea, using remote sensing and geograp
In vitro reversal of chloroquine resistance in Plasmodium falciparum with dihydroethanoanthracene derivatives.
Clinical significance of the cytochrome P450 2C19 genetic polymorphism.
Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development.
Cost of malaria control in China: Henan's consolidation programme from community and government perspectives.
Initiating malaria control programs in the third world: directives for short- and long-term solutions.
Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant.
Reduced levels of chloroquine resistant Plasmodium falciparum in selected foci of the South West Province, Cameroon.
Impact of health care financing reforms on the management of malaria in Ghana.
Malaria vaccines.
Design and selection of vaccine adjuvants: animal models and human trials.
Avoiding the genomics divide.
Unit costs for house spraying and bednet impregnation with residual insecticides in Colombia: a management tool for the con
Operational aspects of insecticide treated nets for malaria control in Assam.
Molecular analysis of ancient microbial infections.
The economic payoffs of integrated malaria control in the Zambian copperbelt between 1930 and 1950.
Field evaluation of the ICT Malaria Pf/Pv immunochromatographic test for the detection of asymptomatic malaria in a Plasmo
Origins and subsequent development of the Istituto Superiore di Sanità in Rome (Italy).
Research that influences policy and practice - characteristics of operational research to improve malaria control in Mpumalan
Cross-species infection of blood parasites between resident and migratory songbirds in Africa.
Epidemic malaria in the Menoreh Hills of Central Java.
The emergence of global disease control priorities.
Global Fund director admits to $8bn shortfall.
Mutations in cytochrome b resulting in atovaquone resistance are associated with loss of fitness in Plasmodium falciparum.
[Treatment of cerebral malaria in African children by intravenous quinine: comparison of a loading dose regimen to a regimen
Editorial: Global Health Fund or Global Fund to fight AIDS, Tuberculosis, and Malaria?
Trends in antimalarial drugs prescribed in New Zealand 1993 to 1998.
APOC's strategy of community-directed treatment with ivermectin (CDTI) and its potential for providing additional health ser
What can be done about the private health sector in low-income countries?
Bush asked for $200 million more for global disease fund.
Malaria vaccine trials.
A theoretical approach to predicting the success of genetic manipulation of malaria mosquitoes in malaria control.
Basic amenities and health in urban India.
HIV prevention before HAART in sub-Saharan Africa.
Needle stick injuries: nurses at risk.
Malaria in pregnancy. 1: Physiological effects on the mother.
The HIV/AIDS epidemic in Africa: implications for U.S. policy.
Parasitic infestation in children.
A comparative cost analysis of insecticide-treated nets and indoor residual spraying in highland Kenya.
People's perception of malaria in Mbarara, Uganda.
Malaria control reinvented: health sector reform and strategy development in Colombia.
Free bednets to pregnant women through antenatal clinics in Kenya: a cheap, simple and equitable approach to delivery.
Alternative insecticides: an urgent need.
Global Fund for AIDS, TB and malaria opens shop.
Free insecticide for nets is cost effective.
[Molecular identification of sibling Anopheles species: example of the Anopheles minimus and Anopheles dirus complexes, m
Global voices on HIV/AIDS. Important facts about global fund were missed.
Clinical signs and symptoms in the assessment of immunodeficiency in men with subtype C HIV infection in Harare, Zimbabwe
Allegations of rushed proposals mar disease fund's first awards.
Malaria transmission risk variations derived from different agricultural practices in an irrigated area of northern Tanzania.
An outbreak of Plasmodium falciparum malaria due to Anopheles minimus in central Assam, India.
Cross-sectional study of morbidity, morbidity-associated factors and cost of treatment in Ngaoundere, Cameroon, with implic
Malaria prevention in highland Kenya: indoor residual house-spraying vs. insecticide-treated bednets.
Poverty and malaria: a study in a Thai-Myanmar border area.
Adapting immunity with subunit vaccines: case studies with group A Streptococcus and malaria.
Multiplexed immunoassays by flow cytometry for diagnosis and surveillance of infectious diseases in resource-poor settings.
New antimalarial promises cheap and effective treatment.
An economic comparison of chloroquine and sulfadoxine-pyrimethamine as first-line treatment for malaria in South Africa: de
Malaria control: achievements, problems and strategies.
Socio-economic factors associated with malaria in a tribal area of Orissa, India.
Community factors associated with malaria prevention by mosquito nets: an exploratory study in rural Burkina Faso.
Are we there yet? The road to a malaria vaccine.
[Noma in children in a hospital environment in Bobo-Dioulasso: epidemiologic, clinical and management aspects]
Clinical status and implications of antimalarial drug resistance.
Introduction. Antimalarial drug resistance: ramifications, explanations and challenges.
WHO: world may be mobilizing for battle against HIV/AIDS.
Modern chemotherapeutic options for malaria.
European trial platform for AIDS, malaria, and tuberculosis.
The global HIV/AIDS pandemic, structural inequalities, and the politics of international health.
Lariam's legacy.
Are the costs correct?
Tackle infectious disease to help the poor, says WHO.
Malaria in pregnancy in rural Mozambique: the role of parity, submicroscopic and multiple Plasmodium falciparum infections
Oral artesunate dose-response relationship in acute falciparum malaria.
The cost of not treating bednets.
Altruistic willingness to pay in community-based sales of insecticide-treated nets exists in Nigeria.
Malaria control--two years' use of insecticide-treated bednets compared with insecticide house spraying in KwaZulu-Natal.
GAVI, the first steps: lessons for the Global Fund.
Global fund on AIDS, tuberculosis, and malaria holds first board meeting.
Examining out-of-pocket expenditure on health care in Nouna, Burkina Faso: implications for health policy.
Socially marketed insecticide-treated nets improve malaria and anaemia in pregnancy in southern Tanzania.
Laboratory and field comparisons of pyriproxyfen, polystyrene beads and other larvicidal methods against malaria vectors in
The economic and social burden of malaria.
Getting science into international aid.
Health care switching behaviour of malaria patients in a Kenyan rural community.
Demonstrating the validity of natural products as anti-infective drugs.
Pharmaceutical pricing in the developing world: issues of access to medicines.
Randomized comparison of quinine-clindamycin versus artesunate in the treatment of falciparum malaria in pregnancy.
International response to the HIV/AIDS epidemic: planning for success.
Economic advantage of a community-based malaria management program in the Brazilian Amazon.
Factors influencing the use of bed nets in Mbarara municipality of Uganda.
Community-based program for malaria case management in the Brazilian Amazon.
Rapid diagnostic tests for malaria parasites.
Portraits of science. Mosquitoes bite more than once.
Vitamin A supplements ameliorate the adverse effect of HIV-1, malaria, and diarrheal infections on child growth.
Malaria remains a military medical problem.
Nutrition education in wartime and peacetime in Vietnam (1945-2000).
Changing the first line drug for malaria treatment--cost-effectiveness analysis with highly uncertain inter-temporal trade-offs.
Community perception of school-based delivery of anthelmintics in Ghana and Tanzania.
Phenothiazines: potential alternatives for the management of antibiotic resistant infections of tuberculosis and malaria in dev
Perception of chloroquine efficacy and alternative treatments for uncomplicated malaria in children in a holoendemic area of
Reducing the risk of blood transfusion.
High-level production and purification of P30P2MSP1(19), an important vaccine antigen for malaria, expressed in the methylo
Can malaria DNA vaccines on their own be as immunogenic and protective as prime-boost approaches to immunization?
Potential cost-savings and quality improvement in travel advice for children and families from a centralized travel medicine cl
Chlorproguanil-dapsone (LAPDAP) for uncomplicated falciparum malaria.
Controlling malaria: challenges and solutions.
Monitoring antimalarial drug resistance within National Malaria Control Programmes: the EANMAT experience.
European Union's research policy: a moving target?
Cost-effectiveness and sustainability of lambdacyhalothrin-treated mosquito nets in comparison to DDT spraying for malaria
Medical relief operation in rural northern Ethiopia: addressing an ongoing disaster.
Prophylactic livestock in malaria control.
Enhancing communications and connectivity in Africa: the multilateral initiative on malaria (MIM) model.
International AIDS and health fund.
Schistosomiasis epidemiology and control: how did we get here and where should we go?
A trial of proguanil-dapsone in comparison with sulfadoxine-pyrimethamine for the clearance of Plasmodium falciparum infec
Efficacy of Sulphadoxine and Pyrimethamine, Doxycycline and their combination in the treatment of chloroquine resistant Fa
Tackling the diseases of poverty.
Building alliances for world health funding.
Efficacy and cost-effectiveness of environmental management for malaria control.
$1.3 billion committed to global AIDS fund at close of G-8 summit. U.S. pledges extra $100 million, work to start in January.
[Current malaria situation in the Republic of Kazakhstan]
Initial lessons from public-private partnerships in drug and vaccine development.
Private investment in AIDS vaccine development: obstacles and solutions.
Treatment of childhood fevers and other illnesses in three rural Nigerian communities.
The Global Health Fund: moral imperative or industry subsidy?
[Present and future of vaccines]
Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Ka
Antimalarial activity of azithromycin, artemisinin and dihydroartemisinin in fresh isolates of Plasmodium falciparum in Thailan
Malaria diagnosis and treatment under the strategy of the integrated management of childhood illness (IMCI): relevance of la
What are today's orphaned vaccines?
Genetically modified viruses: vaccines by design.
Concurrent control of mosquitoes and domestic pests by use of deltamethrin-treated curtains in the New Delhi Municipal Com
Hypothetical and actual willingness to pay for insecticide-treated nets in five Nigerian communities.
Improving adherence to malaria treatment for children: the use of pre-packed chloroquine tablets vs. chloroquine syrup.
A global health fund: a leap of faith?
A colorimetric in vitro drug sensitivity assay for Plasmodium falciparum based on a highly sensitive double-site lactate dehydr
Treating malaria may be too expensive.
Cost-effectiveness of sulfadoxine-pyrimethamine for the prevention of malaria-associated low birth weight.
The increasing burden of infectious diseases on hospital services at St Mary's Hospital Lacor, Gulu, Uganda.
[The new poor expatriates in the third world]
The burden of disease in Maputo City, Mozambique: registered and autopsied deaths in 1994.
Fake artesunate in southeast Asia.
The malaria burden and the need for research and capacity strengthening in Africa.
The neglected burden of Plasmodium vivax malaria.
The economic burden of malaria.
Toward a framework and indicators for monitoring Roll Back Malaria.
Gaps in the childhood malaria burden in Africa: cerebral malaria, neurological sequelae, anemia, respiratory distress, hypogly
The cost-effectiveness of antenatal malaria prevention in sub-Saharan Africa.
The epidemiology and burden of Plasmodium falciparum-related anemia among pregnant women in sub-Saharan Africa.
The burden of malaria in pregnancy in malaria-endemic areas.
The public health impact of chloroquine resistance in Africa.
The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden.
Strategies for prevention of mother-to-child transmission of HIV.
Rapid diagnostic techniques for malaria control.
Efficacy of atovaquone-proguanil?
Bednets and malaria in Africa.
Impact of prepackaging antimalarial drugs on cost to patients and compliance with treatment.
Measuring the local burden of disease. A study of years of life lost in sub-Saharan Africa.
Control of malaria in Pakistan by applying deltamethrin insecticide to cattle: a community-randomised trial.
DDT debate considering costs.
May brings money for Malaria research.
Malaria kills one child every 30 seconds.
Brundtland asks health ministers to build on health-care advances.
Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, p
Management of children with prolonged fever of unknown origin and difficulties in the management of fever of unknown ori
Comparison of the cost and cost-effectiveness of insecticide-treated bednets and residual house-spraying in KwaZulu-Natal, S
[Use of DDT in the antimalarial program]
Costing vaccines versus bednets.
Directed blood donation in pediatric general surgery: Is it worth it?
A new global commitment to disease control in Africa.
Social marketing of insecticide-treated bednets.
[Molecular aspects of chloroquine and antifols resistance in P. falciparum]
Critical issues in the economic evaluation of interventions against communicable diseases.
Combined pyrethroid and carbamate 'two-in-one' treated mosquito nets: field efficacy against pyrethroid-resistant Anophele
[Benefit, effectiveness and cost of parasite investigations in the county of Copenhagen]
The potential impact of integrated malaria transmission control on entomologic inoculation rate in highly endemic areas.
Promotion of insecticide-treated mosquito nets in Myanmar.
Modeling factors influencing malaria incidence in Myanmar.
Fake antimalaria drugs in Cambodia.
Growing pains of East Timor: health of an infant nation.
An old enemy, a new battle plan. Perspective on combating drug-resistant malaria.
Searching for a better willingness to pay elicitation method in rural Nigeria: the binary question with follow-up method versu
Paracheck-Pf: a new, inexpensive and reliable rapid test for P. falciparum malaria.
Parasitaemia and gametocytaemia after treatment with chloroquine, pyrimethamine/sulfadoxine, and pyrimethamine/sulfad
Are people in rural African communities willing to pay for the re-treatment of insecticide-impregnated nets (ITNs)?
Private practitioners and their role in the resurgence of malaria in Mumbai (Bombay) and Navi Mumbai (New Bombay), India:
Natural products for the treatment of tropical diseases.
[Antimalarial drugs and their ways to use in the African milieu]
[Fight against malaria and the fiscal matters: appeal to African countries]
Bank raids malaria centre in dispute over landlord's debt.
Roll back malaria is unarguably both necessary and possible.
Roll back malaria: technically feasible or just politically correct?
Malaria--first, roll back expectations.
Malaria control stymied in 2010, mastered in 2025.
Spatial targeting of interventions against malaria.
Comparison of house spraying and insecticide-treated nets for malaria control.
Combination therapy for malaria in Africa: hype or hope?
Prospects for vaccines to protect against AIDS, tuberculosis, and malaria.
Malaria researchers wait for industry to join fight.
Pharmaceutical companies pledge vaccines for developing countries.
Malaria in the Americas: a model of reemergence.
Analysis of socioeconomic and environmental impacts of waste stabilization pond and unrestricted wastewater irrigation: int
Cost-comparison of DDT and alternative insecticides for malaria control.
Effect of serum dilution in diagnosis of malaria in community.
Drug treatment of tropical parasitic infections: recent achievements and developments.
Treatment of uncomplicated Plasmodium falciparum malaria in Myanmar: a clinical decision analysis.
Using evidence to change antimalarial drug policy in Kenya.
Reducing deaths from diarrhoea through oral rehydration therapy.
Economic burden of malaria illness on households versus that of all other illness episodes: a study in five malaria holo-endem
Atovaquone/Proguanil (Malarone) for malaria.
Artemisinin drugs: novel antimalarial agents.
Malaria--economic implications.
Malaria interventions.
Household costs of 'malaria' morbidity: a study in Matale district, Sri Lanka.
The DDT question.
When is a disease eradicable? 100 years of lessons learned.
Ex post and ex ante willingness to pay (WTP) for the ICT Malaria Pf/Pv test kit in Myanmar.
Unstable vivax malaria in Korea.
Overlooked opportunities for investing in health research and development.
Why aircraft disinsection?
Health impacts of rapid economic changes in Thailand.
Global health policy.
Effect of active prenatal management on pregnancy outcome in sickle cell disease in an African setting.
Public health. Gates Foundation on big funding spree.
Donor responsibilities in rolling back malaria.
[Therapeutic efficacy of different antimalarial regimens in the Costa Rica-Nicaragua border region]
A randomized, parallel-group study in Mumbai (Bombay), comparing chloroquine with chloroquine plus sulfadoxine-pyrimeth
Nutritional modulation of malaria morbidity and mortality.
Malaria.
Donors reject screening panel for malaria projects.
[Malaria vaccines--which vaccines to whom?]
Balancing risks on the backs of the poor.
Willingness to pay for the retreatment of mosquito nets with insecticide in four communities of south-eastern Nigeria.
New economic analysis draws big money to malaria.
Modern medicine and global communicable diseases: new partnerships for progress.
Antimicrobial resistance of nasopharyngeal isolates of Streptococcus pneumoniae and Haemophilus influenzae from children
Host factors affecting the delay of reappearance of Plasmodium falciparum after radical treatment among a semi-immune po
Economic impact of febrile morbidity and use of permethrin-impregnated bed nets in a malarious area II. Determinants of feb
Economic impact of febrile morbidity and use of permethrin-impregnated bed-nets in a malarious area I. Study of demograph
Guide to Community Preventive Services: a commentary.
Unesco backs 'science for debt' plan.
African heads of state promise action against malaria.
The first international meeting of the Research Initiative on Traditional Antimalarial Methods (RITAM).
Risk factors for severe malaria: importance of careful study design: a reply.
Treatment seeking for malaria in Morong, Bataan, the Philippines.
Chemotherapy for falciparum malaria: the armoury, the problems and the prospects.
Malaria control in central Malaita, Solomon Islands. 1. The use of insecticide-impregnated bed nets.
Prospects for pneumococcal vaccination in African children.
Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy ad
A village treatment center for malaria: community response in Sri Lanka.
Cost-effectiveness of iron supplementation and malaria chemoprophylaxis in the prevention of anaemia and malaria among T
Systematics of malaria vectors with particular reference to the Anopheles punctulatus group.
Antimicrobial prophylaxis in adults.
Authors      PubMed ID Malaria Cost Abstract Paper
                20939369           1
Dao A, Kassogue Y, Adamou A, Diallo M, 0   Yaro AS, Traore SF, Lehmann T.
                20937094           1       1          1
Fernandes de Oliveira MR, de Castro Gomes A, Toscano CM. 1
                20929566           1       0
Brooker S, Okello G, Njagi K, Dubeck MM, Halliday KE, Inyega H, Jukes MCh.
                20924674
Passoth V, Olstorpe M, Schnürer 0  J.
                20889879           1
Noor AM, Alegana VA, Patil AP, Snow RW.    0
                20884768           1       0
Tchuenche JM, Chiyaka C, Chan D, Matthews A, Mayer G.
                20874041           1
Mirzaian E, Durham MJ, Hess K, Goad JA.0
Olliaro PL.     20871400           0
Ghebreyesus TA. 20864154           0
                20861510
Corradin G, Kajava AV, Verdini A. 0
                20860809           1       1          0
Widmer LL, Blank PR, Van Herck K, Hatz C, Schlagenhauf P.
                20856897           1       0
Simba DO, Warsame M, Kakoko D, Mrango Z, Tomson G, Premji Z, Petzold M.
                20850869
Pitt C, Greco G, Powell-Jackson T,0Mills A.
                20844433
Yeka A, Harris JC.                 1       0
Frank V, Frank 20841790
                de P, Candide TN, 1        1          0
                                   Gustave K, Emmanuel G, Marc N.
                20838634           1       0
Shabani J, Lutambi AM, Mwakalinga V, Masanja H.
                20838630                   0
Byass P, Fantahun M, Emmelin A,1Molla M, Berhane Y.
                20833303
Ridley DB, Sánchez AC.             0
Galukande M, 20811531
                Kiguli-Malwadde E. 0
                20808923           1       1          1           1
Conteh L, Patouillard E, Kweku M, Legood R, Greenwood B, Chandramohan D.
                20805977           1
Lubell Y, Mills AJ, Whitty CJ, Staedke SG. 1          1           1
Omona J.        20803927           1       1          1x
Onwujekwe O,20739332 O, Ezeoke U, Uzochukwu B, Eze S.
                 Chukwuogo         0
Mutalemwa P,20734708 Kisoka WJ, Kilima S, Njau J, Tenu F, Nkya T, Magesa SM.
                 Kisinza WN,       0
                20734592
Mansotte F, Ravachol F, Carlisi R,1         J,        1x
                                    Caudal1 Pinchon S, Maison D.
                20716742
Gostin LO, Mok EA.                 0
                20712876           0
Uzochukwu BS, Chiegboka LO, Enwereuzo C, Nwosu U, Okorafor D, Onwujekwe OE, Uguru NP, Sibeudu FT, Ezeoke OP.
Usher AD.       20700906           0
                20699507           0
Ali N, Moiz B, Moatter T, Ahmed S, Adil SN, Khurshid M.
                20695144           1
Chukwuocha UM, Dozie IN, Onwuliri CO,0      Ukaga CN, Nwoke BE, Nwankwo BO, Nwoke EA, Nwaokoro JC, Nwoga KS, Udujih OG
Ghebreyesus TA. 20692525           0
Laurance J. 20692517               0
                20691048                   0
Faucher JF, Aubouy A, Béhéton T,1Makoutode P, Abiou G, Doritchamou J, Houzé P, Ouendo E, Deloron P, Cot M.
Van Noorden R.  20686539           1       1          0
                20684764
Macedo de Oliveira A, Wolkon A,1           1          1           0
                                    Krishnamurthy R, Erskine M, Crenshaw DP, Roberts J, Saúte F.
                20670289
Loubiere S, Moatti JP.             1       1          1           1
                20663143
Tsuang A, Lines J, Hanson K.       1       1          0
                20660208           1       1          1
Gingrich CD, Hanson KG, Marchant TJ, Mulligan JA, Mponda H. 0
                20655840
Brändén M, Tabaei SR, Fischer G,0   Neutze R, Höök F.
Di Pentima C. 20653210             0
Mmbando BP, 20650014 LS, Kitua AY, 0
                Vestergaard        1       Lemnge MM, Theander TG, Lusingu JP.
                20644731
Okumu FO, Govella NJ, Moore SJ,1Chitnis0N, Killeen GF.
Kolaczinski JH, 20644619 Robinson E, Picon D, Sabasio A, Mpakateni M, Lado M, Moore S, Petty N, Brooker S.
                Hanson K,          1       0
                20642086            1       0
Daboer JC, John C, Jamda AM, Chingle MP, Ogbonna C.
                20641142
Tuei VC, Maiyoh GK, Ha CE.          0
                20637696            1       0
O'Meara WP, Mangeni JN, Steketee R, Greenwood B.
Gay-Andrieu F.20635461              1       0
                20626844            1       0
Boulton IC, Nwaka S, Bathurst I, Lanzer M, Taramelli D, Vial H, Doerig C, Chibale K, Ward SA.
                20626839            B,      1            0
Krefis AC, Schwarz NG, Nkrumah 1 Acquah S, Loag W, Sarpong N, Adu-Sarkodie Y, Ranft U, May J.
                20594372            1
Cohen JM, Sabot O, Sabot K, Gordon M, 1                  1          1
                                            Gross I, Bishop D, Odhiambo M, Ipuge Y, Ward L, Mwita A, Goodman C.
                20625548            1       EA,
Gething PW, Kirui VC, Alegana VA, Okiro 0 Noor AM, Snow RW.
                20621751
Kamat VR, Nyato DJ.                 1       1            0
CDI Study Group.20616970            0
Perry A.        20607959            1       0
                20606971
Moore EM, Lockwood DN.              0
                20595479            1       1
Yukich J, D'Acremont V, Kahama J, Swai N, Lengeler C.    1          1
Kar S, Kar S. 20592740              1       0
Wilairatana P, 20585537 N, Kano S, Krudsood S.
                Tangpukdee          1       0
Krezanoski PJ, 20579392 Hamer DH. 1
                Comfort AB,         1                    0
                20578778            0
Fonta WM, Ichoku HE, Kabubo-Mariara J.
                20578122
Chrubasik C, Jacobson RL.           1       0
                20576114
Milstien J, Cárdenas V, Cheyne J, 1 Brooks 0A.
Cellier-Holzem20570591              1       0
                 E, Esparza-Salas R, Garnier S, Sorci G.
Beer N, Ali AS, 20565860 D, Al-Mafazy AW, Ramsan0 Abass AK, Omari RS, Björkman A, Källander K.
                de Savigny          1       1            M,
                20559558            1       1            1          P,
Conteh L, Sicuri E, Manzi F, Hutton G, Obonyo B, Tediosi F, Biao 1 Masika P, Matovu F, Otieno P, Gosling RD, Hamel M, Odhia
                20554822            1       1            0
Nkrumah B, Agyekum A, Acquah SE, May J, Tannich E, Brattig N, Nguah SB, von Thien H, Adu-Sarkodie Y, Huenger F.
                20547647
Pasricha SR, Black J, Muthayya S, 1  Shet A,0Bhat V, Nagaraj S, Prashanth NS, Sudarshan H, Biggs BA, Shet AS.
                20529322
King R, Mann V, Boone PD.           0
                20525499            1       0
Lek-Uthai U, Sangsayan J, Kachenchart B, Kulpradit K, Sujirarat D, Honda K.
                20525322            1       1            1          1
Ly AB, Tall A, Perry R, Baril L, Badiane A, Faye J, Rogier C, Touré A, Sokhna C, Trape JF, Michel R.
                20515508
Chuma J, Okungu V, Molyneux C.1             1            1          1
                20510281            1       0
Douglas NM, Anstey NM, Angus BJ, Nosten F, Price RN.
                20509971            1       0
Stergachis A, Bartlein RJ, Dodoo A, Nwokike J, Kachur SP.
Das Gupta RK, 20509472 Sonal GS, Dhillon GP.
                Thakor HG,          1       0
                20507555
Chuma J, Okungu V, Molyneux C.1             1            1          0
Macklin R.      20500758            0
Williams P. 20500439                1       0
                20499780            1
Njoroge FK, Kimani VN, Ongore D, Akwale WS. 0
Moszynski P. 20478964               1       0
                20466925
Mackinnon MJ, Marsh K.              1       0
Roberts L.      20466920            1       0
Bloom BR.       20466888            0
                20465824            1
Adimi F, Soebiyanto RP, Safi N, Kiang R. 0
                20462425
Hjelm K, Mufunda E.                 0
                2
Piva P, Dodd R. 0454484             0
                20452522            1       0
Mbulaiteye SM, Talisuna AO, Ogwang MD, McKenzie FE, Ziegler JL, Parkin DM.
                20444208            1
Lau OS, Ng DW, Chan WW, Chang SP, Sun SS.   0
                 20423536          1     1
Diap G, Amuasi J, Boakye I, Sevcsik AM, Pecoul B.
                 20439448          0
Guindon GE, Lavis JN, Becerra-Posada F, Malek-Afzali H, Shi G, Yesudian CA, Hoffman SJ; Research to Policy and Practice Study
                 20429877
Nkurunziza H, Gebhardt A, Pilz J. 1      0
Moszynski P. 20423972              1     0
                 20421922          1     1
Goldie SJ, Sweet S, Carvalho N, Natchu UC, Hu D. 0
                 20418559
Dua VK, Pandey AC, Dash AP.        1     0
Crawley J, Chu20417858 G, Nosten F. 0
                 C, Mtove          1
                 20417837
[No authors listed]                1     0
                 20413198
Thuilliez J, Sissoko MS, Toure OB,1      0
                                    Kamate P, Berthélemy JC, Doumbo OK.
Kolaczinski JH, 20406448 K, Kyabayinze 1 Strachan1 Temperley M, Wijayanandana N, Kilian A.
                 Kolaczinski       1     D,           D,        1
                 20398318          1     0
Kamanga A, Moono P, Stresman G, Mharakurwa S, Shiff C.
                 20387319          0
U.S. Department of Health and Human Services.
                 20382213
Asase A, Akwetey GA, Achel DG. 1         0
Laxminarayan 20381182 Smith 1 Klein EY.
                 R, Parry IW,      DL,   1           0
                 20380717
McCarthy AE, Coyle D.              1     1           0
Kerouedan D. 20376595              1     0
                 20374478          Mbogo0
Mireji PO, Keating J, Hassanali A, 1      CM, Muturi MN, Githure JI, Beier JC.
                 20348493          1     1
Nnedu ON, Rimel B, Terry C, Jalloh-Vos H, Baryon B, 0 Bausch DG.
Kerouedan D. 20337110              1     0
                 20336009
O'Neill PM, Barton VE, Ward SA. 1        0
Fang J.          20237531          0
                 20232750
Saleh JA, Yusuph H, Zailani SB, Aji1B.   0
                 20226967
[No authors listed]                0
                 20201087
Shankar AH, Fawzi WW.              1     0
                 20186324          0
Suputtamongkol Y, Pongtavornpinyo W, Lubell Y, Suttinont C, Hoontrakul S, Phimda K, Losuwanaluk K, Suwancharoen D, Silpa
                 20176574          1     0
Bridge J.        20167464          0
                 20165870          1
Aditya NP, Patankar S, Madhusudhan B. 0
                 20163707          1     1           1          0
Mubyazi GM, Bloch P, Magnussen P, Olsen ØE, Byskov J, Hansen KS, Bygbjerg IC.
                 20153006          1     1
Biswas AK, Hutin YJ, Ramakrishnan R, Patra B, Gupte1MD.         0
                 20149246          1
Patouillard E, Hanson KG, Goodman CA. 1              1          0
                 20148118          1     1           1
Uzochukwu BS, Onwujekwe OE, Uguru NP, Ughasoro MD, Ezeoke OP.   1
                 20141626          1     0
N'Guessan R, Boko P, Odjo A, Chabi J, Akogbeto M, Rowland M.
                 20139435          1     0
Biedron C, Pagano M, Hedt BL, Kilian A, Ratcliffe A, Mabunda S, Valadez JJ.
                 20126249          0
Moon S, Szlezák NA, Michaud CM, Jamison DT, Keusch GT, Clark WC, Bloom BR.
Onwujekwe O,20116125               1     1
                  Dike N, Uzochukwu B, Ezeoke O.     1          1
Butler D.        20110960          0
                 20109893
Gyapong JO, Gyapong M, Yellu N,0Anakwah K, Amofah G, Bockarie M, Adjei S.
                 20109889
de Sousa A, Salama P, Chopra M. 1        1           0
Kamal-Yanni M.   20109888          1     1           0
Accorsi S, Bilal 20106495 P, Racalbuto V.
                 NK, Farese        0
Miller LH.       20097134          1     0
                 20096130          1     0
Chanthap L, Ariey F, Socheat D, Tsuyuoka R, Bell D.
Ogutu B, Tiono20096111             1     0
                  AB, Makanga M, Premji Z, Gbadoé AD, Ubben D, Marrast AC, Gaye O.
               20090933            1
Mosha JF, Conteh L, Tediosi F, Gesase S, 1              1          1
                                            Bruce J, Chandramohan D, Gosling R.
               20087415            1        0
Keusch GT, Kilama WL, Moon S, Szlezák NA, Michaud CM.
               20070891
Djogbénou L, Noel V, Agnew P. 1             1           0
               20064997            1
Ferral J, Chavez-Nuñez L, Euan-Garcia M,0Ramirez-Sierra MJ, Najera-Vazquez MR, Dumonteil E.
               20056485            1
Cohuet A, Harris C, Robert V, Fontenille D. 0
               20051036            1        0
Davoodi-Semiromi A, Schreiber M, Nalapalli S, Verma D, Singh ND, Banks RK, Chakrabarti D, Daniell H.
               20050716
Dienye PO, Gbeneol PK.             0
               20050266
Tucci D, Merson MH, Wilson BS. 0
van den Berg H.20049114            1        0
               20028563            1
Hawkes M, Katsuva JP, Masumbuko CK. 1                   1          1
Tren R, Hess K,20028536
                 Bate R.           0
Collier R.     20026636            1        0
               20025183            1
Munier A, Diallo A, Sokhna C, Chippaux JP.  1           0
               20015392            1        0
Massad E, Behrens RH, Burattini MN, Coutinho FA.
               20005196            1        0
Mekonnen Z, Ali S, Belay G, Suleman S, Chatterjee S.
               20003328            1        0
Metzger WG, Giron AM, Vivas-Martínez S, González J, Charrasco AJ, Mordmüller BG, Magris M.
Hodel EM, Ley 20003204 Ariey F, 1
                SD, Qi W,                    B,
                                   Genton0 Beck HP.
               20003199            1        0
Khairnar K, Martin D, Lau R, Ralevski F, Pillai DR.
Vezenegho SB,20003184              1        0
                 Bass C, Puinean M, Williamson MS, Field LM, Coetzee M, Koekemoer LL.
               20000028
Oryema-Lalobo M.                   1        1           0
Small PM.      19999594            0
Townson H. 19917071                1        0
Mota RE, Lara 19996420             1
                AM, Kunkwenzu ED, Lalloo DG.0
Sharma VP. 19995437                1        0
               19962364            0
Croce D, Porazzi E, Foglia E, Restelli U, Sinuon M, Socheat D, Montresor A.
               19949824            0
Blavid R, Kusch P, Hauber J, Eschweiler U, Sarite SR, Specht S, Deininger S, Hoerauf A, Kaiser A.
               19940051            1        0
Taylor SM, Juliano JJ, Trottman PA, Griffin JB, Landis SH, Kitsa P, Tshefu AK, Meshnick SR.
Korenromp EL,19939444 KM.
                 Viisainen         0
               19930666            1         OE,        1
Uzochukwu BS, Obikeze EN, Onwujekwe1 Onoka CA, Griffiths UK.       1
               19929818            1        0
Dhanawat M, Das N, Nagarwal RC, Shrivastava SK.
               19919729
Cathcart SJ, Lawrence J, Grant A, 1         0
                                   Quinn D, Whitty CJ, Jones J, Chiodini PL, Fraser G.
               19917038            0
Kalk A, Groos N, Karasi JC, Girrbach E.
               19907632            1
Fürst T, Raso G, Acka CA, Tschannen AB, 1               0
                                            N'Goran EK, Utzinger J.
Callister LC. 19901704             1        0
Maher D.       19891762            0
Onwujekwe O,19891758 Uzochukwu B, 1
                 Hanson K,         1                    1          1
                                            Ichoku H, Ike E, Onwughalu B.
               19887410
Musgrove P, Hotez PJ.              0
               19858945
Atun R, Kazatchkine M.             0
               19858927
El-Sadr WM, De Cock KM.            0
               19879137            1        0
Kumar A, Srivastava K, Raja Kumar S, Puri SK, Chauhan PM.
               19877843
Hall BF, Fauci AS.                 1        0
Williams N. 19866548               1        0
Onwujekwe O,19863803 B, Dike N, Uguru N, Nwobi E, Shu E. 0
                 Uzochukwu         1        1           1
               19861611
Maude RJ, Buapetch W, Silamut K.   1        1           0
                19861605          Vinetz JM, Smith DM.
Bharti AR, Letendre SL, Patra KP, 1       0
                19860674
Stern LJ, Calvo-Calle JM.         0
He Y, Fan J, Lin19859713 Ye Y, Liang L, Zhan Z, Dong X, Sun L, Xu H.
                 H, Yang X,       1       0
                19859537          0
Sturrock HJ, Picon D, Sabasio A, Oguttu D, Robinson E, Lado M, Rumunu J, Brooker S, Kolaczinski JH.
Gomes J, Leão 19858577 F, Afonso MO, Santos C, Josenando T, Seixas J, Atouguia J, Centeno-Lima S.
                C, Ferreira       0
Gbotosho GO, 19852850 Sijuade AO, Sowunmi A, Oduola AM.
                Happi CT,         1       1          0
                19845968          1
Himeidan YE, Zhou G, Yakob L, Afrane Y, 0 Munga S, Atieli H, El-Rayah el-A, Githeko AK, Yan G.
Kokwaro G. 19818169               1       0
                19828052          1       0
Steenkeste N, Dillies MA, Khim N, Sismeiro O, Chy S, Lim P, Crameri A, Bouchier C, Mercereau-Puijalon O, Beck HP, Imwong M
                19819377          1       1
Talisuna A, Grewal P, Rwakimari JB, Mukasa S, Jagoe1G, Banerji J. 0
                19805937
Aliyu AA, Alti-Mu'azu M.          1       0
                19802471          1       1          0
Svihrova V, Szilagyiova M, Krkoska D, Simekova K, Hudeckova H, Avdicova M.
Rijken MJ, Lee 19790099 Papageorghiou AT, Visser GH, Dwell SL, Kennedy SH, Singhasivanon P, White NJ, Nosten F, McGrea
                SJ, Boel ME,      0
                19788718          1       0
Mustafa HS, Malik EM, Tuok HT, Mohamed AA, Julla AI, Bassili A.
                19785779          1       0
Ogoma SB, Kannady K, Sikulu M, Chaki PP, Govella NJ, Mukabana WR, Killeen GF.
                19783724          L,
Mepham SO, Squire SB, Chisuwo 0 Kandulu J, Bates I.
                19782110          1       0
Giraldo MA, Arevalo-Pinzon G, Rojas-Caraballo J, Mongui A, Rodriguez R, Patarroyo MA.
                19761835          1       0
Brown GV, Moorthy VS, Reed Z, Mendis K, Arévalo-Herrera M, Alonso P; WHO MALVAC committee.
                19761827
Asase A, Oppong-Mensah G.         1       0
                19761036
Chattopadhyay R, Kumar S.         1       0
                19755740          1       0
Hussain WM, Bukhari SZ, Fatani MI, Karima TM, Madani TA, Badreddine S.
                19754373
Walsh JJ, Bell A.                 1       0
                19754246
Enayati A, Hemingway J.           1       0
                19752178          1       1          1            1
De Allegri M, Marschall P, Flessa S, Tiendrebéogo J, Kouyaté B, Jahn A, Müller O.
Knight JC.      19737788          0
Adeyi O, Atun R.19734866          0
                19732462          1       1          GC,
Uguru NP, Onwujekwe OE, Uzochukwu BS, Igiliegbe 1 Eze SB. 1
                19725906          0
Tagny CT, Owusu-Ofori S, Mbanya D, Deneys V.
                19724695          1       0
Sultan DM, Khalil MM, Abdouh AS, Doleh WF, Al Muthanna AA.
                19724644          1       1          1            1
Sabot OJ, Mwita A, Cohen JM, Ipuge Y, Gordon M, Bishop D, Odhiambo M, Ward L, Goodman C.
O'Brien J.      19722886          0
                19706921          1       1
Becker-Dreps SI, Biddle AK, Pettifor A, Musuamba G,1Imbie DN, 1   Meshnick S, Behets F.
                19700639          1
Dar A, Prusty D, Mondal N, Dhar SK.       0
Noor RA.        19698692          0
Kilama WL. 19695211               0
                19695126          1       1          1
Rosas Aguirre AM, Llanos Zavalaga LF, Trelles de Belaunde M. 1 Spanish
Kilama W.       19686696          0
Nyika A.        19682966          0
                19666223          1       0
Grimberg BT, Jaworska MM, Hough LB, Zimmerman PA, Phillips JG.
Nyika A.        19665439          0
Patil AP, Okiro 19656373 PW, Guerra CA, Sharma SK, Snow RW, Hay SI.
                EA, Gething       1       0
                19649366          0
Waning B, Kaplan W, King AC, Lawrence DA, Leufkens HG, Fox MP.
                19645076
[No authors listed]               0
                19640283          1       0
Sayang C, Gausseres M, Vernazza-Licht N, Malvy D, Bley D, Millet P.
Sachs JD.       19634559           1       0
                19632479
[No authors listed]                1       0
Babiker HA. 19632155               1       0
                19631186           1       1
Gunasekaran K, Sahu SS, Vijayakumar KN, Jambulingam P.1           1
                19631008           0
Fenwick A, Webster JP, Bosque-Oliva E, Blair L, Fleming FM, Zhang Y, Garba A, Stothard JR, Gabrielli AF, Clements AC, Kabater
                19624812           1
Williams GS, Mweya C, Stewart L, Mtove0G, Reyburn H, Cook J, Corran PH, Riley EM, Drakeley CJ.
                19623251
Breslauer DN, Maamari RN, Switz0NA, Lam WA, Fletcher DA.
Moon S, Pérez19621068              1       0
                Casas C, Kindermans JM, de Smet M, von Schoen-Angerer T.
                19615074           1
Suhanic W, Crandall I, Pennefather P. 0
Stillwaggon E. 19591693            0
                19574316
Hanson K, Marchant T, Nathan R,1           1          1           1
                                    Mponda H, Jones C, Bruce J, Mshinda H, Schellenberg JA.
                19573238
Rocca KA, Gray EM, Costantini C, 1         0
                                   Besansky NJ.
                19560371           0
Yiengprugsawan V, Lim LL, Carmichael GA, Seubsman SA, Sleigh AC.
Bate R, Hess K.19555897            1       1          0
Roehr B.        19546132           1       0
Audibert M. 19545044               1       1          1           0 French
                19542027
Chen HH, Chen AL.                  1       0
Watson R.       19541703           1       0
Bermejo A. 19541034                0
Epstein H.      19541033           0
                19537414           1       0
Chiguzo AN, Mugo RW, Wacira DG, Mwenda JM, Njuguna EW.
                19537405           1
Pemba DF, Bandason E, Namangale J. 0
                19523220                   G,         G,
Rutebemberwa E, Nsabagasani X,1Pariyo1 Tomson 1 Peterson0S, Kallander K.
                19505328           1       1
Tediosi F, Maire N, Penny M, Studer A, Smith TA. 1                1
Rasgon JL.      19503813           1       0
                19500429                   0
Dua VK, Pandey AC, Raghavendra1K, Gupta A, Sharma T, Dash AP.
                19497083           1       0
Mendis K, Rietveld A, Warsame M, Bosman A, Greenwood B, Wernsdorfer WH.
Mathanga DP, 19497078 Campbell CH, Silwimba C, Malenga G.
                Luman ET,          1       0
                19497077           O,      0
Simba DO, Warsame M, Kimbute1 Kakoko D, Petzold M, Tomson G, Premji Z, Gomes M.
                19493074
Crager SE, Price M.                0
                19491291           0
Biesma RG, Brugha R, Harmer A, Walsh A, Spicer N, Walt G.
                19485798           1
Babiker HA, Hastings IM, Swedberg G. 0
Rowe AK.        19478260           0
                19478249           1       1          0
Skarbinski J, Ouma PO, Causer LM, Kariuki SK, Barnwell JW, Alaii JA, de Oliveira AM, Zurovac D, Larson BA, Snow RW, Rowe AK
                19478247            B,     1          0
Abuya T, Fegan G, Rowa Y, Karisa1 Ochola S, Mutemi W, Marsh V.
Kleinschmidt I,19478243 C, Benavente L, 0
                 Schwabe           1       Torrez M, Ridl FC, Segura JL, Ehmer P, Nchama GN.
Steketee RW. 19478241              1       0
Long EG.        19461094           1       0
                19461092
Birx D, de Souza M, Nkengasong JN. 1       0
                19461091           1       0
Vitoria M, Granich R, Gilks CF, Gunneberg C, Hosseini M, Were W, Raviglione M, De Cock KM.
                19460153            V,
Matovu F, Goodman C, Wiseman1 Mwengee W. 1 1                      1
                19457227                   0
Srivastava A, Nagpal BN, Joshi PL,1Paliwal JC, Dash AP.
                19454148           1       0
Bell CE, Slutsker L, Beach RF, Foster SO, Jimenez G, Sarmiento ME.
                19450373           0
Brooker S, Kabatereine NB, Gyapong JO, Stothard JR, Utzinger J.
Markandya A, 19440414
                Chiabai A.         0
Sullivan M. 19434070               0
                19427959           0
McCoy D, Kembhavi G, Patel J, Luintel A.
                19426658           1      0
Valecha N, Joshi H, Mallick PK, Sharma SK, Kumar A, Tyagi PK, Shahi B, Das MK, Nagpal BN, Dash AP.
                19422704           1
McElroy B, Wiseman V, Matovu F, Mwengee W.1          1          1
Grobusch MP. 19416009              1      0
                19407120
Bukhari T, Knols BG.               1      0
                19404247
Olliaro P, Wells TN.               1      0
                19402585           1      0
Kisinza WN, Kisoka WJ, Mutalemwa PP, Njau J, Tenu F, Nkya T, Kilima SP, Magesa SM.
                19400953           1
Williams HA, Vincent-Mark A, Herrera Y, 0 Chang OJ.
                19399160           1      0
Bisoffi Z, Gobbi F, Angheben A, Van den Ende J.
                19399156           1      0
Msellem MI, Mårtensson A, Rotllant G, Bhattarai A, Strömberg J, Kahigwa E, Garcia M, Petzold M, Olumese P, Ali A, Björkman
                19394517
[No authors listed]                1      1          0
Cohee L, Mills 19383173 J, Jacobs I, Galiwango R, Ludigo J, Ssekasanvu J, Reynolds SJ.
                LA, Kagaayi        1      0
Moszynski P. 19380401              1      0
                19374767           1      0
Djogbénou L, Labbé P, Chandre F, Pasteur N, Weill M.
                19371415           1      0
Bernard J, Mtove G, Mandike R, Mtei F, Maxwell C, Reyburn H.
                19371407           1      0
Ng'ang'a PN, Jayasinghe G, Kimani V, Shililu J, Kabutha C, Kabuage L, Githure J, Mutero C.
                19362361           1      0
Staedke SG, Mwebaza N, Kamya MR, Clark TD, Dorsey G, Rosenthal PJ, Whitty CJ.
                19362256           1      BA,
A-Elgayoum SM, El-Feki Ael-K, Mahgoub 0 El-Rayah el-A, Giha HA.
Iwalokun BA. 19357729              1      0
                19356246           1      0
Castro MC, Tsuruta A, Kanamori S, Kannady K, Mkude S.
                19356225           1
Chanda P, Castillo-Riquelme M, Masiye F.  1          1          1
                19332912           1      0
Parija SC, Dhodapkar R, Elangovan S, Chaya DR.
                19331664           1      1          1
Yukich JO, Zerom M, Ghebremeskel T, Tediosi F, Lengeler C.      1
                19309519           S,     0
Morrow M, Nguyen QA, Caruana 1 Biggs BA, Doan NH, Nong TT.
                19301420           1      1
Goodman C, Kachur SP, Abdulla S, Bloland P, Mills A.1           1
Witty A.        19299425           0
                19290792           1      0
Mehlotra RK, Henry-Halldin CN, Zimmerman PA.
                19284673           1      0
Rutebemberwa E, Pariyo G, Peterson S, Tomson G, Kallander K.
                19282971
Garver LS, Dong Y, Dimopoulos G.   1      0
                19281447
Myburgh JA, Finfer S.              0
                19278703           1      0
Maude RJ, Pontavornpinyo W, Saralamba S, Dondorp AM, Day NP, White NJ, White LJ.
Vijayan VK. 19276810               0
                19275555           1      0
Cruz AK, de Toledo JS, Falade M, Terrão MC, Kamchonwongpaisan S, Kyle DE, Uthaipibull C.
                19274364           1      1          1          1
Hutton G, Schellenberg D, Tediosi F, Macete E, Kahigwa E, Sigauque B, Mas X, Trapero M, Tanner M, Trilla A, Alonso P, Menen
Bygbjerg IC. 19265610              1      0
                19263235
Cheraghali AM, Idries AM.          0
Bate R, Tren R,19243589
                 Hess K, Attaran A.1      0
                19230334
Theodorou V, Karakatsani D.        0
                19091041           1      0
Whitty CJ, Chandler C, Ansah E, Leslie T, Staedke SG.
                19091039
Perkins MD, Bell DR.               1      0
                19091035
Mills A, Lubell Y, Hanson K.       1      1          1          1
                19224274
Halsnaes K, Traerup S.             0
               19218332
Chuma J, Molyneux C.              1       1          0
               19210797           1       0
Diamond-Smith N, Singh N, Gupta RK, Dash A, Thimasarn K, Campbell OM, Chandramohan D.
Atta H, Zamani19205607
                G.                1       0
               19195670           0
Cañete R, Escobedo AA, Almirall P, González ME, Brito K, Cimerman S.
               19195447           0
Borrás Salvador R, Cuenca-Estrella M, Domínguez Márquez MV, Gadea Gironés I.
Zarocostas J. 19190020            0
               19187518           1
Lubell Y, Yeung S, Dondorp AM, Day NP, 1             1             Faiz
                                          Nosten F, Tjitra E, Abul 1 M, Yunus EB, Anstey NM, Mishra SK, Mohanty S, White N
               19181673
Kumar D, Aggarwal AK, Kumar R. 0
               19173772           1
Willcox ML, Sanogo F, Graz B, Forster M,0Dakouo F, Sidibe O, Falquet J, Giani S, Diakite C, Diallo D.
               19171013
Luz PM, Grinsztejn B, Galvani AP.0
               19169339           1       0
Ibadin OM, Ofili AN, Airauhi LU, Ozolua EI, Umoru AB.
Molyneux DH, 19167564 Fenwick 0 Newman RD, Greenwood B, Sachs J.
                Hotez PJ,          A,
               19161598           1       1
Ayieko P, Akumu AO, Griffiths UK, English M.         1             1
               19160968           0
Deng Y, Zhou XN, Jia TW, Wang XH, Yang K, Wu XH, Li SZ.
               19157475           0
Accorsi S, Kedir N, Farese P, Dhaba S, Racalbuto V, Seifu A, Manenti F.
Maxmen A. 19153251                0
Ngoasong MZ. 19152991             0
               19149878           1
Mueller DH, Abeku TA, Okia M, Rapuoda1B, Cox J. 1                  1
               19147413
Soyinka JO, Onyeji CO, Omoruyi SI.1       0
               19128455           1       0
Kayentao K, Maiga H, Newman RD, McMorrow ML, Hoppe A, Yattara O, Traore H, Kone Y, Guirou EA, Saye R, Traore B, Djimde
               19127976
Ridde V, Haddad S.                0
               19127975            S,
Ansah EK, Narh-Bana S, Asiamah 0 Dzordzordzi V, Biantey K, Dickson K, Gyapong JO, Koram KA, Greenwood BM, Mills A, Whi
               19127377                   0
Garg A, Dhiman RC, Bhattacharya1S, Shukla PR.
               19124021
Veron V, Simon S, Carme B.        1       0
               19121147           1       1          0
Pettifor A, Taylor E, Nku D, Duvall S, Tabala M, Mwandagalirwa K, Meshnick S, Behets F.
               20830982           1
Aina BA, Tayo F, Taylor O, Eniojukan JF. 0
               20701879
Karunamoorthi K, Bekele M.        1       0
Kawahara N. 20192592              0
               19113955           1       0
Gemma S, Campiani G, Butini S, Joshi BP, Kukreja G, Coccone SS, Bernetti M, Persico M, Nacci V, Fiorini I, Novellino E, Tarame
               19108723
Worrall E, Connor SJ, Thomson MC. 1       1          1             1
               19104653           0
Fèvre EM, Wissmann BV, Welburn SC, Lutumba P.
               19094936
[No authors listed]               1       0
               19091114           1       1          1             1
Yukich JO, Lengeler C, Tediosi F, Brown N, Mulligan JA, Chavasse D, Stevens W, Justino J, Conteh L, Maharaj R, Erskine M, Mue
Plowe CV.      19084883           1       0
Hong SC.       19081796           1       0
               19073344
Haylamicheal ID, Dalvie MA.       0
               19062470
Joda AE, Fanimokun TO.            1       0
Patz JA, Olson 19061763CK, Gibbs HK.
               SH, Uejio          0
Waltz E.       19060849           0
               19059446
Olesen OF, Lonnroth A, Mulligan 0  B.
               19032767           1
Premji ZG, Abdulla S, Ogutu B, Ndong A, 0 Falade CO, Sagara I, Mulure N, Nwaiwu O, Kokwaro G.
Valleron AJ. 19027701             0
Anorlu RI.     19027621           0
               19026600           1       0
Ntale M, Ogwal-Okeng JW, Mahindi M, Gustafsson LL, Beck O.
Enserink M. 19023050              1       1          0
Stoltzfus RJ. 19022987            1       0
                19019422          1       0
Noor AM, Mutheu JJ, Tatem AJ, Hay SI, Snow RW.
                19019399
Drakeley C, Reyburn H.            1       0
Bojang KA.      19012500          1       0
Crawford MA. 19009739             0
Moszynski P. 19004886             1       0
                18991643          1
Arsenault PR, Wobbe KK, Weathers PJ. 0
Williams N. 18983950              1       0
Sagara I, Diallo18981499 Coulibaly M, Diawara SI, Guindo O, Maiga H, Niambele MB, Sissoko M, Dicko A, Djimde A, Doumbo
                 A, Kone M,       1       0
                18976453          1       1          1
Saulo EC, Forsberg BC, Premji Z, Montgomery SM, Björkman A. 1
                18971613
Kang YH, Lim HS, Lee HM, Lee KS,1Choi KM. 0
                18959790          1       0
Daniels R, Volkman SK, Milner DA, Mahesh N, Neafsey DE, Park DJ, Rosen D, Angelino E, Sabeti PC, Wirth DF, Wiegand RC.
Sorber K, Chiu 18941527 D, Dimon M, Ruby JG, Hekele A, DeRisi JL.
                C, Webster        0
Sherman IW. 18940418              1       0
                18937882
Vardo-Zalik AM, Schall JJ.        1       0
                18937746
Belay M, Deressa W.               1       1          0
                18926279
Sridhar D, Batniji R.             0
                18849806          0
Bergman S, Deckelbaum D, Lett R, Haas B, Demyttenaere S, Munthali V, Mbembati N, Museru L, Razek T.
                18844447          1
Evers A, Heppner S, Leippe M, Gelhaus C.  0
                18843307
[No authors listed]               1       0
                18840756           M,     0
Jain V, Nagpal AC, Joel PK, Shukla1 Singh MP, Gupta RB, Dash AP, Mishra SK, Udhayakumar V, Stiles JK, Singh N.
                18834523          1       0
Abeku TA, Kristan M, Jones C, Beard J, Mueller DH, Okia M, Rapuoda B, Greenwood B, Cox J.
Roberts L.      18832613          1       0
                18831742
Cohen JM, Singh I, O'Brien ME. 1          0
                18828893          1       0
Birkholtz LM, Blatch G, Coetzer TL, Hoppe HC, Human E, Morris EJ, Ngcete Z, Oldfield L, Roth R, Shonhai A, Stephens L, Louw A
Tanne JH.       18826977          1       0
Temperley M, 18826594 Njagi JK, Akhwale W, Clarke SE, Jukes MC, Estambale BB, Brooker S.
                Mueller DH,       1       1          1            1
                18820747          0
Hotez PJ, Bottazzi ME, Franco-Paredes C, Ault SK, Periago MR.
                18816373          1       1          1            0
Pettifor A, Taylor E, Nku D, Duvall S, Tabala M, Meshnick S, Behets F.
Wahab KW. 18811746                0
                18724282          0
Shamsi Ts, Hashmi K, Adil S, Ahmad P, Irfan M, Raza S, Masood N, Shaikh U, Satti T, Farzana T, Ansari S.
                18793448
Hetzel MW, Obrist B, Lengeler C, 1        0
                                   Msechu JJ, Nathan R, Dillip A, Makemba AM, Mshana C, Schulze A, Mshinda H.
Zikusooka CM,18793410 D, Barnes KI. 0
                 McIntyre         1
                18767286          0
Plamondon KM, Hanson L, Labonté R, Abonyi S.
                18753880
Mapanga KG, Mapanga MB.           0
                18752675          1       1          1            1
Morel CM, Thang ND, Xa NX, Hung le X, Thuan le K, Van Ky P, Erhart A, Mills AJ, D'Alessandro U.
                18725923
McQueen PG, McKenzie FE.          1       0
                18719728
Montoya AE, Menco J, Osorio N, 1  Zuluaga0MA, Duque J, Torres G, Restrepo M.
                18713802
Lines J, Schapira A, Smith T.     1       0
                18707548          1
Khushiramani R, Shrivastava S, Varma S, 0 Batra HV, Dubey ML.
                18689612          1
Stauffer WM, Weinberg M, Newman RD,0Causer LM, Hamel MJ, Slutsker L, Cetron MS.
                18689296                  0
Jourdan PM, Laoussou P, Lybie A,1Kjetland EF.
                18686230          0
Connor SJ, Ceccato P, Dinku T, Omumbo J, Grover-Kopec EK, Thomson MC.
Zirkle LG Jr. 18685912            0
                18680960          1       1           0
Kamugisha ML, Msangeni H, Beale E, Malecela EK, Akida J, Ishengoma DR, Lemnge MM.
                18671874          1       1                      1
Manzi F, Hutton G, Schellenberg J, Tanner M, Alonso1P, Mshinda H, Schellenberg D.
Sebbag R.       18666459          0
                18665772
Wang L, Coppel RL.                0
                18665256
Hotez PJ, Molyneux DH.            0
                18664242
Cassimon D, Renard R, Verbeke K.  0
                18651964          1       0
Gianotti RL, Bomblies A, Dafalla M, Issa-Arzika I, Duchemin JB, Eltahir EA.
Kiszewski AE. 18651789            1       0
                18651785
Snow RW, Guerra CA, Mutheu JJ,1    Hay SI.0
Selgelid MJ. 18630228             0
                18628947          1       0
Cunha-Rodrigues M, Portugal S, Prudêncio M, Gonçalves LA, Casalou C, Buger D, Sauerwein R, Haas W, Mota MM.
Sachs JD.       18623961          1       0
                18619853
Ravi G, Ella K, Lakshmi Narasu M.1        0
                18615006          1       1
Buabeng KO, Duwiejua M, Matowe LK, Smith F, Enlund H. 0
                18607828          1       0
Omo-Aghoja LO, Abe E, Feyi-Waboso P, Okonofua FE.
                18603960          0
Joshi AB, Banjara MR, Pokhrel S, Jimba M, Singhasivanon P, Ashford RW.
                18603111          1       0
Souares A, Lalou R, Sene I, Sow D, Le Hesran JY.
                18583009          1
Stratton L, O'Neill MS, Kruk ME, Bell ML.0
Teklehaimanot18579874P.
                 A, Mejia         1       0
Kaler SG.       18579873          1       0
                18575476          1       0
Ibadin OM, Ofili AN, Airauhi LU, Ozolua EI, Umoru AB.
                18571111          1       1
Idowu OA, Mafiana CF, Luwoye IJ, Adehanloye O. 0
                18545734          0
Källander K, Hildenwall H, Waiswa P, Galiwango E, Peterson S, Pariyo G.
                18544174          0
Parmanto B, Paramita MV, Sugiantara W, Pramana G, Scotch M, Burke DS.
                18544162
Hanson K, Nathan R, Marchant T,1          1           1          0
                                   Mponda H, Jones C, Bruce J, Stephen G, Mulligan J, Mshinda H, Schellenberg JA.
                18541764          J,      1           1
Zurovac D, Larson BA, Skarbinski 1 Slutsker L, Snow RW, Hamel MJ.1
                18538458          1       1
Wiseman V, Scott A, Conteh L, McElroy B, Stevens W.   1          1
                18536036          0
Mikhailovich V, Gryadunov D, Kolchinsky A, Makarov AA, Zasedatelev A.
Voordouw MJ,18534029 Hurd H. 1
                 Koella JC,               0
Okie S.         18525039          1       0
                18519302          J,
Hounton SH, Sombie I, Townend 0 Ouedraogo T, Meda N, Graham WJ.
Benn C.         18514719          0
                18513771
Ratnawati, Hatta M, Smits HL. 1           0
                18513767                  1
Mbonye AK, Hansen KS, Bygbjerg1IC, Magnussen P. 1                1
                18500352          1       0
Newby ZE, O'Connell J 3rd, Robles-Colmenares Y, Khademi S, Miercke LJ, Stroud RM.
Senior K.       18499903          1       0
                18499204
Ogbonna A, Uneke CJ.              1       0
                18492245                  1
Yeung S, Van Damme W, Socheat1D, White NJ, Mills 1    A.         1
                18488269
[No authors listed]               1       0
Kusumawathie18486171              1
                 PH, Wickremasinghe AR, 1             1          1
                                          Karunaweera ND, Wijeyaratne MJ.
                18478781
Janvier F, Morillon M, Olliaro P. 0
                18472118
Idowu OA, Mafiana CF, Sotiloye D. 1       0
                18471764
[No authors listed]               1       0
                18462316
Marzal A, Bensch S, Reviriego M, 1        0
                                  Balbontin J, De Lope F.
                18461178          1       0
Noor AM, Moloney G, Borle M, Fegan GW, Shewchuk T, Snow RW.
                18458305          1       0
Wilson NO, Adjei AA, Anderson W, Baidoo S, Stiles JK.
                18455457          Chandre F, Weill M.
Alout H, Djogbénou L, Berticat C, 1       0
                18449828
Sawers L, Stillwaggon E, Hertz T. 0
Long GH, Chan18447949 JE, Read1 Graham AL.
                 BH, Allen         AF, 0
                18447050
Olliaro P, Brasseur P.            1       0
Samarasekera 18446925
                U.                1       1          0
                18445255          1       1          1       1
Mueller DH, Wiseman V, Bakusa D, Morgah K, Daré A, Tchamdja P.
                18442373          1
Sharma A, Raghavendra K, Adak T, Dash 0   AP.
                18440663          1       1          0
Pistone T, Schwarzinger M, Chauvin P, Ezzedine K, Receveur MC, Djossou F, Siriwardana M, Larouzé B, Malvy D.
Chambers RG, 18440416 Ghebreyesus TA.
                Gupta RK,         1       0
Onishchenko GG. 18426014          1       0
                18425596          0
Dhama K, Mahendran M, Gupta PK, Rai A.
Singh S.        18423188          0
Lynch M.        18421326          1       0
                18421325          1
Coll-Seck AM, Ghebreyesus TA, Court A. 0
White NJ.       18420924          1       1          0
                18410572          0
Olivieri NF, Muraca GM, O'Donnell A, Premawardhena A, Fisher C, Weatherall DJ.
                18397401          1       0
Skarbinski J, Winston CA, Massaga JJ, Kachur SP, Rowe AK.
                18397398           JD,    1          1
Somi MF, Butler JR, Vahid F, Njau1 Kachur SP, Abdulla S.     0
                18392548          1       0
Jambulingam P, Gunasekaran K, Sahu S, Vijayakumar T.
Bagchi S.       18390933          0
                18385342
Muturi EJ, Burgess P, Novak RJ. 1         0
Onishchenko GG. 18376468          1       0
                18373862
Le MT, Bretschneider TR, Kuss C, 1        PR.
                                  Preiser 0
                18371242
Pullan R, Brooker S.              0
                18366755          0
Fèvre EM, Odiit M, Coleman PG, Woolhouse ME, Welburn SC.
                18358925
Buse K, Samuels F, Pearson M. 0
Baker TD.       18356507          1       0
                18353106          0
Rodrigues FG, Santos MN, de Carvalho TX, Rocha BC, Riehle MA, Pimenta PF, Abraham EG, Jacobs-Lorena M, Alves de Brito CF
                18343702
Penali LK, Jansen FH.             1       0
                18341180
Mustafa MH, Babiker MA.           1       1          1       1
                18338718
Yadav SP, Sharma RC, Joshi V. 1           0
                18338401
Janossy G, Mandy F, O'Gorman MR.  0
                18335058          0
Uzochukwu BS, Onwujekwe EO, Onoka CA, Ughasoro MD.
Sharma VR. 18329773               1       0
                18326345                  1
Legesse Y, Tegegn A, Belachew T,1Tushune K.          1x
Korenromp EL,18313487 JK.
                 Kayondo          0
                19999304          1
Mueller I, Rogerson S, Mola GD, Reeder JC.0
Grabowsky M.18305524              1       0
Maher B.        18305518          1       0
                18305496
[No authors listed]               0
Anorlu RI.      18304395          0
                18304268           1       0
Graves PM, Osgood DE, Thomson MC, Sereke K, Araia A, Zerom M, Ceccato P, Bell M, Del Corral J, Ghebreselassie S, Brantly E
                18297895           D,      0
Stoltzfus RJ, Heidkamp R, Kenkel 1 Habicht JP.
                18297164
Shillcutt S, Morel C, Goodman C, 1         1           1           1
                                   Coleman P, Bell D, Whitty CJ, Mills A.
                18291566
Doyle C, Patel P.                  0
Lidén J.        18291335           0
                18291009
Castillo-Riquelme M, McIntyre D,1Barnes1K.             1           1
                18291008           1       0
Zurovac D, Njogu J, Akhwale W, Hamer DH, Snow RW.
                18282270           1       1           1
Hume JC, Barnish G, Mangal T, Armázio L, Streat E, Bates I.        1
                18279509
Mulligan JA, Yukich J, Hanson K. 1         1           1           1
                18278860           1       1            SS,
Gemma S, Campiani G, Butini S, Kukreja G, Coccone 0 Joshi BP, Persico M, Nacci V, Fiorini I, Novellino E, Fattorusso E, Taglia
                18276869
Kitua AY, Mboera L, Magesa SM, 1           0
                                   Maxwell CA, Curtis CF.
                18272941           0
Uzochukwu BS, Onwujekwe OE, Nwobi EA, Ndu AC, Onoka C.
Fischer Walker18270521 M, Black RE.
                 CL, Ezzati        0
Onwujekwe O,18263563 J, Hanson K. 1
                 Fox-Rushby        1                   1           1
                18258326
Wagacha JM, Muthomi JW.            0
                18256433           1       0
Djogbénou L, Dabiré R, Diabaté A, Kengne P, Akogbéto M, Hougard JM, Chandre F.
                18254503                   0
Mlozi MR, Shayo EH, Senkoro KP,1Mayala BK, Rumisha SF, Mutayoba B, Senkondo E, Maerere A, Mboera LE.
                18165509
Nahlen BL, Low-Beer D.             1       0
                18165508
Bates N, Herrington J.             1       0
                18165507           1       0
Nantulya FN, Kengeya-Kayondo JF, Ogundahunsi OA.
Rugemalila JB, 18165506            1       0
                Ogundahunsi OA, Stedman TT, Kilama WL.
Sadasivaiah S, 18165500
                Tozan Y, Breman JG.1       0
                18165497           1       1           1            M,
Alilio M, Mwenesi H, Barat LM, Payes RM, Prysor-Jones S, Diara 1 McGuire D, Shaw W.
                18165496           1       0
Lengeler C, Grabowsky M, McGuire D, deSavigny D.
                18165495
Gelband H, Seiter A.               1       1           0
                18165494                   1           0
Goodman C, Brieger W, Unwin A,1Mills A, Meek S, Greer G.
                18165492
Bosman A, Mendis KN.               1       1           0
                18165491
Nosten F, White NJ.                1       0
                18165488
Vestergaard LS, Ringwald P.        1       0
Teklehaimanot18165486 GC, Sachs JD. 0
                 A, McCord         1
                18165485           1       0
Cibulskis RE, Bell D, Christophel EM, Hii J, Delacollette C, Bakyaita N, Aregawi MW.
                18165484
Lubell Y, Reyburn H, Mbakilwa H,1          1                       1
                                    Mwangi R, Chonya1K, Whitty CJ, Mills A.
                18165483           1       0
Wongsrichanalai C, Barcus MJ, Muth S, Sutamihardja A, Wernsdorfer WH.
                18165482
Mboera LE, Makundi EA, Kitua AY.   1       0
                18165481
Makundi EA, Mboera LE, Malebo 1            0
                                   HM, Kitua AY.
Price RN, Tjitra18165478 CA, Yeung S, White NJ, Anstey NM.
                 E, Guerra         1       0
                18165477
Kumar A, Valecha N, Jain T, Dash 1 AP.     0
                18165475           1
Coulibaly SO, Gies S, D'Alessandro U. 0
                18165468
Koram KA, Molyneux ME.             1       0
                18228564
Shapiro HM, Perlmutter NG.         1       1           0
                18228555
Janossy G, Shapiro H.              0
                18226224           1       1
Lubell Y, Hopkins H, Whitty CJ, Staedke SG, Mills A. 1             1
Kerouedan D. 18225738              0
                18218148                   MJ,
Fillinger U, Kannady K, William G,1Vanek 0 Dongus S, Nyika D, Geissbühler Y, Chaki PP, Govella NJ, Mathenge EM, Singer BH
                18215334
Koella JC, Zaghloul L.             1      0
                18199700
Lubell Y, Reyburn H, Mbakilwa H,1         1                         1
                                    Mwangi R, Chonya1S, Whitty CJ, Mills A.
                18199699
Bisoffi Z, Van den Ende J.         1      1            1            0
                1
MacKinnon AS. 8198530              1      0
                18190973           0
Jenwitheesuk E, Horst JA, Rivas KL, Van Voorhis WC, Samudrala R.
                18187774
Gu W, Utzinger J, Novak RJ.        1      0
Onwujekwe O,18182095 B, Eze1S, Obikeze E, Okoli0C, Ochonma O.
                 Uzochukwu                1
                18179716           1      1            1            1
Njau JD, Goodman CA, Kachur SP, Mulligan J, Munkondya JS, McHomvu N, Abdulla S, Bloland P, Mills A.
                18165515            J,    1            1
Somi MF, Butler JR, Vahid F, Njau1 Kachur SP, Abdulla S.            0
                18165513
Senn N, D'Acremont V, Landry P, 1  Genton0B.
Lambrechts L, 18164248 Boëte C. 1
                Koella JC,                0
                20845864
Fried ST, Kowalski-Morton S.       0
                19946608           1
Mubyazi GM, Magnussen P, Goodman C,0Bygbjerg IC, Kitua AY, Olsen OE, Byskov J, Hansen KS, Bloch P.
                19736391
Aina BA, Tayo F, Taylor O.         1      1            1            1
                19736382
Rodriguez-Morales AJ.              0
                18160984           0
Stein C, Kuchenmüller T, Hendrickx S, Prüss-Ustün A, Wolfson L, Engels D, Schlundt J.
Klein I.        18159662           1      0
                18157325
Guimarães RM, Asmus CI, Meyer 1    A.     1            1            0
                18093319           Mataya0RH.
Muula AS, Rudatsikira E, Siziya S, 1
                18087901
Edson F, Kayombo EJ.               1      0
                18082862            C,    0
N'guessan R, Knols BG, Pennetier1 Rowland M.
Loewenberg S.18074434              1      0
                18070099           1      0
Loiseau C, Zoorob R, Garnier S, Birard J, Federici P, Julliard R, Sorci G.
                18063190           Lin
Webert KE, Cserti CM, Hannon J, 0 Y, Pavenski K, Pendergrast JM, Blajchman MA.
Singer BH, Ryff18060076
                 CD.               0
Bletter N.      18053260           0
Ntata PR.       18040535           0
                18038063           0
Komatsu R, Low-Beer D, Schwartländer B.
                1
Kazatchkine M. 8038053             0
Anderson T. 18033269               0
                18025042           0
Xiang Z, Todd T, Ku KP, Kovacic BL, Larson CB, Chen F, Hodges AP, Tian Y, Olenzek EA, Zhao B, Colby LA, Rush HG, Gilsdorf JR, J
                18022027
Yasuoka J, Poudel KC, Jimba M. 1          0
                18020620
Tetteh KK, Polley SD.              1      0
                18008244           1      0
Ord R, Alexander N, Dunyo S, Hallett R, Jawara M, Targett G, Drakeley CJ, Sutherland CJ.
Mehra R.        17993308           0
Zuckerman JN,17983971
                 Toovey S.         0
                17973989           BL,    0
Casimiro SL, Hemingway J, Sharp 1 Coleman M.
Enserink M. 17962536               1      0
Roberts L.      17962534           1      0
                17961852
[No authors listed]                0
                17961211           1      1
Killeen GF, Tami A, Kihonda J, Okumu FO, Kotas ME, 1                0
                                                        Grundmann H, Kasigudi N, Ngonyani H, Mayagaya V, Nathan R, Abdulla S
                17956496
Deressa W, Hailemariam D, Ali A.1         1            1            1
                17956495            JD,   1            1
Somi MF, Butler JR, Vahid F, Njau1 Kachur SP, Abdulla S.            1
                17954542           0
Reddy M, Gill SS, Kalkar SR, Wu W, Anderson PJ, Rochon PA.
                17952233          D,
Nojilana B, Norman R, Bradshaw 0 van Stuijvenberg ME, Dhansay MA, Labadorios D; South African Comparative Risk Assessm
                17952231          0
Nannan N, Norman R, Hendricks M, Dhansay MA, Bradshaw D; South African Comparative Risk Assessment Collaborating Gro
Smilkstein T. 17946623            1      0
                17920905
[No authors listed]               1      0
                17897454          1
Menendez C, Schellenberg D, Macete E, 0  Aide P, Kahigwa E, Sanz S, Aponte JJ, Sacarlal J, Mshinda H, Tanner M, Alonso PL.
                17620751
Greco DB, Simão M.                0
                17884314
Soh PN, Benoit-Vical F.           1      0
Callaway E. 17882177              1      0
                17877879          1
Babu BV, Mishra S, Mishra S, Swain BK. 1             1x
                17868471          1      0
Kindermans JM, Pilloy J, Olliaro P, Gomes M.
                17868467          1      0
Boonma P, Christensen PR, Suwanarusk R, Price RN, Russell B, Lek-Uthai U.
                17853605          1      MC,
Federici BA, Park HW, Bideshi DK, Wirth 0 Johnson JJ, Sakano Y, Tang M.
                17827360          1       DR,        0
Collinet-Adler S, Stauffer WM, Boulware 1 Larsen KL, Rogers TB, Williams DN.
Kolaczinski JH, 17826335 NB, Onapa AW, Ndyomugyenyi R, Kakembo AS, Brooker S.
                 Kabatereine      0
                17824319
Aplogan A, Ahanhanzo C.           1      0
                17804664          1      0
Crameri A, Marfurt J, Mugittu K, Maire N, Regös A, Coppee JY, Sismeiro O, Burki R, Huber E, Laubscher D, Puijalon O, Genton B
                17768521          Delacollette C, Crowell V, Tan-Torres T, Ameneshewa B, Teklehaimanot A, Nafo-Traoré F.
Kiszewski A, Johns B, Schapira A, 1      0
                17713981
Noor AM, Amin AA, Akhwale WS,1Snow RW.   0
                17713979
Low-Beer D, Afkhami H, Komatsu0R, Banati P, Sempala M, Katz I, Cutler J, Schumacher P, Tran-Ba-Huy R, Schwartländer B.
                17709089                 0
Manonmani AM, Sadanandane C,1Sahu SS, Mathivanan A, Jambulingam P.
Olakowski T. 17702449             0
                17697325          1      0
Bass C, Nikou D, Donnelly MJ, Williamson MS, Ranson H, Ball A, Vontas J, Field LM.
                17695020                 0
Hougard JM, Martin T, Guillet PF,1Coosemans M, Itoh T, Akogbéto M, Chandre F.
                17695017
Moore SJ, Hill N, Ruiz C, Cameron1MM. 0
                17691441
Mbacham W, Njikam N.              1      0
                17691424
Kiechel JR, Pécoul B.             1      0
                17690054
Dye C, Williams BG.               0
                17686741
Salami KK, Brieger WR.            1      0
                17684865
Qazi S, Shaikh BT.                1      1           1           1
Sharma VP. 17683630               1      0
                17678537          1      1
Moore SJ, Darling ST, Sihuincha M, Padilla N, Devine0 GJ.
McCarthy M. 17668470              0
                17661691
Tilley L, Davis TM, Bray PG.      1      0
                17652852          0
Mikaeili F, Fakhar M, Sarkari B, Motazedian MH, Hatam G.
                17651488          1      0
Kazembe LN, Muula AS, Appleton CC, Kleinschmidt I.
                17645185          1      0
Garavito G, Bertani S, Rincon J, Maurel S, Monje MC, Landau I, Valentin A, Deharo E.
                17642689
Goyal RK, Mohapatra TM.           0
                17640357          1      0
Gerstl S, Cohuet S, Edoh K, Brasher C, Lesage A, Guthmann JP, Checchi F.
                17631372
Killeen GF, Smith TA.             1      0
                17623092
Kindermans JM, Vandenbergh D, 1           E,
                                  Vreeke0 Olliaro P, D'Altilia JP.
                17620634          1      0
Sogoba N, Doumbia S, Vounatsou P, Baber I, Keita M, Maiga M, Traoré SF, Touré A, Dolo G, Smith T, Ribeiro JM.
                17620629
Tolentino K, Friedman JF.         0
Onwujekwe O,17620625 Shu E, Uzochukwu B.
                 Ojukwu J,        1      0
Hasegawa GR. 17615851             1      0
Motoshima K, 17607684 Yoshikawa M, Fujimoto K, Tai A, Kakuta H, Sasaki K.
                Hiwasa Y,         1      0
Webster J, Hill 17599950 Hanson K.
                J, Lines J,       1      1          1            0
Teklehaimanot17597200JD, Curtis C.
                 A, Sachs         1      0
Grabowsky M,17596247 Selanikio J.
                Nobiya T,         1      1          1            0
                17586307
Haines A, Sanders D, Lehmann U,0   Rowe AK, Lawn JE, Jan S, Walker DG, Bhutta Z.
Majambere S, 17555570 Green0C, Kandeh B, Fillinger U.
                Lindsay SW,
Sorenson E. 17554811              0
Holen Ø.        17551569          1      0
                17546312          0
Stenberg K, Johns B, Scherpbier RW, Edejer TT.
                17535417          1      0
Amin AA, Zurovac D, Kangwana BB, Greenfield J, Otieno DN, Akhwale WS, Snow RW.
                17533134          1      0
Cruz-Monteagudo M, Borges F, Perez González M, Cordeiro MN.
                17531888
Radelet S, Siddiqi B.             0
                17531868
Murray C, Lu C, Michaud C.        0
                17521529
Kruse AY, Bygbjerg IC.            0
                17519418
Zuccotti G, DeAngelis CD.         1      0
Idro R, Ndiritu 17519413 B, Mithwani S, Maitland K, Berkley J, Crawley J, Fegan G, Bauni E, Peshu N, Marsh K, Neville B, Newto
                M, Ogutu          1      0
                17519001
Williams M, Louw AI, Birkholtz LM.1      0
                17517643          1      0
O'Donnell A, Premawardhena A, Arambepola M, Allen SJ, Peto TE, Fisher CA, Rees DC, Olivieri NF, Weatherall DJ.
                17517146          1
Jimoh A, Sofola O, Petu A, Okorosobo T. 1           1            1
                17508469
Begovac J, Zekan A, Skoko-Poljak 0D.
Yamada T.       17507956          0
                17488900          1      1
Wiseman V, Scott A, McElroy B, Conteh L, Stevens W. 1            0
                17459906          0
Mubyazi GM, Mushi A, Kamugisha M, Massaga J, Mdira KY, Segeja M, Njunwa KJ.
Attaran A.      17452652          1      0
                17445255          1
Yé Y, Kyobutungi C, Louis VR, Sauerborn 0R.
Nau JY.         17444210          1      1          0
Ratna J, Rifkin 17440001
                S.                0
                17439607          0
Huang Y, Magori K, Lloyd AL, Gould F.
                17425775          0
Kazembe LN, Appleton CC, Kleinschmidt I.
                17414208
Haldar K, Mohandas N.             1      0
                17403557
Bermúdez A, Reyes C, Guzmán F, 1         0
                                  Vanegas M, Rosas J, Amador R, Rodríguez R, Patarroyo MA, Patarroyo ME.
                17401497          1      0
Rodulfo H, De Donato M, Mora R, González L, Contreras CE.
                17399751          1      0
Covello PS, Teoh KH, Polichuk DR, Reed DW, Nowak G.
                17388677          1
Newton PN, Green MD, Fernandez F. 0
                17377541
[No authors listed]               0
                17367208          Imrie H, Migot-Nabias F, Brown SM, McVean GA, Day KP.
Barry AE, Leliwa-Sytek A, Tavul L,1      0
                17362598
Vyas S, Hanson K, Lines J.        1      1          1x
Koech DK.       17348736          1      1          1            0
Kaufmann SH, 17342144
                Parida SK.        0
                17340848
Mbonye AK, Neema S, Magnussen P. 01
Choudhury LP,17329382
                 Tetali S.        0
Ungar WJ.       17326379          0
Halvorson GC. 17315558            0
                17313682          1      1          1            1
Chanda P, Masiye F, Chitah BM, Sipilanyambe N, Hawela M, Banda P, Okorosobo T.
                17313510
Conteh L, Stevens W, Wiseman V.    1       0
                17310681           1
Ntonifor NN, Ngufor CA, Kimbi HK, Oben0     BO.
Nelson CM. 17308719                1       1          0
                17308714
Torres JR, Castro J.               0
                17304756           1
Doannio JM, Konan YL, Amalaman K, Attiah J.0
                17304741                   0
Chiabi A, Tchokoteu PF, Toupouri1A, Mbeng TB, Wefuan J.
                17298144
Edoh D, Brenya A.                  0
Schubert C. 17290251               1       0
                17287244           1       0
Orimadegun AE, Fawole O, Okereke JO, Akinbami FO, Sodeinde O.
                17286032
Chekem L, Wierucki S.              1       0
Pilloy J.       17286020           1       0
                17280483
Moore AC, Hutchings CL.            1       0
Onwujekwe O,17270139 B, Ojukwu J, Dike N, Shu 1
                 Uzochukwu         1       1          E.        1
                17263523           1       0
Gemma S, Campiani G, Butini S, Kukreja G, Joshi BP, Persico M, Catalanotti B, Novellino E, Fattorusso E, Nacci V, Savini L, Tara
Wakabi W. 17261822                 0
                17261185           1       1
Agha S, Van Rossem R, Stallworthy G, Kusanthan T. 1             1
                17258644
[No authors listed]                1       0
                17255221           SO,
Mokuolu OA, Okoro EO, Ayetoro 1 Adewara AA.0
                17251086           1       1           J,
Worrall E, Morel C, Yeung S, Borghi J, Webster J, Hill1 Wiseman1V, Mills A.
                17251083
Menéndez C, D'Alessandro U, ter1           0
                                    Kuile FO.
                17244405
Makani J, Williams TN, Marsh K. 1          0
                17244369           0
Franco-Paredes C, Jones D, Rodríguez-Morales AJ, Santos-Preciado JI.
                17242833           0
Behets FM, Matendo R, Vaz LM, Kilese N, Nanlele D, Kokolomami J, Okitolando EW, Van Rie A.
                17240921
Tomioka H, Namba K.                0
Engle PL, Black17240290
                 MM, Behrman JR,0Cabral de Mello M, Gertler PJ, Kapiriri L, Martorell R, Young ME; International Child Develop
                17239256           1       0
Njama-Meya D, Clark TD, Nzarubara B, Staedke S, Kamya MR, Dorsey G.
                17220424           1       0
Bacon DJ, Latour C, Lucas C, Colina O, Ringwald P, Picot S.
                17209310           1
Idowu ET, Mafe MA, Otubanjo OA, Adeneye AK.0
                17207158           1
Wacira DG, Hill J, McCall PJ, Kroeger A. 1            1         1
Waltz E.        17206113           1       0
Darnton-Hill I, 17204980E, Cogill B, Hossain SM.
                Kennedy            0
                17199752
Stachurski F, Lancelot R.          0
Bate R.         17197684           0
                17196105           1       1
Larson BA, Amin AA, Noor AM, Zurovac D, Snow RW.      1         1
                17181502
Martin JA, Mak DB.                 0
                17176001
Girón SL, Mateus JC, Castellar CE.1        1          1         1 Spanish
                17172390           1       0
Temu EA, Kimani I, Tuno N, Kawada H, Minjas JN, Takagi M.
                17167966
Pray R, Nunn P, Luelmo F.          0
                17164791           1       Sow PS, Hofmann C, Lieber A.
Strauss R, Hüser A, Ni S, Tuve S, Kiviat N,0
                17163809
Kokwaro G, Mwai L, Nzila A.        1       0
                17159893                   0
Rafael ME, Taylor T, Magill A, Lim1YW, Girosi F, Allan R.
Uhlemann AC, 17152017 R, Ashley EA, Brockman A, Singhasivanon P, Krishna S, White NJ, Nosten F, Price RN.
                McGready           1       0
Onwujekwe O,17140449               Uzochukwu B, Ezumah N, Shu E, Okonkwo P.
                 Dike N, Ojukwu J, 0
Kerr T, Kaplan 17136907            0
                K, Suwannawong P, Wood E.
                17131241         1
Westerfeld N, Pluschke G, Zurbriggen R. 0
                17116676
Baniecki ML, Wirth DF, Clardy J. 1        0
                17111981         1        0
Ndour CT, Ba O, Manga NM, Fortes ML, Nyamwasa D, Sow PS.
Kshirsagar NA.17102549           1        0
                17096840         1        0
Killeen GF, Kihonda J, Lyimo E, Oketch FR, Kotas ME, Mathenge E, Schellenberg JA, Lengeler C, Smith TA, Drakeley CJ.
Rugemalila JB, 17090308 Kilama 1
                 Wanga CL,        WL. 0
Pulcinelli C. 17080629           0
                17080030
Nwaka S, Hudson A.               0
                17071287         0
Filippi V, Ronsmans C, Campbell OM, Graham WJ, Mills A, Borghi J, Koblinsky M, Osrin D.
                17067053         1        0
Curtis CF, Maxwell CA, Magesa SM, Rwegoshora RT, Wilkes TJ.
                17061176         0
Wandja SN, Mussa K, Kamche EM, Kalangu K.
                17054742
Fillinger U, Lindsay SW.         1        0
                17050066         1        0
Briggs C, Da Costa A, Freeman L, Aucamp I, Ngubeni B, Machin SJ.
Blackburn BG, 17038688Gotau H,1
                Eigege A,                 0
                                  Gerlong G, Miri E, Hawley WA, Mathieu E, Richards F.
Sagara I, Dicko17038684 A, Guindo O, Kone M, Tolo Y, Thera MA, Sogoba M, Fofana M, Ouattara A, Sissoko M, Jansen HF, Do
                 A, Djimde       1        0
                17038683
Eliades MJ, Wolkon A, Morgah K,1          0
                                  Crawford SB, Dorkenoo A, Sodahlon Y, Hawley WA, Hightower AW, Kuile FO, Terlouw DJ.
                17032061         1
Beyrer C, Suwanvanichkij V, Mullany LC, 0 Richards AK, Franck N, Samuels A, Lee TJ.
                17032059          TK,
Wiseman V, Kim M, Mutabingwa 1 Whitty CJ. 1             1          1
                17021299
Sidibe M, Ramiah I, Buse K.      1        0
                17015763         1        D,
Walther M, Woodruff J, Edele F, Jeffries 0 Tongren JE, King E, Andrews L, Bejon P, Gilbert SC, De Souza JB, Sinden R, Hill AV, R
Chowdhury K, 17014967
                Bagasra O.       1        0
                17013993         0
Berndt ER, Glennerster R, Kremer MR, Lee J, Levine R, Weizsäcker G, Williams H.
                17003770         1
Bell D, Wongsrichanalai C, Barnwell JW. 0
                16999885
Kruse AY, Bygbjerg IC.           0
                16997716         1        1             0
Plebanski M, Lopez E, Proudfoot O, Cooke BM, Itzstein M, Coppel RL.
Shiffman J. 16984894             0
                16979202
Erhart A, Thang ND, Xa NX, Thieu1         0
                                  NQ, Hung LX, Hung NQ, Nam NV, Toi LV, Tung NM, Bien TH, Tuy TQ, Cong LD, Thuan LK, Coo
Prüss-Ustün A,16971860 C.
                 Corvalán        0
                16970824
Ernst KC, Adoka SO, Kowuor DO, 1          ML,
                                  Wilson 0 John CC.
                16968935         0
Polage CR, Bedu-Addo G, Owusu-Ofori A, Frimpong E, Lloyd W, Zurcher E, Hale D, Petti CA.
Onwujekwe O,16968915 Ezumah1N, Uzochukwu B, Dike N, Soludo E.
                 Ojukwu J,                1             1          1
Bryan JP.       16968914         1        1             0
                16966402         1        0
Dow GS, Heady TN, Bhattacharjee AK, Caridha D, Gerena L, Gettayacamin M, Lanteri CA, Obaldia N 3rd, Roncal N, Shearer T, S
                16957045         1        0
Zhou Z, Poe AC, Limor J, Grady KK, Goldman I, McCollum AM, Escalante AA, Barnwell JW, Udhayakumar V.
Mhalu FS.       16941945         1        0
                16939658
Chuma JM, Thiede M, Molyneux CS. 1        1             1          1
                16934158
Adam I, Magzoub M, Osman ME,1             0
                                  Khalil IF, Alifrangis M, Elmardi KA.
                16931824         1        1             1
Tediosi F, Hutton G, Maire N, Smith TA, Ross A, Tanner M.          1
                16931823
Hutton G, Tediosi F.             1        1             1          1
                16931820         1        1             1          1
Tediosi F, Maire N, Smith T, Hutton G, Utzinger J, Ross A, Tanner M.
                16931810         1        0
Smith T, Killeen GF, Maire N, Ross A, Molineaux L, Tediosi F, Hutton G, Utzinger J, Dietz K, Tanner M.
                16924820         1        1             J,         1 French
Besnard P, Foumane V, Foucher JF, Beliaud P, Costa 1 Monnot N, Le Mire J, Carnevale P.
Bournazos SN, 16924651 Patrinos0 Papadakis MN.
                 Tserga A,        GP,
Willis RC.      16913058         0
                  16912713        1
Bell D, Wongsrichanalai C, Barnwell JW. 1            0
                  16903882        1
Zurovac D, Larson BA, Akhwale W, Snow1     RW.       1            1
                  16895033
Fantahun M, Degu G.               0
                  16892622        1       0
Coleman M, Sharp B, Seocharan I, Hemingway J.
Check E.          16892022        0
                  16892014
[No authors listed]               1       0
                  16890842
Feachem RG, Sabot OJ.             0
Lu C, Michaud 16890835 K, Murray CJ. 0
                  CM, Khan        1
                  16884613
Uzochukwu BS, Onwujekwe OE. 0
                  16883302
Brogan D, Mossialos E.            0
                  16879742         KA, 0
Malik EM, Mohamed TA, Elmardi1 Mowien RM, Elhassan AH, Elamin SB, Mannan AA, Ahmed ES.
                  16878232
Kapiriri L, Martin DK.            0
                  16872529        1
Kimani EW, Vulule JM, Kuria IW, Mugisha F.0
                  16871329        1       0
Bukirwa H, Yeka A, Kamya MR, Talisuna A, Banek K, Bakyaita N, Rwakimari JB, Rosenthal PJ, Wabwire-Mangen F, Dorsey G, St
                  16862939
Temple VJ, Masta A.               0
                  16854546
Le Bras J, Musset L, Clain J.     1       0
                  16844496
Sarbib JL, Nankani G, Patel P.    1       1          0
                  16844495        1       0
Attaran A, Barnes KI, Bate R, Binka F, d'Alessandro U, Fanello CI, Garrett L, Mutabingwa TK, Roberts D, Sibley CH, Talisuna A, V
Lambo E.          16844476        1       0
                  16841136        0
Losina E, Anglaret X, Yazdanpanah Y, Wang B, Toure S, Seage GR 3rd, N'Dri-Yoman T, Walensky RP, Dakoury-Dogbo N, Goldie
                  16837699        0
Rwakimari JB, Hopkins DR, Ruiz-Tiben E.
Anegón Blanco16834952 J, Valcárcel Rivera Y, Bastero Gil R, Gil de Miguel A.
                   M, Esteban     1       0
                  16821444        0
Khieu V, Odermatt P, Mel Y, Keluangkhot V, Strobel M.
Moree M.          16821285        0
                  16820067        1       0
Kulkarni MA, Rowland M, Alifrangis M, Mosha FW, Matowo J, Malima R, Peter J, Kweka E, Lyimo I, Magesa S, Salanti A, Rau M
                  16816845        1       0
Chong CR, Chen X, Shi L, Liu JO, Sullivan DJ Jr.
                  16815354
[No authors listed]               1       0
Floyd K, Arora 16799727 KJ, Lonnroth K, Singla N, Akbar Y, Zignol M, Uplekar M.
                  VK, Murthy      0
                  16798391         KZ,    0
Smithuis F, Kyaw MK, Phe O, Aye1 Htet L, Barends M, Lindegardh N, Singtoroj T, Ashley E, Lwin S, Stepniewska K, White NJ.
                  16798368
Duffy PE, Mutabingwa TK.          1       0
                  16788522        0
Dia Kane Y, Toure NO, Diatta A, Ndiaye EH, Niang A, Thiam K, Mbaye Sylva FB, Hane AA.
                  16772004        1       1          S,           0
Macintyre K, Keating J, Okbaldt YB, Zerom M, Sosler 1 Ghebremeskel T, Eisele TP.
Renne E.          16765498        0
                  16765473        1       0
Betanzos-Reyes AF, Rodríguez MH, Duran-Arenas LG, Hernández-Avila JE, Méndez-Galván JF, Monroy OJ, Coyner RT.
                  16752952        1       0
Newton PN, McGready R, Fernandez F, Green MD, Sunjio M, Bruneton C, Phanouvong S, Millet P, Whitty CJ, Talisuna AO, Prou
                  16735163
Hill J, Lines J, Rowland M.       1       0
Molyneux DH. 16735161             1       0
                  16731270
Lopez AD, Mathers CD, Ezzati M, 0 Jamison DT, Murray CJ.
                  16729389
[No authors listed]               0
                  16725373        1       0
Greenwood BM, Bhasin A, Bowler CH, Naylor H, Targett GA.
                  1
Rabinovich NR. 6723275            0
Kaplan WA. 16719925               0
                  16713358        M,      0
Hemingway J, Beaty BJ, Rowland 1 Scott TW, Sharp BL.
                  16712738        1       1
Maxwell CA, Rwegoshora RT, Magesa SM, Curtis CF. 1                0
Vasan A, Hoos 16710550            0
                D, Mukherjee JS, Farmer PE, Rosenfield AG, Perriëns JH.
Hale VG.        16710392          1       0
                16707275
Malkin E, Dubovsky F, Moree M. 1          0
United States. 16700110
                Congress.         1       0
                16690361          1
Osman ME, Mockenhaupt FP, Bienzle U, 0    Elbashir MI, Giha HA.
Loewenberg S.16683301             1       0
                16682433                  1
Goodman CA, Mutemi WM, Baya1EK, Willetts A, Marsh V. 1          1
                16681856
Kolaczinski J, Hanson K.          1       1          1          1
                16676415          1
Polley SD, McRobert L, Sutherland CJ. 0
Su TT, Pokhrel 16673075 A, Flessa S.
                S, Gbangou        0
                16650629
[No authors listed]               1       0
                16646330          1       0
Ansari MA, Sreehari U, Razdan RK, Mittal PK.
Hopkin M.       16641962          1       0
                16615615          1       0
Doannio JM, Doudou DT, Konan LY, Djouaka R, Pare Toe L, Baldet T, Akogbeto M, Monjour L.
Bourée P.       16614591          1       0
                16612385          1       0
Ro DK, Paradise EM, Ouellet M, Fisher KJ, Newman KL, Ndungu JM, Ho KA, Eachus RA, Ham TS, Kirby J, Chang MC, Withers ST,
Towie N.        16612346          1       0
                16606973
Killeen GF, Tanner M, Mukabana 1          0
                                  WR, Kalongolela MS, Kannady K, Lindsay SW, Fillinger U, de Castro MC.
White NJ.       16573360          1       0
                16569252          1
Kachur SP, Black C, Abdulla S, Goodman C. 1          0
                16565802
Laurent D, Pietra F.              1       0
                16564223
Marrelli MT, Moreira CK, Kelly D,1         L,
                                  Alphey0 Jacobs-Lorena M.
                16553929          1       0
Newman RD, Moran AC, Kayentao K, Benga-De E, Yameogo M, Gaye O, Faye O, Lo Y, Moreira PM, Doumbo O, Parise ME, Stek
                16553928          1       0
Mulligan JA, Mandike R, Palmer N, Williams H, Abdulla S, Bloland P, Mills A.
                16553925
Wiseman V, McElroy B, Conteh L,1Stevens W.1          1          1
Hill J, Kazembe16553924
                 P.               1       0
                16553923          1                   JP,
Rolland E, Checchi F, Pinoges L, Balkan S,1Guthmann 1 Guerin PJ.1
                16553910          1       N,
Njau JD, Goodman C, Kachur SP, Palmer 0 Khatib RA, Abdulla S, Mills A, Bloland P.
                16543418
Sachs JD, Hotez PJ.               0
                16525099          1       0
McNamara DT, Kasehagen LJ, Grimberg BT, Cole-Tobian J, Collins WE, Zimmerman PA.
Laxminarayan 16522574 Smith DL.
                R, Over M,        1       0
                16517998          0
Mathur P, Samantaray J, Chauhan NK.
                16515516
Binka F, Akweongo P.              1       0
Vasan A, Hoos 16515506            1       0
                D, Mukherjee JS, Farmer PE, Rosenfield AG, Perriëns JH.
                16513493
Okoko BJ, Yamuah LK.              1       1          0
                16512325
Labonte R, Schrecker T.           0
                16507643          1       0
Rowe AK, Rowe SY, Snow RW, Korenromp EL, Schellenberg JR, Stein C, Nahlen BL, Bryce J, Black RE, Steketee RW.
                16505556          1       1
Mendiratta DK, Bhutada K, Narang R, Narang P.        0
Davidson C. 16501706              1       0
Chen I.         16497574          0
                16492359          1       0
Mboera LE, Fanello CI, Malima RC, Talbert A, Fogliati P, Bobbio F, Molteni F.
                16490155
Mbonye AK, Neema S, Magnussen P. 01
                16488909
Maydt J, Lengauer T.              0
                16463750          1
Rajab JA, Waithaka PM, Orinda DA, Scott1CS.          1x
                16462987
Townson H, Nathan MB, Zaim M,1               P,
                                     Guillet 0 Manga L, Bos R, Kindhauser M.
                16457724            1        0
Mukabana WR, Kannady K, Kiama GM, Ijumba JN, Mathenge EM, Kiche I, Nkwengulila G, Mboera L, Mtasiwa D, Yamagata Y, v
                16456965
[No authors listed]                 0
Vogel G.        16456044            0
                16454394            1        0
Jayatilaka KD, Taviri J, Kemiki A, Hwaihwanje I, Bulungol P.
                16452936
[No authors listed]                 1        0
                16451729            1        0
Yé Y, Hoshen M, Louis V, Séraphin S, Traoré I, Sauerborn R.
                16451343
Noor AM, Amin AA, Gething PW, 0     Atkinson PM, Hay SI, Snow RW.
                16450675
Osero JS, Otieno MF, Orago AS. 1             0
Ongore D.       16450674            1        0
                16442544            1        0
Sacci JB Jr, Alam U, Douglas D, Lewis J, Tyrrell DL, Azad AF, Kneteman NM.
                16438784            1        1          1          0
Mubyazi G, Massaga J, Kamugisha M, Mubyazi JN, Magogo GC, Mdira KY, Gesase S, Sukwa T.
                16438676
Marsh K, Kinyanjui S.               1        0
                16438128            1        0
Amerasinghe PH, Alifrangis M, van der Hoek W, Wirtz RA, Amerasinghe FP, Konradsen F.
                16436216
Noor AM, Omumbo JA, Amin AA,0       Zurovac D, Snow RW.
                16435910
Utzinger J, de Savigny D.           0
                16435908            A,       0
Hotez PJ, Molyneux DH, Fenwick 1 Ottesen E, Ehrlich Sachs S, Sachs JD.
                16420686
Ferreira ID, Rosário VE, Cravo PV.1          0
Murray S.       16415459            1        0
                16412105                     0
Rodríguez-Morales AJ, Delgado L,1Martínez N, Franco-Paredes C.
Ahmad K.        16411291            0
Barat LM.       16407339            1        0
Kamat VR.       16403595            0
                16377534            1        0
Lang T, Hughes D, Kanyok T, Kengeya-Kayondo J, Marsh V, Haaland A, Pirmohamed M, Winstanley P.
Wolfson W. 16356840                 1        0
Onwujekwe O,16356177                1
                 Malik el-FM, Mustafa SH,1    Mnzava A. 1          1
                16356176
Masiye F, Rehnberg C.               1        1          1          1
Onwujekwe O,16354477                1
                 Dike N, Uzochukwu B. 0
Panter-Brick C,16352385 Lomas H, Pinder M, Lindsay SW.
                 Clarke SE,         1        0
Vogel G.        16339425            0
                16339303             KH, 0
Poon LL, Wong BW, Ma EH, Chan1 Chow LM, Abeyewickreme W, Tangpukdee N, Yuen KY, Guan Y, Looareesuwan S, Peiris J
Dunavan CP. 16323694                1        0
                16317032
Mbonye AK, Neema S, Magnussen P. 0  1
Bass E.         16315356            0
                16302058            1        0
Basso LA, da Silva LH, Fett-Neto AG, de Azevedo WF Jr, Moreira Ide S, Palma MS, Calixto JB, Astolfi Filho S, dos Santos RR, Soa
                16302041            1        1          1
Wiseman V, Onwujekwe O, Matovu F, Mutabingwa TK, Whitty CJ.        1
                16301667            1
Calvo-Calle JM, Oliveira GA, Nardin EH. 0
Onwujekwe O,16301307 Mustafa SH, Mnzavaa A. 1
                 Malik el-F,        1        1                     1
Tami A, Mbati 16301306 R, Mponda H, Lengeler C, Schellenberg JR.
                J, Nathan           1        1          0
Mockenhaupt 16297285 S, Eggelte TA, Agana-Nsiire P, Stollberg K, Mathieu A, Markert M, Otchwemah RN, Bienzle U.
                FP, Ehrhardt        1        0
                16294806
Okogun GR, Amadi AN.                1        1          1          1
Parry J.        16283044            0
                16282381
Morel CM, Lauer JA, Evans DB. 1              1          1
Boutayeb A. 16274715                0
                16271626
[No authors listed]               1       0
Okie S.         16267316          1       0
Grabowsky M,16262740 Hawley W, Chimumbwa J, Hoyer S, Wolkon A, Selanikio J.
                Farrell N,        1       1          1           1
                16261915          1       0
Rhee M, Sissoko M, Perry S, Dicko A, McFarland W, Doumbo O.
                16258328
Ashley EA, White NJ.              1       0
Keiser J, Singer16253887
                 BH, Utzinger J. 1        0
                16243092          0
Premawardhena A, Fisher CA, Olivieri NF, de Silva S, Arambepola M, Perera W, O'Donnell A, Peto TE, Viprakasit V, Merson L, M
                16242017
Mubyazi GM, Gonzalez-Block MA.    1       0
                16232398
Kurtzhals JA, Vestergaard LS.     1       0
                16228800
Leonard L, VanLandingham M. 0
                16210483          0
Scott JA, Mlacha Z, Nyiro J, Njenga S, Lewa P, Obiero J, Otieno H, Sampson JS, Carlone GM.
                16206082          1       0
Meerman L, Ord R, Bousema JT, van Niekerk M, Osman E, Hallett R, Pinder M, Walraven G, Sutherland CJ.
                16198941          0
Camargo EC, Bacheschi LA, Massaro AR.
                16191732
Morgan M, Figueroa-Muñoz JI. 1            0
Ratte S, Slama 16190257
                K.                0
Chilaka MA. 16188287              1       0
                16185240
Worrall E, Basu S, Hanson K.      1       1          1           0
                16175672
[No authors listed]               1       0
Godal T.        16175171          0
                16172466
Duffy P, Fried M.                 1       0
                16168785          0
Rowe AK, de Savigny D, Lanata CF, Victora CG.
                16164605
Rasgon JL, Gould F.               1       0
                16163625
Whitty CJ, Staedke SG.            1       0
                16153298          1       0
Wang SJ, Lengeler C, Smith TA, Vounatsou P, Cissé G, Diallo DA, Akogbeto M, Mtasiwa D, Teklehaimanot A, Tanner M.
Eaton L.        16141151          0
                16138914          1       0
Ackerman H, Usen S, Jallow M, Sisay-Joof F, Pinder M, Kwiatkowski DP.
                16138310          0
Patrinos GP, Kollia P, Papadakis MN.
                16135201
Agnamey P, Brasseur P, Cisse M, 1         1          1x
                                  Gaye O, Dumoulin J, Rigal J, Taylor WR, Olliaro P.
                16134971
Andreasen MH, Curtis CF.          1       0
Cohen J.        16123274          0
                16122115
Deressa W, Olana D, Chibsa S. 1           0
                16119535
[No authors listed]               1       0
                16100424
Nandwani S, Mathur M, Rawat S.1           0
Mutabingwa TK.  16098946          1       0
Williams N. 16092150              1       0
Croft SL.       16087204          0
Rombo L.        16086897          1       0
                16084770          1
Biagini GA, O'Neill PM, Bray PG, Ward SA. 0
                16081889          1
Malhotra I, Dent A, Mungai P, Muchiri E,0  King CL.
                16077028          0
Zhong XB, Leng L, Beitin A, Chen R, McDonald C, Hsiao B, Jenison RD, Kang I, Park SH, Lee A, Gregersen P, Thuma P, Bray-Ward
Stevens W. 16076233               1       0
                16061450          1       0
Tsakala TM, Tona GL, Mesia K, Mboma JC, Vangu JM, Voso SM, Kanja GL, Kodondi KK, Mabela M, Walo R.
Williams N. 16059994              1       0
Ginsburg H. 16054105              1       0
Malone JB. 16044674               0
               16044241
Chanda I, Pan A, Dutta C.         1       0
               16042815
Amin AA, Snow RW.                 1       1           1           1
               16042780           1       1           RJ,
Magesa SM, Lengeler C, deSavigny D, Miller JE, Njau0 Kramer K, Kitua A, Mwita A.
Tangy F, Naim 16035943
               HY.                0
Olliaro P.     16032560           1       0
Onwujekwe O,16026623 B, Ezumah N,1Shu E.
                Uzochukwu         1                   1           1
               16018959           1       0
Sendagire H, Kaddumukasa M, Ndagire D, Aguttu C, Nassejje M, Pettersson M, Swedberg G, Kironde F.
               16012807
Munnur U, Karnad DR, Bandi VD, 0   Lapsia V, Suresh MS, Ramshesh P, Gardner MA, Longmire S, Guntupalli KK.
Mwenesi HA. 16011829              0
               16011828           1
Aguilar R, Dong Y, Warr E, Dimopoulos G.  0
               16010653
Seed CR, Kitchen A, Davis TM. 1           0
               16000348
Arrow KJ, Gelband H, Jamison DT.  1       0
               15999839           1
Danis M, Legros F, Brousse G; Groupe de0travail permanent du Conseil supérieur d'hygiène publique de France.
               15994838
O'Hare B, Venables J, Southall D. 0
               15992839           0
Sinuon M, Tsuyuoka R, Socheat D, Montresor A, Palmer K.
               15979769
Peny JM, Gleizes O, Covilard JP. 1        1           0
               15964964           0
Clark DV, Mammen MP Jr, Nisalak A, Puthimethee V, Endy TP.
               15964951           1       0
Causer LM, Bishop HS, Sharp DJ, Flagg EW, Calderon JF, Keane V, Shah JJ, Macarthur JR, Maloney SA, Cetron MS, Bloland PB.
               15960708           0
Oum S, Chandramohan D, Cairncross S.
               15960707           1       0
Van Geertruyden JP, Ntakirutimana D, Erhart A, Rwagacondo C, Kabano A, D'Alessandro U.
Brugha R.      15960700           0
Greenwood B. 15955523             1       0
Rudan I, Lawn 15950717 S, Rowe0AK, Boschi-Pinto C, Tomaskovid L, Mendoza W, Lanata CF, Roca-Feltrer A, Carneiro I, Schelle
               J, Cousens
Mockenhaupt 15941413 S, Dzisi SY, Teun Bousema J, Wassilew N, Schreiber J, Anemana SD, Cramer JP, Otchwemah RN, Sa
               FP, Ehrhardt       1       0
Nau JY.        15941092           1       1           0
Sibbald B.     15939906           1       0
               15939341
Hastings IM, Donnelly MJ.         1       0
Butler D.      15917762           1       0
               15917236           1       0
Mather MW, Darrouzet E, Valkova-Valchanova M, Cooley JW, McIntosh MT, Daldal F, Vaidya AB.
               15916239           1
Ali MS, Yousif AG, Mustafa MS, Ibrahim MH.1           0
               15916045           1       0
Vannaphan S, Saengnetswang T, Suwanakut P, Kllangbuakong A, Klinnak W, Rungmatcha P, Yeamput C, Tanachartwet W, Krud
Butler D.      15902217           1       0
               1
Mackinnon MJ. 5894181             1       0
Das P.         15889476           1       0
               15885143           1
Stevens W, Wiseman V, Ortiz J, Chavasse D.1           1           1
               15884471
Shubhakaran, Jakhar R.            1       1           1           0
               15868981           1
Mujinja PG, Makwaya CK, Sauerborn R. 1                1           1
               15850634           1       0
Greenwood BM, Bojang K, Whitty CJ, Targett GA.
               15850631           1       0
Mutabingwa TK, Anthony D, Heller A, Hallett R, Ahmed J, Drakeley C, Greenwood BM, Whitty CJ.
               15850630           1       0
Piola P, Fogg C, Bajunirwe F, Biraro S, Grandesso F, Ruzagira E, Babigumira J, Kigozi I, Kiguli J, Kyomuhendo J, Ferradini L, Taylo
               15838785           1       0
Drakeley CJ, Carneiro I, Reyburn H, Malima R, Lusingu JP, Cox J, Theander TG, Nkya WM, Lemnge MM, Riley EM.
               15832455
Van den Enden E.                  0
               15829188           0
Fauci AS, Touchette NA, Folkers GK.
                 15828586          1      0
Nambei WS, Gbagba FE, Ndémanga J, Doui-Doumgba K, Diallo TO, Ndadjimbaye V, Flori P, Perraut R, Garraud O.
Celli A, Coluzzi 15828438
                 M.                1      0
                 15828432
Opinel A, Gachelin G.              1      0
                 15823976          1      1           1x
Sauerborn R, Gbangou A, Dong H, Przyborski JM, Lanzer M.
                 15802726
Feachem RG, Sekhri NK.             0
                 15799458
Jowett M, Miller NJ.               1      0
Grabowsky M,15798843 Ahun M, Donna1R, Lengor M, Zimmerman D, Ladd H, Hoekstra E, Bello A, Baffoe-Wilmot A, Amofah G
                 Nobiya T,         1                  1            1
                 15790654          1      0
ter Veen A, Bouma M, van Herp M, Keiluhu K, Subianto B.
Dunavan CP. 15784849               0
                 15780338          1      1           1            0
Nkuo Akenji TK, Ntonifor NN, Ching JK, Kimbi HK, Ndamukong KN, Anong DN, Boyo MG, Titanji VP.
                 15774428
Birbeck GL, Taylor TE.             1      0
                 15772315
Bereczky S, Mårtensson A, Gil JP, 1Färnert0A.
                 15759000          1      0
Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI.
                 15757987          1      1
Croft AM, Winfield CR, Horsfall M, Quarrell MA.       0
                 15752520          0
Duffield A, Reid G, Shoham J, Walker D.
                 15748060
Parvez SD, Al-Wahaibi SS.          1      1           1            1
                 1
Abdo-Rabbo A. 5748057              1      1           0
Croft SL, Vivas 15748049 S.
                 L, Brooker        1      0
Couitchéré GL,15734134             1
                  Niangué-Beugré M, Oulaï1            1            1 French
                                           SM, Kouma M, Yao A, Atimère YN, Andoh J.
                 15720175
Davis TM, Karunajeewa HA, Ilett KF.1      0
Panosian CB. 15714418              1      1           0
Hook C.          15712565          1      0
Attaran A.       15712564          1      0
Aginam O.        15709301          1      0
                 15705005                 0
van Riemsdijk MM, Sturkenboom1MC, Pepplinkhuizen L, Stricker BH.
Senior K.        15702504          1      0
Onwujekwe O,15694504 B. 1
                  Uzochukwu               1           1            1
                 15689425
Johns B, Torres TT; WHO-CHOICE.    1      1           1            0
                 15686571
Hayward R, Saliba KJ, Kirk K.      1      0
                 15686067
Espino F, Beltran M, Carisma B. 1         0
                 15686066
Kajula PW, Kintu F, Barugahare J,1 Neema1S.           0
Uzochukwu B, 15686064 O, Eriksson B.1
                 Onwujekwe         1                  1x
                 15686063
Abdu Z, Mohammed Z, Bashier I, 1          1
                                   Eriksson B.        0
                 15679557          1      0
Checchi F, Roddy P, Kamara S, Williams A, Morineau G, Wurie AR, Hora B, Lamotte N, Baerwaldt T, Heinzelmann A, Danks A, P
                 15672521
[No authors listed]                0
                 15669385
Ansari MA, Razdan RK.              1      0
                 15664200
[No authors listed]                0
                 15663795          1      0
Grover-Kopec E, Kawano M, Klaver RW, Blumenthal B, Ceccato P, Connor SJ.
Agid F.          15662937          1      0
                 15662580          1      0
Rabe C, Paar WD, Knopp A, Münch J, Musch A, Rockstroh J, Martin S, Sauerbruch T, Dumoulin FL.
                 15655010          1
Worrall E, Hill J, Webster J, Mortimer J. 1           1            1
                 15653126          0
Accorsi S, Fabiani M, Nattabi B, Corrado B, Iriso R, Ayella EO, Pido B, Onek PA, Ogwang M, Declich S.
Benoit-Vical F. 15650942           1      0
Bonn D.          15645550          0
Bonn D.        15645540            0
               15642118
Brabin L, Brabin BJ.               1       0
Wise J.        15640926            1       0
Enserink M. 15637249               1       0
               15635037
Petithory JC, Ardoin F, Ash LR. 1          0
               15619273            0
Hanson K, McPake B, Nakamba P, Archard L.
               15610051            1       HA,
Davis TM, Hung TY, Sim IK, Karunajeewa 0 Ilett KF.
Temel T.       15607379            1       0
               15599985
Gatton ML, Cho-Min-Naing.          1       1           1x
               15589802             DD, 0
Wilson PE, Kazadi W, Kamwendo 1 Mwapasa V, Purfield A, Meshnick SR.
               15587443
[No authors listed]                1       0
               15579214             C,     0
Ngalame PM, Williams HA, Jones 1 Nyamongo I, Diop S, Gaspar F.
               15555670
Amexo M, Tolhurst R, Barnish G, 1  Bates I.0
Macauley C. 15550304               1       0
Onwujekwe O,15550301 Fox-Rushby J.
                Hanson K,          0
Bellamy C.     15550218            0
               15550119
Silva DG, Cooper PD, Petrovsky N.  0
               15548382            1       0
Dell'Eva R, Pfeffer U, Vené R, Anfosso L, Forlani A, Albini A, Efferth T.
               15544643            0
Adler RN, Smith J, Fishman P, Larson EB.
               15535968
Leung WH, Meng ZQ, Hui G, Ho WK.   1       0
               15534561
Olliaro P, Smith PG.               0
               15522492            1       1           1
Kikumbih N, Hanson K, Mills A, Mponda H, Schellenberg JA.           1
               15500290
Mandelbaum-Schmid J.               1       0
Vogel G.       15498976            1       0
               15484972
Ezhov MN, Zvantsov AB, Sergiev VP. 1       0
               15482406            1       1           0
Nathan R, Masanja H, Mshinda H, Schellenberg JA, de Savigny D, Lengeler C, Tanner M, Victora CG.
Bradbury J. 15470761               1       0
               15461570             SL,
Wang L, Webster DE, Wesselingh1 Coppel RL. 0
               15459161
Williams HA, Durrheim D, Shretta1R.        0
               15458449
Olowu WA, Adelusola KA.            0
Temel T.       15452735            1       0
               15450709            1
Samuelsen H, Toé LP, Baldet T, Skovmand O. 0
               15386683
Johns B, Baltussen R.              1       1           1            0
Onwujekwe O,15386652 J, Hanson K.
                Fox-Rushby         0
Hruska AJ.     15364175            0
Soto Tarazona 15361993             0
                A, Solari Zerpa L, Mendoza Requena D, Llanos-Cuentas A, Magill A.
               15361108
Muheki C, McIntyre D, Barnes KI.1          1           1            1
               15358726            0
Premawardhena A, De Silva S, Arambepola M, Olivieri N, Merson L, Muraco J, Allen A, Fisher C, Peto T, Vichinsky E, Weathera
               15331849
[No authors listed]                1       0
               15331846                    0
Royall J, Bennett M, van Schayk I,1Alilio M.
               15331844
Moree M, Ewart S.                  1       0
               15331841
de Savigny D, Binka F.             1       0
               15331838
Coleman PG, Morel C, Shillcutt S,1         1           1
                                    Goodman C, Mills AJ.            1
Laxminarayan 15331837
               R.                  1       1           0
                15331836          1     0
Yeung S, Pongtavornpinyo W, Hastings IM, Mills AJ, White NJ.
Hanson K.       15331834          1     1          1          0
                15331833
Agyepong IA, Kangeya-Kayonda J.   1     0
                15331832
Jones CO, Williams HA.            1     0
Russell S.      15331831          1     1          0
                15331830
Malaney P, Spielman A, Sachs J. 1       0
                15331829          1
Worrall E, Rietveld A, Delacollette C.  1          1          0
                15331828
Kiszewski AE, Teklehaimanot A. 1        0
                15331821
Holding PA, Kitsao-Wekulo PK. 1         0
                15331820          1
Mung'Ala-Odera V, Snow RW, Newton CR.   0
                15331819          1
Caulfield LE, Richard SA, Black RE.     0
Crawley J.      15331816          1     0
                15331815
Snow RW, Korenromp EL, Gouws1       E.  0
                15331814
Breman JG, Alilio MS, Mills A. 1        0
                15320751
Romanelli F, Smith KM, Hoven AD.  1     0
                15318240
Ridley R, Toure Y.                0
                15318238
Moree M, Ewart S, Diggs C.        0
                15318237
Clayton J, Butler D.              0
Mandavilli A. 15318235            0
Attaran A.      15318233          0
                15318232
Klausner R, Alonso P.             0
Butler D.       15318231          0
Greenwood B. 15318230             0
Mocumbi P. 15318229               0
                15318224          1     0
Vennerstrom JL, Arbe-Barnes S, Brun R, Charman SA, Chiu FC, Chollet J, Dong Y, Dorn A, Hunziker D, Matile H, McIntosh K, Pad
                15306410
Mackinnon MJ, Read AF.            1     0
Majori G.       15305693          1     0
Dupouy-Camet J. 15305692          1     0
                15298229          1
Whitty CJ, Allan R, Wiseman V, Ochola S,0Nakyanzi-Mugisha MV, Vonhm B, Mwita M, Miaka C, Oloo A, Premji Z, Burgess C, M
Shetty P.       15298018          1     0
                15296412
Anberber S, Tessema T, Yimer A. 1       0
Shapiro HM. 15290712              0
                15288715
[No authors listed]               1     0
McFadden DL, 15277676
                Sunkara V.        1     0
                15276317
Dzator J, Asafu-Adjaye J.         1     0
Paranjape S. 15274477             0
Tatem AJ, Hay 15273262
                SI.               1     0
                15259467          1     1
Mundy CJ, Bates I, Nkhoma W, Floyd K, Kadewele G,1 xNgwira M, Khuwi A, Squire SB, Gilks CF.
                15256523          1     0
Zurovac D, Rowe AK, Ochola SA, Noor AM, Midia B, English M, Snow RW.
Okoromah CN,15254567 MT. 0
                 Egri-Qkwaji
Check E.        15254499          0
                15248674
Nuwaha F, Okware J, Timbyetaho1HN. 0
                15242703
Sinden RE, Alavi Y, Raine JD.     1     0
                15237660
Issifou S, Kremsner PG.           1     1          1          0
Lell B.         15237652          1      1          0
                15234862          0
Brugha R, Donoghue M, Starling M, Ndubani P, Ssengooba F, Fernandes B, Walt G.
Kerr T, Kaplan 15234838           1      0
                K, Suwannawong P, Jürgens R, Wood E.
Onwujekwe O,15234659 B, Shu E, Ibeh C, Okonkwo P.
                 Uzochukwu        1      1          1           1
Danso-Appiah 15228488 SJ, Bosompem KM, Habbema JD.
                A, De Vlas        0
                15225349          1      0
Tami A, Mubyazi G, Talbert A, Mshinda H, Duchon S, Lengeler C.
                15217846
Barnish G, Bates I, Iboro J.      1      0
                15213157          1
Bartholomay LC, Cho WL, Rocheleau TA, 0  Boyle JP, Beck ET, Fuchs JF, Liss P, Rusch M, Butler KM, Wu RC, Lin SP, Kuo HY, Tsao I
                15212866
Bertozzi S, Gutierrez JP, Opuni M,0Walker N, Schwartländer B.
Bates I.        15209890          1      0
                15206058
Gavazzi G, Herrmann F, Krause KH. 0
                15202941
Uzochukwu BS, Onwujekwe OE. 0
James JS.       15199865          0
                15194254
English M, Esamai F, Wasunna A, 0  Were F, Ogutu B, Wamae A, Snow RW, Peshu N.
Kolaczinski JH, 15191614 N, Khan QS, Jan Z, Rehman N, Leslie TJ, Rowland M.
                Muhammad          1      1          0
                15190322
[No authors listed]               0
Butler D.       15190315          1      0
Rassool GH. 15188782              0
Melton LJ 3rd, 15176986 Lau E, Mautalen CA, Seeman E.
                Johnell O,        0
                15173372          0
DeCosta A, D'Souza N, Krishnan S, Chhabra MS, Shihaam I, Goswami K.
Ferguson HM, 15151700
                Read AF.          1      0
                15144762
Bhatia MR, Fox-Rushby J, Mills A.1       1          1           1
                15134129
Ehiri JE, Anyanwu EC, Scarlett H. 1      0
                15132606          1
Madrid PB, Wilson NT, DeRisi JL, Guy RK.0
Kapp C.         15132149          1      0
Molyneux DH, 15130985VM.
                Nantulya          0
Yamey G.        15130971          1      0
Yamey G.        15130956          1      0
Onwujekwe O,15127427 B. 1
                 Uzochukwu               1          1           1
                15125111          0
Ogwal-Okeng JW, Obua C, Waako P, Aupont O, Ross-Degnan D.
                15120105          1
Garraud O, Relave J, Flori P, Perraut R. 0
                15119065          1
Curtis CF, Jana-Kara B, Maxwell CA.      0
                15110502
Lidén J, Nantulya VM.             1      0
                15105139          1      0
Bennett TN, Paguio M, Gligorijevic B, Seudieu C, Kosar AD, Davidson E, Roepe PD.
                15100837          1      0
Gascoyne P, Mahidol C, Ruchirawat M, Satayavivad J, Watcharasit P, Becker FF.
Onwujekwe O,15099453 J, Hanson K. 1
                 Fox-Rushby       1                 1           1
                15086372
Farmer P, Campos NG.              0
                15082552          1      0
Moreira LA, Wang J, Collins FH, Jacobs-Lorena M.
Nafo-Traoré F.15070574            0
                15070573
Nantulya VM, Lidén J.             0
                15064042          1      0
Watkins B, Kokwaro G, Galinski M, Mutabingwa TK, Trape JF.
                15064041
Adelman CC, Norris J.             1      0
                15064040          1
de Vries PJ, Kager PA, Borgdorff MW. 0
                15064038          1      0
White N, Nosten F, Björkman A, Marsh K, Snow RW.
                15051411           1
Feng Z, Smith DL, McKenzie FE, Levin SA.0
Laxminarayan 15040565
                R.                 1      1           1           0
                15040559           1      0
Talisuna AO, Nalunkuma-Kazibwe A, Bakyaita N, Langi P, Mutabingwa TK, Watkins WW, Van Marck E, D'Alessandro U, Egwang
                15033556
Mensah OA, Kumaranayake L. 1              0
Basco LK.       15031511           1      0
                15031509           1      0
Duarte EC, Gyorkos TW, Pang L, Abrahamowicz M.
Onwujekwe O,15023234 Fox-Rushby J. 1
                 Hanson K,         1                  1           1
                15019062           0
Salas E, Ramírez A, Otero-Bilbao A, Vázquez R, Reyes O, Mendiola J, Duarte CA, Otero-González A, Gutiérrez OA, Chávez MA.
Hoshen M. 15001342                 1      0
                15000725           1      1           1x
Fernando SD, Karunaweera ND, Fernando WP, Attanayake N, Wickremasinghe AR.
                14999633           0
Hotez PJ, Remme JH, Buss P, Alleyne G, Morel C, Breman JG.
Burton B.       14988175           0
Björkman A. 14986448               1      0
                14982889
Ngugi IK, Chiguzo AN, Guyatt HL. 1        1           1           1
                14980653           1      0
de Andrade-Neto VF, Goulart MO, da Silva Filho JF, da Silva MJ, Pinto Mdo C, Pinto AV, Zalis MG, Carvalho LH, Krettli AU.
                14974756           0
Kumaresan J, Smith I, Arnold V, Evans P.
Mathenge EM,14971695GO, Irungu LW, Ndegwa PN, Walczak E, Smith TA, Killeen GF, Knols BG.
                 Omweri            1      0
                14965906           1
Ricklefs RE, Fallon SM, Bermingham E. 0
Nelson R.       14964034           0
                14962313
Shehata N, Kohli M, Detsky A. 1           1           1           0
                14763308           0
Diagne I, Diagne-Gueye ND, Signate-Sy H, Camara B, Lopez-Sall P, Diack-Mbaye A, Sarr M, Ba M, Sow HD, Kuakuvi N.
                14763291
Cot M, Deloron P.                  1      0
                14754491           1
Yadav RS, Bhatt RM, Kohli VK, Sharma VP.  0
                14738799           1      0
Attaran A, Barnes KI, Curtis C, d'Alessandro U, Fanello CI, Galinski MR, Kokwaro G, Looareesuwan S, Makanga M, Mutabingwa
Sule SS.        14737985           0
Klinkenberg E, 14732243            1      0
                van der Hoek W, Amerasinghe FP.
                14732235           1      0
Afrane YA, Klinkenberg E, Drechsel P, Owusu-Daaku K, Garms R, Kruppa T.
                14732234           1      0
Girardin O, Dao D, Koudou BG, Essé C, Cissé G, Yao T, N'Goran EK, Tschannen AB, Bordmann G, Lehmann B, Nsabimana C, Kei
                14732233           1      0
Konradsen F, van der Hoek W, Amerasinghe FP, Mutero C, Boelee E.
                14728616           1      1
Conteh L, Sharp BL, Streat E, Barreto A, Konar S.     1           1
                14720489
Harling R, Crook P, Lewthwaite P,0Evans M, Schmid ML, Beeching NJ.
                14720085
Taylor WR, White NJ.               1      0
Chambers JA. 14719625              1      0
Fleck F.        14715592           1      0
Tenenbaum DJ.   14714543           1      1           0
                14710972           1       KD,        1
Gogtay NJ, Kadam VS, Desai S, Kamtekar1 Dalvi SS, Kshirsagar NA.  1
                14704095           1      0
Hougard JM, Corbel V, N'Guessan R, Darriet F, Chandre F, Akogbéto M, Baldet T, Guillet P, Carnevale P, Traoré-Lamizana M.
Das P.          14700064           1      0
                14686114
Ansari MA, Razdan RK.              1      1           0
Butler D.       14685194           0
                14668812
Nwaka S, Ridley RG.                0
Larkin M.       14664250           0
Segall M.       14661938           0
Onwujekwe O.14652049               0
                14641851           0
Amin AA, Marsh V, Noor AM, Ochola SA, Snow RW.
                14641838           1       1           1            0
Howard N, Chandramohan D, Freeman T, Shafi A, Rafi M, Enayatullah S, Rowland M.
Yamey G.        14630748           1       0
                14629767                   0
Seyoum A, Killeen GF, Kabiru EW,1Knols BG, Hassanali A.
                14615112
Guyatt H, Ochola S.                1       1           0
                14615104
D'Alessandro U, Coosemans M. 1             1           1            0
Kapp C.         14594000           1       0
                14585518           0
Kapiriri L, Robberstad B, Frithjof Norheim O.
                14584944           1       0
O'Neill PM, Mukhtar A, Stocks PA, Randle LE, Hindley S, Ward SA, Storr RC, Bickley JF, O'Neil IA, Maggs JL, Hughes RH, Winstan
Molyneux DH. 14584362              1       0
                14576890           1       0
Schellenberg D, Schellenberg JR, Mushi A, Savigny D, Mgalula L, Mbuya C, Victora CG.
                14550688
[No authors listed]                0
                14523403
[No authors listed]                0
                14516299           1       0
Clarke SE, Rowley J, Bøgh C, Walraven GE, Lindsay SW.
                14516298           1       0
Murray CK, Bell D, Gasser RA, Wongsrichanalai C.
                14515110
Ungar WJ, Santos MT.               0
                14513936           1
Abdel-Hameed AA, Abdalla HM, Alnaury 1     AH.         1            1
                14511807           AF,
Cheesman SJ, de Roode JC, Read 1 Carter R. 0
                14510166            YO, 0
Nwuba RI, Anumudu CI, Omosun 1 Sodeinde O, Nwagwu M.
Butler D.       14508444           1       0
                14506223           1       MC,
Federici BA, Park HW, Bideshi DK, Wirth 0 Johnson JJ.
Rosenthal PJ. 14506208             1       0
                14501795           0
Fabiani M, Accorsi S, Aleni R, Rizzardini G, Nattabi B, Gabrielli A, Opira C, Declich S.
Hotez PJ, Zhan13678639 JM, Loukas A, Williamson A, Goud GN, Hawdon JM, Dobardzic A, Dobardzic R, Ghosh K, Bottazzi ME
                 B, Bethony        0
                12971694           1       0
Chanon KE, Méndez-Galván JF, Galindo-Jaramillo JM, Olguín-Bernal H, Borja-Aburto VH.
                12971557           1       1           1
Bualombai P, Prajakwong S, Aussawatheerakul N, Congpoung K,1Sudathip S, Thimasarn K, Sirichaisinthop J, Indaratna K, Kidso
                12962587           1
Leggat PA, Dürrheim DN, Blumberg L. 0
Fleck F.        12958089           0
                12957515           1
Hay S, Renshaw M, Ochola SA, Noor AM,0Snow RW.
Schubert C. 12949508               1       0
                12929855           1       0
Prakash A, Bhattacharyya DR, Mohapatra PK, Barua U, Phukan A, Mahanta J.
                12921058
[No authors listed]                0
                12920437           0
Folch E, Hernandez I, Barragan M, Franco-Paredes C.
Pincock S.      12919982           1       0
Onwujekwe O,12917269 Fox-Rushby JA.1
                 Hanson K,         1                   1            1
                12901938           1
Snow RW, Eckert E, Teklehaimanot A. 0
Brentlinger PE,12901887            1       0
                 Sherr K, Mercer MA, Gloyd S.
                12901886           1       0
Lines J, Lengeler C, Cham K, de Savigny D, Chimumbwa J, Langi P, Carroll D, Mills A, Hanson K, Webster J, Lynch M, Addington
                12901602
Riddell A, Pollard AJ.             0
                12901581           0
Lieu TA, Thompson KM, Prosser LA, O'Brien MA, Yusuf HR, Shefer AM, Weinstein MC, Rickert DL.
                12901572
Taylor-Robinson AW.                1       0
Jobin W.        12894326           0
Dorozynski A. 12881241             0
                12875290           1       0
Sumawinata IW, Bernadeta, Leksana B, Sutamihardja A, Purnomo, Subianto B, Sekartuti, Fryauff DJ, Baird JK.
               12870450
[No authors listed]               0
               12858279
Koella JC, Boëte C.               1       0
               12856055           0
Russell FM, Shann F, Curtis N, Mulholland K.
               12856049           1       Slutsker L, Muga R, Sharif SK, Hill J, Steketee RW.
Parise ME, Lewis LS, Ayisi JG, Nahlen BL, 0
Hänscheid T. 12848724             1       0
Prugnaud JL. 12843955             0
Powledge TM. 12835681             0
               12812525
Tavrow P, Shabahang J, Makama 1    S.     1           1           0
               12791059           1       0
Rimón MM, Kheng S, Hoyer S, Thach V, Ly S, Permin AE, Pièche S.
               12791054            L,     0
Newman RD, Parise ME, Slutsker 1 Nahlen B, Steketee RW.
Narasimhan V,12787469
                Attaran A.        1       0
               12781485
[No authors listed]               1       0
Adera TD.      12764998           1       0
Fleck F.       12764500           0
               12764493           1       1           1           1
Hanson K, Kikumbih N, Armstrong Schellenberg J, Mponda H, Nathan R, Lake S, Mills A, Tanner M, Lengeler C.
Breslow NE. 12762435              0
               12757689           1       0
Hänscheid T, Melo-Cristino J, Grobusch MP, Pinto BG.
Winstanley P. 12755808            1       0
               12753824
Morey ER, Sharma VR, Mills A. 1           1           1           1
               12753643
Audibert M, Mathonnat J, Henry 1   MC. 0
Boller C, Wyss 12751419 D, Tanner M.
                K, Mtasiwa        0
               12749500           1       1           1           1
Wiseman V, Hawley WA, ter Kuile FO, Phillips-Howard PA, Vulule JM, Nahlen BL, Mills AJ.
               12749499           1       1
Meltzer MI, Terlouw DJ, Kolczak MS, Odhacha A, ter1               1
                                                       Kuile FO, Vulule JM, Alaii JA, Nahlen BL, Hawley WA, Phillips-Howard PA.
               12740321           1       1
Mushi AK, Schellenberg JR, Mponda H, Lengeler C. 1                0
Frankish H. 12737875              1       0
Haivas I.      12727754           1       0
               12726981           1       1           0
Curtis C, Maxwell C, Lemnge M, Kilama WL, Steketee RW, Hawley WA, Bergevin Y, Campbell CC, Sachs J, Teklehaimanot A, Oc
Kano S.        12722287           1       0
Andreopoulos 12702858
                S.                0
               12684579           1       0
Carré N, Eono P, Kouakou K, Duponchel JL, Marquis M, Zahui KH.
               12667226           1       0
Dupouy-Camet J, Yera H, Tourte-Schaeffer C.
               12667225
Danis M, Bricaire F.              1       0
               12667224
Le Bras J, Durand R.              1       0
               12667149            A,     0
Geerligs PP, Brabin B, Mkumbwa 1 Broadhead R, Cuevas LE.
               12665363           1       0
Harpstrite SE, Beatty AA, Collins SD, Oksman A, Goldberg DE, Sharma V.
Clark J.       12663396           0
               12643812
Koella JC, Antia R.               1       0
               12641399                   0
Gasasira AF, Dorsey G, Nzarubara1B, Staedke SG, Nassali A, Rosenthal PJ, Kamya MR.
               12639587
Audibert M, Mathonnat J, Henry 0   MC.
               12637768
Taylor-Robinson AW.               1       0
               12631315
Hongoro C, McPake B.              1       1           1           1
               12625939
Mishra SK, Mohanty S, Das BS. 1           0
               12625261
[No authors listed]               0
               12614733
Lang T, Greenwood B.              1       1           0
                12612752
Duarte EC, Fontes CJ.              1      0
Genton B.       12611180           0
                12602088           0
Mills A, Brugha R, Hanson K, McPake B.
                12597733
Busch MP, Kleinman SH, Nemo GJ.    0
                12595691           1
Catteruccia F, Godfray HC, Crisanti A. 0
                12593873           0
Wiseman V, Mooney G, Berry G, Tang KC.
                12581438           1       N,
Sirima SB, Konaté A, Tiono AB, Convelbo0 Cousens S, Pagnoni F.
Xu JW, Yang H,12568035 Yang GC, Ma XW, Wang WR, Gu YA, Wang LB, Yang XW, Ma J.
                 Yang ZQ,          1      1           1        1 Chinese
                12560195           1      0
Moerman F, Lengeler C, Chimumbwa J, Talisuna A, Erhart A, Coosemans M, D'Alessandro U.
                12560005
Utarini A, Winkvist A, Ulfa FM. 1         0
Butler D.       12556848           0
                12537626           1      0
Keiser J, Utzinger J, Premji Z, Yamagata Y, Singer BH.
                12535250
Kolaczinski J, Webster J.          1      0
                12535245                  0
Schwöbel B, Jordan S, Vanisaveth1V, Phetsouvanh R, Christophel EM, Phompida S, von Sonnenburg F, Jelinek T.
Nossal GJ.      12534942           0
                12530504           1      0
Htut Y, Aye KH, Han KT, Kyaw MP, Shimono K, Okada S.
                12520262
[No authors listed]                1      0
                12516025           0
Howard DH, Scott RD 2nd, Packard R, Jones D.
                12514863
[No authors listed]                1      0
McDowell N. 12511923               0
                12508162
Li T, Glushakova S, Zimmerberg J.1        0
Smaglik P.      12501123           0
                12495438           1      0
Macintyre K, Keating J, Sosler S, Kibe L, Mbogo CM, Githeko AK, Beier JC.
                12488224
Boëte C, Koella JC.                1      0
                12481212           1
Simon JL, Larson BA, Zusman A, Rosen S.1              1        1
                12477306           1
Dubovsky F, Moree M, Rabinovich R. 0
André FE.       12477303           0
                12474486           0
Garg R, Lee LA, Beach MJ, Wamae CN, Ramakrishnan U, Deming MS.
                12473529           1
Mbanya D, Tapko JB, Azowe F, Kaptue L.0
                12473181           1
Kroeger A, Aviñna A, Ordoñnez-Gonzalez0J, Escandon C.
                12468115
Chima RI, Goodman CA, Mills A. 1          1           1        1
                12467689
Moore SA, Surgey EG, Cadwgan AM.   1      0
Paccaud F.      12462378           0
                12460424
Dhindsa KS, Sangodkar UM, Kumar A. 0
Kager PA.       12460395           1      0
                12460394           1      0
Kamya MR, Bakyaita NN, Talisuna AO, Were WM, Staedke SG.
                1
Sauerwein RW. 2460391              1      0
Butler D.       12459751           1      0
                12459742
[No authors listed]                1      0
Banerji D.      12456123           0
                12430867
Lee SH, Kara UA, Koay E, Lee MA,1Lam S,0 D.Teo
                12424212
Bhatia MR, Fox-Rushby JA.          1      1           1        1
Reeder JC.      12418674           1      0
Onwujekwe O,12409125D.
                 Nwagbo            1      1           1        1
Siringi S.     12409030            1       1           0
Desowitz RS. 12407783              0
Kapp C.        12401252            0
Boivin MJ.     12394524            1       0
               12387952
[No authors listed]                1       0
               12378776
[No authors listed]                0
               12378742
[No authors listed]                1       0
               12377587            1       0
Killeen GF, Knols BG, Fillinger U, Beier JC, Gouagna LC.
               12377256
Hänscheid T, Grobusch MP.          1       0
Ssemakula JK. 12369390             1       0
Doolittle RF. 12368861             0
Butler D.      12368829            0
Sachs JD.      12364788            1       0
Vogel G.       12364780            0
               12364370
Carter R, Mendis KN.               1       0
               12358619
Guyatt HL, Ochola SA, Snow RW. 1           1           1          1
               12358615            1       1           1          0
Rowland M, Webster J, Saleh P, Chandramohan D, Freeman T, Pearcy B, Durrani N, Rab A, Mohammed N.
Teklehaimanot12354467RW.
                 A, Snow           1       0
               12349444
[No authors listed]                0
               12296147
[No authors listed]                1       0
               12296146
[No authors listed]                0
Pates HV, Line 12243228 Miller 1
                JD, Keto AJ,        JE.    0
               12239258            0
Phu NH, Hien TT, Mai NT, Chau TT, Chuong LV, Loc PP, Winearls C, Farrar J, White N, Day N.
               12238318
[No authors listed]                1       0
               12236178
[No authors listed]                0
               12224574            1       1           1
Claborn DM, Masuoka PM, Klein TA, Hooper T, Lee A, Andre RG.      0
               12224571            1
Pradines B, Alibert-Franco S, Houdoin C, 0 Mosnier J, Santelli-Rouvier C, Papa V, Rogier C, Fusai T, Barbe J, Parzy D.
               12222994            0
Desta Z, Zhao X, Shin JG, Flockhart DA.
               12206972            1
Guerin PJ, Olliaro P, Nosten F, Druilhe P, 0Laxminarayan R, Binka F, Kilama WL, Ford N, White NJ.
               12219157
Jackson S, Sleigh AC, Liu XL.      1       1           1          1
Basu S.        12212933            1       0
BenMohamed 12209640 Y, Loing 0 Brahimi K, Gras-Masse H, Druilhe P.
                L, Belkaid          E,
               12201020            1       0
Titanji VP, Nkuo-Akenji T, Ntopi W, Djokam R.
Biritwum RB. 12199444              1       0
               12197814
Brown GV, Reeder JC.               1       0
Alving CR.     12184368            0
               12175761
Calva E, Cardosa MJ, Gavilondo JV. 0
               12171622
Kroeger A, Ayala C, Medina Lara A. 1       1           1x
Dev V.         12170936            1       1           0
               12167530            0
Zink AR, Reischl U, Wolf H, Nerlich AG.
               12167093            1
Utzinger J, Tozan Y, Doumani F, Singer BH. 1           1          0
               12164291            1       0
Coleman RE, Maneechai N, Rachapaew N, Kumpitak C, Soyseng V, Miller RS, Thimasarn K, Sattabongkot J.
Bignami G. 12162138                0
               12153708
Durrheim DN, Speare R, Harries AD. 1       0
                12144673           0
Waldenström J, Bensch S, Kiboi S, Hasselquist D, Ottosson U.
                12139222           1
Barcus MJ, Laihad F, Sururi M, Sismadi P,0Marwoto H, Bangs MJ, Baird JK.
                12135988
Shiffman J, Beer T, Wu Y.          0
Vass A.         12130600           0
                12121915           1      0
Peters JM, Chen N, Gatton M, Korsinczky M, Fowler EV, Manzetti S, Saul A, Cheng Q.
                12108312           1      0
Assimadi JK, Gbadoé AD, Agbodjan-Djossou O, Ayéwada K, Goeh-Akué E, Kusiaku K, Dogba A, Adjogblé K, Gayibor A.
                12100436
Lambert ML, van der Stuyft P. 1           0
                12088583
Leggat PA, Heydon JL.              1      0
                12081254                  0
Homeida M, Braide E, Elhassan E,1Amazigo UV, Liese B, Benton B, Noma M, Etya'alé D, Dadzie KY, Kale OO, Sékétéli A.
                12075370           0
Mills A, Brugha R, Hanson K, McPake B.
                12066150
[No authors listed]                0
Greenwood B, 12058650
                Alonso P.          1      0
                12057019
Boëte C, Koella JC.                1      0
Gupta I, Mitra 12047129
                A.                 0
                12044394
Marseille E, Hofmann PB, Kahn JG.  0
                12040556
[No authors listed]                0
Jones E.        12026491           1      0
Gow J.          12026004           0
Estambale BB. 12002100             0
                12000774           1
Guyatt HL, Kinnear J, Burini M, Snow RW.  1          1        1
Nuwaha F.       12000657           1      0
                12000655           1
Kroeger A, Ordoñez-Gonzalez J, Aviña AI.0
                12000650           1
Guyatt HL, Gotink MH, Ochola SA, Snow 1    RW.       1        1
                11998703
Zaim M, Guillet P.                 1      0
Walgate R. 11984617                1      0
                11983598
Curtis CF, Maxwell CA.             1      1          1        1
                11980390           1
Manguin S, Mouchet J, Coosemans M. 0
Nordström A. 11977256              0
Machekano R, 11976993 McFarland W, Katzenstein D.
                Bassett M,         0
Check E.        11976634           0
                11963979
Ijumba JN, Mosha FW, Lindsay SW.   1      0
                11963818           1
Dev V, Ansari MA, Hira CR, Barman K. 0
                11955291
Holtedahl K, Hurum H.              1      0
                11952944           1      0
Guyatt HL, Corlett SK, Robinson TP, Ochola SA, Snow RW.
Panvisavas S. 11944725             1      0
                11943230
Good MF, Xu H, Batzloff M.         1      0
                11937424           0
Jani IV, Janossy G, Brown DW, Mandy F.
Bonn D.         11937408           1      1          0
Wilkins JJ, Folb11926003           1      1
                 PI, Valentine N, Barnes KI.         1        1
Nájera JA.      11921521           1      0
                11917328
Sharma SK, Pradhan P, Padhi DM.    1      1          1x
                11903986           1
Okrah J, Traoré C, Palé A, Sommerfeld J, 1 Müller O. 0
                1
Rabinovich NR. 1897725             1      0
Tall F, Ki-Zerbo11887586           0
                 G, Ouedraogo I, Guigma Y.
                11880047
Winstanley PA, Ward SA, Snow RW.  1        0
Ridley RG.      11880046          1        0
                11873554
[No authors listed]               0
Winstanley P. 11871511            1        0
Burton A.       11871502          1        0
Parker R.       11867304          0
                11863012
[No authors listed]               1        0
Guyatt H.       11854081          1        1           1         0
Ashraf H.       11853801          0
                11851951          1        0
Saute F, Menendez C, Mayor A, Aponte J, Gomez-Olive X, Dgedge M, Alonso P.
                11850261          1        0
Angus BJ, Thaiaporn I, Chanthapadith K, Suputtamongkol Y, White NJ.
                11850008
Guyatt HL, Snow RW.               1        1           1         1
Onwujekwe O,11848272 Shu E, Nwagbo D, Akpala C,1
                 Chima R,         1        1                     1
                                                        Okonkwo P.
                11847921          1        0
Mnzava AE, Sharp BL, Mthembu DJ, le Sueur D, Dlamini SS, Gumede JK, Kleinschmidt I.
                11844535
Brugha R, Starling M, Walt G.     0
Kapp C.         11844526          1        0
                11841709          0
Mugisha F, Kouyate B, Gbangou A, Sauerborn R.
                11841705          1        1           1         0
Marchant T, Schellenberg JA, Edgar T, Nathan R, Abdulla S, Mukasa O, Mponda H, Lengeler C.
                11835898
Yapabandara AM, Curtis CF.        1        0
                11832956
Sachs J, Malaney P.               1        1           0
Lob-Levyt J. 11830243             0
Nyamongo IK. 11824914             1        0
Schuster BG. 11822638             0
Mrazek MF. 19807429               0
                11816439          1        0
McGready R, Cho T, Samuel, Villegas L, Brockman A, van Vugt M, Looareesuwan S, White NJ, Nosten F.
                11799442
Piot P, Coll Seck AM.             0
                11791992
Pang LW, Piovesan-Alves F.        1        0
Nuwaha F.       11791991          1        1           0
                11791990          1
Cunha ML, Piovesan-Alves F, Pang LW. 0
Moody A.        11781267          1        0
Bynum WF. 11778027                1        0
                11773574          1        0
Villamor E, Mbise R, Spiegelman D, Hertzmark E, Fataki M, Peterson KE, Ndossi G, Fawzi WW.
World MJ.       11766209          1        0
Tu G, Cao TH. 19496295            0
                11747054
Goodman CA, Coleman PG, Mills 1   AJ.      1           1         1
                11737845          0
Brooker S, Marriot H, Hall A, Adjei S, Allan E, Maier C, Bundy DA, Drake LJ, Coombes MD, Azene G, Lansdown RG, Wen ST, Dzo
                11737839          JE.
Amaral L, Viveiros M, Kristiansen 0
                11737836
Tarimo DS, Minjas JN, Bygbjerg IC.1        0
                11722997
Snyder EL, Dodd RY.               0
                11722185          1
Brady CP, Shimp RL, Miles AP, Whitmore0M, Stowers AW.
                11713810
Hoffman SL, Doolan DL.            1        0
                11703907
Backer H, Mackell S.              0
Winstanley P. 11703851            1        0
                11703847
Olliaro P, Taylor WR, Rigal J.    1        0
                 11703843           1       0
East African Network for Monitoring Antimalarial Treatment (EANMAT).
                 11703836           0
Boelaert M, Matthys F, Henkens M, D'Alessandro U.
                 11693869           1       1            1           1
Kamolratanakul P, Butraporn P, Prasittisuk M, Prasittisuk C, Indaratna K.
                 11692556           0
Kasis I, Lak L, Adler J, Choni R, Shazberg G, Fekede TD, Shoshani E, Miller D, Heyman S.
Reithinger R. 11685891              1       0
                 11604704
Siegel ER, Royall J, Bennett M. 1           0
                 11601410
[No authors listed]                 0
Sturrock RF. 11586422               0
                 11579891            IG,    0
Mutabingwa TK, Maxwell CA, Sia 1 Msuya FH, Mkongewa S, Vannithone S, Curtis J, Curtis CF.
                 11573114           1       0
Elkheir HK, Elkarim EF, Eltayeb IB, Elkadaru AE, Babiker HA, Ibrahim AM.
Kvåle G.         11570414           0
James JS.        11569955           0
                 11555434
Utzinger J, Tozan Y, Singer BH. 1           1            1           0
                 11548467
[No authors listed]                 0
                 11548308           1
Bismil'din FB, Shapieva ZhZh, Anpilova EN.  0
                 11545329
Wheeler C, Berkley S.               0
                 11545328
Batson A, Ainsworth M.              0
                 11523765           1       0
Salako LA, Brieger WR, Afolabi BM, Umeh RE, Agomo PU, Asa S, Adeneye AK, Nwankwo BO, Akinlade CO.
                 11520549
Ford N, 't Hoen E.                  0
Oya A.           11519127           0
                 11502317           1       0
Staedke SG, Kamya MR, Dorsey G, Gasasira A, Ndeezi G, Charlebois ED, Rosenthal PJ.
                 11495642           1       0
Noedl H, Wernsdorfer WH, Krudsood S, Wilairatana P, Kollaritsch H, Wiedermann G, Looareesuwan S.
                 11487366
Tarimo DS, Minjas JN, Bygbjerg IC.  1       0
Wilde H.         11486287           0
                 1
Stephenson JR. 1482348              0
                 11480821
Ansari MA, Razdan RK.               1       0
Onwujekwe O,11469949 Shu E, Nwagbo D, Okonkwo1P.
                  Chima R,          1       1                        1
                 11469941
Ansah EK, Gyapong JO, Agyepong1IA, Evans DB.0
Brugha R, Walt11463689
                  G.                0
                 11463109           1       0
Druilhe P, Moreno A, Blanc C, Brasseur PH, Jacquier P.
Hor DK.          11458576           1       1            0
                 11442215           1       BL,                      1
Wolfe EB, Parise ME, Haddix AC, Nahlen 1 Ayisi JG,1Misore A, Steketee RW.
                 11442210
Accorsi S, Fabiani M, Lukwiya M, 0  Onek PA, Mattei PD, Declich S; Italian-Ugandan AIDS Cooperation Program.
Perret JL, Sane11436594 PS, Fall0 Diop M, Jousseaume JF.
                  M, Mbaye            F,
                 11436477
Dgedge M, Novoa A, Macassa G, 0     Sacarlal J, Black J, Michaud C, Cliff J.
                 11425421           1
Newton P, Proux S, Green M, Smithuis F,0Rozendaal J, Prakongpan S, Chotivanich K, Mayxay M, Looareesuwan S, Farrar J, Nos
Kilama WL. 11425184                 1       0
Mendis K, Sina11425182              1       0
                  BJ, Marchesini P, Carter R.
                 11425181
Gallup JL, Sachs JD.                1       1            0
                 11425180
Remme JH, Binka F, Nabarro D. 1             0
                 11425178
Murphy SC, Breman JG.               1       0
                 11425177
Goodman CA, Coleman PG, Mills 1     AJ.     1            1           1
                 11425176
Guyatt HL, Snow RW.                 1       0
                 11425175           1       0
Steketee RW, Nahlen BL, Parise ME, Menendez C.
Trape JF.       11425173           1      0
Breman JG. 11425172                1      0
Luo C.          11424244           0
                11423356
Wongsrichanalai C.                 1      0
Croft A, Geary 11421209 L.
                K, Morgan          1      0
                11418141
Mathanga D, Molyneux ME.           1      0
Yeboah-Antwi 11417034 JO, Asare IK, Barnish G, Evans DB, Adjei S.
                K, Gyapong         1      1              1           1
                11416072           0
Würthwein R, Gbangou A, Sauerborn R, Schmidt CM.
                11410192           1      0
Rowland M, Durrani N, Kenward M, Mohammed N, Urahman H, Hewitt S.
Schofield CJ. 11394349             1      1              1           0
Bonetta L.      11385487           1      0
Webster D. 11382088                1      0
Kapp C.         11377661           0
                11377597           1
Schellenberg D, Menendez C, Kahigwa E,0Aponte J, Vidal J, Tanner M, Mshinda H, Alonso P.
                11354697
Akpede GO, Akenzua GI.             1      0
                11348519           1      1              1
Goodman CA, Mnzava AE, Dlamini SS, Sharp BL, Mthembu DJ, Gumede JK.  1
                11345935
[No authors listed]                1      0
Charlwood JD, 11339205 Bøgh C. 1
                Clarke SE,                1              1           0
Wales PW, Lau11329574
                 W, Kim PC.        1      0
Sachs JD.       11329042           1      0
Hay SI.         11323293           1      1              1           0
                11320332
Le Bras J, Durand R.               1      0
Hutubessy RC, 11311183 Evans 0
                Bendib LM,         DB.
                11297094           Traore-Lamizana M, Chandre F, Carnevale P.
Guillet P, N'Guessan R, Darriet F, 1      0
                11293313
Engbaek K, Vilting K.              0
                11289662
Killeen GF, McKenzie FE, Foy BD, 1        0
                                   Schieffelin C, Billingsley PF, Beier JC.
                11288998           NN, 0
Lin K, Aung S, Lwin S, Min H, Aye 1 Webber R.
                11288996           1      0
Cho-Min-Naing, Lertmaharit S, Kamol-Ratanakul P, Saul A.
Rozendaal J. 11265991              1      0
Morris K.       11265969           0
                11258713
Cowman AF, Duraisingh MT.          1      0
Onwujekwe O.11252045               0
                11251904           1      1              1
Proux S, Hkirijareon L, Ngamngonkiri C, McConnell S, Nosten F. 0
von Seidlein L, 11251903 Coleman R, Doherty T, Walraven G, Targett G.
                Jawara M,          1      0
Brieger WR. 11251900               1      1              1           0
Kamat VR.       11234863           1      1              0
                11228001           0
Willcox ML, Cosentino MJ, Pink R, Bodeker G, Wayling S.
                11226940
Zoguéreh DD, Delmont J.            1      0
                11221702
[No authors listed]                1      0
Bosch X.        11214289           1      0
                11196497
Nabarro D, Mendis K.               1      0
Druilhe P.      11196496           1      0
Greenwood B. 11196495              1      0
Breman JG. 11196493                1      0
               11196487
Carter R, Mendis KN, Roberts D. 1        0
               11196486
Curtis CF, Mnzava AE.             1      1         1          0
               11196485
Bloland PB, Ettling M, Meek S. 1         0
               11176867
Letvin NL, Bloom BR, Hoffman SL.  1      0
Enserink M. 10755950              1      0
Rovner J.      10752716           0
               11149057
Butler WP, Roberts DR.            1      0
Agunwamba JC.  11148770           0
Walker K.      11129697           1      1         1          1
               11129562           1
Mya MM, Saxena RK, Bhakat P, Roy A. 0
               11129130
Stephenson I, Wiselka M.          0
               11127319
Cho-Min-Naing, Saul A.            1      0
               11123822           1
Shretta R, Omumbo J, Rapuoda B, Snow 0   RW.
               11100619           0
Victora CG, Bryce J, Fontaine O, Monasch R.
Onwujekwe O,11094267 Okonkwo P. 1
                Chima R,          1                1          1
               11093830
[No authors listed]               1      0
Price RN.      11060779           1      0
               11050896
[No authors listed]               1      1         0
               11045077
[No authors listed]               1      0
Attanayake N, 11044273 J, Mills A.
               Fox-Rushby         1      1         1          1
Watterson A. 11030319             1      0
               11029980           0
Aylward B, Hennessey KA, Zagaria N, Olivé JM, Cochi S.
               11023075           1      1         1x
Cho-Min-Naing, Lertmaharit S, Kamol-Ratanakul P, Saul AJ.
Ree HI.        11002647           1      0
Fraser DW. 10994289               0
               10994283
Gratz NG, Steffen R, Cocksedge W. 0
               10972425           0
Tangcharoensathien V, Harnvoravongchai P, Pitayarangsarit S, Kasemsup V.
               10968460
Doryan EA, Lovelace JC.           0
               10961864           0
Rahimy MC, Gangbo A, Adjou R, Deguenon C, Goussanou S, Alihonou E.
Hagmann M. 10960309               0
               10950221
[No authors listed]               1      0
               10949896
Bergonzoli G, Rivers Cuadra JC. 1        0
               10945039           1       KD,
Gogtay NJ, Desai S, Kadam VS, Kamtekar0 Dalvi SS, Kshirsagar NA.
Shankar AH. 10944483              1      0
               10943166
[No authors listed]               1      0
Yamey G.       10903636           1      0
Jepsen S.      10901079           1      0
               10888909           Kilama WL.
Attaran A, Roberts DR, Curtis CF, 0
Onwujekwe O,10886802              1      1         1
                Shu E, Chima R, Onyido A, Okonkwo P.          1
Dove A.        10835659           1      0
Nossal GJ.     10833122           0
               10819340           0
Rowe AK, Deming MS, Schwartz B, Wasas A, Rolka D, Rolka H, Ndoyo J, Klugman KP.
               10813483           1
Sokhna CS, Rogier C, Dieye A, Trape JF. 0
               10813470           1                1          1
Rashed S, Johnson H, Dongier P, Moreau1R, Lee C, Lambert J, Schaefer C.
              10813469          1                  1          1
Rashed S, Johnson H, Dongier P, Moreau1R, Lee C, Lambert J, Schaefer C.
Duhl L.       10806973          0
Dickson D.    10841690          0
Yamey G.      10797028          1      0
              10784278
Bodeker G, Willcox M.           1      0
              10748909
Carme B, Rogier C, Trape JF.    1      0
              10728850
Espino F, Manderson L.          1      0
              1
Winstanley PA. 0725901          1      0
              10708657          1      1           0
Yohannes K, Dulhunty JM, Kourleoutov C, Manuopangai VT, Polyn MK, Parks WJ, Williams GM, Bryan JH.
Obaro SK.     10708654          0
Le TP, Coonan 10699338
              KM, Hedstrom RC,1        0
                                 Charoenvit Y, Sedegah M, Epstein JE, Kumar S, Wang R, Doolan DL, Maguire JD, Parker SE, H
              10695984          1
Konradsen F, Amerasinghe PH, Perera D,0Van der Hoek W, Amerasinghe FP.
              10686744                 1                      1
Alonzo González M, Menéndez C,1Font F, Kahigwa E,1Kimario J, Mshinda H, Tanner M, Bosch-Capblanch X, Alonso PL.
              10675739
Beebe NW, Cooper RD.            1      0
Osmon DR. 10630764              1      0

                            1134    293         208        142
A PubMed for all articles published since 2000 with the terms (malaria OR
falciparum) AND cost was undertaken on 21-10-2010.

The exact search terms were:

(((malaria OR falciparum) AND cost) AND "2000"[Publication Date] :
"3000"[Publication Date]) AND "0"[Publication Date] : "3000"[Publication Date]

In total 1598 publications were identified. These publications were filtered as
follows.

malaria: papers that were not about malaria were excluded.

cost: papers that did not relate to costs were excluded.

abstract: the abstracts of the remaining papers were examined and those that
did not appear to be relevant were excluded.

paper: pdfs of the remaining papers were downloaded and examined to see if
they contained any costing information.

The inclusion/exclusion criteria were conservative. If it was unclear whether a
publication contained relevant cost information then it was retained for further
examination at a later stage.

Notes: Studies on the costs of malaria chemoprophylaxis and treatment for
travellers from European and North American countries were excluded.
The title of all the publications are hyperlinked to the relevant page on PubMed.
Title
Analysis of cost and effectiveness of pre-transfusion screening of donor blood and anti-malarial prophylaxis for recipients
Malaria treatment in Northern Ghana: What is the treatment cost per case to households?
Childhood malaria: mothers' perception and treatment-seeking behaviour in a community in Ebonyi State, South East Nigeria
Cost-efficacy of managing severe malaria in children in two district hospitals in Cameroon
Review Article: Recent Advances in the Laboratory Diagnosis of Malaria
Impact of Malaria on Productivity and Coping Strategies among Small -Scale Gari Processorsin Odeda Local Government Area Of Og
Is Chloroquine better than Artemisinin combination therapy as first line treatment in adult Nigerians with uncomplicated malaria?
Perceptions on the use of insecticide treated nets in parts of the Imo River Basin, Nigeria: Implications for preventing malaria in pre
Pattern and outcome of Anaemia in Children Managed at the Federal Medical Centre, Azare.
Authors              References            Pubmed Malaria       Cost     Abstract Paper
                     Vol 82, No 11 (2005):
JA Rajab, PM Waithaka, DAO Orinda, CS Scott 836               1        1         1          0
                     Vol 14, No
J Akazili, M Aikins, FN Binka 1 (2007)     no                 1        1         1          1
AP Agu, JO Nwojiji Vol 17, No 1 (2005)     no                 1        1         0
                     Vol 2, No 1 M Beyeme no
EA Forlack, MT Abena Obama,(2005)                             1        1         1 F
                                           Owono, E Manga, A Same-Ekobo, MM Ondoa, x Tietche, EM Minkoulou
BA Onile, SS TaiwoVol 6, No 2 (2005)       no                 1        0
                     Vol 1, No 2
E O Oluwalana, O O Ogunsusi (2007)         no                 1        1         0
                     Vol 4, No
SO Bello, A Chika, AY Bello 2 (2010)       no                 1        1         1x
                     Vol 14, No 1 (2010)         31           1        0
UM Chukwuocha, INS Dozie, COE Onwuliri, CN Ukaga, BEB Nwoke, BO Nwankwo, EA Nwoke, JC Nwaokoro, KS Nwoga, OG Udujih, C
                     Vol 49,
O.A Adegboye, H Ahmed No 2 (2008)          no                 1        0
African Journals Online was searched for publications with the terms (malaria
OR falciparum) AND cost. The search was undertaken on 24-10-2010.

9 publications were identified. These were then filtered in the same way as the
PubMed search results. The AJOL search produced 7 publications that weren't
on PubMed.

I was unable to locate .pdfs of two of the publications deemed potentially
useful . I was unable to locate e-mail addresses for the authors.
Title
Efficacy and cost-effectiveness of environmental management for malaria control
The burden of malaria epidemics and cost-effectiveness of interventions in epidemic situations in Africa
[HTML] Cost-effectiveness of social marketing of insecticide-treated nets for malaria control in the United Republic of T
The impact of response to the results of diagnostic tests for malaria: cost-benefit analysis
[HTML] Cost-effectiveness of malaria diagnostic methods in sub-Saharan Africa in an era of combination therapy
The cost and cost-effectiveness of malaria vector control by residual insecticide house-spraying in southern Mozambiqu
[HTML] Cost effectiveness analysis of strategies to combat malaria in developing countries
pfmdr1 mutations associated with chloroquine resistance incur a fitness cost in Plasmodium falciparum
Operational response to malaria epidemics: are rapid diagnostic tests cost-effective?
Free Distribution or Cost-Sharing? Evidence from a Randomized Malaria Prevention Experiment*
The cost-effectiveness of permethrin-treated bed nets in an area of intense malaria transmission in western Kenya
*HTML+ Cost-sharing strategies combining targeted public subsidies with private-sector delivery achieve high bednet co
Cost-effectiveness of iron supplementation and malaria chemoprophylaxis in the prevention of anaemia and malaria am
The cost-effectiveness of parasitologic diagnosis for malaria-suspected patients in an era of combination therapy
Cost-effectiveness of sulfadoxine-pyrimethamine for the prevention of malaria-associated low birth weight
The cost-effectiveness of antenatal malaria prevention in sub-Saharan Africa
Cost-comparison of DDT and alternative insecticides for malaria control
[HTML] Achieving the millennium development goals for health: Cost effectiveness analysis of strategies to combat ma
The cost-effectiveness of improving malaria home management: shopkeeper training in rural Kenya
Changing the first line drug for malaria treatment—cost-effectiveness analysis with highly uncertain inter-temporal trad
Cost-effectiveness and sustainability of lambdacyhalothrin-treated mosquito nets in comparison to DDT spraying for m
The cost-effectiveness of screening blood donors for malaria by PCR
[HTML] A cost-effectiveness analysis of artemether lumefantrine for treatment of uncomplicated malaria in Zambia
[PDF] Determining cost-effectiveness and cost component of three malaria diagnostic models being used in remote no
A cost comparison of two malaria control methods in Kyunggi Province, Republic of Korea, using remote sensing and ge
… associated with chloroquine (pfcrt/pfmdr1) and sulfadoxine-pyrimethamine (pfdhfr/pfdhps) resistance and for the fit
Cost-effectiveness of malaria control interventions when malaria mortality is low: insecticide-treated nets versus in-ho
… of febrile morbidity and use of permethrin-impregnated bed nets in a malarious area II. Determinants of febrile episo
[HTML] A low-cost repellent for malaria vectors in the Americas: results of two field trials in Guatemala and Peru
Cost considerations of malaria chemoprophylaxis including use of primaquine for primary or terminal chemoprophylax
[HTML] From strategy development to routine implementation: the cost of Intermittent Preventive Treatment in Infan
[CITATION] Changing national malaria treatment protocols in Africa: What is the cost and who will pay
[HTML] Cost-effectiveness of malaria intermittent preventive treatment in infants (IPTi) in Mozambique and the United
[CITATION] The economic burden of illness for households: A review of cost of illness and coping strategy studies focus
Predicting the cost-effectiveness of introducing a pre-erythrocytic malaria vaccine into the expanded program on immu
[CITATION] Simulation of the cost-effectiveness of malaria vaccines
A cost analysis of the use of the rapid, whole-blood, immunochromatographic Pf/Pv assay for the diagnosis of Plasmod
[CITATION] Preliminary estimates of the cost of expanding TB, malaria and HIV/AIDS activities for sub-Saharan Africa
[PDF] The costs, effects and cost-effectiveness of changing the first line drug for the treatment of malaria in Tanzania
[HTML] Household cost of malaria overdiagnosis in rural Mozambique
[HTML] Cost of malaria control in China: Henan's consolidation programme from community and government perspect
*HTML+ Cost-effectiveness analysis of rapid diagnostic test, microscopy and syndromic approach in the diagnosis of ma
[HTML] Cost-effectiveness analysis of the available strategies for diagnosing malaria in outpatient clinics in Zambia
[CITATION] Economics of malaria control in China: cost, performance and effectiveness of Henan's consolidation progra
[HTML] Cost implications of improving malaria diagnosis: findings from north-eastern Tanzania
[CITATION] Efficacy and cost effectiveness of environmental management for malaria control. Trop
[CITATION] Changing national malaria treatment protocols in Africa: what is the cost and who will pay? Case studies: Bu
Epidemiology, therapeutic agents and cost of management of paediatric malaria in a Nigerian tertiary hospital.
Intermittent preventive treatment of malaria in pregnancy: the incremental cost-effectiveness of a new delivery system
[HTML] DDT reintroduction for malaria control: the cost-benefit debate for public health
Reimbursement of malaria chemoprophylaxis for travellers from Europe to Sub-Saharan Africa: Cost-effectiveness anal
Malaria parasites (Apicomplexa, Haematozoea) and their relationships with their hosts: is there an evolutionary cost fo
Prevention and Treatment of Malaria and the Medical Cost [J]
A cost-effectiveness analysis of three antimalarial treatments for acute, uncomplicated Plasmodium falciparum malaria
Cost-effectiveness of artesunate for the treatment of severe malaria
[CITATION] Seasonal fluctuation of drug-resistant malaria parasites: a sign of fitness cost.
[CITATION] Cost-Effectiveness of Malaria Control Interventions
*CITATION+ Evaluating the cost effectiveness of malaria control strategies: A comparison of insecticide-treated nets, lon
[CITATION] Free Distribution or Cost-Sharing? Evidence from a Malaria Prevention Experiment in Kenya
[CITATION] Free distribution or cost-sharing? Evidence from a randomized malaria experiment in Kenya
*CITATION+ The cost-effectiveness of parasitologic 29. Baker J, McCarthy J, Gatton M, et al. Genetic diversity of Plasmod
[CITATION] The cost of climate change: The case of Malaria
*CITATION+ The economic burden of illness for households: A review of cost of illness and coping strategy studies focus
[CITATION] Cost analyses for large scale use of larval source management in malaria control
[CITATION] Cost-effectiveness of social marketing of insecticide-treated nets to prevent malaria in the United Republic
*CITATION+ Cost-effectiveness study of three methods for diagnosis and therapeutic monitoring of malaria: a field stud
Household cost of malaria overdiagnosis in rural Mozambique
[PDF] A dual effect for the black seed oil on the malaria vector Anopheles gambiae: Enhances immunity and reduces th
[HTML] Malaria treatment in Northern Ghana: What is the treatment cost per case to households?
[HTML] Simulation of the cost-effectiveness of malaria vaccines
[HTML] The Cost-Effectiveness of Intermittent Preventive Treatment for Malaria in Infants in Sub-Saharan Africa
[CITATION] When is confirmed malaria diagnosis cost-effective?
[CITATION] Cost and Cost-effectiveness Analysis of the Available Strategies for Diagnosing Malaria in Outpatient Clinics
[CITATION] Vitamin A supplementation is a cost effective intervention for reducing malaria morbidity
Cost of Quality Assurance of Malaria Microscopy: The Philippines and Thailand
[PDF] Cost-effectiveness analysis of malaria chemoprophylaxis for travellers to West-Africa
Cost effectiveness of OptiMal (R) rapid diagnostic test for malaria in remote areas of the Amazon Region, Brazil.
Cost-effectiveness analysis of the current measures for malaria prevention in Yuanjiang valley, Yunnan province
Correction: Cost Implications of Improving Malaria Diagnosis: Findings from North-Eastern Tanzania
[PDF] The Cost-Effectiveness of Intermittent Preventive Treatment for Malaria in Infants in Sub
[CITATION] ECONOMIC EVALUATION-Changing the First Line Drug Malaria Treatment--Cost-effectiveness Analysis with
[CITATION] Cost-effectiveness of malaria control interventions in Surat, India: treated mosquito nets versus in-house re
Is Chloroquine better than Artemisinin combination therapy as first line treatment in adult Nigerians with uncomplicate
[CITATION] The cost of malaria epidemics to the private sector in Ethiopia
*CITATION+ MALARIA IN THE URBAN, EPIDEMIC, AND COMPLEX EMERGENCY SETTING-The Burden of Malaria Epidemics
[CITATION] A Comparative Study of Cost and Quality of Care of Malaria Treatment in Public and Private Health Facilities
THE HEAVY COST OF MALARIA AND AIDS.
[HTML] Cost-Effectiveness of Intermittent Preventive Treatment of Malaria in Pregnancy in Southern Mozambique
Cost-efficacy of managing severe malaria in children in two district hospitals in Cameroon
[CITATION] The Cost and Quality of Malaria Care-Implications for Microinsurance in Urban Uganda
*PDF+ Use of HRP-2-based rapid diagnostic test for Plasmodium falciparum malaria: assessing accuracy and cost-effectiv
Cost effectiveness of OptiMal (R) rapid diagnostic test for malaria in remote areas of the Amazon Region, Brazil
[CITATION] Cost effective treatment of acute, uncomplicated Plasmodium falciparum malaria.
[CITATION] HOW MUCH DOES IT COST TO ROLL BACK MALARIA IN CHINA? ECONOMICS OF CONSOLIDATION STAGE IN H
*CITATION+ … ON THE INTOLERABLE BURDEN OF MALARIA: A NEW LOOK AT THE NUMBERS-The cost-effectiveness of a
*CITATION+ … CONTROL-Cost-effectiveness and sustainability of lambdacyhalothrin-treated mosquito nets in compariso
Cost-effectiveness of adding bed net distribution for malaria prevention to antenatal services in Kinshasa, Democratic R
*CITATION+ Evaluating the Cost-effectiveness of Artemisinin-based Combination Antimalarial Drugs and Malaria Rapid D
[CITATION] A decision analytic approach to identifying cost-effective combinations of vector control methods for malar
Impact of a new parasitologic laboratory for malaria diagnosis on diagnosis and cost of malaria in a company setting: ex
[CITATION] Utilisation and Cost of Malaria Treatment in Shan State, Myanmar, 2000
*CITATION+ United States Leadership Against HIV/AIDS, Tuberculosis, and Malaria Act of 2003: Report (to Accompany H
[PDF] The Malaria Cost Estimation Tool
*CITATION+ INTERVENTIONS: MONITORING, EFFECTIVENESS, AND COST-EFFECTIVENESS-Malaria Control at the District L
[CITATION] Economic cost in the treatment of clinical malaria in Aba
Cost-effectiveness ratio of using rapid tests for malaria diagnosis in the Peruvian Amazon
*CITATION+ The impact of response to the results of diagnostic tests for malaria: cost-benefit analysis Data from a clinic
Cost-efficacy of managing severe malaria in children in two district hospitals in Cameroon
Cost Savings with Rapid Diagnostic Tests for Malaria in Low-Transmission Areas: Evidence from Dar es Salaam, Tanzania
[HTML] Cost-effectiveness analysis of two strategies for malaria control in the urban area of Buenaventura, Colombia
*CITATION+ … : MONITORING, EFFECTIVENESS, AND COST-EFFECTIVENESS-Impregnated Nets or DDT Residual Spraying?
[CITATION] BED-NETS OR SPRAYING? COST ANALYSES OF MALARIA CONTROL IN THE SOLOMON ISLANDS
*CITATION+ BioMed Central Research article From strategy development to routine implementation: the cost of Interm
[CITATION] Review Article: Cost-comparison of DDT and alternative insecticides for malaria control
*CITATION+ … : MONITORING, EFFECTIVENESS, AND COST-EFFECTIVENESS-Child Coverage with Mosquito Nets and Mala
… del uso de pruebas rápidas para el diagnóstico de la malaria en la Amazonia peruana; Cost-effectiveness ratio of usin
Cost-effectiveness ratio of using rapid tests for malaria diagnosis in the Peruvian Amazon
[CITATION] pfmdr1mutations associated with chloroquine resistance incur a fitness cost inPlasmodium falciparum
[CITATION] Interventions for malaria control in Nicaragua A cost-effectiveness analysis
[HTML] Cost-effectiveness ratio of using rapid tests for malaria diagnosis in the Peruvian Amazon
Pubmed New       Malaria       Cost       Paper
    1465     0
    1063     0                                        A Google Scholar search for all articles with the terms (mala
    1247     0                                        AND cost in the title was undertaken on 24
     530     0
     487     0                                        The exact search terms were:
    1174     0
                                                      allintitle: cost malaria OR falciparum
     879     0
     997     0                                        When the search was extended to the entire
     819     0                                        overwhelming 23,700 articles were located, so I restricted th
no           1             1          1           1   publication titles.
    1254     0
     569     0                                        Where possible the titles of the study are hyperlinked to the
    1597     0                                        publication.
     516     0
    1484     0
    1494     0
    1549     0
     879     0
     799     0
    1443     0
    1455     0
    1164     0
     660     0
    1214     0
    1346     0
     797     0
    1122     0
    1584     0
     603     0
     736     0
     399     0
no           1             1          0
     300     0
    1061     0
     742     0
     244     0
    1362     0
no           1             1          0
no           1             1          1           1
     492     0
    1350     0
     161     0
     287     0
no           1             1          1           1
     133     0
    1465     0
no           1             1          1           1
        877   0
        431   0
        546   0
        451   0
no            1   1   0
no            1   1   1x
       1180   0
        315   0
        223   0
       1122   0
no            1
no            1   1   1    1
no            1   1   1x
        516   0
no            1   1   1x
       1061   0
no            1   1   1x
       1247   0
no            1   1   1x
        492   0
no            1   1   0
AJOL          0
        244   0
         66   0
no            1   1   1x
        287   0
no            1   1   1x
no            1   1   1    1
         12   0
          3   0
       1284   0
        133   0
         66   0
       1443   0
       1122   0
AJOL          0
no            1   1   1x
       1063   0
no            1   1   1x
no            1   1   1x
no            1   1   1    1
AJOL          0
no            1   1   1x
         71   0
          3   0
        961   0
       1350   0
       1494   0
       1455   0
        208   0
no            1   1   1x
no            1   1   1x
        746   0
no            1   1   1x
no            1   1   1x
no            1   1   1    1
no            1   1   0
no            1   1   1x
        212   0
no            1   1   1    1
AJOL          0
         57   0
        696   0
no            1   1   0
no            1   1   1    1 Solomon Islands - 1992
        399   0
       1549   0
no            1   1   0
no            1   1   1x
        212   0
        997   0
no            1   1   1x
        212   0
lar search for all articles with the terms (malaria OR falciparum)
e title was undertaken on 24-10-2010.



malaria OR falciparum

ch was extended to the entire text of the articles, an
23,700 articles were located, so I restricted the search to just


e the titles of the study are hyperlinked to the relevant
Title                                                                        Authors
Impact of Malaria Control on the Demand for ACTs                             Ramanan Laxminarayan, Eili Klein and David Smith
                                                                             Joshua (Eritrea, Malawi, Tanzania, Togo, Senegal)
Operations, Costs and Cost-Effectiveness of Five Insecticide-Treated Net ProgramsYukich, Fabrizio Tediosi, Christian Lengeler
The Economics of Malaria Control Interventions                               Kara Hanson, Catherine Goodman, Jo Lines, Sylvia
Economic Analysis of Malaria Control in Sub-Saharan Africa                   Catherine Goodman, Paul Coleman and Anne Mills
                                                                             who should pay?
Scaling-up coverage with insecticide-treated nets against malaria in Africa: Curtis C, Maxwell C, Lemnge M, Kilama WL, Steket
                                                                             Kroeger Colombia: a management
Unit costs for house spraying and bednet impregnation with residual insecticides inA, Ayala C, Medina Lara A. tool for the con
                                                                             Joshua Yukich (PhD thesis)
Costs and consequences of malaria control in sub-Saharan Africa: the economics of vector control and parasitological diagnos
 n, Eili Klein and David Smith                            Additional studises identified during the searching process, including Phd
  Tediosi, Christian Lengeler                             theses, internal reports and review papers. The references of the review paper
 e Goodman, Jo Lines, Sylvia Meek, David Bradley and Anne Mills also examined.
                                                          were
 aul Coleman and Anne Mills
 mnge M, Kilama WL, Steketee RW, Hawley WA, Bergevin Y, Campbell CC, Sachs J, Teklehaimanot A, Ochola S, Guyatt H, Snow RW.
edina Lara A.
ching process, including Phd
he references of the review papers


ola S, Guyatt H, Snow RW.
Title
Cost-effectiveness of parenteral artesunate for treating children with severe malaria in sub-Saharan Africa.
Relative costs and effectiveness of treating uncomplicated malaria in two rural districts in Zambia: implications for nationwid
Two-tier charging in Maputo Central Hospital: Costs, revenues and effects on equity of access to hospital services.
Climate change and vector-borne diseases: an economic impact analysis of malaria in Africa.
[Economic evaluation of rapid diagnostic tests in malaria treatment].
Determinants of the cost-effectiveness of intermittent preventive treatment for malaria in infants and children.
Assessing the cost-effectiveness of prereferral rectal artesunate for treatment of severe childhood malaria.
Cost-effectiveness of artemisinin combination therapy for uncomplicated malaria in children: data from Papua New Guinea.
Cost-effectiveness of three malaria treatment strategies in rural Tigray, Ethiopia where both Plasmodium falciparum and Plas
Cost-effectiveness of pre-referral antimalarial, antibacterial, and combined rectal formulations for severe febrile illness.
Cost comparison of microscopy vs. empiric treatment for malaria in Southwestern Nigeria: a prospective study.
Prereferral rectal artesunate for treatment of severe childhood malaria: a cost-effectiveness analysis.
Costs and financial feasibility of malaria elimination.
An economic evaluation of home management of malaria in Uganda: an interactive Markov model.
Social marketing and the fight against malaria in Africa: population services international (PSI) and insecticide treated nets (IT




A cost analysis of the use of the rapid, whole-blood, immunochromatographic P.f/P.v assay for the diagnosis of Plasmodium v
Authors PubMed ID               Malaria Cost         Abstract Paper            2010
                    21734764                       1         1         1           0
Lubell Y, Riewpaiboon A, Dondorp AM,1von Seidlein L, Mokuolu OA, Nansumba M, Gesase S, Kent A, Mtove G, Olaosebikan R,
                                        1          1         1
Chanda P, Hamainza B, Moonga HB, Chalwe V, Banda P, Pagnoni F.         1           0
McPake B, Hongoro C, Russo G.           0
                                        1
Egbendewe-Mondzozo A, Musumba M, McCarl BA, Wu X.  0
                                        1
Faye A, Ndiaye P, Diagne-Camara M, Badiane O, Wone I, Diongue M, Seck I, Dia AT, Dia AL.
                                        1
Ross A, Maire N, Sicuri E, Smith T, Conteh L.      1         1         1           0
Conteh L, Yeung S.                      1
                                        1          1         1         TM.
Davis WA, Clarke PM, Siba PM, Karunajeewa HA, Davy C, Mueller I, Davis 1           0
Lemma H, San Sebastian M, Löfgren C,1              1
                                         Barnabas G.         1         1           0
                                        1
Buchanan J, Mihaylova B, Gray A, White N.          1         1         1           1
                                         D,        1         1
Parikh R, Amole I, Tarpley M, Gbadero 1 Davidson M, Vermund SH.        1           1
Tozan Y, Klein EY, Darley S, Panicker R,1          1         1
                                         Laxminarayan R, Breman JG.    1           1
                                        1          1         1         0
Sabot O, Cohen JM, Hsiang MS, Kahn JG, Basu S, Tang L, Zheng B, Gao Q, Zou L, Tatarsky A, Aboobakar S, Usas J, Barrett S, Coh
                                        1
Lubell Y, Mills AJ, Whitty CJ, Staedke SG.         1         1         1
Omona J.                                1          1         0




                 15000725         1          1          Wickremasinghe AR.
Fernando SD, Karunaweera ND, Fernando WP, Attanayake N, 1        1
                                                           Publication

Title                                                                           Authors         PubMed ID
                                                                                                   20406448
                                                                                Kolaczinski JH, Kolaczinski K, Kyabayinze D, Strac
Costs and effects of two public sector delivery channels for long-lasting insecticidal nets in Uganda.
                                                                                                   20406448
                                                                                Kolaczinski JH, Kolaczinski K, Kyabayinze D, Strac
Costs and effects of two public sector delivery channels for long-lasting insecticidal nets in Uganda.
                                                                                                   20406448
                                                                                Kolaczinski JH, Kolaczinski K, Kyabayinze D, Strac
Costs and effects of two public sector delivery channels for long-lasting insecticidal nets in Uganda.

                                                                                Yukich nets.     19331664
Costs and cost-effectiveness of vector control in Eritrea using insecticide-treated bedJO, Zerom M, Ghebremeskel T, Tediosi F

                                                                                De Allegri by social marketing and Tiendrebéog
                                                                                                   19752178
Comparative cost analysis of insecticide-treated net delivery strategies: sales supportedM, Marschall P, Flessa S,free distribu
                                                                                De Allegri by social marketing and Tiendrebéog
                                                                                                   19752178
Comparative cost analysis of insecticide-treated net delivery strategies: sales supportedM, Marschall P, Flessa S,free distribu
                                                                                De Allegri by social marketing and Tiendrebéog
                                                                                                   19752178
Comparative cost analysis of insecticide-treated net delivery strategies: sales supportedM, Marschall P, Flessa S,free distribu
                                                                                De Allegri by social marketing and Tiendrebéog
                                                                                                   19752178
Comparative cost analysis of insecticide-treated net delivery strategies: sales supportedM, Marschall P, Flessa S,free distribu

                                                                            case of W, Wiseman V, Ortiz
The costs and effects of a nationwide insecticide-treated net programme: theStevens Malawi. 15885143 J, Chavasse D.

                                                                                 Mueller DH, Wiseman V, Bakusa D, Morgah
                                                                                                   18445255
Cost-effectiveness analysis of insecticide-treated net distribution as part of the Togo Integrated Child Health Campaign. K, D

                                                                             Goodman CA, Mnzava AE, Dlamini SS, Sharp S
                                                                                               11348519
Comparison of the cost and cost-effectiveness of insecticide-treated bednets and residual house-spraying in KwaZulu-Natal,B

                                                                              Guyatt HL, Kinnear12000774
                                                                                                  J, Burini
A comparative cost analysis of insecticide-treated nets and indoor residual spraying in highland Kenya. M, Snow RW.
                                                                              Guyatt HL, Corlett 11952944 TP, Ochola SA, S
                                                                                                 SK, Robinson
Malaria prevention in highland Kenya: indoor residual house-spraying vs. insecticide-treated bednets.

                                                                                           14982889
                                                                         Ngugi IK, Chiguzo AN, Guyatt HL.
A cost analysis of the employer-based bednet programme in Coastal and Western Kenya.

                                                                                Hanson K, Kikumbih Republic of Tanzania.
                                                                                                   12764493
Cost-effectiveness of social marketing of insecticide-treated nets for malaria control in the United N, Armstrong Schellenberg

                                                                             Wiseman V, Hawley WA, ter Kuile FO,
                                                                                               12749500
The cost-effectiveness of permethrin-treated bed nets in an area of intense malaria transmission in western Kenya. Phillips-H

                                                                                                  15144762
                                                                              Bhatia MR, Fox-Rushby J, Mills A.
Cost-effectiveness of malaria control interventions when malaria mortality is low: insecticide-treated nets versus in-house res

                                                                            Kamolratanakul P, Butraporn
Cost-effectiveness and sustainability of lambdacyhalothrin-treated mosquito nets in comparison11693869 P, Prasittisuk M, Pr
                                                                                               to DDT spraying for malaria

                                                                             Mulligan JA,     18279509
Costs and effects of the Tanzanian national voucher scheme for insecticide-treated nets. Yukich J, Hanson K.
                                                                             Mulligan JA,     18279509
Costs and effects of the Tanzanian national voucher scheme for insecticide-treated nets. Yukich J, Hanson K.

http://www.rbm.who.int/partnership/wg/wg_itn/docs/Yukich2007.pdf                Joshua Yukich, Fabrizio Tediosi, Christian Lengel

                                                                                               15798843
                                                                             Grabowsky achieving T, Ahun equitable R, Len
Distributing insecticide-treated bednets during measles vaccination: a low-cost means of M, Nobiyahigh and M, Donna covera

                                                                                             12000650
                                                                           simple and equitable approach to delivery.
Free bednets to pregnant women through antenatal clinics in Kenya: a cheap,Guyatt HL, Gotink MH, Ochola SA, Snow RW.
                                                                                             12000650
                                                                           simple and equitable approach to delivery.
Free bednets to pregnant women through antenatal clinics in Kenya: a cheap,Guyatt HL, Gotink MH, Ochola SA, Snow RW.

Cost-effectiveness of adding bed net distribution for malaria prevention to antenatal services in 19706921 Democratic Republ
                                                                                                  Kinshasa,
                                                                              Becker-Dreps SI, Biddle AK, Pettifor A, Musuamb
Costing of Uganda ITN Activities
Costing of Uganda ITN Activities

Costing of ZMCP ITN Program
Costing of ZMCP ITN Program
Costing of ZMCP ITN Program

Costing of PSI-Kenya ITN Program
Costing of PSI-Kenya ITN Program
Costing of PSI-Kenya ITN Program
Costing of PSI-Kenya ITN Program
Costing of PSI-Kenya ITN Program

                                                                             Kroeger A, Ayala C, Medina Lara A
Unit costs for house spraying and bednet impregnation with residual insecticides in Colombia: a management tool for the con
                                                                             Kroeger A, Ayala C, Medina Lara A
Unit costs for house spraying and bednet impregnation with residual insecticides in Colombia: a management tool for the con

http://www.rbm.who.int/partnership/wg/wg_itn/docs/Yukich2007.pdf           Joshua Yukich, Fabrizio Tediosi, Christian Lengel

Costs and consequences of large-scale vector control for malaria.                            19091114
                                                                           Yukich JO, Lengeler C, Tediosi F, Brown N, Mullig
                                                                                   Intervention details

Publication year     name            Intervention   Intervention details      Life time of net
              2010   Uganda          LLIN           PermaNet 2.0              3 years
              2010   Uganda          LLIN           Olyset                    3 years
              2010   Uganda          LLIN           PermaNet 2.0              3 years

             2009 Eritrea            ITN            ITNs & LLINs              3 years

             2009    Burkina Faso    LLIN           deltamethrin              5 years
             2009    Burkina Faso*   LLIN           deltamethrin              5 years
             2009    Burkina Faso    LLIN           deltamethrin              5 years
             2009    Burkina Faso*   LLIN           deltamethrin              5 years

             2005 Malawi             ITN

             2008 Togo               LLIN                                     3 years

             2001 South Africa       ITN            permethrin                4 years

             2002 Kenya*             ITN            deltamethrin              5 years
             2002 Kenya              ITN            deltamethrin              5 years

             2004 Kenya              ITN

             2003 Tanzania*          ITN                                     5 years
                                                    pretreated with deltamethrin, retreated with lambdacyhalothrin

             2003 Kenya              ITN            permethrin                5 years

             2004 India              ITN            deltamethrin              3-4 years

             2001 Thailand                           lambdacyhalothrin
                                     ITN - retreatment only

             2008 Tanzania           LLIN                                     3 years
             2008 Tanzania*          LLIN                                     3 years

             2007 Senegal            LLIN                                      3 years
                                                    KO-net, Netto, Sentinelle, Permanet, Dawa

             2005 Ghana              ITN                                      3
                                                    LLIN and ITN (deltamethrin) years

             2002 Kenya              ITN            K-O TABs (deltamethrin)
             2002 Kenya              ITN            K-O TABs (deltamethrin)

             2009 Congo              LLIN           PermaNet
2009 Uganda     LLIN-GF       PermaNet Olyset          4 years
2009 Uganda     LLIN-UNICEF   LLIN                     4 years

2009 Zanzibar   LLIN          LLIN                     4 years
2009 Zanzibar   LLIN          LLIN                     4 years
2009 Zanzibar   LLIN          LLIN                     4 years

2009   Kenya    LLIN          Permanet, Olyset         3 years
2009   Kenya    LLIN          Permanet, Olyset         3 years
2009   Kenya    LLIN          Permanet, Olyset         3 years
2009   Kenya    LLIN          Permanet, Olyset         3 years
2009   Kenya    LLIN          Permanet, Olyset         3 years

2002 Colombia   ITN           treatment only, deltamethrin
2002 Colombia   ITN           treatment only, deltamethrin

2007 Tanzania   ITN                                    3 years
                              ITNs with retreatement packs

2008 Malawi     ITN           ITNs with retreatment    3 years
ion details

              Retreatment             Delivery              Study Period       Costing year     Country   Location
              no                      Campaign              2006-2007                    2007   Uganda    Jinja
              no                      Campaign              2006-2007                    2007   Uganda    Adjumani
              no                      ANC                   2006-2007                    2007   Uganda    Adjumani

              yes                     Government            2001-2005                   2005 Eritrea

              no                      ANC                   2006-2007                   2006               N
                                                                                                Burkina Faso ouna
              no                      ANC                   2006-2007                   2006               N
                                                                                                Burkina Faso ouna
              no                      Social marketing      2006-2007                   2006               N
                                                                                                Burkina Faso ouna
              no                      Social marketing      2006-2007                   2006               N
                                                                                                Burkina Faso ouna

              yes                                         1999-2003
                                      Government - social marketing                     1999 Malawi

                                      measles vaccination               2004            2004 Togo

              yes (KO-Tab)                                1998-1999
                                      community distribution                                            KwaZulu Natal
                                                                                        1999 South Africa

              yes                     campaign - highly subsidized      2000            2000 Kenya        Kisii & Gucha, Nyanza Province
              yes                     campaign - highly subsidized      2000            2000 Kenya        Kisii & Gucha, Nyanza Province

                                        employer campaign subsidized
              KO-Tab (deltamethrin), Peripel (permathrin) -1998-2002                    2002 Kenya        Western & Coastal

              yes                     social marketing      1996-2000                   2000 Tanzania     Kilombero & Ulanga

              yes                     campaign              1996-1999                   1996 Kenya        Asembo & Gem

              yes                     campaign              1997-1998                   1997 India        Surat

              yes                     campaign              1993-1994                   1994 Thailand     Mae-Rand district

              yes                     voucher scheme        2002-2005                   2006 Tanzania     nationwide
              yes                     voucher scheme        2002-2005                   2006 Tanzania     nationwide

              yes                                        2000-2005
                                      government - discount voucher & NGO-UNICEF 2005 Senegal

              no                      measles vaccination               2002            2002 Ghana        Lawa

              yes                     ANC                               2001            2001 Kenya
              yes                     ANC                               2001            2001 Kenya

              no                      ANC                   2005-2006                   2005 DRC Congo Kinshasha
no                       campaign - free      2006-2007              2007 Uganda
no                       campaign - free      2008-2009              2009 Uganda       Lamgo & Karamojo

no                                             2005-2006
                         ANC clinics - free & subsidized             2006 Tanzania     Zanzibar
no                                             2007-2008
                         children < 5 - free and subsidized          2008 Tanzania     Zanzibar
no                       All household members 2008-2009             2009 Tanzania     Zanzibar

yes, net sold with kit   ANC sales                        2007       2007   Kenya      nationwide
yes, net sold with kit   rural sales                      2007       2007   Kenya      nationwide
yes, net sold with kit   urban sales                      2007       2007   Kenya      nationwide
yes, net sold with kit   ANC sales                        2008       2008   Kenya      nationwide
yes, net sold with kit   rural sales                      2008       2008   Kenya      nationwide

yes                                         by health centre - twice yearly Colombia
                         community targeted 1999-2000                   2001
yes                                         by health centre - twice yearly Colombia
                         community targeted 1999-2000                   2001

yes                      ANC & U5 children 2002-2005                 2005 Tanzania     nationwide

yes                                          1999-2005
                         Government - social marketing               2005 Malawi       nationwide
                                                  Study information

Scale      Cohort          Number in study     Study design             Transmission     Currency
district                                44560 3 campaigns
           Households with pregnant women or children under 5                            2007 USD
district                                44560 3 campaigns
           Households with pregnant women or children under 5                            2007 USD
district   pregnant women               44560 3 campaigns                                2007 USD

national   all Eritreans                2900000                         varies - seasonal 2005 USD

district   pregnant women~20000                   trial                                  2006 USD
district   pregnant women~20000                   trial                                  2006 USD
district                 ~20000                   trial                                  2006 USD
district                 ~20000                   trial                                  2006 USD

national                                       Health system costs
           all through SM, pregnant women and children < 5 through PH facilities         1999 USD

national                                                                                 children
                                                  Health system costs 1209/1000 cases in2004 USD<5

              entire community
distirct - study                                  comparative trial     174.5/1000 cases 1999 USD

district   community         ~20000               comparative study                      2000 USD
district   community         ~20000               comparative study                      2000 USD

region     company employees                      observational                          2002 USD

district                                          case-control          EIR = 200-300    2000 USD

district   children 1-59 months                   group-randomized      intense, perennial 1996 USD

district   full community                 93000 RCT                     low, seasonal    1997 USD

district                                   2958 controlled trial                         1994
                                                                        7/1000 case per week USD

national   pregnant women and infants 2424987                                            2006 USD
national   pregnant women and infants 2424987                                            2006 USD

national                                        monitored intervention
           pregnant women and children <5 targetted                  seasonal            2005 USD

district   families with children < 5                                                    2002 USD ?

             pregnant
districts nationwide women and children           observed district costs                2001 USD
national pregnant women and children              projected national costs               2001 USD

clinics    pregnant women and children 33541                                             2005 USD
                       pregnant women and children < 5                                             2007 USD
             2 regions pregnant women and children < 5                                             2009 USD

                        pregnant women                                                             2006 USD
                        children < 5 years                                                         2008 USD
                        everyone                                                                   2009 USD

             national   pregnant women                                                             2007 USD
             national                                                                              2007 USD
             national                                                                              2007 USD
             national                                                                              2008 USD
             national                                                                              2008 USD

             11 states nearby community                 9203 data from control staff               2001 USD
             11 states far away community               9203 data from control staff               2001 USD

nationwide              pregenatn women and chidlren                              variable, seasonal 2005
                                                              NATNETS - Tanzanian national net programme USD

                                                           Health system costs
             nationwideall through SM, pregnant women and children < 5 through PH facilities
Exchange rate        Perspective Number of nets distributed    nets      insecticide          personnel
1 USD = 1741 UGX     Provider                            12994      85.0         -                         1.5
1 USD = 1741 UGX     Provider                            16378      81.2         -                         0.7
1 USD = 1741 UGX     Provider                            15188      79.8         -                         0.3

                                  900000                             57.5
1 USD = 10-15 Nafka Provider - governmentnets and 2000000 retreatments                 10.8               18.0

1 USD = CFA 492.7    Provider                             5227          80.2    -                          8.6
1 USD = CFA 492.7    Societal                             5227      -           -                   -
1 USD = CFA 492.7    Provider                            15000          71.6    -                          7.4
1 USD = CFA 492.7    Societal                            15000      -           -                   -

                     Provider                         1461941           70.5            3.0                5.6

1 USD = 493 Franc CFA Provider                         907500           59.5    -                         15.9

1 USD = R 6.12       Provider                             5450          81.0    -                   -

1 USD = 78.32 KSH    Society                             15000          45.8           10.7         -
1 USD = 78.32 KSH    Provider                            15000          33.3           13.2         -

1 USD = 78 KSH       Provider - employer                 39131          27.1            9.8               37.1

1 USD = 803 TSH      Provider                            65111          39.4            4.3               21.4

1 USD = 78 KSH       Provider                            45667      -           -                   -

1 USD = 35.83 Rs     Provider                            35136          32.4           10.1               33.5

                     Provider                             1034      -                  33.4               66.6

1 USD = 1340 TSH     Provider     1157885/2424987                       29.2           11.2               24.4
1 USD = 1340 TSH     Societal     1157885/2424987                       26.4           10.1               22.0

1 USD = 500 XOF      Provider     ~750000                               58.0            6.0                7.0

1 USD = 8140 cedis   Provider                            14600          91.4    -                   -

                     Provider                           70000           59.6           32.3         -
                     Provider                         1440000           56.8           30.8         -

                     Provider                            17893          84.0    -                   -
1 USD = 1794 UGX     Provider         1721906       84.7   -               2.9
1 USD = 1924 UGX     Provider - NGO    606906       81.9   -               5.4

                     Provider           21707       82.0   -               1.7
                     Provider          219537       84.2   -               1.8
                     Provider          249773       85.0   -               1.6

                     Provider         1593522       70.9   -              11.4
                     Provider          292436       34.5       22.1       17.9
                     Provider           65868       35.4       17.7       21.2
                     Provider         1853178       73.0   -              17.1
                     Provider          214370       71.7   -              17.1

1 USD = 2100 pesos   Provider            4353   -              42.0       44.0
1 USD = 2100 pesos   Provider            4850   -              12.0       61.0

                     Provider         6383805       57.0       12.0        7.0

                     Provider         4700000   -          -          -
                                                                                         Financial costs
                                                 Breakdown %
training          IEC            overheads     capital      distribution transport storage
            1.0              2.6           5.8         -               1.9      0.8       0.2
            1.4              2.1           6.4         -               4.0      2.5       0.0
            3.3              3.3           6.4         -               0.0      6.8       0.0

       -                     1.7            2.9           1.3      -                7.8   -

       -                -              -             -             -               10.3   -
       -                -              -             -             -           -          -
       -                     2.6       -             -             -                3.1   -
       -                -              -             -             -           -          -

       -                     6.6            5.5           2.7      -                5.3       0.7

       -                     0.1           11.8           2.3                       8.2   -

       -                -              -             -             -           -          -

           24.3         -              -             -             -           -          -
           29.9         -              -             -             -           -          -

            4.2              3.7            5.1          11.0          0.4          1.6

       -                     4.3       -                  5.9      -           -          -

       -                -              -             -             -           -          -

       -                     2.2            5.7          15.2      -           -

       -                -              -             -             -           -          -

            5.9             15.4            1.4           1.9      -                4.9   -
            5.3             13.9            1.3           1.7      -                4.4   -

       -                    20.0            4.0      -             -           -          -

            4.4              0.8       -             -             -                3.2   -

       -                -              -             -                 5.3          2.8   -
       -                     4.4       -             -                 5.5          2.6   -

            4.6         -              -             -                 0.2          8.8       2.3
    1.3        1.3       2.0        0.5       6.9   -              0.5
    3.3        1.2   -         -              7.5        0.7   -

    3.0        3.2       5.6        1.3       2.9   -              0.3
    0.3        3.3       5.8        1.3       3.0   -              0.3
    0.3        2.9       6.7        1.3       2.2   -              0.1

    0.9        7.2       3.1        0.3       5.4   -              0.8
-             10.2       4.4        3.3       6.4   -              1.1
-              8.2       3.5        4.5       8.7   -              0.9
    0.7        3.6       1.7        0.2       3.9   -              0.5
-              3.6       1.6        2.3       3.2   -              0.5

-         -          -              5.0   -              8.0   -
-         -          -             11.0   -             15.0   -

-             12.0       4.0   -          -              2.0   -

-         -          -         -          -         -          -
Financial costs
                                                                                                              Cost per
     study costs         other              user             NA       net distributed        distribution
            -                         1.3          -              -                     6.19           0.67
            -                         1.7          -              -                     7.08           1.04
            -                    -                 -              -                     6.59           1.07

            -                    -                 -              -                     4.72       -

            -                         0.9          -              -                     7.21           1.42
            -                    -                 -              -            -                   -
            -                        15.3          -              -                     8.08           2.29
            -                    -                 -              -            -                   -

            -                    -                 -              -                     4.32       -

            -                         2.1          -              -                     5.95       -

            -                        19.0          -              -                 10.11          -

                  10.2                9.0          -              -                     4.21       -
                  12.6               11.1          -              -                     3.42       -

            -                    -                 -              -                 15.80          -

            -                        24.7          -              -                 11.90          -

            -                    -                 -              -            -                   -

            -                         0.8          -              -                     2.43       -

            -                    -                 -              -                     1.99       -

            -                         5.6          -              -                     7.69       -
            -                         5.1              9.8        -                     8.49       -

            -                         5.0          -              -                 10.34              3.72

            -                         0.2          -              -                     3.70           0.32

            -                    -                 -              -                     3.81       -
            -                    -                 -              -                     4.00       -

            -                    -                 -              -                     9.52           1.52
-         -         -   -    6.85   -
-         -         -   -    6.87   -

-         -         -   -    7.95       1.43
-         -         -   -    7.74       1.22
-         -         -   -    7.76       1.24

-         -         -   -    8.34       2.21
-         -         -   -    5.63       3.52
-         -         -   -    6.71       4.01
-         -         -   -    6.58       1.37
-         -         -   -    6.52       1.31

-             1.0   -   -    5.10   -
-             1.0   -   -   12.40   -

    3.0       3.0   -   -    5.87       1.89

-         -         -   -
     Cost per
treated net year          person protected          nets            insecticide         personnel
          -                              -                     64.6         -                        3.1
          -                              -                     57.2         -                        1.4
          -                              -                     42.4         -                        5.9

                   1.43                 -                      51.4            12.0                 21.3

          -                             -                  -               -                  -
          -                             -                      23.3        -                        54.3
          -                             -                  -               -                  -
          -                             -                      23.3        -                        21.8

                   7.23                 -                      55.4               4.9                9.2

          -                             -                      59.5        -                        15.9

                   4.36                 -                      54.0            15.0                 24.0

          -                             -                      18.7            19.3           -
          -                             -                  -               -                  -

          -                             -                  -               -                  -

                   6.70                 -                      25.4               5.5               27.7

          -                             -                      40.4               9.2               21.0

          -                                  1.55          -               -                  -

          -                             -                  -               -                  -

          -                             -                      22.0            12.2                 27.3
          -                             -                      20.3            11.3                 25.2

                   7.00                 -                      47.0               8.0                8.0

          -                             -                  -               -                  -

          -                             -                  -               -                  -
          -                             -                  -               -                  -

          -                             -                  -               -                  -
-          -          -          -          -
-          -          -          -          -

-          -          -          -          -
-          -          -          -          -
-          -          -          -          -

-          -              46.3   -              21.1
-          -              19.3       12.4       28.4
-          -              18.9        9.6       32.3
-          -              48.3   -              32.0
-          -              47.2   -              32.1

-              3.70   -          -          -
-              8.50   -          -          -

    2.65   -              49.0       14.0        9.0

                          55.4        4.9        9.2
                                                                                         Economic costs
                                                      Breakdown %
training          IEC            overheads      capital       distribution      transport     storage
            2.4              5.6           12.5         -                   5.6           1.7         0.3
            3.4              4.5           12.7         -                  10.1           5.1         0.3
           11.6             11.6            9.6         -                   1.4         17.1          0.2

       -                     2.0            3.4            0.7         -                   9.2     -

       -                -              -               -               -              -            -
       -                -              -               -               -                  15.4         5.7
       -                -              -               -               -              -            -
       -                     4.4       -                   2.1         -                   5.2         1.9

       -                     9.8            9.1            1.7         -                   8.7         1.2

       -                     0.1           11.8            2.3                             8.2     -

       -                -              -                   1.0         -                   3.0         1.0

           25.8         -              -               -               -              -            -
       -                -              -               -               -              -            -

       -                -              -               -               -              -            -

       -                     5.6       -                   3.8         -              -            -

            1.7         -                  18.9            7.1         -                   0.3     -

       -                -              -               -               -              -            -

       -                -              -               -               -              -            -

            6.4             16.8            5.1            0.7         -                   6.5     -
            5.9             15.5            4.7            0.6         -                   6.0     -

       -                    24.0            4.0            3.0         -              -            -

       -                -              -               -               -              -            -

       -                -              -               -               -              -            -
       -                -              -               -               -              -            -

       -                -              -               -               -              -            -
-         -          -         -         -          -         -
-         -          -         -         -          -         -

-         -          -         -         -          -         -
-         -          -         -         -          -         -
-         -          -         -         -          -         -

    1.7       13.4       5.8       0.4       10.0   -             1.5
    0.0       16.2       7.0       5.2       10.1   -             1.8
-             12.5       5.4       6.8       13.1   -             1.4
    1.3        6.8       3.1       0.3        7.3   -             0.8
-              6.7       3.1       4.4        5.9   -             0.8

-         -          -         -         -          -         -
-         -          -         -         -          -         -

-             15.0       4.0   -         -              2.0   -

-              9.8       9.1       1.7   -              8.7       1.2
omic costs
                                                                                                          Cost per
             study costs      other              user             NA       net distributed distribution     treated net year
                    -                      4.2          -              -                2.88           0.76               0.96
                    -                      5.4          -              -                3.55           1.23               1.18
                    -                 -                 -              -                4.39           2.27               1.46

                   -                  -                 -              -               3.98            1.46              1.21

                   -                  -                 -              -          -                -                -
                   -                       1.3          -              -               4.81            3.68         -
                   -                  -                 -              -          -                -                -
                   -                      41.3          -              -               4.81            3.69         -

                   -                  -                 -              -               2.63        -                     4.41

                   -                       2.1          -              -               4.41        -                -

                   -                       2.0          -              -               7.61        -                     3.81

                       19.2               17.0          -              -               2.34        -                -
                   -                  -                 -              -          -                -                -

                   -                  -                 -              -          -                -                -

                   -                      32.0          -              -               2.30        -                -

                   -                       1.3          -              -               2.20        -                -

                   -                  -                 -              -          -                -                -

                   -                  -                 -              -          -                -                -

                   -                       2.6          -              -         6.77 (6.13)       -                -
                   -                       2.4              7.5        -         7.57 (6.93)       -               4.23 (3.87)

                   -                       6.0          -              -               8.05            3.62              6.05

                   -                  -                 -              -          -                -                -

                   -                  -                 -              -          -                -                -
                   -                  -                 -              -          -                -                -

                   -                  -                 -              -          -                -                -
-         -         -   100.0       3.10   -          -
-         -         -   100.0       3.23   -          -

-         -         -   100.0       3.74       1.44   -
-         -         -   100.0       3.52       1.22   -
-         -         -   100.0       3.54       1.24   -

-         -         -     -         4.69       2.52   -
-         -         -     -         3.88       3.13   -
-         -         -     -         5.02       4.07   -
-         -         -     -         3.81       1.97   -
-         -         -     -         3.90       2.06   -

-         -         -     -     -          -          -
-         -         -     -     -          -          -

    4.0       3.0   -     -          4.8       1.79       2.17

-         -         -     -         3.36                  3.04
                                                                                       Additional Information

person protected   Sensitivity analysis   Ingredients approach    Discounting and annualisation
         -         yes                    yes                                                  3%
         -         yes                    yes                                                  3%
         -         yes                    yes                                                  3%

        -          yes                    yes                                                    3%

        -          yes                               yes                                         3%
        -          yes                               yes                                         3%
        -          yes                               yes                                         3%
        -          yes                               yes                                         3%

        -          yes                               yes                                         3%

        -          yes                               yes                                         5%

        -          yes                    yes                                                 5.30%

        -                                             yes
                   yes - reduction in insecticide price                                          3%
        -                                             yes
                   yes - reduction in insecticide price                                          3%

        -          no                                yes                                         3%

        -          yes                               yes                                         3%

        -          yes                               yes                                         3%

        -          yes                               yes         lending rate of Reserve Bank of India

        -          no                     yes                                                    0%

        -          yes                    yes                                                    3%
        -          yes                    yes                                                    3%

        -          yes                    yes                                                    3%

        -          no                     no

        -          no                     yes                     no
        -          no                     yes                     no

        -          yes                    yes                                                    3%
-   no    yes                  3.00%
-   no    yes                  3.00%

-   no    yes                    3%
-   no    yes                    3%
-   no    yes                    3%

-   no    yes                    3%
-   no    yes                    3%
-   no    yes                    3%
-   no    yes                    3%
-   no    yes                    3%

-   yes   yes   vehicles 15%
-   yes   yes   vehicles 15%

-   yes   yes                    3%

    no    yes                    3%
dditional Information

            Urban/Rural Shared resources   User contribution    Baseline coverage
                                                                21.9% ITN coverage
                                                                33.7% ITN coverage
                                                                33.7% ITN coverage

                                                                4% children sleeping under ITNs

       24 rural, 1 urban cluster
       24 rural, 1 urban cluster
       24 rural, 1 urban cluster           3 US$
       24 rural, 1 urban cluster           3 US$

                                           $5-6 through private sector, $0.6 to pregnant women and children <5 through health facl

            both           yes                                  54% after campaign                           The numbers in their tab
                                                                                                  The financial cost here is the groos

            rural

            rural                          50-350 KSH
            rural                          50-350 KSH

                                           280-480 KSH

                                           $5 for a net, $0.42 for a treatment kit                Costs per net distributed are total e

                                                                low                               Costs per net distributed are total e

Bank of India                                                                                                This doesn't account for
                                                                                                  The paper doesn't specify if costs ar

                                                                                                  These costs include malaria surveill

                                           1019 TSH
                                           1019 TSH                                               The extra economic costs in bracke

            both           yes             USD 2-3 for pregant women at ANCs 34%

            rural          yes                                  4.1% children < 5                 Marginal cost on top of measles cam



                                                                                                  Distribtuion scaled up to 1.44 millio

            urban
                                                       Not entirely clear what year the pri
                                                       Not entirely clear what year the pri


        yes                                            The financial and economic costs in




rural                     50-100 KSH
urban                     320 KSH
rural                     50-100 KSH
urban                     320 KSH

                                                                 ITN treatment only.
                                                       Assumes 1.4-1.5 sleepers per net.


        yes, marginal costs yes in TNVS and SMARTNET   For financial costs, the source is sub

                                                       this data is an update on the Steven
                                                           This sheet contains all studies on the cost of distributing ITNs published in the
                                                           years 2000-2010. as wells as a selection of unpublished studies.




n <5 through health faclilities

            I've assumed the same breakdown for financial and economic costs.




et distributed are total economic/financial costs divided by number of nets delivered

et distributed are total economic/financial costs divided by number of nets delivered

This doesn't account for savings on treatment due to the intervention

            Include data from both Tables 3 and 5.



conomic costs in brackets are for when start-up costs are removed.




ost on top of measles campaign



n scaled up to 1.44 million nets
y clear what year the prices are in.
y clear what year the prices are in.


al and economic costs in Tble 4 and the table in the summary do not match. Not quite sure why, maybe inflation. We take the costs from




            Costs are assumed to be financial and not economic.


al costs, the source is subcontractor expenditure

an update on the Stevens Malawi study. The cost breakdown is assumed to be the same as the original study.
distributing ITNs published in the
npublished studies.
inflation. We take the costs from Table 4.
                                                  Publication

Title                                                              Authors PubMed ID Publication year
                                                                                  19108723
                                                                   Worrall E, Connor SJ, Thomson MC.
Improving the cost-effectiveness of IRS with climate informed health surveillance systems.           2008

                                                                   Goodman and residual house-spraying Sharp
                                                                                 11348519
Comparison of the cost and cost-effectiveness of insecticide-treated bednets CA, Mnzava AE, Dlamini SS, in2001 BL, Mthemb
                                                                                                           KwaZulu-Natal, S

                                                                    Guyatt spraying in J, Burini Kenya.
                                                                                  12000774
A comparative cost analysis of insecticide-treated nets and indoor residualHL, Kinnear highland M, Snow RW.
                                                                                                          2002

                                                                   mosquito nets in comparisonP, Prasittisuk M, Prasittisuk C
                                                                                  P, Butraporn to DDT spraying for malaria
Cost-effectiveness and sustainability of lambdacyhalothrin-treated Kamolratanakul11693869                  2001

                                                                  Bhatia MR, Fox-Rushby J,
Cost-effectiveness of malaria control interventions when malaria mortality is low: 15144762 Mills A. nets versus in-house res
                                                                                   insecticide-treated     2004

                                                                                    14728616
                                                                   Conteh L, Sharp BL, Streat E, Barreto A, Konar
                                                                                                             Mozambique: a r
The cost and cost-effectiveness of malaria vector control by residual insecticide house-spraying in southern 2004 S.
                                                                                    14728616
                                                                   Conteh L, Sharp BL, Streat E, Barreto A, Konar
                                                                                                             Mozambique: a r
The cost and cost-effectiveness of malaria vector control by residual insecticide house-spraying in southern 2004 S.

                                                                 Kroeger A, Ayala C, Medina Lara A      2002
Unit costs for house spraying and bednet impregnation with residual insecticides in Colombia: a management tool for the con
                                                                 Kroeger A, Ayala C, Medina Lara A      2002
Unit costs for house spraying and bednet impregnation with residual insecticides in Colombia: a management tool for the con
                              Intervention details

name           Intervention   Insecticide           Delivery    Study Period Costing year
Zimbabwe       IRS                                              1998-1999
                              deltamethrin (K-Othrin), lambdacyhalothrin (Icon)        2000

South Africa   IRS            pyrethroid                        1998-1999
                                                     community distribution           1999

Kenya          IRS                                  campaign
                              lambdacyhalothrin (Icon)                    2000        2000

Thailand       IRS            DDT                               1993-1994             1994

India          IRS            deltamethrin                      1997-1998             1997

Mozambique     IRS            Ficam, Propoxur        spray campaign       2001        2000
Mozambique     IRS            Ficam                  spray campaign       2001        2000

Colombia       IRS            lambdacyhalothrin      twice yearly 1999-2000           2001
Colombia       IRS            lambdacyhalothrin      twice yearly 1999-2000           2001
                                                    Study information

Country        Location   Scale       Cohort       Transmission    Currency    Exchange rate
Zimbabwe       Hwange     district    villages     low             2000 USD

South Africa             distirct - study
               KwaZulu Natal                       174.5/1000 cases 1999 USD   1 USD = R 6.12

Kenya                      district   community
               Kisii & Gucha, Nyanza Province                      2000 USD    1 USD = 78.32 KSH

Thailand                district
               Mae-Rand district      12 hamlets                    1994
                                                   7/1000 case per week USD

India          Surat      district                 low, seasonal   1997 USD    1 USD = 35.83 Rs

Mozambique Lubombo (Zone 1 - rural)                                2000 USD
                                                   seasonal 3500/9000 cases    1 USD = R 6.50
Mozambique Mozal (peri-urban - Zone 1A)                            2000 USD
                                                   seasonal 3500/9000 cases    1 USD = R 6.50

Colombia                  11 states nearby community               2001 USD    1 USD = 2100 pesos
Colombia                  11 states far away community             2001 USD    1 USD = 2100 pesos
Perspective   Houses sprayed People covered       insecticide personnel training         IEC
Provider                24236               39416          81.0       4.0     -                    1.0

Provider                                    26703      -           -          -                -

Provider      97967 rooms                                  76.4        20.4        1.6         -

Provider                    265              1423          32.1        47.6   -                -

Provider                                    30503          37.1        33.5   -                    2.9

Provider               46906                71047          28.6        37.7        2.6         -
Provider               85000               180871          45.3        31.5        2.7         -

Provider                                    27338          80.2        15.2   -                -
Provider                                    13882           39          45    -                -
                                              Financial costs
                            Breakdown %
overheads      capital      distribution transport storage      study costs     other             user
     -                 11.0        -            3.0      -             -                -                -

     -              -             -           -          -            -                 -                -

     -              -             -           -          -            -                     1.7          -

     -                  20.3      -           -          -            -                 -                -

         1.8            19.8      -               4.0    -            -                     0.9          -

         2.2            20.1      -           -          -                8.9           -                -
         0.7            12.0      -           -          -                7.8           -                -

     -                   2.2      -                 2    -            -                     0.4          -
     -                   6.2      -               8.4    -            -                     1.4          -
                        Cost per                                                                             Bre
NA       house sprayed      person protected    insecticide personnel training       IEC       overheads
     -                 1.94                1.19      -          -          -               -       -

 100.0            -                        2.54          18.5       57.1   -               -       -

     -            -                        0.86          74.7       22.6       1.0         -       -

     -                14.10                2.63      -          -          -               -       -

     -                 7.42                1.41      -          -          -               -       -

     -            -                        5.25          37.3       43.0       1.0         -           2.9
     -            -                        3.13          50.8       31.8       1.4         -           0.8

     -                 36.8                 7.4      -          -          -               -       -
     -                 47.8               10.30      -          -          -               -       -
                                Economic costs
            Breakdown %                                                                                     Cost per
capital      distributiontransport storage     study costsother         user       NA       house sprayed
     -             -          -          -          -         -                -        -           -

          3.0     -              2.3        12.2   -              6.8          -        -          -

     -            -          -          -          -              1.8          -        -          -

     -            -          -          -          -          -                -        -          -

     -            -          -          -          -          -                -        -          -

          9.9     -          -          -              5.9    -                -        -          -
          6.3     -          -          -              8.9    -                -        -          -

     -            -          -          -          -          -                -        -          -
     -            -          -          -          -          -                -        -          -
                                                                                 Additional Information
Cost per
   person protected   Sensitivity analysis    Ingredients approach    Discounting and annualisation
            -         no                      yes                                                  5%

                 2.39 yes                     yes                                                 5.30%

                 0.88 yes - reduction in insecticide priceyes                                        3%

            -         no                      yes

            -         no                      yes                    lending rate of Reserve Bank of India

                 4.82 yes                     yes                                                 5.30%
                 2.83 yes                     yes                                                 5.30%

            -         yes                     yes                     vehicles 15%
            -         yes                     yes                     vehicles 15%
Information

              Urban/Rural   Shared resources   Baseline coverage
              rural

              rural

              rural

              rural

Bank of India

              rural                                                These are the costs for spraying, project management
              peri-urban                                           These are the costs for spraying, project management

                                                                   Costs are assumed to be financial and not economic.
r spraying, project management, and monitoring & surveillance
r spraying, project management, and monitoring & surveillance

be financial and not economic.
                                            Publication

Title                                                Authors PubMed ID           Publication year
                                                                       20808923
                                                     Conteh L, Patouillard E, Kweku M, artesunate or sulphadoxine-pyrimetha
                                                                                               2010
Cost effectiveness of seasonal intermittent preventive treatment using amodiaquine & Legood R, Greenwood B, Chandramoh
                                                                       20808923
                                                     Conteh L, Patouillard E, Kweku M, artesunate or sulphadoxine-pyrimetha
                                                                                               2010
Cost effectiveness of seasonal intermittent preventive treatment using amodiaquine & Legood R, Greenwood B, Chandramoh
                                                                       20808923
                                                     Conteh L, Patouillard E, Kweku M, artesunate or sulphadoxine-pyrimetha
                                                                                               2010
Cost effectiveness of seasonal intermittent preventive treatment using amodiaquine & Legood R, Greenwood B, Chandramoh
                                                                       20808923
                                                     Conteh L, Patouillard E, Kweku M, artesunate or sulphadoxine-pyrimetha
                                                                                               2010
Cost effectiveness of seasonal intermittent preventive treatment using amodiaquine & Legood R, Greenwood B, Chandramoh
                                                                       20808923
                                                     Conteh L, Patouillard E, Kweku M, artesunate or sulphadoxine-pyrimetha
                                                                                               2010
Cost effectiveness of seasonal intermittent preventive treatment using amodiaquine & Legood R, Greenwood B, Chandramoh
                                                                       20808923
                                                     Conteh L, Patouillard E, Kweku M, artesunate or sulphadoxine-pyrimetha
                                                                                               2010
Cost effectiveness of seasonal intermittent preventive treatment using amodiaquine & Legood R, Greenwood B, Chandramoh

                                                   Patouillard, E, Conteh L, Webster J, Kweku 2011
                                                                                              M, Chandramohan D, Greenw
Coverage, adherence and costs of intermittent preventive treatment of malaria in children employing different delivery strate
                                                   Patouillard, E, Conteh L, Webster J, Kweku 2011
                                                                                              M, Chandramohan D, Greenw
Coverage, adherence and costs of intermittent preventive treatment of malaria in children employing different delivery strate
                                                   Patouillard, E, Conteh L, Webster J, Kweku 2011
                                                                                              M, Chandramohan D, Greenw
Coverage, adherence and costs of intermittent preventive treatment of malaria in children employing different delivery strate
                                                   Patouillard, E, Conteh L, Webster J, Kweku 2011
                                                                                              M, Chandramohan D, Greenw
Coverage, adherence and costs of intermittent preventive treatment of malaria in children employing different delivery strate

                                                                      19274364
                                                    Hutton G, Schellenberg D, Tediosi F, Macete E, Kahigwa E, Republic of T
                                                                                              2009
Cost-effectiveness of malaria intermittent preventive treatment in infants (IPTi) in Mozambique and the UnitedSigauque B, M
                                                                      19274364
                                                    Hutton G, Schellenberg D, Tediosi F, Macete E, Kahigwa E, Republic of T
                                                                                              2009
Cost-effectiveness of malaria intermittent preventive treatment in infants (IPTi) in Mozambique and the UnitedSigauque B, M

                                                                    18671874
                                                 Manzi F, Hutton G, Schellenberg J, Tanner M, Alonso P, Mshinda H, Schel
                                                                                            2008
From strategy development to routine implementation: the cost of Intermittent Preventive Treatment in Infants for malaria c

                                                                     18513767
                                                    Mbonye AK, Hansen KS, Bygbjerg IC, Magnussen P.
                                                                                              2008
Intermittent preventive treatment of malaria in pregnancy: the incremental cost-effectiveness of a new delivery system in Ug
                                                                     18513767
                                                    Mbonye AK, Hansen KS, Bygbjerg IC, Magnussen P.
                                                                                              2008
Intermittent preventive treatment of malaria in pregnancy: the incremental cost-effectiveness of a new delivery system in Ug

                                                                       18826594
                                                     Temperley M, Mueller DH, Njagi schools in2008
                                                                                               western Kenya.
Costs and cost-effectiveness of delivering intermittent preventive treatment through JK, Akhwale W, Clarke SE, Jukes MC, Est

The cost-effectiveness of antenatal malaria prevention in sub-Saharan11425177 Mills AJ.
                                                                     Africa.
                                                    Goodman CA, Coleman PG,                   2001
The cost-effectiveness of antenatal malaria prevention in sub-Saharan11425177 Mills AJ.
                                                                     Africa.
                                                    Goodman CA, Coleman PG,                   2001
The cost-effectiveness of antenatal malaria prevention in sub-Saharan11425177 Mills AJ.
                                                                     Africa.
                                                    Goodman CA, Coleman PG,                   2001
The cost-effectiveness of antenatal malaria prevention in sub-Saharan11425177 Mills AJ.
                                                                     Africa.
                                                    Goodman CA, Coleman PG,                   2001
The cost-effectiveness of antenatal malaria prevention in sub-Saharan11425177 Mills AJ.
                                                                     Africa.
                                                    Goodman CA, Coleman PG,                   2001
The cost-effectiveness of antenatal malaria prevention in sub-Saharan11425177 Mills AJ.
                                                                     Africa.
                                                    Goodman CA, Coleman PG,                   2001

Cost-effectiveness of intermittent preventive treatment ofE, Bardají A,20976217 in southern Mozambique A, Nhalungo D, A
                                                                        Nhampossa            2010
                                                    Sicuri malaria in pregnancy T, Maixenchs M, Nhacolo

The cost-effectiveness of intermittent preventive treatment L, Sicuri E,20559558Hutton G, Obonyo B, Tediosi F, Biao P, Masika
                                                                         Manzi F,               2010
                                                     Conteh for malaria in infants in Sub-Saharan Africa.
The cost-effectiveness of intermittent preventive treatment L, Sicuri E,20559558Hutton G, Obonyo B, Tediosi F, Biao P, Masika
                                                                         Manzi F,               2010
                                                     Conteh for malaria in infants in Sub-Saharan Africa.
The cost-effectiveness of intermittent preventive treatment L, Sicuri E,20559558Hutton G, Obonyo B, Tediosi F, Biao P, Masika
                                                                         Manzi F,               2010
                                                     Conteh for malaria in infants in Sub-Saharan Africa.
The cost-effectiveness of intermittent preventive treatment L, Sicuri E,20559558Hutton G, Obonyo B, Tediosi F, Biao P, Masika
                                                                         Manzi F,               2010
                                                     Conteh for malaria in infants in Sub-Saharan Africa.
The cost-effectiveness of intermittent preventive treatment L, Sicuri E,20559558Hutton G, Obonyo B, Tediosi F, Biao P, Masika
                                                                         Manzi F,               2010
                                                     Conteh for malaria in infants in Sub-Saharan Africa.
The cost-effectiveness of intermittent preventive treatment L, Sicuri E,20559558Hutton G, Obonyo B, Tediosi F, Biao P, Masika
                                                                         Manzi F,               2010
                                                     Conteh for malaria in infants in Sub-Saharan Africa.
The cost-effectiveness of intermittent preventive treatment L, Sicuri E,20559558Hutton G, Obonyo B, Tediosi F, Biao P, Masika
                                                                         Manzi F,               2010
                                                     Conteh for malaria in infants in Sub-Saharan Africa.
The cost-effectiveness of intermittent preventive treatment L, Sicuri E,20559558Hutton G, Obonyo B, Tediosi F, Biao P, Masika
                                                                         Manzi F,               2010
                                                     Conteh for malaria in infants in Sub-Saharan Africa.
The cost-effectiveness of intermittent preventive treatment L, Sicuri E,20559558Hutton G, Obonyo B, Tediosi F, Biao P, Masika
                                                                         Manzi F,               2010
                                                     Conteh for malaria in infants in Sub-Saharan Africa.
The cost-effectiveness of intermittent preventive treatment L, Sicuri E,20559558Hutton G, Obonyo B, Tediosi F, Biao P, Masika
                                                                         Manzi F,               2010
                                                     Conteh for malaria in infants in Sub-Saharan Africa.
The cost-effectiveness of intermittent preventive treatment L, Sicuri E,20559558Hutton G, Obonyo B, Tediosi F, Biao P, Masika
                                                                         Manzi F,               2010
                                                     Conteh for malaria in infants in Sub-Saharan Africa.
The cost-effectiveness of intermittent preventive treatment L, Sicuri E,20559558Hutton G, Obonyo B, Tediosi F, Biao P, Masika
                                                                         Manzi F,               2010
                                                     Conteh for malaria in infants in Sub-Saharan Africa.
The cost-effectiveness of intermittent preventive treatment L, Sicuri E,20559558Hutton G, Obonyo B, Tediosi F, Biao P, Masika
                                                                         Manzi F,               2010
                                                     Conteh for malaria in infants in Sub-Saharan Africa.
The cost-effectiveness of intermittent preventive treatment L, Sicuri E,20559558Hutton G, Obonyo B, Tediosi F, Biao P, Masika
                                                                         Manzi F,               2010
                                                     Conteh for malaria in infants in Sub-Saharan Africa.
The cost-effectiveness of intermittent preventive treatment L, Sicuri E,20559558Hutton G, Obonyo B, Tediosi F, Biao P, Masika
                                                                         Manzi F,               2010
                                                     Conteh for malaria in infants in Sub-Saharan Africa.
                            Intervention details

name         Intervention    Intervention details Delivery Study Period Costing year
Ghana        IPTc                                  community 2005-2006
                                                              based volunteer
                             SP bimonthly (6 months => 3 doses)                   2008
Ghana        IPTc                                  community 2005-2006
                             AQ & AS monthly (6 doses)        based volunteer     2008
Ghana        IPTc                                  community 2005-2006
                             AQ & AS bimonthly (3 doses)      based volunteer     2008
Ghana        IPTc                                             based volunteer
                             SP bimonthly (3 doses)community 2005-2006            2008
Ghana        IPTc                                  community 2005-2006
                             AQ & AS monthly (6 doses)        based volunteer     2008
Ghana        IPTc                                  community 2005-2006
                             AQ & AS bimonthly (3 doses)      based volunteer     2008

Ghana        IPTc            SP&AQ (4 courses)                            2006
                                                     VHW community based delivery   2008
Ghana        IPTc            SP&AQ (4 courses)                            2006
                                                     VHW facility based delivery    2008
Ghana        IPTc            SP&AQ (4 courses)       outpatient department2006      2008
Ghana        IPTc            SP&AQ (4 courses)       EPI                  2006      2008

Tanzania     IPTi                                    2,        1999-2001
                             SP (costs are for 1 dose) 3, 9 months with EPI         2006
Mozambique   IPTi                                    3,        2002-2004
                             SP (costs are for 1 dose) 4, 9 months with EPI         2006

Tanzania     IPTi                                    2,        2004-2007
                             SP (costs are for 1 dose) 3, 9 months with EPI         2005

Uganda       IPTp            SP (2 doses)            community 2003-2005
Uganda       IPTp            SP (2 doses)                       2003-2005
                                                     health centre

Kenya        IPTc                                     doses)
                             SP (costs for 1 year = 3 schools   2005-2006           2006

Africa       IPTp                                   ANC
                             CQ - primigravidae (2 doses)                  1995     1995
Africa       IPTp                                   ANC
                             SP - primigravidae (2 doses)                  1995     1995
Africa       IPTp                                   ANC
                             CQ - primigravidae (2 doses)                  1995     1995
Africa       IPTp                                   ANC
                             SP - primigravidae (2 doses)                  1995     1995
Africa       IPTp                                   ANC
                             CQ - primigravidae (2 doses)                  1995     1995
Africa       IPTp                                   ANC
                             SP - primigravidae (2 doses)                  1995     1995

Mozambique   IPTp            SP (2 doses) - with ITN ANC clinic 2007-2008           2007

             IPTi            SP                                   1999-2001
                                                     2, 3, 9 months with EPI        2007
             IPTi            SP                                   2000-2004
                                                     3, 4, 9, 12 months with EPI    2007
             IPTi            SP                                   2002-2004
                                                     3, 4, 9 months with EPI        2007
             IPTi            SP                                   2003-2005
                                                     3, 9, 15 months with EPI       2007
             IPTi            SP                                   2003-2005
                                                     3, 9, 15 months with EPI       2007
             IPTi            SP                                   2003-2005
                                                     3, 9, 15 months with EPI       2007
             IPTi            SP-AS3                               2004-2007
                                                     2, 3, 9 months with EPI        2007
             IPTi            AQ3-AS3                              2004-2007
                                                     2, 3, 9 months with EPI        2007
             IPTi            CD3                                  2004-2007
                                                     2, 3, 9 months with EPI        2007
             IPTi            SP                                   2004-2008
                                                     2, 3, 9 months with EPI        2007
             IPTi            CD3                                  2004-2008
                                                     2, 3, 9 months with EPI        2007
IPTi   MQ               2004-2008
             2, 3, 9 months with EPI   2007
IPTi   SP               2004-2008
             2, 3, 9 months with EPI   2007
IPTi   CD3              2004-2008
             2, 3, 9 months with EPI   2007
IPTi   MQ               2004-2008
             2, 3, 9 months with EPI   2007
                                                            Study information

Country      Location     Scale          Study design   Cohort      Number in study      Transmission
Ghana        Hohoe                       trial          children 3-59 months     2451    EIR=65
Ghana        Hohoe                       trial          children 3-59 months     2451    EIR=65
Ghana        Hohoe                       trial          children 3-59 months     2451    EIR=65
Ghana        Hohoe        district       model          children 3-59 months     2451    EIR=65
Ghana        Hohoe        district       model          children 3-59 months     2451    EIR=65
Ghana        Hohoe        district       model          children 3-59 months     2451    EIR=65

Ghana                      12
             Jasikan district villages   RCT            children 3-59 months       964   seasonal, 3-6 clinical attacks per year
Ghana                      12
             Jasikan district villages   RCT            children 3-59 months       964   seasonal, 3-6 clinical attacks per year
Ghana                      12
             Jasikan district villages   RCT            children 3-59 months       964   seasonal, 3-6 clinical attacks per year
Ghana                      12
             Jasikan district villages   RCT            children 3-59 months       964   seasonal, 3-6 clinical attacks per year

Tanzania   Ifakara                       RCT            infants                    701 perennial, EIR=29
Mozambique Manhica                       RCT            infants                   1503 perennial with seasonal peaks, EIR=3

Tanzania     southern Tanzania           RCT            infants

Uganda       Mukono       district       RCT            pregnant women            2785 high transmission
Uganda       Mukono       district       RCT            pregnant women            2785 high transmission

Kenya        Bondo district              RCT            school children 5-18 years 6758 stable and perennial

SSA - low income                         model          pregnant women - primigravidaemoderate to high
SSA - low income                         model          pregnant women - primigravidaemoderate to high
SSA - middle income                      model          pregnant women - primigravidaemoderate to high
SSA - middle income                      model          pregnant women - primigravidaemoderate to high
SSA - high income                        model          pregnant women - primigravidaemoderate to high
SSA - high income                        model          pregnant women - primigravidaemoderate to high

                      district   RCT
Mozambique Manhica, Maputo Province                     pregnant women             992 perennial, EIR=38

Tanzania     Ifakara                     RCT            infants                    701   perennial, EIR=29
Ghana        Navrongo                    RCT            infants                   2485   highly seasonal, EIR=418
Mozambique   Manhica                     RCT            infants                   1503   perennial with seasonal peaks, EIR=3
Ghana        Kumasi                      RCT            infants                   1070   perennial with seasonal peaks, EIR=4
Ghana        Tamale                      RCT            infants                   1200   Perennial with seasonal peaks , EIR=N
Gabon        Lambarene                   RCT            infants                   1011   perennial with seasonal peaks, EIR=5
Kenya        western Kenya               RCT            infants                   1365   perennial, EIR=7
Kenya        western Kenya               RCT            infants                   1365   perennial, EIR=7
Kenya        western Kenya               RCT            infants                   1365   perennial, EIR=7
Tanzania     Korogwe                     RCT            infants                   1276   perennial with seasonal peak, EIR NA
Tanzania     Korogwe                     RCT            infants                   1276   perennial with seasonal peak, EIR NA
Tanzania   Korogwe   RCT   infants   1276   perennial with seasonal peak, EIR NA
Tanzania   Some      RCT   infants   1136   low, EIR NA
Tanzania   Some      RCT   infants   1136   low, EIR NA
Tanzania   Some      RCT   infants   1136   low, EIR NA
Currency   Exchange rate Perspective      People covered         cost of drugs personnel    training
2008 USD                   Provider
           1 USD = 9074 cedis                              613              2.8        58.2          17.3
2008 USD                   Provider
           1 USD = 9074 cedis                              626            17.9         58.8           5.7
2008 USD                   Provider
           1 USD = 9074 cedis                              562            14.5         57.5          11.3
2008 USD                   Provider
           1 USD = 9074 cedis                            33000          -            -             -
2008 USD                   Provider
           1 USD = 9074 cedis                            33000          -            -             -
2008 USD                   Provider
           1 USD = 9074 cedis                            33000          -            -             -

2008 USD                  P
           1 USD = 9781 GHC rovider                        472              9.0         38.0      -
2008 USD                  P
           1 USD = 9781 GHC rovider                        492              8.0         54.0      -
2008 USD                  P
           1 USD = 9781 GHC rovider                        248              8.0         56.0      -
2008 USD                  P
           1 USD = 9781 GHC rovider                        244              8.0         53.0      -

2006 USD                   Provider                        350             14.2         16.6          39.6
2006 USD                   Provider                        748             34.5         12.6          30.2

2005 USD   1 USD = 1205 TSHProvider - health system                        71.0          7.2          17.3

                          P
2002/3 USD 1 USD = 1750 UGX rovider       1st dose: 2081, 2nd dose: 14048.8             52.4      -
                          P
2002/3 USD 1 USD = 1750 UGX rovider       1st dose: 704, 2nd dose: 281 13.6             44.5      -

2006 USD   1 USD = 67.8 KSHProvider                       3535             60.4          6.0      -

1995 USD                   Provider                                        38.5         27.7          33.8
1995 USD                   Provider                                        28.6         32.1          39.3
1995 USD                   Provider                                        35.2         33.8          31.0
1995 USD                   Provider                                        25.8         38.7          35.5
1995 USD                   Provider                                        21.6         59.5          19.0
1995 USD                   Provider                                        15.0         64.5          20.6

2007 USD                   Provider       1000 - model                     31.8         45.5          22.7

2007 USD                                                   350         -            -             -
2007 USD                                                  1243         -            -             -
2007 USD                                                   748         -            -             -
2007 USD                                                   535         -            -             -
2007 USD                                                   600         -            -             -
2007 USD                                                   504         -            -             -
2007 USD                                                   339         -            -             -
2007 USD                                                   347         -            -             -
2007 USD                                                   342         -            -             -
2007 USD                                                   319         -            -             -
2007 USD                                                   317         -            -             -
2007 USD   320   -   -   -
2007 USD   283   -   -   -
2007 USD   285   -   -   -
2007 USD   284   -   -   -
                                                                Financial costs
                                          Breakdown %
IEC                overheads    capital      distribution     transport    storage    study costs   other
       -                    2.8       -             -                 18.9      -           -               -
       -                    1.1       -             -                 16.5      -           -               -
       -                    1.8       -             -                 14.9      -           -               -
       -                -             -             -               -           -           -               -
       -                -             -             -               -           -           -               -
       -                -             -             -               -           -           -               -

      4.0               -             -            -              49.0            -         -               -
      3.0               -             -            -              35.0            -         -               -
      3.0               -             -            -              33.0            -         -               -
      4.0               -             -            -              35.0            -         -               -

            10.2        -             -                19.4        -              -         -               -
             7.8        -             -                14.8        -              -         -               -

             4.5        -             -            -               -              -         -                    0.1

       -                -             -            -                   38.8       -         -               -
       -                -             -            -                   41.9       -         -               -

       -                    5.6           4.0      -                   13.4       -         -                   10.6

       -                -             -            -               -              -         -               -
       -                -             -            -               -              -         -               -
       -                -             -            -               -              -         -               -
       -                -             -            -               -              -         -               -
       -                -             -            -               -              -         -               -
       -                -             -            -               -              -         -               -

       -                -             -            -               -              -         -               -

       -                -             -            -               -              -         -               -
       -                -             -            -               -              -         -               -
       -                -             -            -               -              -         -               -
       -                -             -            -               -              -         -               -
       -                -             -            -               -              -         -               -
       -                -             -            -               -              -         -               -
       -                -             -            -               -              -         -               -
       -                -             -            -               -              -         -               -
       -                -             -            -               -              -         -               -
       -                -             -            -               -              -         -               -
       -                -             -            -               -              -         -               -
-   -   -   -   -   -   -   -
-   -   -   -   -   -   -   -
-   -   -   -   -   -   -   -
-   -   -   -   -   -   -   -
                                    Cost per
user       NA                          person
                    person treated (compliant)treated (all) cost of drugs personnel
       -        -                4.94                   4.20            1.7         73.8
       -        -               11.75                  10.46           14.2         66.7
       -        -                  7.3                  6.44            9.9         70.2
       -        -            -                   -                      7.0         84.4
       -        -            -                   -                     47.1         47.8
       -        -            -                   -                     37.9         56.5

       -        -                3.23           -                6.0           56.0
       -        -                3.82           -                6.0           65.0
       -        -                3.51           -                6.0           66.0
       -        -                4.20           -                6.0           64.0

       -        -                0.07           -                      10.6           20.7
       -        -                0.10           -                      24.6           17.4

       -        -                0.18           -                      56.3           11.5

       -        -                2.34           -                 -             -
       -        -                2.57           -                 -             -

       -        -                1.20           -                      38.4           40.2

       -        -                1.30           -                 -             -
       -        -                1.13           -                 -             -
       -        -                1.42           -                 -             -
       -        -                1.25           -                 -             -
       -        -                2.31           -                 -             -
       -        -                2.14           -                 -             -

       -        -                0.44           -                 -             -

       -        -           -                   -                 -             -
       -        -           -                   -                 -             -
       -        -           -                   -                 -             -
       -        -           -                   -                 -             -
       -        -           -                   -                 -             -
       -        -           -                   -                 -             -
       -        -           -                   -                 -             -
       -        -           -                   -                 -             -
       -        -           -                   -                 -             -
       -        -           -                   -                 -             -
       -        -           -                   -                 -             -
-   -   -   -   -   -
-   -   -   -   -   -
-   -   -   -   -   -
-   -   -   -   -   -
                                                                                   Economic costs
                                                                 Breakdown %
training          IEC                overheads         capital         distribution transport storage
           11.5          -                       1.7           -              -              11.4  -
            5.1          -                       0.9           -              -              13.1  -
            8.5          -                       1.2           -              -              10.2  -
       -                 -                       6.5           -              -               2.2  -
       -                 -                       2.5           -              -               2.5  -
       -                 -                       4.1           -              -               1.9  -

       -                3.0               2.0                -             -          33.0         -
       -                3.0               2.0                -             -          24.0         -
       -                2.0               3.0                -             -          23.0         -
       -                2.0               3.0                -             -          25.0         -

           41.8               15.3         -                 -                 11.7    -           -
           35.2               12.9         -                 -                  9.9    -           -

           23.5                8.6         -                 -             -           -           -

       -                 -                 -                 -             -           -           -
       -                 -                 -                 -             -           -           -

       -                 -                       3.6             2.6       -                 8.6   -

       -                 -                 -                 -             -           -           -
       -                 -                 -                 -             -           -           -
       -                 -                 -                 -             -           -           -
       -                 -                 -                 -             -           -           -
       -                 -                 -                 -             -           -           -
       -                 -                 -                 -             -           -           -

       -                 -                 -                 -             -           -           -

       -                 -                 -                 -             -           -           -
       -                 -                 -                 -             -           -           -
       -                 -                 -                 -             -           -           -
       -                 -                 -                 -             -           -           -
       -                 -                 -                 -             -           -           -
       -                 -                 -                 -             -           -           -
       -                 -                 -                 -             -           -           -
       -                 -                 -                 -             -           -           -
       -                 -                 -                 -             -           -           -
       -                 -                 -                 -             -           -           -
       -                 -                 -                 -             -           -           -
-   -   -   -   -   -   -
-   -   -   -   -   -   -
-   -   -   -   -   -   -
-   -   -   -   -   -   -
                                                                  Cost per
study costs   other             user       NA                        person treated (all)
                                                    person treated (compliant)
      -               -                -        -               8.19                 6.95
      -               -                -        -              14.79               13.16
      -               -                -        -              10.67                 9.45
      -               -                -        -               1.86           -
      -               -                -        -               4.33           -
      -               -                -        -               2.69           -

      -               -                -        -         4.58                -
      -               -                -        -         5.27                -
      -               -                -        -         4.93                -
      -               -                -        -         5.65                -

      -               -                -        -                0.13         -
      -               -                -        -                0.15         -

      -                   0.1          -        -                0.23         -

      -               -                -        -          -                  -
      -               -                -        -          -                  -

      -                   6.7          -        -                1.88         -

      -               -                -        -          -                  -
      -               -                -        -          -                  -
      -               -                -        -          -                  -
      -               -                -        -          -                  -
      -               -                -        -          -                  -
      -               -                -        -          -                  -

      -               -                -        -          -                  -

      -               -                -        -          -                  -
      -               -                -        -          -                  -
      -               -                -        -          -                  -
      -               -                -        -          -                  -
      -               -                -        -          -                  -
      -               -                -        -          -                  -
      -               -                -        -          -                  -
      -               -                -        -          -                  -
      -               -                -        -          -                  -
      -               -                -        -          -                  -
      -               -                -        -          -                  -
-   -   -   -   -   -
-   -   -   -   -   -
-   -   -   -   -   -
-   -   -   -   -   -
                                                      Additional Information

Sensitivity analysis   Ingredients approach   Discounting and annualisation    Urban/Rural
no                     yes                                                3%   rural
no                     yes                                                3%   rural
no                     yes                                                3%   rural
no                     yes                                                3%   rural
no                     yes                                                3%   rural
no                     yes                                                3%   rural

yes                    yes                                               3%    rural
yes                    yes                                               3%    rural
yes                    yes                                               3%    rural
yes                    yes                                               3%    rural

yes                    yes
yes                    yes

yes                    yes                                                     rural

yes                    no                                               10% rural



yes                    yes                                               5% rural

yes                    yes                                               3%
yes                    yes                                               3%
yes                    yes                                               3%
yes                    yes                                               3%
yes                    yes                                               3%
yes                    yes                                               3%

yes                    no                                               0.03 rural
Shared resources     Baseline coverage
no                                             The economic costs from Table 2 will only match the calculated costs fr
no
no
no
no
no

                     ~33% ITN                  This study presents several different costs dependent on compliance. A
                     ~33% ITN
                     ~33% ITN
                     ~33% ITN

                     70% ITN                   Economic costs are taken to be the total costs, i.e. financial + opportuni
                     0% ITN




yes, 20% allocated to IPTp




yes, incremental costs only                    Costs are assumed to be financial. The costs in Table 3 are increementa
yes, incremental costs only
yes, incremental costs only
yes, incremental costs only
yes, incremental costs only
yes, incremental costs only

                       to other
yes - costs attributed 80% ITN interventions   The costs of IPTp-SP are just the marginal costs on top of ITN distributio

                     67% ITN
                     18% ITN
                     0% ITN
                     1.6% ITN
                     3% ITN
                     5% ITN
                     57% ITN
                     57% ITN
                     57% ITN
                     88% ITN
                     88% ITN
88% ITN
88% ITN
88% ITN
88% ITN
tch the calculated costs from Table 1 when they are adjusted for adherence



                                                                                             Cost data from published studies on IPT. Stu
                                                                                             excluded due to insufficient information.



pendent on compliance. All costs here are for "Children who received the first supervised dose of 4 courses"




s, i.e. financial + opportunity costs




n Table 3 are increemental costs only. They do not account for shared resources with other ANC operations.




ts on top of ITN distribution, and so don't include many factors.
from published studies on IPT. Studies shaded grey have been
due to insufficient information.
                                             Publication

Title                                            Authors       PubMed ID Publication year
                                                 Chanda P, Hamainza two rural districts in Zambia: implications for
                                                                    21651828                   Banda
Relative costs and effectiveness of treating uncomplicated malaria in B, Moonga HB, Chalwe V,2011 P, Pagnoni F.nationwid
                                                 Chanda P, Hamainza two rural districts in Zambia: implications for
                                                                    21651828                   Banda
Relative costs and effectiveness of treating uncomplicated malaria in B, Moonga HB, Chalwe V,2011 P, Pagnoni F.nationwid

                                                Lemma in rural Tigray, Ethiopia where both Plasmodium falciparum and Plas
                                                                    21303500                  2011
Cost-effectiveness of three malaria treatment strategies H, San Sebastian M, Löfgren C, Barnabas G.
                                                Lemma in rural Tigray, Ethiopia where both Plasmodium falciparum and Plas
                                                                    21303500                  2011
Cost-effectiveness of three malaria treatment strategies H, San Sebastian M, Löfgren C, Barnabas G.
                                                Lemma in rural Tigray, Ethiopia where both Plasmodium falciparum and Plas
                                                                    21303500                  2011
Cost-effectiveness of three malaria treatment strategies H, San Sebastian M, Löfgren C, Barnabas G.

                                               Parikh R, Amole Tarpley M,
                                                                   Southwestern Nigeria: a prospective study.
                                                                                            2010
Cost comparison of microscopy vs. empiric treatment for malariaI,in21176228 Gbadero D, Davidson M, Vermund SH.
                                               Parikh R, Amole Tarpley M,
                                                                   Southwestern Nigeria: a prospective study.
                                                                                            2010
Cost comparison of microscopy vs. empiric treatment for malariaI,in21176228 Gbadero D, Davidson M, Vermund SH.
                                               Parikh R, Amole Tarpley M,
                                                                   Southwestern Nigeria: a prospective study.
                                                                                            2010
Cost comparison of microscopy vs. empiric treatment for malariaI,in21176228 Gbadero D, Davidson M, Vermund SH.
                                               Parikh R, Amole Tarpley M,
                                                                   Southwestern Nigeria: a prospective study.
                                                                                            2010
Cost comparison of microscopy vs. empiric treatment for malariaI,in21176228 Gbadero D, Davidson M, Vermund SH.
                                               Parikh R, Amole Tarpley M,
                                                                   Southwestern Nigeria: a prospective study.
                                                                                            2010
Cost comparison of microscopy vs. empiric treatment for malariaI,in21176228 Gbadero D, Davidson M, Vermund SH.
                                               Parikh R, Amole Tarpley M,
                                                                   Southwestern Nigeria: a prospective study.
                                                                                            2010
Cost comparison of microscopy vs. empiric treatment for malariaI,in21176228 Gbadero D, Davidson M, Vermund SH.

                                                  Chanda diagnosing19356225 Masiye F.
                                                                        malaria M,                2009
Cost-effectiveness analysis of the available strategies forP, Castillo-Riquelmein outpatient clinics in Zambia.
                                                  Chanda diagnosing19356225 Masiye F.
                                                                        malaria M,                2009
Cost-effectiveness analysis of the available strategies forP, Castillo-Riquelmein outpatient clinics in Zambia.
                                                  Chanda diagnosing19356225 Masiye F.
                                                                        malaria M,                2009
Cost-effectiveness analysis of the available strategies forP, Castillo-Riquelmein outpatient clinics in Zambia.
                                                  Chanda diagnosing19356225 Masiye F.
                                                                        malaria M,                2009
Cost-effectiveness analysis of the available strategies forP, Castillo-Riquelmein outpatient clinics in Zambia.
                                                  Chanda diagnosing19356225 Masiye F.
                                                                        malaria M,                2009
Cost-effectiveness analysis of the available strategies forP, Castillo-Riquelmein outpatient clinics in Zambia.
                                                  Chanda diagnosing19356225 Masiye F.
                                                                        malaria M,                2009
Cost-effectiveness analysis of the available strategies forP, Castillo-Riquelmein outpatient clinics in Zambia.

                                                                   16553923
                                               Rolland E, Checchi F, cost-effective?          2006
Operational response to malaria epidemics: are rapid diagnostic testsPinoges L, Balkan S, Guthmann JP, Guerin PJ.
                                                                   16553923
                                               Rolland E, Checchi F, cost-effective?          2006
Operational response to malaria epidemics: are rapid diagnostic testsPinoges L, Balkan S, Guthmann JP, Guerin PJ.
                                                                   16553923
                                               Rolland E, Checchi F, cost-effective?          2006
Operational response to malaria epidemics: are rapid diagnostic testsPinoges L, Balkan S, Guthmann JP, Guerin PJ.
                                                                   16553923
                                               Rolland E, Checchi F, cost-effective?          2006
Operational response to malaria epidemics: are rapid diagnostic testsPinoges L, Balkan S, Guthmann JP, Guerin PJ.
                                                                   16553923
                                               Rolland E, Checchi F, cost-effective?          2006
Operational response to malaria epidemics: are rapid diagnostic testsPinoges L, Balkan S, Guthmann JP, Guerin PJ.
                                                                   16553923
                                               Rolland E, Checchi F, cost-effective?          2006
Operational response to malaria epidemics: are rapid diagnostic testsPinoges L, Balkan S, Guthmann JP, Guerin PJ.

                                                                 12971557
                                              Bualombai P, Prajakwong S, Aussawatheerakul N, Congpoung K, Sudathip S, T
                                                                                           2003
Determining cost-effectiveness and cost component of three malaria diagnostic models being used in remote non-microscop
                                                                 12971557
                                              Bualombai P, Prajakwong S, Aussawatheerakul N, Congpoung K, Sudathip S, T
                                                                                           2003
Determining cost-effectiveness and cost component of three malaria diagnostic models being used in remote non-microscop
                                                                 12971557
                                              Bualombai P, Prajakwong S, Aussawatheerakul N, Congpoung K, Sudathip S, T
                                                                                           2003
Determining cost-effectiveness and cost component of three malaria diagnostic models being used in remote non-microscop
                                                                 12971557
                                              Bualombai P, Prajakwong S, Aussawatheerakul N, Congpoung K, Sudathip S, T
                                                                                           2003
Determining cost-effectiveness and cost component of three malaria diagnostic models being used in remote non-microscop
                                                                 12971557
                                              Bualombai P, Prajakwong S, Aussawatheerakul N, Congpoung K, Sudathip S, T
                                                                                           2003
Determining cost-effectiveness and cost component of three malaria diagnostic models being used in remote non-microscop
                                                                 12971557
                                              Bualombai P, Prajakwong S, Aussawatheerakul N, Congpoung K, Sudathip S, T
                                                                                           2003
Determining cost-effectiveness and cost component of three malaria diagnostic models being used in remote non-microscop

                                                  test for malaria in 20937094
                                                                      remote areas of the Amazon Region, Brazil.
                                                                                              2010
Cost effectiveness of OptiMal(R) rapid diagnosticFernandes de Oliveira MR, de Castro Gomes A, Toscano CM.
                                                  test for malaria in 20937094
                                                                      remote areas of the Amazon Region, Brazil.
                                                                                              2010
Cost effectiveness of OptiMal(R) rapid diagnosticFernandes de Oliveira MR, de Castro Gomes A, Toscano CM.

                                                 Yukich J                                     2009
Lack of cost-savings from Rapid Diagnostic Tesr for malaria in Dar es Salaam, Tanzania (PhD thesis)
                                                 Yukich J                                     2009
Lack of cost-savings from Rapid Diagnostic Tesr for malaria in Dar es Salaam, Tanzania (PhD thesis)
                                                 Yukich J                                     2009
Lack of cost-savings from Rapid Diagnostic Tesr for malaria in Dar es Salaam, Tanzania (PhD thesis)
                                                 Yukich J                                     2009
Lack of cost-savings from Rapid Diagnostic Tesr for malaria in Dar es Salaam, Tanzania (PhD thesis)
                                                  Fernando SD, Karunaweera ND, Fernando for the
                                                                   15000725                  Attanayake N, Wickremasingh
A cost analysis of the use of the rapid, whole-blood, immunochromatographic P.f/P.v assayWP,2004diagnosis of Plasmodium v
                                                  Fernando SD, Karunaweera ND, Fernando for the
                                                                   15000725                  Attanayake N, Wickremasingh
A cost analysis of the use of the rapid, whole-blood, immunochromatographic P.f/P.v assayWP,2004diagnosis of Plasmodium v
                             Intervention details

name        Intervention      Intervention details   Delivery      Study Period    Costing year
Zambia                        ACT treatment
            diagnosis with home management           at home                  2009            2009
Zambia                        ACT treatment
            diagnosis at health facility             health facility          2009            2009

Ethiopia                      AL
            presumptive treatment                    health post            2007             2007
Ethiopia    RDT: AL for Pf , CQ for the rest
                              AL & CQ                health post            2007             2007
Ethiopia                      AL & CQ
            RDT and referral where necessary         health post            2007             2007

Nigeria*    clinical diagnosis ART & AQ              hospital               2009             2009
Nigeria*    clinical diagnosis ART & SP              hospital               2009             2009
Nigeria*    clinical diagnosis ART & AQ              hospital               2009             2009
Nigeria*                       ART &
            Giemsa smear diagnosisAQ                 hospital               2009             2009
Nigeria*                       ART &
            Giemsa smear diagnosisSP                 hospital               2009             2009
Nigeria*                       ART &
            Giemsa smear diagnosisAQ                 hospital               2009             2009

Zambia      clinical                                 clinic                 2005             2005
Zambia      microscopy                               clinic                 2005             2005
Zambia      RDT                                      clinic                 2005             2005
Zambia      clinical         and treatment ACT       clinic                 2005             2005
Zambia      microscopy       and treatment ACT       clinic                 2005             2005
Zambia      RDT              and treatment ACT       clinic                 2005             2005

Africa      presumptive      and treatment AS+AQ     community health workers                2004
Africa      RDT              and treatment AS+AQ     community health workers                2004
Africa      presumptive      and treatment AS+AQ     community health workers                2004
Africa      RDT              and treatment AS+AQ     community health workers                2004
Africa      presumptive      and treatment AS+AQ     community health workers                2004
Africa      RDT              and treatment AS+AQ     community health workers                2004

Thailand    microscopy       and ACT              mobile malaria clinics    2000             2000
Thailand    RDT              Optimal and ACT      mobile malaria clinics    2000             2000
Thailand    RDT                                   test (ICT) and clinics
                             Immunochromatographicmobile malariaACT         2000             2000
Thailand*   microscopy       and ACT              mobile malaria clinics    2000             2000
Thailand*   RDT              Optimal and ACT      mobile malaria clinics    2000             2000
Thailand*   RDT                                   test (ICT) and clinics
                             Immunochromatographicmobile malariaACT         2000             2000

Brazil      microscopy                               health facility        2006             2006
Brazil      RDT              Optimal                 health facility        2006             2006

Tanzania    microscopy       with ACT treatment      health facility        2008             2008
Tanzania    RDT              with ACT treatment      health facility        2008             2008
Tanzania*   microscopy       with ACT treatment      health facility        2008             2008
Tanzania*   RDT              with ACT treatment      health facility        2008             2008
Sri Lanka                    test for P. vivax
            microscopy of blood smears                          2001-2002
                                                  health facility           2002
Sri Lanka                    test for P. vivax                  2001-2002
            RDT: immunochromatographic text (ICT) health facility           2002
                                                            Study information

Country    Location    Scale    Study design   Cohort              Number in study         Transmission
Zambia                 16079                    Kalomo
           Chongwe, Kalomo in Chongwe, 18279 inall ages            ~34358                  moderate
Zambia                 16079                    Kalomo
           Chongwe, Kalomo in Chongwe, 18279 inall ages            ~34358                  moderate

Ethiopia   Tigray                                      all ages
                                      routine health service delivery                      seasonal, unstable
Ethiopia   Tigray                                      all ages
                                      routine health service delivery                      seasonal, unstable
Ethiopia   Tigray                                      all ages
                                      routine health service delivery                      seasonal, unstable

Nigeria    Ogbomoso        304 patients                                              304
                                                       all patients presenting with clinical malaria
Nigeria    Ogbomoso        304 patients                                              304
                                                       all patients presenting with clinical malaria
Nigeria    Ogbomoso        304 patients                                              304
                                                       all patients presenting with clinical malaria
Nigeria    Ogbomoso        304 patients                                              304
                                                       all patients presenting with clinical malaria
Nigeria    Ogbomoso        304 patients                                              304
                                                       all patients presenting with clinical malaria
Nigeria    Ogbomoso        304 patients                                              304
                                                       all patients presenting with clinical malaria

Zambia                  4 districts cluster trial
           Chingola, Kabwe, Kalomo, Chongwe                       catchment = 28528
                                                       malaria outpatient                  seasonal, low and high
Zambia                  4 districts cluster trial
           Chingola, Kabwe, Kalomo, Chongwe                       catchment = 82434
                                                       malaria outpatient                  seasonal, low and high
Zambia                  4 districts cluster trial
           Chingola, Kabwe, Kalomo, Chongwe                       catchment = 35260
                                                       malaria outpatient                  seasonal, low and high
Zambia                  4 districts cluster trial
           Chingola, Kabwe, Kalomo, Chongwe                       catchment = 28528
                                                       malaria outpatient                  seasonal, low and high
Zambia                  4 districts cluster trial
           Chingola, Kabwe, Kalomo, Chongwe                       catchment = 82434
                                                       malaria outpatient                  seasonal, low and high
Zambia                  4 districts cluster trial
           Chingola, Kabwe, Kalomo, Chongwe                       catchment = 35260
                                                       malaria outpatient                  seasonal, low and high

SSA - Sudan and Ethiopia              model                                                prevalence = 25%
                                                       all patients with fever or history of fever
SSA - Sudan and Ethiopia              model                                                prevalence = 25%
                                                       all patients with fever or history of fever
SSA - Sudan and Ethiopia              model                                                prevalence = 50%
                                                       all patients with fever or history of fever
SSA - Sudan and Ethiopia              model                                                prevalence = 50%
                                                       all patients with fever or history of fever
SSA - Sudan and Ethiopia              model                                                prevalence = 75%
                                                       all patients with fever or history of fever
SSA - Sudan and Ethiopia              model                                                prevalence = 75%
                                                       all patients with fever or history of fever

Thailand   Thai-Myanmar border        RCT              mostly 1-14 years             436   seasonal - API 57.19&10.08/1000
Thailand   Thai-Myanmar border        RCT              mostly 1-14 years             436   seasonal - API 57.19&10.08/1000
Thailand   Thai-Myanmar border        RCT              mostly 1-14 years             436   seasonal - API 57.19&10.08/1000
Thailand   Thai-Myanmar border        RCT              mostly 1-14 years             436   seasonal - API 57.19&10.08/1000
Thailand   Thai-Myanmar border        RCT              mostly 1-14 years             436   seasonal - API 57.19&10.08/1000
Thailand   Thai-Myanmar border        RCT              mostly 1-14 years             436   seasonal - API 57.19&10.08/1000

Brazil     Amazon, Para region                        NMCP data33491 - to health facility
                                      models based onpatients presenting hypothetical 6.28-184.27/1000 cases per year
Brazil     Amazon, Para region                        NMCP data33491 - to health facility
                                      models based onpatients presenting hypothetical 6.28-184.27/1000 cases per year

Tanzania                6          trial
           Dar es Salaam health facilities                                           facilities
                                                       patients presenting to health257 EIR=1.3
Tanzania                6          trial
           Dar es Salaam health facilities                                           facilities
                                                       patients presenting to health257 EIR=1.3
Tanzania                6          trial
           Dar es Salaam health facilities                                           facilities
                                                       patients presenting to health257 EIR=1.3
Tanzania                6          trial
           Dar es Salaam health facilities                                           facilities
                                                       patients presenting to health257 EIR=1.3
Sri Lanka   Moneragala district                                328 moderate
                                  patients >5 years with history of fever
Sri Lanka   Moneragala district                                328 moderate
                                  patients >5 years with history of fever
Currency    Exchange rate Perspective People covered diagnostics    treatment          personnel
2009 USD    1USD = ZMK4900Provider                9847    94.5           5.5                 -
2009 USD    1USD = ZMK4900Provider              53450          80.6      19.4                -

2007 USD                    Provider               453           0.0    100.0                -
2007 USD                    Provider               580          55.5     44.5                -
2007 USD                    Provider              2143          72.1     27.9                -

2009 USD                   S
            1USD = 147 Naira ociety                 134     -             -                  -
2009 USD                   S
            1USD = 147 Naira ociety                 170     -             -                  -
2009 USD                   S
            1USD = 147 Naira ociety                 170     -             -                  -
2009 USD                   S
            1USD = 147 Naira ociety                 134     -             -                  -
2009 USD                   S
            1USD = 147 Naira ociety                 170     -             -                  -
2009 USD                   S
            1USD = 147 Naira ociety                 170     -             -                  -

2005 USD                   ZMK
            1 USD = 4512.51Provider               6520      -             -                        83.4
2005 USD                   ZMK
            1 USD = 4512.51Provider              10460          13.5      -                        64.3
2005 USD                   ZMK
            1 USD = 4512.51Provider               6685          32.7      -                        51.8
2005 USD                   ZMK
            1 USD = 4512.51Provider               6520      -                   34.5               54.6
2005 USD                   ZMK
            1 USD = 4512.51Provider              10460          11.8            12.9               56.0
2005 USD                   ZMK
            1 USD = 4512.51Provider               6685          26.1            20.1               41.4

2004 Euro   1 Euro = 1.219 USD         10000 hypothetical   -             -                  -
2004 Euro   1 Euro = 1.219 USD         10000 hypothetical   -             -                  -
2004 Euro   1 Euro = 1.219 USD         10000 hypothetical   -             -                  -
2004 Euro   1 Euro = 1.219 USD         10000 hypothetical   -             -                  -
2004 Euro   1 Euro = 1.219 USD         10000 hypothetical   -             -                  -
2004 Euro   1 Euro = 1.219 USD         10000 hypothetical   -             -                  -

2000 Baht                   Provider
            1 USD = 42.36 Baht                      145     -                    4.1               77.4
2000 Baht                   Provider
            1 USD = 42.36 Baht                      145         57.4             7.0               29.8
2000 Baht                   Provider
            1 USD = 42.36 Baht                      146         55.5             7.0               27.2
2000 Baht                   Society
            1 USD = 42.36 Baht                      145     -                    3.1               58.4
2000 Baht                   Society
            1 USD = 42.36 Baht                      145         56.6             6.9               29.4
2000 Baht                   Society
            1 USD = 42.36 Baht                      146         54.1             6.8               26.5

2006 USD                    Provider
            1 USD = 2.17 Reais                   33491      -             -                        18.2
2006 USD                    Provider
            1 USD = 2.17 Reais                   33491          83.2      -                        10.2

2008 USD                   P
            1 USD = 1222 TSHrovider                  80          0.0            74.0         -
2008 USD                   P
            1 USD = 1222 TSHrovider                 177         21.5            35.1         -
2008 USD                   S
            1 USD = 1222 TSHociety                   80          0.0            46.6         -
2008 USD                   S
            1 USD = 1222 TSHociety                  177         16.6            27.0         -
2002 USD   1 USD = 96 SL RsProvider   328   44.7   -   45.8
2002 USD   1 USD = 96 SL RsProvider   328   99.1   -   0.9
                                                                                 Financial costs
                                             Breakdown %
training          IEC       overheads        capital     distribution   transport storage
       -                -         -                  -          -            -         -
       -                -         -                  -          -            -         -

       -                -         -                -            -           -           -
       -                -         -                -            -           -           -
       -                -         -                -            -           -           -

       -                -         -                -            -           -           -
       -                -         -                -            -           -           -
       -                -         -                -            -           -           -
       -                -         -                -            -           -           -
       -                -         -                -            -           -           -
       -                -         -                -            -           -           -

       -                -             12.8             3.8      -           -           -
       -                -             12.7             9.5      -           -           -
       -                -             13.6             2.0      -           -           -
       -                -              8.4             2.5      -           -           -
       -                -             11.1             8.3      -           -           -
       -                -             10.9             1.6      -           -           -

       -                -         -                -            -           -           -
       -                -         -                -            -           -           -
       -                -         -                -            -           -           -
       -                -         -                -            -           -           -
       -                -         -                -            -           -           -
       -                -         -                -            -           -           -

           14.0         -         -                    0.6      -           -           -
            0.1         -         -                -            -           -           -
            0.1         -         -                -            -           -           -
           10.6         -         -                    0.4      -           -           -
            0.1         -         -                -            -           -           -
            0.1         -         -                -            -           -           -

           58.8         -             13.6             1.3      -               8.0     -
            0.8         -              0.4         -            -               5.3     -

       -                -             25.5         -            -           -           -
       -                -             43.6         -            -           -           -
       -                -             16.1         -            -           -           -
       -                -             33.6         -            -           -           -
0.6   -       6.1   2.8   -   -   -
 -    -   -          -    -   -   -
nancial costs
                                                                                                           Cost per
           study costs   other              user               NA       patient diagnosed     patient diagnosed and treated
                 -               -                  -               -                    3.99                   4.22
                 -               -                  -               -                    5.33                   6.61

                 -               -                  -               -             -                     -
                 -               -                  -               -             -                     -
                 -               -                  -               -             -                     -

                 -               -                  -           100.0             -                     -
                 -               -                  -           100.0             -                     -
                 -               -                  -           100.0             -                     -
                 -               -                  -           100.0                    3.74           -
                 -               -                  -           100.0                    3.74           -
                 -               -                  -           100.0                    3.74           -

                 -               -                  -               -                    2.70           -
                 -               -                  -               -                    8.20           -
                 -               -                  -               -                    4.70           -
                 -               -                  -               -             -                            4.20
                 -               -                  -               -             -                            9.40
                 -               -                  -               -             -                            5.90

                 -               -                  -           100.0                    0.54           -
                 -               -                  -           100.0             -                     -
                 -               -                  -           100.0                    0.54           -
                 -               -                  -           100.0             -                     -
                 -               -                  -           100.0                    0.54           -
                 -               -                  -           100.0             -                     -

                 -                    3.9           -               -             -                         304.71
                 -                    5.6           -               -             -                         249.47
                 -                   10.2           -               -             -                         271.72
                 -                    2.9          24.5             -             -                         403.44
                 -                    5.5          1.4              -             -                         252.99
                 -                   10.0          2.6              -             -                         278.86

                 -               -                  -               -                    6.79           -
                 -               -                  -               -                    5.14           -

                 -               -                  -               -             -                            2.31
                 -               -                  -               -             -                            3.62
                 -               -                      37.1        -             -                            3.67
                 -               -                      23.0        -             -                            4.70
-   -   -   -   0.28   -
-   -   -   -   3.82   -
Cost per                                                                                                  Br
                                             cost
           patient diagnosed and treated correctlyof drugs treatment   distribution   transport storage
                           -                        -            -             -           -         -
                           -                        -            -             -           -         -

                                      11.08       -             -             -           -         -
                                       4.66       -             -             -           -         -
                                       1.69       -             -             -           -         -

                                       4.49       -             -             -           -         -
                                       4.14       -             -             -           -         -
                                       4.63       -             -             -           -         -
                                       6.04       -             -             -           -         -
                                       4.84       -             -             -           -         -
                                       4.97       -             -             -           -         -

                          -                       -             -             -           -         -
                          -                       -             -             -           -         -
                          -                       -             -             -           -         -
                                       4.20       -             -             -           -         -
                                       8.80       -             -             -           -         -
                                       5.20       -             -             -           -         -

                                      10.00       -             -             -           -         -
                                      10.80       -             -             -           -         -
                                       5.00       -             -             -           -         -
                                       6.00       -             -             -           -         -
                                       3.30       -             -             -           -         -
                                       4.40       -             -             -           -         -

                          -                       -             -             -           -         -
                          -                       -             -             -           -         -
                          -                       -             -             -           -         -
                          -                       -             -             -           -         -
                          -                       -             -             -           -         -
                          -                       -             -             -           -         -

                          -                       -             -             -           -         -
                          -                       -             -             -           -         -

                          -                       -             -             -           -         -
                          -                       -             -             -           -         -
                          -                       -             -             -           -         -
                          -                       -             -             -           -         -
-   -   -   -   -   -
-   -   -   -   -   -
                                          Economic costs
               Breakdown %
personnel   training IEC      overheads   capital   study costs   other       user
     -           -        -        -           -           -              -          -
     -           -        -        -           -           -              -          -

     -          -         -        -           -           -              -          -
     -          -         -        -           -           -              -          -
     -          -         -        -           -           -              -          -

     -          -         -        -           -           -              -          -
     -          -         -        -           -           -              -          -
     -          -         -        -           -           -              -          -
     -          -         -        -           -           -              -          -
     -          -         -        -           -           -              -          -
     -          -         -        -           -           -              -          -

     -          -         -        -           -           -              -          -
     -          -         -        -           -           -              -          -
     -          -         -        -           -           -              -          -
     -          -         -        -           -           -              -          -
     -          -         -        -           -           -              -          -
     -          -         -        -           -           -              -          -

     -          -         -        -           -           -              -          -
     -          -         -        -           -           -              -          -
     -          -         -        -           -           -              -          -
     -          -         -        -           -           -              -          -
     -          -         -        -           -           -              -          -
     -          -         -        -           -           -              -          -

     -          -         -        -           -           -              -          -
     -          -         -        -           -           -              -          -
     -          -         -        -           -           -              -          -
     -          -         -        -           -           -              -          -
     -          -         -        -           -           -              -          -
     -          -         -        -           -           -              -          -

     -          -         -        -           -           -              -          -
     -          -         -        -           -           -              -          -

     -          -         -        -           -           -              -          -
     -          -         -        -           -           -              -          -
     -          -         -        -           -           -              -          -
     -          -         -        -           -           -              -          -
-   -   -   -   -   -   -   -
-   -   -   -   -   -   -   -
                                   Cost per
NA       patient diagnosed                         patient              treated correctly
                             patient diagnosed and treated diagnosed andSensitivity analysis
     -              -                   -                     -         no
     -              -                   -                     -         no

     -             -                   -                     -           yes
     -             -                   -                     -           yes
     -             -                   -                     -           yes

     -             -                   -                     -           no
     -             -                   -                     -           no
     -             -                   -                     -           no
     -             -                   -                     -           no
     -             -                   -                     -           no
     -             -                   -                     -           no

     -             -                   -                     -           yes
     -             -                   -                     -           yes
     -             -                   -                     -           yes
     -             -                   -                     -           yes
     -             -                   -                     -           yes
     -             -                   -                     -           yes

     -             -                   -                     -           yes
     -             -                   -                     -           yes
     -             -                   -                     -           yes
     -             -                   -                     -           yes
     -             -                   -                     -           yes
     -             -                   -                     -           yes

     -             -                   -                     -           yes
     -             -                   -                     -           yes
     -             -                   -                     -           yes
     -             -                   -                     -           yes
     -             -                   -                     -           yes
     -             -                   -                     -           yes

     -             -                   -                     -           yes
     -             -                   -                     -           yes

     -             -                   -                     -           no
     -             -                   -                     -           no
     -             -                   -                     -           no
     -             -                   -                     -
-   -   -   -   no
-   -   -   -   no
                               Additional Information

Ingredients approach   Discounting and annualisation Urban/Rural   Shared resources
no                                                  5% rural
no

no                                                      rural
no
no

no
no
no
no
no
no

yes                                               5%    both       yes
yes                                               5%    both       yes
yes                                               5%    both       yes
yes                                               5%    both       yes
yes                                               5%    both       yes
yes                                               5%    both       yes

no
no
no
no
no
no

yes                                                     rural
yes                                                     rural
yes                                                     rural
yes                                                     rural
yes                                                     rural
yes                                                     rural

yes                                               5%
yes                                               5%

yes                                               3% urban
yes                                               3% urban
yes                                               3% urban
yes   6% rural
yes   6% rural
Baseline coverage
                    The number of people covered here refers to the number of cases treated through that cha




                    Based on 10000 hypothetical patients presenting with fever.




                    I'm not quite sure what the role of the 'Grand total' in Table 3 is. I've added the internal an
r of cases treated through that channel.




ble 3 is. I've added the internal and external costs separately.
                                           Publication

Title                                            Authors         PubMed ID Publication year
                                                 Lubell Y, Riewpaiboon A, Dondorp AM, von Seidlein L, Mokuolu OA, Nansumb
                                                                     21734764                  2011
Cost-effectiveness of parenteral artesunate for treating children with severe malaria in sub-Saharan Africa.
                                                 Lubell Y, Riewpaiboon A, Dondorp AM, von Seidlein L, Mokuolu OA, Nansumb
                                                                     21734764                  2011
Cost-effectiveness of parenteral artesunate for treating children with severe malaria in sub-Saharan Africa.
                                                 Lubell Y, Riewpaiboon A, Dondorp AM, von Seidlein L, Mokuolu OA, Nansumb
                                                                     21734764                  2011
Cost-effectiveness of parenteral artesunate for treating children with severe malaria in sub-Saharan Africa.
                                                 Lubell Y, Riewpaiboon A, Dondorp AM, von Seidlein L, Mokuolu OA, Nansumb
                                                                     21734764                  2011
Cost-effectiveness of parenteral artesunate for treating children with severe malaria in sub-Saharan Africa.
                                                 Lubell Y, Riewpaiboon A, Dondorp AM, von Seidlein L, Mokuolu OA, Nansumb
                                                                     21734764                  2011
Cost-effectiveness of parenteral artesunate for treating children with severe malaria in sub-Saharan Africa.
                                                 Lubell Y, Riewpaiboon A, Dondorp AM, von Seidlein L, Mokuolu OA, Nansumb
                                                                     21734764                  2011
Cost-effectiveness of parenteral artesunate for treating children with severe malaria in sub-Saharan Africa.
                                                 Lubell Y, Riewpaiboon A, Dondorp AM, von Seidlein L, Mokuolu OA, Nansumb
                                                                     21734764                  2011
Cost-effectiveness of parenteral artesunate for treating children with severe malaria in sub-Saharan Africa.
                                                 Lubell Y, Riewpaiboon A, Dondorp AM, von Seidlein L, Mokuolu OA, Nansumb
                                                                     21734764                  2011
Cost-effectiveness of parenteral artesunate for treating children with severe malaria in sub-Saharan Africa.
                                                 Lubell Y, Riewpaiboon A, Dondorp AM, von Seidlein L, Mokuolu OA, Nansumb
                                                                     21734764                  2011
Cost-effectiveness of parenteral artesunate for treating children with severe malaria in sub-Saharan Africa.
                                                 Lubell Y, Riewpaiboon A, Dondorp AM, von Seidlein L, Mokuolu OA, Nansumb
                                                                     21734764                  2011
Cost-effectiveness of parenteral artesunate for treating children with severe malaria in sub-Saharan Africa.

                                                Davis for Clarke PM, Siba PM, Karunajeewa data from Papua New Guinea.
                                                                  21379417                  2011
Cost-effectiveness of artemisinin combination therapyWA,uncomplicated malaria in children: HA, Davy C, Mueller I, Davis TM
                                                Davis for Clarke PM, Siba PM, Karunajeewa data from Papua New Guinea.
                                                                  21379417                  2011
Cost-effectiveness of artemisinin combination therapyWA,uncomplicated malaria in children: HA, Davy C, Mueller I, Davis TM
                                                Davis for Clarke PM, Siba PM, Karunajeewa data from Papua New Guinea.
                                                                  21379417                  2011
Cost-effectiveness of artemisinin combination therapyWA,uncomplicated malaria in children: HA, Davy C, Mueller I, Davis TM
                                                Davis for Clarke PM, Siba PM, Karunajeewa data from Papua New Guinea.
                                                                  21379417                  2011
Cost-effectiveness of artemisinin combination therapyWA,uncomplicated malaria in children: HA, Davy C, Mueller I, Davis TM
                                                Davis for Clarke PM, Siba PM, Karunajeewa data from Papua New Guinea.
                                                                  21379417                  2011
Cost-effectiveness of artemisinin combination therapyWA,uncomplicated malaria in children: HA, Davy C, Mueller I, Davis TM
                                                Davis for Clarke PM, Siba PM, Karunajeewa data from Papua New Guinea.
                                                                  21379417                  2011
Cost-effectiveness of artemisinin combination therapyWA,uncomplicated malaria in children: HA, Davy C, Mueller I, Davis TM
                                                Davis for Clarke PM, Siba PM, Karunajeewa data from Papua New Guinea.
                                                                  21379417                  2011
Cost-effectiveness of artemisinin combination therapyWA,uncomplicated malaria in children: HA, Davy C, Mueller I, Davis TM
                                                Davis for Clarke PM, Siba PM, Karunajeewa data from Papua New Guinea.
                                                                  21379417                  2011
Cost-effectiveness of artemisinin combination therapyWA,uncomplicated malaria in children: HA, Davy C, Mueller I, Davis TM

                                                                   17313682
                                                Chanda for treatment of uncomplicated malaria Hawela M,
                                                                                             N, in
A cost-effectiveness analysis of artemether lumefantrineP, Masiye F, Chitah BM, Sipilanyambe 2007 Zambia. Banda P, Okoros
                                                                   17313682
                                                Chanda for treatment of uncomplicated malaria Hawela M,
                                                                                             N, in
A cost-effectiveness analysis of artemether lumefantrineP, Masiye F, Chitah BM, Sipilanyambe 2007 Zambia. Banda P, Okoros

Cost-effectiveness study of three antimalarial drug combinations M,17032059
                                                                    Mutabingwa TK, Whitty CJ.
                                                 Wiseman V, Kim in Tanzania.               2006
Cost-effectiveness study of three antimalarial drug combinations M,17032059
                                                                    Mutabingwa TK, Whitty CJ.
                                                 Wiseman V, Kim in Tanzania.               2006
Cost-effectiveness study of three antimalarial drug combinations M,17032059
                                                                    Mutabingwa TK, Whitty CJ.
                                                 Wiseman V, Kim in Tanzania.               2006
Cost-effectiveness study of three antimalarial drug combinations M,17032059
                                                                    Mutabingwa TK, Whitty CJ.
                                                 Wiseman V, Kim in Tanzania.               2006
Cost-effectiveness study of three antimalarial drug combinations M,17032059
                                                                    Mutabingwa TK, Whitty CJ.
                                                 Wiseman V, Kim in Tanzania.               2006
Cost-effectiveness study of three antimalarial drug combinations M,17032059
                                                                    Mutabingwa TK, Whitty CJ.
                                                 Wiseman V, Kim in Tanzania.               2006
Cost-effectiveness study of three antimalarial drug combinations M,17032059
                                                                    Mutabingwa TK, Whitty CJ.
                                                 Wiseman V, Kim in Tanzania.               2006
Cost-effectiveness study of three antimalarial drug combinations M,17032059
                                                                    Mutabingwa TK, Whitty CJ.
                                                 Wiseman V, Kim in Tanzania.               2006
Cost-effectiveness study of three antimalarial drug combinations M,17032059
                                                                    Mutabingwa TK, Whitty CJ.
                                                 Wiseman V, Kim in Tanzania.               2006
Cost-effectiveness study of three antimalarial drug combinations M,17032059
                                                                    Mutabingwa TK, Whitty CJ.
                                                 Wiseman V, Kim in Tanzania.               2006

                                                                     14710972
                                                 Gogtay NJ, Kadam VS, Desai S, Kamtekar KD, Dalvi SS, Kshirsagar NA.
                                                                                              2003
A cost-effectiveness analysis of three antimalarial treatments for acute, uncomplicated Plasmodium falciparum malaria in Mu
                                                                     14710972
                                                 Gogtay NJ, Kadam VS, Desai S, Kamtekar KD, Dalvi SS, Kshirsagar NA.
                                                                                              2003
A cost-effectiveness analysis of three antimalarial treatments for acute, uncomplicated Plasmodium falciparum malaria in Mu
                                                                     14710972
                                                 Gogtay NJ, Kadam VS, Desai S, Kamtekar KD, Dalvi SS, Kshirsagar NA.
                                                                                              2003
A cost-effectiveness analysis of three antimalarial treatments for acute, uncomplicated Plasmodium falciparum malaria in Mu
                                                                     14710972
                                                 Gogtay NJ, Kadam VS, Desai S, Kamtekar KD, Dalvi SS, Kshirsagar NA.
                                                                                              2003
A cost-effectiveness analysis of three antimalarial treatments for acute, uncomplicated Plasmodium falciparum malaria in Mu
                                                                     14710972
                                                 Gogtay NJ, Kadam VS, Desai S, Kamtekar KD, Dalvi SS, Kshirsagar NA.
                                                                                              2003
A cost-effectiveness analysis of three antimalarial treatments for acute, uncomplicated Plasmodium falciparum malaria in Mu
                                                                     14710972
                                                 Gogtay NJ, Kadam VS, Desai S, Kamtekar KD, Dalvi SS, Kshirsagar NA.
                                                                                              2003
A cost-effectiveness analysis of three antimalarial treatments for acute, uncomplicated Plasmodium falciparum malaria in Mu

                                                                    19187518
                                                Lubell Y, Yeung S, Dondorp AM, Day NP, Nosten F, Tjitra E, Abul Faiz M, Yunu
Cost-effectiveness of artesunate for the treatment of severe malaria.                       2009
                                                                    19187518
                                                Lubell Y, Yeung S, Dondorp AM, Day NP, Nosten F, Tjitra E, Abul Faiz M, Yunu
Cost-effectiveness of artesunate for the treatment of severe malaria.                       2009
                                                                    19187518
                                                Lubell Y, Yeung S, Dondorp AM, Day NP, Nosten F, Tjitra E, Abul Faiz M, Yunu
Cost-effectiveness of artesunate for the treatment of severe malaria.                       2009
                                                                    19187518
                                                Lubell Y, Yeung S, Dondorp AM, Day NP, Nosten F, Tjitra E, Abul Faiz M, Yunu
Cost-effectiveness of artesunate for the treatment of severe malaria.                       2009
                                                                    19187518
                                                Lubell Y, Yeung S, Dondorp AM, Day NP, Nosten F, Tjitra E, Abul Faiz M, Yunu
Cost-effectiveness of artesunate for the treatment of severe malaria.                       2009
                                                                    19187518
                                                Lubell Y, Yeung S, Dondorp AM, Day NP, Nosten F, Tjitra E, Abul Faiz M, Yunu
Cost-effectiveness of artesunate for the treatment of severe malaria.                       2009
                                                                    19187518
                                                Lubell Y, Yeung S, Dondorp AM, Day NP, Nosten F, Tjitra E, Abul Faiz M, Yunu
Cost-effectiveness of artesunate for the treatment of severe malaria.                       2009
                                                                    19187518
                                                Lubell Y, Yeung S, Dondorp AM, Day NP, Nosten F, Tjitra E, Abul Faiz M, Yunu
Cost-effectiveness of artesunate for the treatment of severe malaria.                       2009

Artemisinin-based combination therapy reduces Muheki C, McIntyre15361108 KI. in KwaZulu2004 South Africa.
                                                                 D, Barnes
                                              expenditure on malaria treatment          Natal,
Artemisinin-based combination therapy reduces Muheki C, McIntyre15361108 KI. in KwaZulu2004 South Africa.
                                                                 D, Barnes
                                              expenditure on malaria treatment          Natal,
Artemisinin-based combination therapy reduces Muheki C, McIntyre15361108 KI. in KwaZulu2004 South Africa.
                                                                 D, Barnes
                                              expenditure on malaria treatment          Natal,
Artemisinin-based combination therapy reduces Muheki C, McIntyre15361108 KI. in KwaZulu2004 South Africa.
                                                                 D, Barnes
                                              expenditure on malaria treatment          Natal,
Artemisinin-based combination therapy reduces Muheki C, McIntyre15361108 KI. in KwaZulu2004 South Africa.
                                                                 D, Barnes
                                              expenditure on malaria treatment          Natal,
Artemisinin-based combination therapy reduces Muheki C, McIntyre15361108 KI. in KwaZulu2004 South Africa.
                                                                 D, Barnes
                                              expenditure on malaria treatment          Natal,

                                                                  18179716
                                               Njau JD, Goodman CA, Kachur SP, Mulligan J, Munkondya JS, in rural Tanzan
                                                                                             2008
The costs of introducing artemisinin-based combination therapy: evidence from district-wide implementationMcHomvu N, Ab

                                                                   11926003
                                             Wilkins JJ, Folb PI, Valentine N, Barnes KI. 2002
An economic comparison of chloroquine and sulfadoxine-pyrimethamine as first-line treatment for malaria in South Africa: de
                                                                   11926003
                                             Wilkins JJ, Folb PI, Valentine N, Barnes KI. 2002
An economic comparison of chloroquine and sulfadoxine-pyrimethamine as first-line treatment for malaria in South Africa: de

                                                                 19161598
                                               Ayieko P, Akumu AO, and provider costs M. 2009
The economic burden of inpatient paediatric care in Kenya: householdGriffiths UK, English for treatment of pneumonia, malar
                                                                 19161598
                                               Ayieko P, Akumu AO, and provider costs M. 2009
The economic burden of inpatient paediatric care in Kenya: householdGriffiths UK, English for treatment of pneumonia, malar

                                                 Hongoro C, McPake12631315
                                                                   B.                         2003
Hospital costs of high-burden diseases: malaria and pulmonary tuberculosis in a high HIV prevalence context in Zimbabwe.

                                                                  18492245
                                                Yeung S, Van the Cambodian experience.      Mills
Cost of increasing access to artemisinin combination therapy: Damme W, Socheat D, White NJ,2008 A.
                                                                  18492245
                                                Yeung S, Van the Cambodian experience.      Mills
Cost of increasing access to artemisinin combination therapy: Damme W, Socheat D, White NJ,2008 A.

                                                               16682433
                                               Goodman CA, Mutemi WM, training in rural A, Marsh
                                                                                         2006
The cost-effectiveness of improving malaria home management: shopkeeperBaya EK, WillettsKenya. V.
                                                               16682433
                                               Goodman CA, Mutemi WM, training in rural A, Marsh
                                                                                         2006
The cost-effectiveness of improving malaria home management: shopkeeperBaya EK, WillettsKenya. V.
                                                               16682433
                                               Goodman CA, Mutemi WM, training in rural A, Marsh
                                                                                         2006
The cost-effectiveness of improving malaria home management: shopkeeperBaya EK, WillettsKenya. V.
                                                               16682433
                                               Goodman CA, Mutemi WM, training in rural A, Marsh
                                                                                         2006
The cost-effectiveness of improving malaria home management: shopkeeperBaya EK, WillettsKenya. V.
                                                               16682433
                                               Goodman CA, Mutemi WM, training in rural A, Marsh
                                                                                         2006
The cost-effectiveness of improving malaria home management: shopkeeperBaya EK, WillettsKenya. V.
                                                               16682433
                                               Goodman CA, Mutemi WM, training in rural A, Marsh
                                                                                         2006
The cost-effectiveness of improving malaria home management: shopkeeperBaya EK, WillettsKenya. V.
                                     Intervention details

name                Intervention     Intervention details     Delivery       Study Period    Costing year
Tanzania            quinine for severe malaria                inpatient      2009-2010                  2009
Tanzania            artesunate for severe malaria             inpatient      2009-2010                  2009
Tanzania            quinine for severe malaria                inpatient      2009-2010                  2009
Tanzania            artesunate for severe malaria             inpatient      2009-2010                  2009
Uganda              quinine for severe malaria                inpatient      2009-2010                  2009
Uganda              artesunate for severe malaria             inpatient      2009-2010                  2009
Nigeria             quinine for severe malaria                inpatient      2009-2010                  2009
Nigeria             artesunate for severe malaria             inpatient      2009-2010                  2009
Africa              quinine for severe malaria                inpatient      2009-2010                  2009
Africa              artesunate for severe malaria             inpatient      2009-2010                  2009

Papua New Guinea*                   CQ & SP
                    treatment of uncomplicated P. falciparum health clinic   2005-2007                 2008
Papua New Guinea*                   ART & SP
                    treatment of uncomplicated P. falciparum health clinic   2005-2007                 2008
Papua New Guinea*                   DHA & PQ
                    treatment of uncomplicated P. falciparum health clinic   2005-2007                 2008
Papua New Guinea*                   AL
                    treatment of uncomplicated P. falciparum health clinic   2005-2007                 2008
Papua New Guinea*                   CQ & SP
                    treatment of uncomplicated P. vivax      health clinic   2005-2007                 2008
Papua New Guinea*                   ART & SP
                    treatment of uncomplicated P. vivax      health clinic   2005-2007                 2008
Papua New Guinea*                   DHA & PQ
                    treatment of uncomplicated P. vivax      health clinic   2005-2007                 2008
Papua New Guinea*                   AL
                    treatment of uncomplicated P. vivax      health clinic   2005-2007                 2008

Zambia                              AL
                    treatment of uncomplicated malaria                                  2004
                                                              outpatient facilities - health centres   2005
Zambia                              SP
                    treatment of uncomplicated malaria                                  2004
                                                              outpatient facilities - health centres   2005

Tanzania                            SP
                    malaria treatment                         hospital       2002-2004                 2005
Tanzania                            AQ
                    malaria treatment                         hospital       2002-2004                 2005
Tanzania                            AQ
                    malaria treatment + SP                    hospital       2002-2004                 2005
Tanzania                            AQ
                    malaria treatment + artesunate            hospital       2002-2004                 2005
Tanzania                            AL
                    malaria treatment                         hospital       2002-2004                 2005
Tanzania*                           SP
                    malaria treatment                         hospital       2002-2004                 2005
Tanzania*                           AQ
                    malaria treatment                         hospital       2002-2004                 2005
Tanzania*                           AQ
                    malaria treatment + SP                    hospital       2002-2004                 2005
Tanzania*                           AQ
                    malaria treatment + artesunate            hospital       2002-2004                 2005
Tanzania*                           AL
                    malaria treatment                         hospital       2002-2004                 2005

India                               chloroquine
                    malaria treatment                         hospital       1996-1998                 1998
India                               mefloquine
                    malaria treatment                         hospital       1996-1998                 1998
India                               co-artemether
                    malaria treatment                         hospital       1996-1998                 1998
India*                              chloroquine
                    malaria treatment                         hospital       1996-1998                 1998
India*                              mefloquine
                    malaria treatment                         hospital       1996-1998                 1998
India*                              co-artemether
                    malaria treatment                         hospital       1996-1998                 1998

Bangladesh                           artesunate
                    treatment for severe malaria              hospital       2003-2005                 2008
India                           artesunate
               treatment for severe malaria          hospital     2003-2005               2008
Indonesia                       artesunate
               treatment for severe malaria          hospital     2003-2005               2008
Myanmar                         artesunate
               treatment for severe malaria          hospital     2003-2005               2008
Bangladesh                      Quinine
               treatment for severe malaria          hospital     2003-2005               2008
India                           Quinine
               treatment for severe malaria          hospital     2003-2005               2008
Indonesia                       Quinine
               treatment for severe malaria          hospital     2003-2005               2008
Myanmar                         Quinine
               treatment for severe malaria          hospital     2003-2005               2008

South Africa                    SP
               treatment for uncomplicated malaria                  Manguzi subdistrict
                                                     outpatient in2000-2002               2002
South Africa                    AL
               treatment for uncomplicated malaria                  Manguzi subdistrict
                                                     outpatient in2000-2002               2002
South Africa                    SP
               treatment for uncomplicated malaria                 2000-2002
                                                     outpatients in Manguzi hospital      2002
South Africa                    AL
               treatment for uncomplicated malaria                 2000-2002
                                                     outpatients in Manguzi hospital      2002
South Africa                    SP
               treatment for severe malaria                        Manguzi hospital
                                                     inpatients in 2000-2002              2002
South Africa                    AL
               treatment for severe malaria                        Manguzi hospital
                                                     inpatients in 2000-2002              2002

Tanzania                       ACTs: SP+AS or AL
               treatment for uncomplicated malaria   health centre2002-2005               2003

South Africa                   CQ
               treatemtn for uncomplicated malaria   health centre             1997       1997
South Africa                   SP
               treatemtn for uncomplicated malaria   health centre             1997       1997

Kenya                          NA
               treatment for malaria in hospital                   2004-2005
                                                     national hospital                    2005
Kenya                          NA
               treatment for malaria in hospital                   2004-2005
                                                     district hospitals                   2005

                               NA
               hospital treatment for malaria        hospitals                 1999       1999

                               A
               malaria treatment CT                  malaria outreach team                2005
                               A
               malaria treatment CT                  village malaria worker               2005

                               Development phase
               treatment through shopkeepers         shopkeepers1999-2000                 2000
                               Set up year
               treatment through shopkeepers         shopkeepers1999-2000                 2000
                               Continuation
               treatment through shopkeepers         shopkeepers1999-2000                 2000
                               Development phase
               treatment through shopkeepers         shopkeepers1999-2000                 2000
                               Set up year
               treatment through shopkeepers         shopkeepers1999-2000                 2000
                               Continuation
               treatment through shopkeepers         shopkeepers1999-2000                 2000
                                                           Study information

Country Location          Scale       Study design      Cohort      Number in study       Transmission
Tanzania Teule                                                                     5400
                          secondary hospital (district) children presenting to hospital   Endemic and perennial with seasonal p
Tanzania Teule                                                                     5400
                          secondary hospital (district) children presenting to hospital   Endemic and perennial with seasonal p
Tanzania Korogwe                                                                   5400
                          primary hospital (district) children presenting to hospital     Endemic and perennial with seasonal p
Tanzania Korogwe                                                                   5400
                          primary hospital (district) children presenting to hospital     Endemic and perennial with seasonal p
Uganda    Mbarara         tertiary hospital                                        5400
                                                        children presenting to hospital   Endemic and perennial with seasonal p
Uganda    Mbarara         tertiary hospital                                        5400
                                                        children presenting to hospital   Endemic and perennial with seasonal p
Nigeria   Ilorin          tertiary hospital                                        5400
                                                        children presenting to hospital   Endemic and perennial with seasonal p
Nigeria   Ilorin          tertiary hospital                                        5400
                                                        children presenting to hospital   Endemic and perennial with seasonal p
sub-Saharan Africa                                                                 5400
                                                        children presenting to hospital
sub-Saharan Africa                                                                 5400
                                                        children presenting to hospital

          Guinea
Papua New Madanf and East Sepik      RCT              children 6-60 months         656
          Guinea
Papua New Madanf and East Sepik      RCT              children 6-60 months         656
          Guinea
Papua New Madanf and East Sepik      RCT              children 6-60 months         656
          Guinea
Papua New Madanf and East Sepik      RCT              children 6-60 months         656
          Guinea
Papua New Madanf and East Sepik      RCT              children 6-60 months         656
          Guinea
Papua New Madanf and East Sepik      RCT              children 6-60 months         656
          Guinea
Papua New Madanf and East Sepik      RCT              children 6-60 months         656
          Guinea
Papua New Madanf and East Sepik      RCT              children 6-60 months         656

Zambia                  6 district sites
                                      health system data
                                                      patients presenting at clinics
             Kabwe, Chongwe, Chipata, Kalomo, Chingola, Samfya                    55509 429.3/1000 cases
Zambia                  6 district sites
                                      health system data
                                                      patients presenting at clinics
             Kabwe, Chongwe, Chipata, Kalomo, Chingola, Samfya                    55509 429.3/1000 cases

Tanzania                 h
             Tuele, Muhezaospital                    children presenting to hospital
                                     health system data                         1811      EIR ~ 300
Tanzania                 h
             Tuele, Muhezaospital                    children presenting to hospital
                                     health system data                         1811      EIR ~ 300
Tanzania                 h
             Tuele, Muhezaospital                    children presenting to hospital
                                     health system data                         1811      EIR ~ 300
Tanzania                 h
             Tuele, Muhezaospital                    children presenting to hospital
                                     health system data                         1811      EIR ~ 300
Tanzania                 h
             Tuele, Muhezaospital                    children presenting to hospital
                                     health system data                         1811      EIR ~ 300
Tanzania                 h
             Tuele, Muhezaospital                    children presenting to hospital
                                     health system data                         1811      EIR ~ 300
Tanzania                 h
             Tuele, Muhezaospital                    children presenting to hospital
                                     health system data                         1811      EIR ~ 300
Tanzania                 h
             Tuele, Muhezaospital                    children presenting to hospital
                                     health system data                         1811      EIR ~ 300
Tanzania                 h
             Tuele, Muhezaospital                    children presenting to hospital
                                     health system data                         1811      EIR ~ 300
Tanzania                 h
             Tuele, Muhezaospital                    children presenting to hospital
                                     health system data                         1811      EIR ~ 300

India                     hospital                   people presenting to hospital 54
                                     data from hospital records                  2
India                     hospital                   people presenting to hospital 54
                                     data from hospital records                  2
India                     hospital                   people presenting to hospital 54
                                     data from hospital records                  2
India                     hospital                   people presenting to hospital 54
                                     data from hospital records                  2
India                     hospital                   people presenting to hospital 54
                                     data from hospital records                  2
India                     hospital                   people presenting to hospital 54
                                     data from hospital records                  2

Bangladesh                hospital                                                1461
                                     multi-centre trialpeople presenting to hospital
India                         hospital                                                   1461
                                            multi-centre trialpeople presenting to hospital
Indonesia                     hospital                                                   1461
                                            multi-centre trialpeople presenting to hospital
Myanmar                       hospital                                                   1461
                                            multi-centre trialpeople presenting to hospital
Bangladesh                    hospital                                                   1461
                                            multi-centre trialpeople presenting to hospital
India                         hospital                                                   1461
                                            multi-centre trialpeople presenting to hospital
Indonesia                     hospital                                                   1461
                                            multi-centre trialpeople presenting to hospital
Myanmar                                                                                  1461
                                            multi-centre trialpeople presenting to hospital

           KwaZulu Natal
South Africa                                                 p                          23186 low,
                                            longitudinal study eople presenting to health centres EIR < 1
           KwaZulu Natal
South Africa                                                 p                          23186 low,
                                            longitudinal study eople presenting to health centres EIR < 1
           KwaZulu Natal
South Africa                                                 h
                                            longitudinal study ospital outpatients      23186 low, EIR < 1
           KwaZulu Natal
South Africa                                                 h
                                            longitudinal study ospital outpatients      23186 low, EIR < 1
           KwaZulu Natal
South Africa                                                 h
                                            longitudinal study ospital inpatients       23186 low, EIR < 1
           KwaZulu Natal
South Africa                                                 h
                                            longitudinal study ospital inpatients       23186 low, EIR < 1

Tanzania     Rufiji           district                         people                  212144 EIR
                                            analysis of district data presenting to health centres 79-1209

           Mpumalanga,district Natal
South Africa           KwaZulu model                                                           high,
                                                            patients presenting to health facility seasonal
           Mpumalanga,district Natal
South Africa           KwaZulu model                                                           high,
                                                            patients presenting to health facility seasonal

Kenya                                                      children - inpatients
                              7 hospitals health centre data                             572
Kenya                                                      children - inpatients
                              7 hospitals health centre data                             572

Zimbabwe                      6 hospitals                   people presenting to hospital

Cambodia                                                                                        low, seasonal
Cambodia                                                                                        low, seasonal

Kenya,       Bahara, Kilifi   Early implementation phase                                        stable, endemic
Kenya,       Bahara, Kilifi   Early implementation phase                                        stable, endemic
Kenya,       Bahara, Kilifi   Early implementation phase                                        stable, endemic
Kenya,       Bahara, Kilifi   Recommended district phase                                        stable, endemic
Kenya,       Bahara, Kilifi   Recommended district phase                                        stable, endemic
Kenya,       Bahara, Kilifi   Recommended district phase                                        stable, endemic
Currency   Exchange rate Perspective People covered diagnostics       treatment         personnel
2009 USD                 Provider                2300     -                 -                 -
2009 USD                 Provider                2300     -                 -                 -
2009 USD                 Provider                2300     -                 -                 -
2009 USD                 Provider                2300     -                 -                 -
2009 USD                 Provider                2300     -                 -                 -
2009 USD                 Provider                2300     -                 -                 -
2009 USD                 Provider                2300     -                 -                 -
2009 USD                 Provider                2300     -                 -                 -
2009 USD                 Provider                2300     -                 -                 -
2009 USD                 Provider                2300     -                 -                 -

2008 USD                  Societal
           1 PGK = USD 0.345                        81     -              1.4                 -
2008 USD                  Societal
           1 PGK = USD 0.345                       103     -              13.6                -
2008 USD                  Societal
           1 PGK = USD 0.345                       100     -              8.4                 -
2008 USD                  Societal
           1 PGK = USD 0.345                       104     -              8.5                 -
2008 USD                  Societal
           1 PGK = USD 0.345                        46     -              1.7                 -
2008 USD                  Societal
           1 PGK = USD 0.345                        39     -              9.6                 -
2008 USD                  Societal
           1 PGK = USD 0.345                        36     -              6.6                 -
2008 USD                  Societal
           1 PGK = USD 0.345                        33     -              6.0                 -

2005 USD                  Provider
           1 USD = 3500 ZMK                      55509         57.9              18.1               11.4
2005 USD                  Provider
           1 USD = 3500 ZMK                      55509         68.7               2.9               13.6

2005 USD                  P
           1 USD = 1076 TSHrovider                         -                      0.8               78.2
2005 USD                  P
           1 USD = 1076 TSHrovider                 270     -                      1.6               77.6
2005 USD                  P
           1 USD = 1076 TSHrovider                 507     -                      2.5               76.8
2005 USD                  P
           1 USD = 1076 TSHrovider                 515     -                      9.2               71.6
2005 USD                  P
           1 USD = 1076 TSHrovider                 519     -                     15.3               66.8
2005 USD                  S
           1 USD = 1076 TSHociety                          -                      0.2               19.2
2005 USD                  S
           1 USD = 1076 TSHociety                  270     -                      0.4               19.2
2005 USD                  S
           1 USD = 1076 TSHociety                  507     -                      1.1               35.2
2005 USD                  S
           1 USD = 1076 TSHociety                  515     -                      5.0               39.2
2005 USD                  S
           1 USD = 1076 TSHociety                  519     -                      9.3               40.7

1998?                     Provider - hospital
           1 USD = 50 Rupees                        76     -                      4.3               28.8
1998?                     Provider - hospital
           1 USD = 50 Rupees                        58     -                     20.6               23.9
1998?                     Provider - hospital
           1 USD = 50 Rupees                        65     -                      2.6               29.3
1998?                     Society
           1 USD = 50 Rupees                        76     -                      2.3               15.7
1998?                     Society
           1 USD = 50 Rupees                        58     -                     12.2               14.1
1998?                     Society
           1 USD = 50 Rupees                        65     -                      1.4               16.0

2008 USD                   Provider - hospital     222     -                -                 -
2008 USD                  Provider - hospital       70   -          -          -
2008 USD                  Provider - hospital      143   -          -          -
2008 USD                  Provider - hospital      295   -          -          -
2008 USD                  Provider - hospital      231   -          -          -
2008 USD                  Provider - hospital       72   -          -          -
2008 USD                  Provider - hospital      146   -          -          -
2008 USD                  Provider - hospital      282   -          -          -

2002 USD                  Provider
           1 USD = 10.5 ZAR                      19929   -          -          -
2002 USD                  Provider
           1 USD = 10.5 ZAR                       1025   -          -          -
2002 USD                  Provider
           1 USD = 10.5 ZAR                       3261   -          -          -
2002 USD                  Provider
           1 USD = 10.5 ZAR                        287   -          -          -
2002 USD                  Provider
           1 USD = 10.5 ZAR                       1902   -          -          -
2002 USD                  Provider
           1 USD = 10.5 ZAR                        108   -          -          -

2003 USD                  P
           1 USD = 1065 TZS rovider             212144   -              72.8        7.6

1997 USD                  Provider                            4.5        3.8       70.4
1997 USD                  Provider                           15.9       20.7       37.6

2005 USD                   Provider
           1 USD = 75.25 KSH                       211       17.3        4.3   -
2005 USD                   Provider
           1 USD = 75.25 KSH                       211       25.8        5.2   -

           1 USD = 55 ZWDProvider                  197        3.4        3.3       30.4

2005 USD                   Provider
           1 USD = 3900 riels                    10029   -          -          -
2005 USD                   Provider
           1 USD = 3900 riels                   100000   -          -          -

2000 USD                   Provider
           1 USD = 76.28 KSH                     35770   -          -          -
2000 USD                   Provider
           1 USD = 76.28 KSH                     35770   -          -          -
2000 USD                   Provider
           1 USD = 76.28 KSH                     35770   -          -          -
2000 USD                   Provider
           1 USD = 76.28 KSH                    472750   -          -          -
2000 USD                   Provider
           1 USD = 76.28 KSH                    472750   -          -          -
2000 USD                   Provider
           1 USD = 76.28 KSH                    472750   -          -          -
                                                             Financial costs
                      Breakdown %
training   IEC       overheads    capital           transport storage    other
       -         -         -              -              -         -             -
       -         -         -              -              -         -             -
       -         -         -              -              -         -             -
       -         -         -              -              -         -             -
       -         -         -              -              -         -             -
       -         -         -              -              -         -             -
       -         -         -              -              -         -             -
       -         -         -              -              -         -             -
       -         -         -              -              -         -             -
       -         -         -              -              -         -             -

       -         -       98.6             -             -         -              -
       -         -       86.4             -             -         -              -
       -         -       91.6             -             -         -              -
       -         -       91.5             -             -         -              -
       -         -       98.3             -             -         -              -
       -         -       90.4             -             -         -              -
       -         -       93.4             -             -         -              -
       -         -       94.0             -             -         -              -

       -         -               7.4          5.2       -         -              -
       -         -               8.7          6.1       -         -              -

       -         -              11.2          9.8       -         -              -
       -         -              11.1          9.7       -         -              -
       -         -              11.0          9.7       -         -              -
       -         -              10.3          9.0       -         -              -
       -         -               9.6          8.4       -         -              -
       -         -               2.7          2.4       -         -              -
       -         -               2.7          2.4       -         -              -
       -         -               5.0          4.4       -         -              -
       -         -               5.6          4.9       -         -              -
       -         -               5.8          5.1       -         -              -

       -         -              66.9      -             -         -              -
       -         -              55.5      -             -         -              -
       -         -              68.1      -             -         -              -
       -         -              36.5      -             -         -              -
       -         -              32.8      -             -         -              -
       -         -              37.1      -             -         -              -

       -         -         -              -             -         -              -
-         -         -          -         -         -   -
-         -         -          -         -         -   -
-         -         -          -         -         -   -
-         -         -          -         -         -   -
-         -         -          -         -         -   -
-         -         -          -         -         -   -
-         -         -          -         -         -   -

-         -         -          -         -         -   -
-         -         -          -         -         -   -
-         -         -          -         -         -   -
-         -         -          -         -         -   -
-         -         -          -         -         -   -
-         -         -          -         -         -   -

    2.1       7.5   -              3.0       5.0   -       1.9

    0.8   -             18.8   -             1.7   -   -
    2.7   -             22.5   -             0.7   -   -

-         -             78.5   -         -         -   -
-         -             69.0   -         -         -   -

-         -             62.9   -         -         -   -

-         -         -          -         -         -   -
-         -         -          -         -         -   -

-         -         -          -         -         -   -
-         -         -          -         -         -   -
-         -         -          -         -         -   -
-         -         -          -         -         -   -
-         -         -          -         -         -   -
-         -         -          -         -         -   -
s
                                                                       Cost per
    user              NA       patient treated           per year for treatment patient diagnosed and treated correctly
           -               -              -                         -                           -
           -               -              -                         -                           -
           -               -              -                         -                           -
           -               -              -                         -                           -
           -               -              -                         -                           -
           -               -              -                         -                           -
           -               -              -                         -                           -
           -               -              -                         -                           -
           -               -              -                         -                           -
           -               -              -                         -                           -

           -               -                      3.50             -                            -
           -               -                      3.90             -                            -
           -               -                      3.69             -                            -
           -               -                      4.46             -                            -
           -               -                      4.03             -                            -
           -               -                      4.60             -                            -
           -               -                      3.93             -                            -
           -               -                      5.19             -                            -

           -               -                      7.34             -                            -
           -               -                      6.19             -                            -

           -               -                      5.09             -                            -
           -               -                      5.13             -                            -
           -               -                      5.18             -                            -
           -               -                      5.56             -                            -
           -               -                      5.96             -                            -
               75.4        -                     20.73             -                            -
               75.3        -                     20.77             -                            -
               54.2        -                     11.31             -                            -
               45.2        -                     10.15             -                            -
               39.1        -                      9.79             -                            -

           -               -                  583.00               -                            -
           -               -                  703.00               -                            -
           -               -                    573*               -                            -
               45.5        -                 1068.00               -                            -
               40.8        -                 1188.00               -                            -
               45.5        -                   1051*               -                            -

           -               -             -                         -                            -
-   -   -             -          -
-   -   -             -          -
-   -   -             -          -
-   -   -             -          -
-   -   -             -          -
-   -   -             -          -
-   -   -             -          -

-   -   -             -          -
-   -   -             -          -
-   -   -             -          -
-   -   -             -          -
-   -   -             -          -
-   -   -             -          -

-   -          1.97       1.63   -

-   -        100.46   -          -
-   -         20.80   -          -

-   -         95.58   -          -
-   -         62.42   -          -

-   -       1559.35   -          -

-   -         19.31       0.67   -
-   -         11.28       1.51   -

-   -   -             -          -
-   -   -             -          -
-   -   -             -          -
-   -   -             -          -
-   -   -             -          -
-   -   -             -          -
                                                                                                   Economic c
                                                                        Breakdown %
diagnostics   treatment         personnel         training    IEC       overheads      capital
      -                   1.8         -                   -         -             98.2         -
      -                   4.1         -                   -         -             95.9         -
      -                   2.8         -                   -         -             97.2         -
      -                   6.4         -                   -         -             93.6         -
      -                   2.0         -                   -         -             98.0         -
      -                   6.2         -                   -         -             93.8         -
      -                   1.3         -                   -         -             98.7         -
      -                   3.2         -                   -         -             96.8         -
      -                   2.0         -                   -         -             98.0         -
      -                   4.9         -                   -         -             95.1         -

      -            -                  -                   -         -          -               -
      -            -                  -                   -         -          -               -
      -            -                  -                   -         -          -               -
      -            -                  -                   -         -          -               -
      -            -                  -                   -         -          -               -
      -            -                  -                   -         -          -               -
      -            -                  -                   -         -          -               -
      -            -                  -                   -         -          -               -

      -            -                  -                   -         -          -               -
      -            -                  -                   -         -          -               -

      -            -                  -                   -         -          -               -
      -            -                  -                   -         -          -               -
      -            -                  -                   -         -          -               -
      -            -                  -                   -         -          -               -
      -            -                  -                   -         -          -               -
      -            -                  -                   -         -          -               -
      -            -                  -                   -         -          -               -
      -            -                  -                   -         -          -               -
      -            -                  -                   -         -          -               -
      -            -                  -                   -         -          -               -

      -            -                  -                   -         -          -               -
      -            -                  -                   -         -          -               -
      -            -                  -                   -         -          -               -
      -            -                  -                   -         -          -               -
      -            -                  -                   -         -          -               -
      -            -                  -                   -         -          -               -

      -                35.9                 2.5           -         -              61.4        -
-              30.7        2.0   -          -       67.3   -
-              20.0       78.5   -          -        1.5   -
-              48.3       48.0   -          -        3.7   -
-              14.3       62.3   -          -       23.4   -
-               9.1       75.5   -          -       15.4   -
-               7.2       78.7   -          -       14.1   -
-              18.5       48.8   -          -       32.7   -

    15.6       18.5   -          -          -   -               8.7
    52.7       12.2   -          -          -   -               4.0
     5.8        8.6   -          -          -   -               4.2
    39.9        1.3   -          -          -   -               3.3
     1.2        4.5   -          -          -   -              11.9
     5.2        3.1   -          -          -   -               9.6

-          -          -          -          -   -          -

-          -          -          -          -   -          -
-          -          -          -          -   -          -

-          -          -          -          -   -          -
-          -          -          -          -   -          -

-          -          -          -          -   -          -

-          -          -          -          -   -          -
-          -          -          -          -   -          -

-          -              67.0        7.0            3.0   -
-          -              39.0       22.0           19.0   -
-          -              27.0       38.0           16.0   -
-          -               75         12               5   -
-          -               12         36             29    -
-          -               11         39             31    -
Economic costs
                                                                                  Cost per
transport storage    other   user       NA       patient treated            per year for treatment
     -         -         -          -        -                      65.50              -
     -         -         -          -        -                      66.70              -
     -         -         -          -        -                      55.60              -
     -         -         -          -        -                      54.00              -
     -         -         -          -        -                      58.60              -
     -         -         -          -        -                      59.60              -
     -         -         -          -        -                      86.20              -
     -         -         -          -        -                     108.70              -
     -         -         -          -        -                      63.50              -
     -         -         -          -        -                      66.50              -

    -            -       -          -        -             -                          -
    -            -       -          -        -             -                          -
    -            -       -          -        -             -                          -
    -            -       -          -        -             -                          -
    -            -       -          -        -             -                          -
    -            -       -          -        -             -                          -
    -            -       -          -        -             -                          -
    -            -       -          -        -             -                          -

    -            -       -          -        -             -                          -
    -            -       -          -        -             -                          -

    -            -       -          -        -             -                          -
    -            -       -          -        -             -                          -
    -            -       -          -        -             -                          -
    -            -       -          -        -             -                          -
    -            -       -          -        -             -                          -
    -            -       -          -        -             -                          -
    -            -       -          -        -             -                          -
    -            -       -          -        -             -                          -
    -            -       -          -        -             -                          -
    -            -       -          -        -             -                          -

    -            -       -          -        -             -                          -
    -            -       -          -        -             -                          -
    -            -       -          -        -             -                          -
    -            -       -          -        -             -                          -
    -            -       -          -        -             -                          -
    -            -       -          -        -             -                          -

    -            -       -          -        -                      44.00             -
-          -   -          -   -        70.30   -
-          -   -          -   -        67.00   -
-          -   -          -   -        26.90   -
-          -   -          -   -        35.00   -
-          -   -          -   -        60.40   -
-          -   -          -   -        63.80   -
-          -   -          -   -        26.00   -

-          -       57.2   -             7.52   -
-          -       31.1   -            13.50   -
-          -       81.5   -            23.49   -
-          -       55.5   -            31.26   -
-          -       82.4   -           173.50   -
-          -       82.1   -           237.60   -

-          -   -          -   -   -            -

-          -   -          -   -   -            -
-          -   -          -   -   -            -

-          -   -          -   -   -            -
-          -   -          -   -   -            -

-          -   -          -   -   -            -

-          -   -          -   -   -            -
-          -   -          -   -   -            -

    25.0       -          -   -         0.43   -
    19.0       -          -   -         1.06   -
    19.0       -          -   -         0.25   -
       8       -          -   -        0.018   -
     21        -          -   -         0.19   -
     19        -          -   -         0.07   -
                                                                                  Additional Information
per
                           treated correctly
      patient diagnosed andSensitivity analysis   Ingredients approach   Discounting and annualisation
                 -         yes                    yes                                                 3%
                 -         yes                    yes                                                 3%
                 -         yes                    yes                                                 3%
                 -         yes                    yes                                                 3%
                 -         yes                    yes                                                 3%
                 -         yes                    yes                                                 3%
                 -         yes                    yes                                                 3%
                 -         yes                    yes                                                 3%
                 -         yes                    yes                                                 3%
                 -         yes                    yes                                                 3%

                -           yes                   yes                    undiscounted
                -           yes                   yes                    undiscounted
                -           yes                   yes                    undiscounted
                -           yes                   yes                    undiscounted
                -           yes                   yes                    undiscounted
                -           yes                   yes                    undiscounted
                -           yes                   yes                    undiscounted
                -           yes                   yes                    undiscounted

                -           yes                   yes                                                3%
                -           yes                   yes                                                3%

                -           yes                   yes                                                3%
                -           yes                   yes                                                3%
                -           yes                   yes                                                3%
                -           yes                   yes                                                3%
                -           yes                   yes                                                3%
                -           yes                   yes                                                3%
                -           yes                   yes                                                3%
                -           yes                   yes                                                3%
                -           yes                   yes                                                3%
                -           yes                   yes                                                3%

                -           no                    yes
                -           no                    yes
                -           no                    yes
                -           no                    yes
                -           no                    yes
                -           no                    yes

                -           no                    yes                    no
-   no    yes   no
-   no    yes   no
-   no    yes   no
-   no    yes   no
-   no    yes   no
-   no    yes   no
-   no    yes   no

-   yes   yes        8%
-   yes   yes        8%
-   yes   yes        8%
-   yes   yes        8%
-   yes   yes        8%
-   yes   yes        8%

-   yes   yes        5%

-   yes   yes   no
-   yes   yes   no

-   yes   yes
-   yes   yes

-   no    no

-
-

-   yes   yes        3%
-   yes   yes        3%
-   yes   yes        3%
-   yes   yes        3%
-   yes   yes        3%
-   yes   yes        3%
nformation

             Urban/Rural   Shared resources   Baseline coverage




                                                                  This is a pooled analysis of the previosu 4 studies. If in
                                                                  This is a pooled analysis of the previosu 4 studies. If in

             rural                                                It wasn't clear if costs were financial or economic so I
             rural
             rural
             rural
             rural
             rural
             rural
             rural

                                              4-6% ITN
                                              4-6% ITN




                                                                  Includes direct and indirect cost s to the patient
                                                                  Includes direct and indirect cost s to the patient
                                                                  Includes direct and indirect cost s to the patient
                                                                  Includes direct and indirect cost s to the patient
                                                                  Includes direct and indirect cost s to the patient




                                                                  *The cost of co-artemether was unavailable



                                                                  *The cost of co-artemether was unavailable

                                                                  Costs presented here include administration costs, i.e
        widespread IRS   Between 2000 and 2002 there was a massive decline
        widespread IRS
        widespread IRS
        widespread IRS
        widespread IRS
        widespread IRS

rural                                This study also estimates the per capita
                         This study presents the cost of treatmentcost when sp

rural                               The costs are those
                         Prob drug resistance = 47.92% in Fig 2 and the break
rural                               The costs are those
                         Prob drug resistance = 5.5% in Fig 2 and the break

rural
rural




rural
rural
rural
rural
rural
rural
is of the previosu 4 studies. If including this data make sure not to double count.
is of the previosu 4 studies. If including this data make sure not to double count.

were financial or economic so I've assumed financial.




                                                                                      Cost data from published studies on drug treatment. St
                                                                                      been excluded due to insufficient information.




irect cost s to the patient
irect cost s to the patient
irect cost s to the patient
irect cost s to the patient
irect cost s to the patient




ether was unavailable



ether was unavailable

nclude administration costs, i.e. from Table 3 and not Table 4.
02 there was a massive decline in malaria.




also estimates the cost when scaled up to a national Tanzanian scale

re those in Fig 2 and the breakdwon is from Table 2
re those in Fig 2 and the breakdwon is from Table 2
hed studies on drug treatment. Studies shaded grey have
 insufficient information.
                                              Publication

Title                                Authors                         PubMed IDPublication year
                                                                      10686744
                                     Alonzo González chemoprophylaxis in the prevention of anaemia and malaria among T
                                                                                              2000
Cost-effectiveness of iron supplementation and malariaM, Menéndez C, Font F, Kahigwa E, Kimario J, Mshinda H, Tanner M, B
                                                                      10686744
                                     Alonzo González chemoprophylaxis in the prevention of anaemia and malaria among T
                                                                                              2000
Cost-effectiveness of iron supplementation and malariaM, Menéndez C, Font F, Kahigwa E, Kimario J, Mshinda H, Tanner M, B
                                                                      10686744
                                     Alonzo González chemoprophylaxis in the prevention of anaemia and malaria among T
                                                                                              2000
Cost-effectiveness of iron supplementation and malariaM, Menéndez C, Font F, Kahigwa E, Kimario J, Mshinda H, Tanner M, B

Comparison of three larviciding options for malaria vector control.
                                      Parvez SD, Al-Wahaibi SS.       15748060               2003
Comparison of three larviciding options for malaria vector control.
                                      Parvez SD, Al-Wahaibi SS.       15748060               2003
Comparison of three larviciding options for malaria vector control.
                                      Parvez SD, Al-Wahaibi SS.       15748060               2003

                                                                            18486171
                                       of Poecilia reticulata (guppy) and temephos in anopheline Wijeyaratne MJ.
                                                                                                 2008
Costs and effectiveness of application Kusumawathie PH, Wickremasinghe AR, Karunaweera ND, mosquito control in river bas
                                                                            18486171
                                       of Poecilia reticulata (guppy) and temephos in anopheline Wijeyaratne MJ.
                                                                                                 2008
Costs and effectiveness of application Kusumawathie PH, Wickremasinghe AR, Karunaweera ND, mosquito control in river bas
                                                                            18486171
                                       of Poecilia reticulata (guppy) and temephos in anopheline Wijeyaratne MJ.
                                                                                                 2008
Costs and effectiveness of application Kusumawathie PH, Wickremasinghe AR, Karunaweera ND, mosquito control in river bas
                                                                            18486171
                                       of Poecilia reticulata (guppy) and temephos in anopheline Wijeyaratne MJ.
                                                                                                 2008
Costs and effectiveness of application Kusumawathie PH, Wickremasinghe AR, Karunaweera ND, mosquito control in river bas

Costs of early detection systems for epidemic malaria in highland areas of19149878 Uganda.
                                                                           Kenya Cox
                                      Mueller DH, Abeku TA, Okia M, Rapuoda B,and J.         2009
Costs of early detection systems for epidemic malaria in highland areas of19149878 Uganda.
                                                                           Kenya Cox
                                      Mueller DH, Abeku TA, Okia M, Rapuoda B,and J.         2009
                                        Intervention details

         name
Study number         Intervention Intervention details     Delivery             Study Period Costing year
                     iron supplementation and chemoprophylaxis
         Tanzania iron chemo EPI Deltaprim + iron          EPI                            1996         1996
                     iron EPI      Deltaprim
         Tanzania chemosupplementation and chemoprophylaxisEPI                            1996         1996
                     iron supplementation and chemoprophylaxis
         Tanzania iron EPI         iron                    EPI                            1996         1996

                     larvicide
          Oman larvicide full-dose temephos                                      2001-2002
                                                                    full-dose fortnightly
                     larvicide       temephos
          Oman larvicide half-dose wekly                            half-dose weekly
                     larvicide       temephos
          Oman larvicide test and treat                             treat only if positive

                       larvicide
          Sri Lanka larivicide          temephos                                  below dams
                                                                     river basins 2000-2002           2001
                       larvivorous fish Poecilia reticulata (guppy) river basins 2000-2002
          Sri Lanka fish                                                          below dams          2001
                       larvivorous fish Poecilia reticulata (guppy) -river basins 2000-2002
          Sri Lanka fish no surveillance                                          below
                                                                      no surveillance dams            2001
                       larvivorous fish Poecilia reticulata (guppy) -river basins 2000-2002
          Sri Lanka fish community application                                     application
                                                                      communitybelow dams             2001

                      Malaria early warning system                              2002-2006             2006
                      Malaria early warning system                              2002-2006             2006
                                                     Study information

Country     Location    Scale      Study design Cohort      Number in study Transmission   Currency
Tanzania    Kilombero   district                            2322
                                                infants < 1 year infants in region         1996 USD
Tanzania    Kilombero   district                            2322
                                                infants < 1 year infants in region         1996 USD
Tanzania    Kilombero   district                            2322
                                                infants < 1 year infants in region         1996 USD

Oman        Batineh
Oman        Batineh
Oman        Batineh

Sri Lanka   Kandy and Nuwara Eliya districts                                               2001 SLR
Sri Lanka   Kandy and Nuwara Eliya districts                                               2001 SLR
Sri Lanka   Kandy and Nuwara Eliya districts                                               2001 SLR
Sri Lanka   Kandy and Nuwara Eliya districts                                               2001 SLR

Uganda      highlands: Rukungiri and Kabale districts      4 districts                     2006 USD
Kenya       highlands: North Nandi and Gucha districts     4 districts                     2006 USD
                                                                                                       Break
Exchange rate     Perspective                                                   personnel
                                People covered insecticide treatment hospital costs and feestraining
1 USD = 580 TSH   Provider                  2322
1 USD = 580 TSH   Provider                  2322
1 USD = 580 TSH   Provider                  2322

                  Provider      2000 breeding sites 10.29866                       89.70134
                  Provider      2000 breeding sites 2.790179                       97.20982
                  Provider      2000 breeding sites 0.005563                       99.99444

1 USD = 95 SL Rupees            6 sites near dams                                  97.64838
1 USD = 95 SL Rupees            6 sites near dams                                  86.46292
1 USD = 95 SL Rupees            6 sites near dams
1 USD = 95 SL Rupees            6 sites near dams

                 Provider
1 USD = 1805.67 USH
1 USD = 77.28 KSHProvider
               Financial costs
      Breakdown %                                                                 Cost per
IEC    overheads capital     transport storage   other       user   NA      person
                                                                         100 3.756245
                                                                         100 2.766581
                                                                         100 1.774763




                                                  2.351624
                             0.931322             12.60576
                                                                                         Economic costs
Cost per                                                                        Breakdown %
                d                                personnel
     intervention iagnosticstreatment hospital costs and feestraining     IEC    overheads capital




           971
          1792
          5572

     938.1622
     360.3392
     93.68818
     75.67122

                                                        40.7        4.1                7.8      27.3
                                                         57         0.4                5.7      25.9
conomic costs
%                                                              Cost per
           transport storage   other         user   NA   person                S
                                                                    interventionensitivity analysis
                                                                               yes
                                                                               yes
                                                                               yes




                11.8                   8.3                              14439 yes
                   3                     8                              15512 yes
                                Additional Information

Ingredients approach   Discounting and annualisation        Urban/Rural   Shared resources
no                     vehicle 8%
no                     vehicle 8%
no                     vehicle 8%




yes
yes
yes
yes

yes                                                    5%
yes                                                    5%
Baseline coverage
                                Costs are assumed to inferred from
                    Costs per intervention have been be financial Table 2.




                    over 2000 breeding sites are trated over 6 months




                                 are included.
                    Travel costsFinancial costs is cost per 1000 m2
                 Study description

name       Currency   PerspectiveInflation factor     nets      insecticide personnel training IEC
Uganda     2007 USD   Provider                1.06706      85.0      -            1.5         1.0         2.6
Uganda     2007 USD   Provider                1.06706      81.2      -            0.7         1.4         2.1
Uganda     2007 USD   Provider                1.06706      79.8      -            0.3         3.3         3.3

Eritrea    2005 USD Provider - government 1.13865            57.5       10.8       18.0   -               1.7

           2006 USD
Burkina Faso          Provider             1.10121           80.2   -               8.6   -          -
           2006
Burkina Faso* USD     Societal             1.10121       -          -          -          -          -
           2006 USD
Burkina Faso          Provider             1.10121           71.6   -               7.4   -               2.6
           2006
Burkina Faso* USD     Societal             1.10121       -          -          -          -          -

Malawi     1999 USD Provider               1.32036           70.5        3.0        5.6   -               6.6

Togo       2004 USD Provider               1.16939           59.5   -              15.9   -               0.1

           1999 USD Provider
South Africa                               1.32036           81.0   -          -          -          -

Kenya*     2000 USD Society                1.29194           45.8       10.7   -              24.3   -
Kenya      2000 USD Provider               1.29194           33.3       13.2   -              29.9   -

Kenya      2002 USD Provider - employer    1.21543           27.1        9.8       37.1        4.2        3.7

Tanzania* 2000 USD Provider                1.29194           39.4        4.3       21.4   -               4.3

Kenya      1996 USD Provider               1.41351           31.0        8.0       31.0        1.0   -

India      1997 USD Provider               1.37234           32.4       10.1       33.5   -               2.2

Thailand   1994 USD Provider               1.49087       -              33.4       66.6   -          -

Tanzania 2006 USD Provider                 1.10121           29.2       11.2       24.4        5.9       15.4
Tanzania* 2006 USD Societal                1.10121           26.4       10.1       22.0        5.3       13.9

Senegal    2005 USD Provider               1.13865           58.0        6.0        7.0   -              20.0

Ghana      2002 USD ?Provider              1.21543           91.4   -          -               4.4        0.8

Kenya      2001 USD Provider               1.24946           59.6       32.3   -          -          -
Kenya      2001 USD Provider               1.24946           56.8       30.8   -          -               4.4

Congo      2005 USD Provider               1.13865           84.0   -          -               4.6   -

Uganda     2007 USD Provider               1.06706           84.7   -               2.9        1.3        1.3
Uganda     2009 USD Provider - NGO               1           81.9   -               5.4        3.3        1.2
Zanzibar   2006 USD Provider               1.10121            82.0   -               1.7       3.0        3.2
Zanzibar   2008 USD Provider                  1.038           84.2   -               1.8       0.3        3.3
Zanzibar   2009 USD Provider                      1           85.0   -               1.6       0.3        2.9

Kenya      2007 USD   Provider             1.06706            70.9   -              11.4       0.9        7.2
Kenya      2007 USD   Provider             1.06706            34.5       22.1       17.9   -             10.2
Kenya      2007 USD   Provider             1.06706            35.4       17.7       21.2   -              8.2
Kenya      2008 USD   Provider             1.06706            73.0   -              17.1       0.7        3.6
Kenya      2008 USD   Provider             1.06706            71.7   -              17.1   -              3.6

Colombia 2001 USD Provider                 1.24946        -              42.0       44.0   -         -
Colombia 2001 USD Provider                 1.24946        -              12.0       61.0   -         -

Tanzania   2005 USD Provider               1.13865            57.0       12.0        7.0   -             12.0

Malawi     2005 USD Provider               1.13865        -          -          -          -         -




            Thailand India      Colombia                                  Malawi
                                                      Colombia South Africa          Tanzania* Kenya
nets               0.0     32.4                0.0          0.0      81.0      70.5       39.4       33.3
insecticide       33.4     10.1               42.0         12.0       0.0        3.0        4.3      13.2
diagnostics        0.0      0.0                0.0          0.0       0.0        0.0        0.0       0.0
treatment          0.0      0.0                0.0          0.0       0.0        0.0        0.0       0.0
personnel         66.6     33.5               44.0         61.0       0.0        5.6      21.4        0.0
training           0.0      0.0                0.0          0.0       0.0        0.0        0.0      29.9
overheads          0.0      5.7                0.0          0.0       0.0        5.5        0.0       0.0
IEC                0.0      2.2                0.0          0.0       0.0        6.6        4.3       0.0
distribution       0.0      0.0                0.0          0.0       0.0        0.0        0.0       0.0
transport          0.0      0.0                8.0         15.0       0.0        5.3        0.0       0.0
storage            0.0      0.0                0.0          0.0       0.0        0.7        0.0       0.0
capital            0.0     15.2                5.0         11.0       0.0        2.7        5.9       0.0
study costs        0.0      0.0                0.0          0.0       0.0        0.0        0.0      12.6
other              0.0      0.8                1.0          1.0      19.0        0.0      24.7       11.1
user               0.0      0.0                0.0          0.0       0.0        0.0        0.0       0.0
not costed         0.0      0.0                0.0          0.0       0.0        0.0        0.0       0.0
net distributed 2.97       3.33               6.37        15.49    13.35       5.70      15.37       4.42




            Thailand India      Colombia                                  Malawi
                                                      Colombia South Africa         Tanzania* Kenya
nets              0.00     1.08               0.00         0.00    10.82       4.02      6.06       1.47
insecticide       0.99     0.34               2.68         1.86      0.00      0.17      0.66       0.58
diagnostics       0.00     0.00               0.00         0.00      0.00      0.00      0.00       0.00
treatment         0.00     0.00               0.00         0.00      0.00      0.00      0.00       0.00
personnel          1.98           1.12   2.80   9.45   0.00   0.32     3.29   0.00
training           0.00           0.00   0.00   0.00   0.00   0.00     0.00   1.32
overheads          0.00           0.19   0.00   0.00   0.00   0.32     0.00   0.00
IEC                0.00           0.07   0.00   0.00   0.00   0.38     0.67   0.00
distribution       0.00           0.00   0.00   0.00   0.00   0.00     0.00   0.00
transport          0.00           0.00   0.51   2.32   0.00   0.30     0.00   0.00
storage            0.00           0.00   0.00   0.00   0.00   0.04     0.00   0.00
capital            0.00           0.51   0.32   1.70   0.00   0.16     0.90   0.00
study costs        0.00           0.00   0.00   0.00   0.00   0.00     0.00   0.55
other              0.00           0.03   0.06   0.15   2.54   0.00     3.80   0.49
user               0.00           0.00   0.00   0.00   0.00   0.00     0.00   0.00
not costed         0.00           0.00   0.00   0.00   0.00   0.00     0.00   0.00



                                                                     A: Unit financ
                          25.00




                          20.00




                          15.00
               2009 USD




                          10.00




                           5.00




                           0.00
                                              Financial costs
                   Breakdown %
overheads      capital   distributiontransport storage      study costsother     user           NA
      5.8           -            1.9        0.8         0.2      -           1.3      -              -
      6.4           -            4.0        2.5         0.0      -           1.7      -              -
      6.4           -            0.0        6.8         0.0      -         -          -              -

         2.9            1.3   -                7.8   -          -          -          -              -

    -              -          -               10.3   -          -               0.9   -              -
    -              -          -           -          -          -          -          -              -
    -              -          -                3.1   -          -              15.3   -              -
    -              -          -           -          -          -          -          -              -

         5.5            2.7   -                5.3       0.7    -          -          -              -

        11.8            2.3                    8.2   -          -               2.1   -              -

    -              -          -           -          -          -              19.0   -              -

    -              -          -           -          -              10.2        9.0   -              -
    -              -          -           -          -              12.6       11.1   -              -

         5.1           11.0       0.4          1.6              -          -          -              -

    -                   5.9   -           -          -          -              24.7   -              -

        17.0           12.0   -           -          -          -          -          -              -

         5.7           15.2   -           -                     -               0.8   -              -

    -              -          -           -          -          -          -          -              -

         1.4            1.9   -                4.9   -          -               5.6   -              -
         1.3            1.7   -                4.4   -          -               5.1       9.8        -

         4.0       -          -           -          -          -               5.0   -              -

    -              -          -                3.2   -          -               0.2   -              -

    -              -              5.3          2.8   -          -          -          -              -
    -              -              5.5          2.6   -          -          -          -              -

    -              -              0.2          8.8       2.3    -          -          -              -

         2.0            0.5       6.9     -              0.5    -          -          -              -
    -              -              7.5          0.7   -          -          -          -              -
         5.6            1.3           2.9   -              0.3   -          -         -         -
         5.8            1.3           3.0   -              0.3   -          -         -         -
         6.7            1.3           2.2   -              0.1   -          -         -         -

         3.1            0.3           5.4   -              0.8   -          -         -         -
         4.4            3.3           6.4   -              1.1   -          -         -         -
         3.5            4.5           8.7   -              0.9   -          -         -         -
         1.7            0.2           3.9   -              0.5   -          -         -         -
         1.6            2.3           3.2   -              0.5   -          -         -         -

    -                   5.0       -              8.0   -         -              1.0   -         -
    -                  11.0       -             15.0   -         -              1.0   -         -

         4.0       -              -              2.0   -             3.0        3.0   -         -

    -              -              -         -          -         -          -         -         -




Kenya          Kenya          Ghana     Kenya      Togo      Senegal    Eritrea     Tanzania Congo
        59.6           56.8        91.4       27.1      59.5      58.0         57.5      57.0     84.0
        32.3           30.8         0.0        9.8       0.0        6.0        10.8      12.0      0.0
         0.0            0.0         0.0        0.0       0.0        0.0         0.0        0.0     0.0
         0.0            0.0         0.0        0.0       0.0        0.0         0.0        0.0     0.0
         0.0            0.0         0.0       37.1      15.9        7.0        18.0        7.0     0.0
         0.0            0.0         4.4        4.2       0.0        0.0         0.0        0.0     4.6
         0.0            0.0         0.0        5.1      11.8        4.0         2.9        4.0     0.0
         0.0            4.4         0.8        3.7       0.1      20.0          1.7      12.0      0.0
         5.3            5.5         0.0        0.4       0.0        0.0         0.0        0.0     0.2
         2.8            2.6         3.2        1.6       8.2        0.0         7.8        2.0     8.8
         0.0            0.0         0.0        0.0       0.0        0.0         0.0        0.0     2.3
         0.0            0.0         0.0       11.0       2.3        0.0         1.3        0.0     0.0
         0.0            0.0         0.0        0.0       0.0        0.0         0.0        3.0     0.0
         0.0            0.0         0.2        0.0       2.1        5.0         0.0        3.0     0.0
         0.0            0.0         0.0        0.0       0.0        0.0         0.0        0.0     0.0
         0.0            0.0         0.0        0.0       0.0        0.0         0.0        0.0     0.0
        4.76           5.00        4.50     19.20       6.96     11.77         5.37      6.68    10.84




Kenya          Kenya          Ghana     Kenya      Togo      Senegal   Eritrea     Tanzania Congo
        2.84           2.84        4.11       5.20      4.14      6.83        3.09      3.81     9.11
        1.54           1.54        0.00       1.88      0.00      0.71        0.58      0.80     0.00
        0.00           0.00        0.00       0.00      0.00      0.00        0.00      0.00     0.00
        0.00           0.00        0.00       0.00      0.00      0.00        0.00      0.00     0.00
       0.00   0.00   0.00   7.12   1.10   0.82   0.97   0.47   0.00
       0.00   0.00   0.20   0.81   0.00   0.00   0.00   0.00   0.50
       0.00   0.00   0.00   0.98   0.82   0.47   0.15   0.27   0.00
       0.00   0.22   0.04   0.71   0.01   2.35   0.09   0.80   0.00
       0.25   0.27   0.00   0.08   0.00   0.00   0.00   0.00   0.02
       0.13   0.13   0.15   0.31   0.57   0.00   0.42   0.13   0.96
       0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.25
       0.00   0.00   0.00   2.11   0.16   0.00   0.07   0.00   0.00
       0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.20   0.00
       0.00   0.00   0.01   0.00   0.15   0.59   0.00   0.20   0.00
       0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00
       0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00



nit financial cost of ITN distribution
                         Cost per
            distributiontreated netperson protected
net distributed                    year                  nets       cost
                                             standardised financial insecticide personnel training
      6.61         0.71      -         -            2.20      64.6       -            3.1         2.4
      7.55         1.11      -         -            2.52      57.2       -            1.4         3.4
      7.03         1.14      -         -            2.34      42.4       -            5.9        11.6

        5.37    -              1.63   -               1.63       51.4       12.0        21.3   -

        7.94        1.56   -          -               1.59   -          -           -          -
    -           -          -          -                          23.3   -               54.3   -
        8.90        2.52   -          -               1.78   -          -           -          -
    -           -          -          -                          23.3   -               21.8   -

        5.70    -              9.54   -               9.54       55.4        4.9         9.2   -

        6.96    -          -          -               2.32       59.5   -               15.9   -

    13.35       -              5.76   -               5.76       54.0       15.0        24.0   -

        5.44    -          -          -               1.09       18.7       19.3    -              25.8
        4.42    -          -          -               0.88   -          -           -          -

    19.20       -          -          -               6.40   -          -           -          -

    15.37       -              8.66   -               8.66       25.4        5.5        27.7   -

    -           -          -          -           -              40.4        9.2        21.0        1.7

        3.33    -          -          -               1.11   -          -           -          -

        2.97    -          -          -               0.99   -          -           -          -

        8.47    -          -          -               2.82       22.0       12.2        27.3        6.4
        9.35    -          -          -               3.12       20.3       11.3        25.2        5.9

    11.77           4.24       7.97   -               7.97       47.0        8.0         8.0   -

        4.50        0.39   -          -               1.50   -          -           -          -

        4.76    -          -          -               1.59   -          -           -          -
        5.00    -          -          -               1.67   -          -           -          -

    10.84           1.73   -          -               3.61   -          -           -          -

        7.31    -          -          -               1.83   -          -           -          -
        6.87    -          -          -               1.72   -          -           -          -
        8.75       1.57   -          -           2.19   -          -          -          -
        8.03       1.27   -          -           2.01   -          -          -          -
        7.76       1.24   -          -           1.94   -          -          -          -

        8.90       2.36   -          -           2.97       46.3   -              21.1       1.7
        6.01       3.76   -          -           2.00       19.3       12.4       28.4       0.0
        7.16       4.28   -          -           2.39       18.9        9.6       32.3   -
        7.02       1.46   -          -           2.34       48.3   -              32.0       1.3
        6.96       1.40   -          -           2.32       47.2   -              32.1   -

     6.37      -          -           4.62       2.12   -          -          -          -
    15.49      -          -          10.62       5.16   -          -          -          -

        6.68       2.15       3.02   -           3.02       49.0       14.0        9.0   -

    -          -          -          -       -              55.4        4.9        9.2   -




                    Burkina Faso
Tanzania Burkina Faso          Zanzibar Uganda    Uganda    Uganda    Uganda    Kenya
     29.2      80.2       71.6       82.0    85.0      81.2      79.8      84.7       70.9
     11.2       0.0        0.0        0.0     0.0       0.0       0.0       0.0        0.0
       0.0      0.0        0.0        0.0     0.0       0.0       0.0       0.0        0.0
       0.0      0.0        0.0        0.0     0.0       0.0       0.0       0.0        0.0
     24.4       8.6        7.4        1.7     1.5       0.7       0.3       2.9       11.4
       5.9      0.0        0.0        3.0     1.0       1.4       3.3       1.3        0.9
       1.4      0.0        0.0        5.6     5.8       6.4       6.4       2.0        3.1
     15.4       0.0        2.6        3.2     2.6       2.1       3.3       1.3        7.2
       0.0      0.0        0.0        2.9     1.9       4.0       0.0       6.9        5.4
       4.9     10.3        3.1        0.0     0.8       2.5       6.8       0.0        0.0
       0.0      0.0        0.0        0.3     0.2       0.0       0.0       0.5        0.8
       1.9      0.0        0.0        1.3     0.0       0.0       0.0       0.5        0.3
       0.0      0.0        0.0        0.0     0.0       0.0       0.0       0.0        0.0
       5.6      0.9       15.3        0.0     1.3       1.7       0.0       0.0        0.0
       0.0      0.0        0.0        0.0     0.0       0.0       0.0       0.0        0.0
       0.0      0.0        0.0        0.0     0.0       0.0       0.0       0.0        0.0
     8.47      7.94       8.90       8.75    6.61      7.55      7.03      7.31       8.90




                    Burkina Faso
Tanzania Burkina Faso          Zanzibar Uganda    Uganda    Uganda    Uganda    Kenya
     2.48      6.37       6.37       7.18    5.61      6.14      5.61      6.19       6.31
     0.95      0.00       0.00       0.00    0.00      0.00      0.00      0.00       0.00
     0.00      0.00       0.00       0.00    0.00      0.00      0.00      0.00       0.00
     0.00      0.00       0.00       0.00    0.00      0.00      0.00      0.00       0.00
2.07   0.68   0.66   0.15   0.10   0.05   0.02   0.21   1.02
0.50   0.00   0.00   0.27   0.06   0.11   0.23   0.09   0.08
0.12   0.00   0.00   0.49   0.38   0.48   0.45   0.15   0.28
1.30   0.00   0.23   0.28   0.17   0.16   0.23   0.09   0.64
0.00   0.00   0.00   0.25   0.13   0.30   0.00   0.50   0.48
0.41   0.82   0.28   0.00   0.05   0.19   0.48   0.00   0.00
0.00   0.00   0.00   0.03   0.01   0.00   0.00   0.03   0.07
0.16   0.00   0.00   0.11   0.00   0.00   0.00   0.03   0.02
0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00
0.48   0.07   1.36   0.00   0.09   0.13   0.00   0.00   0.00
0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00
0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00
                                                       Economic costs
                                  Breakdown %
IEC            overheads      capital   distributiontransport storage     study costsother     user
           5.6      12.5           -            5.6        1.7        0.3      -           4.2      -
           4.5      12.7           -           10.1        5.1        0.3      -           5.4      -
          11.6       9.6           -            1.4       17.1        0.2      -         -          -

           2.0          3.4           0.7    -               9.2   -          -          -          -

      -            -              -          -          -          -          -          -          -
      -            -              -          -              15.4       5.7    -               1.3   -
      -            -              -          -          -          -          -          -          -
           4.4     -                  2.1    -               5.2       1.9    -              41.3   -

           9.8          9.1           1.7    -               8.7       1.2    -          -          -

           0.1         11.8           2.3                    8.2   -          -               2.1   -

      -            -                  1.0    -               3.0       1.0    -               2.0   -

      -            -              -          -          -          -              19.2       17.0   -
      -            -              -          -          -          -          -          -          -

      -            -              -          -          -          -          -          -          -

           5.6     -                  3.8    -          -          -          -              32.0   -

      -                18.9           7.1    -               0.3   -          -               1.3   -

      -            -              -          -          -          -          -          -          -

      -            -              -          -          -          -          -          -          -

          16.8          5.1           0.7    -               6.5   -          -               2.6   -
          15.5          4.7           0.6    -               6.0   -          -               2.4       7.5

          24.0          4.0           3.0    -          -          -          -               6.0   -

      -            -              -          -          -          -          -          -          -

      -            -              -          -          -          -          -          -          -
      -            -              -          -          -          -          -          -          -

      -            -              -          -          -          -          -          -          -

      -            -              -          -          -          -          -          -          -
      -            -              -          -          -          -          -          -          -
    -              -              -         -          -         -         -         -          -
    -              -              -         -          -         -         -         -          -
    -              -              -         -          -         -         -         -          -

        13.4            5.8           0.4       10.0   -             1.5   -         -          -
        16.2            7.0           5.2       10.1   -             1.8   -         -          -
        12.5            5.4           6.8       13.1   -             1.4   -         -          -
         6.8            3.1           0.3        7.3   -             0.8   -         -          -
         6.7            3.1           4.4        5.9   -             0.8   -         -          -

    -              -              -         -          -         -         -         -          -
    -              -              -         -          -         -         -         -          -

        15.0            4.0       -         -              2.0   -             4.0       3.0    -

         9.8            9.1           1.7   -              8.7       1.2   -         -          -




Kenya          Kenya          Zanzibar Kenya      Kenya      Uganda    Zanzibar Kenya*     Tanzania*
        34.5           35.4         84.2     73.0       71.7      81.9       85.0    45.8       26.4
        22.1           17.7          0.0      0.0        0.0       0.0        0.0    10.7       10.1
         0.0            0.0          0.0      0.0        0.0       0.0        0.0      0.0        0.0
         0.0            0.0          0.0      0.0        0.0       0.0        0.0      0.0        0.0
        17.9           21.2          1.8     17.1       17.1       5.4        1.6      0.0      22.0
         0.0            0.0          0.3      0.7        0.0       3.3        0.3    24.3         5.3
         4.4            3.5          5.8      1.7        1.6       0.0        6.7      0.0        1.3
        10.2            8.2          3.3      3.6        3.6       1.2        2.9      0.0      13.9
         6.4            8.7          3.0      3.9        3.2       7.5        2.2      0.0        0.0
         0.0            0.0          0.0      0.0        0.0       0.7        0.0      0.0        4.4
         1.1            0.9          0.3      0.5        0.5       0.0        0.1      0.0        0.0
         3.3            4.5          1.3      0.2        2.3       0.0        1.3      0.0        1.7
         0.0            0.0          0.0      0.0        0.0       0.0        0.0    10.2         0.0
         0.0            0.0          0.0      0.0        0.0       0.0        0.0      9.0        5.1
         0.0            0.0          0.0      0.0        0.0       0.0        0.0      0.0        9.8
         0.0            0.0          0.0      0.0        0.0       0.0        0.0      0.0        0.0
        6.01           7.16         8.03     7.02       6.96      6.87       7.76    5.44       9.35




Kenya          Kenya          Zanzibar Kenya      Kenya      Uganda    Zanzibar Kenya*    Tanzania*
        2.07           2.53         6.77     5.12       4.99      5.63       6.60    2.49      2.47
        1.33           1.27         0.00     0.00       0.00      0.00       0.00    0.58      0.95
        0.00           0.00         0.00     0.00       0.00      0.00       0.00    0.00      0.00
        0.00           0.00         0.00     0.00       0.00      0.00       0.00    0.00      0.00
1.08       1.51   0.14   1.20   1.19   0.37   0.12   0.00   2.06
0.00       0.00   0.03   0.05   0.00   0.23   0.02   1.32   0.50
0.27       0.25   0.46   0.12   0.11   0.00   0.52   0.00   0.12
0.61       0.59   0.26   0.26   0.25   0.08   0.22   0.00   1.30
0.39       0.62   0.24   0.27   0.22   0.52   0.17   0.00   0.00
0.00       0.00   0.00   0.00   0.00   0.05   0.00   0.00   0.41
0.07       0.06   0.02   0.03   0.03   0.00   0.01   0.00   0.00
0.20       0.32   0.11   0.01   0.16   0.00   0.10   0.00   0.16
0.00       0.00   0.00   0.00   0.00   0.00   0.00   0.55   0.00
0.00       0.00   0.00   0.00   0.00   0.00   0.00   0.49   0.48
0.00       0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.91
0.00       0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00


       12.00




       10.00




        8.00




        6.00




        4.00




        2.00




        0.00
                            Cost per
NA                   distributiontreated netperson protected
         net distributed                    year               This sheet contains data from the sheet 'ITN
     -         3.07         0.81       1.02     -              to 2009 US$.
     -         3.79         1.31       1.26     -
     -         4.68         2.42       1.56     -

     -           4.53        1.66       1.38   -

     -       -           -          -          -
     -           5.30        4.05   -          -
     -       -           -          -          -
     -           5.30        4.06   -          -

     -           3.47    -              5.82   -

     -           5.16    -          -          -

     -       10.05       -              5.03   -

     -           3.02    -          -          -
     -       -           -          -          -

     -       -           -          -          -

     -           2.97    -          -          -

     -           3.11    -          -          -

     -       -           -          -          -

     -       -           -          -          -

     -           7.46    -          -          -
     -           8.34    -              4.68   -

     -           9.17        4.12       6.89   -

     -       -           -          -          -

     -       -           -          -          -
     -       -           -          -          -

     -       -           -          -          -

 100.0           3.31    -          -          -
 100.0           3.23    -          -          -
100.0        4.12       1.59   -               -
100.0        3.65       1.27   -               -
100.0        3.54       1.24   -               -

  -          5.00       2.69   -               -
  -          4.14       3.34   -               -
  -          5.36       4.34   -               -
  -          4.07       2.10   -               -
  -          4.16       2.20   -               -

  -      -          -          -               -
  -      -          -          -               -

  -          5.47       2.04       2.47        -

  -          3.83   -              3.46        -




                                                        Kenya                     Malawi
                                                                       South Africa          Malawi
                                          nets                  40.4         54.0      55.4       55.4
                                          insecticide            9.2         15.0        4.9        4.9
                                          diagnostics            0.0          0.0        0.0        0.0
                                          treatment              0.0          0.0        0.0        0.0
                                          personnel             21.0         24.0        9.2        9.2
                                          training               1.7          0.0        0.0        0.0
                                          overheads             18.9          0.0        9.1        9.1
                                          IEC                    0.0          0.0        9.8        9.8
                                          distribution           0.0          0.0        0.0        0.0
                                          transport              0.3          3.0        8.7        8.7
                                          storage                0.0          1.0        1.2        1.2
                                          capital                7.1          1.0        1.7        1.7
                                          study costs            0.0          0.0        0.0        0.0
                                          other                  1.3          2.0        0.0        0.0
                                          user                   0.0          0.0        0.0        0.0
                                          not costed             0.0          0.0        0.0        0.0
                                          net distributed       3.11       10.05       3.47       3.83




                                                        Kenya                     Malawi
                                                                       South Africa         Malawi
 56.2%                                    nets                  1.26         5.43      1.92      2.12
  7.0%                                    insecticide           0.29         1.51      0.17      0.19
  0.0%                                    diagnostics           0.00         0.00      0.00      0.00
  0.0%                                    treatment             0.00         0.00      0.00      0.00
15.1%   personnel      0.65   2.41   0.32   0.35
 2.3%   training       0.05   0.00   0.00   0.00
 2.7%   overheads      0.59   0.00   0.31   0.35
 4.3%   IEC            0.00   0.00   0.34   0.38
 1.7%   distribution   0.00   0.00   0.00   0.00
 3.1%   transport      0.01   0.30   0.30   0.33
 0.2%   storage        0.00   0.10   0.04   0.05
 2.6%   capital        0.22   0.10   0.06   0.07
 0.5%   study costs    0.00   0.00   0.00   0.00
 4.0%   other          0.04   0.20   0.00   0.00
 0.3%   user           0.00   0.00   0.00   0.00
 0.0%   not costed     0.00   0.00   0.00   0.00




                                                   not costed
                                                   user
                                                   other
                                                   study costs
                                                   capital
                                                   storage
                                                   transport
                                                   distribution
                                                   IEC
                                                   overheads
                                                   training
                                                   personnel
                                                   treatment
                                                   diagnostics
                                                   insecticide
                                                   nets
contains data from the sheet 'ITN data'. All prices have been inflated
Tanzania* Togo      Senegal    Eritrea     Tanzania Tanzania Zanzibar Uganda    Uganda
     25.4      59.5      47.0         51.4      49.0     22.0       0.0    64.6      57.2
       5.5      0.0        8.0        12.0      14.0     12.2       0.0     0.0       0.0
       0.0      0.0        0.0         0.0        0.0      0.0      0.0     0.0       0.0
       0.0      0.0        0.0         0.0        0.0      0.0      0.0     0.0       0.0
     27.7      15.9        8.0        21.3        9.0    27.3       0.0     3.1       1.4
       0.0      0.0        0.0         0.0        0.0      6.4      0.0     2.4       3.4
       0.0     11.8        4.0         3.4        4.0      5.1      0.0    12.5      12.7
       5.6      0.1      24.0          2.0      15.0     16.8       0.0     5.6       4.5
       0.0      0.0        0.0         0.0        0.0      0.0      0.0     5.6      10.1
       0.0      8.2        0.0         9.2        2.0      6.5      0.0     1.7       5.1
       0.0      0.0        0.0         0.0        0.0      0.0      0.0     0.3       0.3
       3.8      2.3        3.0         0.7        0.0      0.7      0.0     0.0       0.0
       0.0      0.0        0.0         0.0        4.0      0.0      0.0     0.0       0.0
     32.0       2.1        6.0         0.0        3.0      2.6      0.0     4.2       5.4
       0.0      0.0        0.0         0.0        0.0      0.0      0.0     0.0       0.0
       0.0      0.0        0.0         0.0        0.0      0.0    100.0     0.0       0.0
     2.97      5.16      9.17         4.53      5.47     7.46      4.12    3.07      3.79




Tanzania* Togo      Senegal   Eritrea     Tanzania Tanzania Zanzibar Uganda    Uganda
     0.75      3.07      4.31        2.33      2.68     1.64      0.00    1.98      2.17
     0.16      0.00      0.73        0.54      0.77     0.91      0.00    0.00      0.00
     0.00      0.00      0.00        0.00      0.00     0.00      0.00    0.00      0.00
     0.00      0.00      0.00        0.00      0.00     0.00      0.00    0.00      0.00
        0.82   0.82   0.73   0.97   0.49   2.03   0.00   0.10   0.05
        0.00   0.00   0.00   0.00   0.00   0.48   0.00   0.07   0.13
        0.00   0.61   0.37   0.15   0.22   0.38   0.00   0.38   0.48
        0.17   0.01   2.20   0.09   0.82   1.25   0.00   0.17   0.17
        0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.17   0.38
        0.00   0.42   0.00   0.42   0.11   0.49   0.00   0.05   0.19
        0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.01   0.01
        0.11   0.12   0.27   0.03   0.00   0.05   0.00   0.00   0.00
        0.00   0.00   0.00   0.00   0.22   0.00   0.00   0.00   0.00
        0.95   0.11   0.55   0.00   0.16   0.19   0.00   0.13   0.20
        0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00
        0.00   0.00   0.00   0.00   0.00   0.00   4.12   0.00   0.00




not costed
user
other
study costs
capital
storage
transport
distribution
IEC
overheads
training
personnel
treatment
diagnostics
insecticide
nets
Uganda    Uganda    Kenya      Kenya      Kenya      Zanzibar Kenya      Kenya      Uganda
     42.4       0.0       46.3       19.3       18.9        0.0     48.3       47.2       0.0
      0.0       0.0        0.0       12.4        9.6        0.0      0.0        0.0       0.0
      0.0       0.0        0.0        0.0        0.0        0.0      0.0        0.0       0.0
      0.0       0.0        0.0        0.0        0.0        0.0      0.0        0.0       0.0
      5.9       0.0       21.1       28.4       32.3        0.0     32.0       32.1       0.0
     11.6       0.0        1.7        0.0        0.0        0.0      1.3        0.0       0.0
      9.6       0.0        5.8        7.0        5.4        0.0      3.1        3.1       0.0
     11.6       0.0       13.4       16.2       12.5        0.0      6.8        6.7       0.0
      1.4       0.0       10.0       10.1       13.1        0.0      7.3        5.9       0.0
     17.1       0.0        0.0        0.0        0.0        0.0      0.0        0.0       0.0
      0.2       0.0        1.5        1.8        1.4        0.0      0.8        0.8       0.0
      0.0       0.0        0.4        5.2        6.8        0.0      0.3        4.4       0.0
      0.0       0.0        0.0        0.0        0.0        0.0      0.0        0.0       0.0
      0.0       0.0        0.0        0.0        0.0        0.0      0.0        0.0       0.0
      0.0       0.0        0.0        0.0        0.0        0.0      0.0        0.0       0.0
      0.0     100.0        0.0        0.0        0.0      100.0      0.0        0.0     100.0
     4.68      3.31       5.00       4.14       5.36       3.65     4.07       4.16      3.23




Uganda    Uganda    Kenya      Kenya      Kenya      Zanzibar Kenya      Kenya      Uganda
     1.98      0.00       2.32       0.80       1.01       0.00     1.96       1.96      0.00
     0.00      0.00       0.00       0.51       0.51       0.00     0.00       0.00      0.00
     0.00      0.00       0.00       0.00       0.00       0.00     0.00       0.00      0.00
     0.00      0.00       0.00       0.00       0.00       0.00     0.00       0.00      0.00
0.28   0.00   1.06   1.17   1.73   0.00   1.30   1.33   0.00
0.54   0.00   0.09   0.00   0.00   0.00   0.05   0.00   0.00
0.45   0.00   0.29   0.29   0.29   0.00   0.13   0.13   0.00
0.54   0.00   0.67   0.67   0.67   0.00   0.28   0.28   0.00
0.06   0.00   0.50   0.42   0.70   0.00   0.30   0.25   0.00
0.80   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00
0.01   0.00   0.07   0.07   0.07   0.00   0.03   0.03   0.00
0.00   0.00   0.02   0.21   0.36   0.00   0.01   0.18   0.00
0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00
0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00
0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00   0.00
0.00   3.31   0.00   0.00   0.00   3.65   0.00   0.00   3.23
Zanzibar Kenya*                          Burkina Faso*
                    Tanzania* Burkina Faso*
       0.0    18.7         20.3     23.3       23.3
       0.0    19.3         11.3      0.0        0.0
       0.0      0.0         0.0      0.0        0.0
       0.0      0.0         0.0      0.0        0.0
       0.0      0.0        25.2     54.3       21.8
       0.0    25.8          5.9      0.0        0.0
       0.0      0.0         4.7      0.0        0.0
       0.0      0.0        15.5      0.0        4.4
       0.0      0.0         0.0      0.0        0.0
       0.0      0.0         6.0     15.4        5.2
       0.0      0.0         0.0      5.7        1.9
       0.0      0.0         0.6      0.0        2.1
       0.0    19.2          0.0      0.0        0.0
       0.0    17.0          2.4      1.3       41.3
       0.0      0.0         7.5      0.0        0.0
     100.0      0.0         0.0      0.0        0.0
      3.54    3.02         8.34     5.30       5.30




Zanzibar Kenya*                         Burkina Faso*
                   Tanzania* Burkina Faso*
      0.00    0.57        1.69     1.23       1.23
      0.00    0.58        0.94     0.00       0.00
      0.00    0.00        0.00     0.00       0.00
      0.00    0.00        0.00     0.00       0.00
0.00   0.00   2.10   2.88   1.15
0.00   0.78   0.49   0.00   0.00
0.00   0.00   0.39   0.00   0.00
0.00   0.00   1.29   0.00   0.23
0.00   0.00   0.00   0.00   0.00
0.00   0.00   0.50   0.82   0.28
0.00   0.00   0.00   0.30   0.10
0.00   0.00   0.05   0.00   0.11
0.00   0.58   0.00   0.00   0.00
0.00   0.51   0.20   0.07   2.19
0.00   0.00   0.63   0.00   0.00
3.54   0.00   0.00   0.00   0.00
name               Currency    Perspective       Inflation factor           insecticide personnel
Zimbabwe           2000 USD    Provider                             1.29194          81.0       4.0

South Africa       1999 USD    Provider                             1.32036        -                -

Kenya              2000 USD    Provider                             1.29194             76.4            20.4

Thailand           1994 USD    Provider                             1.49087             32.1            47.6

India              1997 USD    Provider                             1.37234             37.1            33.5

Mozambique         2000 USD    Provider                             1.29194             28.6            37.7
Mozambique         2000 USD    Provider                             1.29194             45.3            31.5

Colombia           2001 USD    Provider                             1.24946             80.2            15.2
Colombia           2001 USD    Provider                             1.24946              39              45




                   Thailand    India             Colombia                     Colombia         South Africa
nets                       0.0             0.0                          0.0              0.0            0.0
insecticide               32.1            37.1                         80.2             39.0            0.0
diagnostics                0.0             0.0                          0.0              0.0            0.0
treatment                  0.0             0.0                          0.0              0.0            0.0
personnel                 47.6            33.5                         15.2             45.0            0.0
training                   0.0             0.0                          0.0              0.0            0.0
overheads                  0.0             1.8                          0.0              0.0            0.0
IEC                        0.0             2.9                          0.0              0.0            0.0
distribution               0.0             0.0                          0.0              0.0            0.0
transport                  0.0             4.0                          2.0              8.4            0.0
storage                    0.0             0.0                          0.0              0.0            0.0
capital                   20.3            19.8                          2.2              6.2            0.0
study costs                0.0             0.0                          0.0              0.0            0.0
other                      0.0             0.9                          0.4              1.4            0.0
user                       0.0             0.0                          0.0              0.0            0.0
not costed                 0.0             0.0                          0.0              0.0         100.0
person protected          3.91            1.94                         9.25            12.87           3.35




                   Thailand    India             Colombia                     Colombia    South Africa
nets                      0.00            0.00                         0.00          0.00         0.00
insecticide               1.26            0.72                         7.42          5.02         0.00
diagnostics               0.00            0.00                         0.00          0.00         0.00
treatment                 0.00            0.00                         0.00          0.00         0.00
personnel      1.86   0.65              1.41    5.79      0.00
training       0.00   0.00              0.00    0.00      0.00
overheads      0.00   0.03              0.00    0.00      0.00
IEC            0.00   0.06              0.00    0.00      0.00
distribution   0.00   0.00              0.00    0.00      0.00
transport      0.00   0.08              0.18    1.08      0.00
storage        0.00   0.00              0.00    0.00      0.00
capital        0.80   0.38              0.20    0.80      0.00
study costs    0.00   0.00              0.00    0.00      0.00
other          0.00   0.02              0.04    0.18      0.00
user           0.00   0.00              0.00    0.00      0.00
not costed     0.00   0.00              0.00    0.00      3.35




                                                       B: Unit financia
                                        14.00



                                        12.00



                                        10.00
                             2009 USD


                                         8.00



                                         6.00



                                         4.00



                                         2.00



                                         0.00
                                                                                        Financial costs
                                                          Breakdown %
training         IEC           overheads     capital      distribution transport storage     study costs
      -                    1.0      -                11.0        -            3.0     -              -

      -                -           -              -            -            -          -           -

           1.6         -           -              -            -            -          -           -

      -                -           -                  20.3     -            -          -           -

      -                    2.9         1.8            19.8     -                4.0    -           -

           2.6         -               2.2            20.1     -            -          -               8.9
           2.7         -               0.7            12.0     -            -          -               7.8

      -                -           -                   2.2     -                  2    -           -
      -                -           -                   6.2     -                8.4    -           -




Zimbabwe Kenya      Mozambique Mozambique
       0.0      0.0        0.0        0.0
      81.0     76.4       28.6       45.3
       0.0      0.0        0.0        0.0
       0.0      0.0        0.0        0.0
       4.0     20.4       37.7       31.5
       0.0      1.6        2.6        2.7
       0.0      0.0        2.2        0.7
       1.0      0.0        0.0        0.0
       0.0      0.0        0.0        0.0
       3.0      0.0        0.0        0.0
       0.0      0.0        0.0        0.0
      11.0      0.0       20.1       12.0
       0.0      0.0        8.9        7.8
       0.0      1.7        0.0        0.0
       0.0      0.0        0.0        0.0
       0.0      0.0        0.0        0.0
      1.54     1.11       6.78       4.04




Zimbabwe Kenya      Mozambique Mozambique
      0.00     0.00       0.00       0.00                       0.00%
      1.25     0.85       1.94       1.83                      48.92%
      0.00     0.00       0.00       0.00                       0.00%
      0.00     0.00       0.00       0.00                       0.00%
         0.06   0.23   2.55     1.27   33.35%
         0.00   0.02   0.18     0.11    0.73%
         0.00   0.00   0.15     0.03    0.51%
         0.02   0.00   0.00     0.00    0.17%
         0.00   0.00   0.00     0.00    0.00%
         0.05   0.00   0.00     0.00    3.35%
         0.00   0.00   0.00     0.00    0.00%
         0.17   0.00   1.36     0.49   10.13%
         0.00   0.00   0.60     0.31    2.21%
         0.00   0.02   0.00     0.00    0.61%
         0.00   0.00   0.00     0.00    0.00%
         0.00   0.00   0.00     0.00




B: Unit financial cost of IRS
l costs
                                                                              Cost per
          other             user          NA        house sprayed      person protected     standardised cost per person protected
                  -                -           -                  2.51                 1.54                   3.08

                  -                -        100.0            -                         3.35                  6.70

                      1.7          -           -             -                         1.11                  2.22

                  -                -           -                 21.02                 3.91                  7.82

                      0.9          -           -                 10.19                 1.94                  3.88

                  -                -           -             -                         6.78                  6.78
                  -                -           -             -                         4.04                  4.04

                      0.4          -           -                 45.98                 9.25                  9.25
                      1.4          -           -                 59.72                12.87                 12.87




                                                     Kenya
                                          South Africa                   Mozambique           Mozambique
                            nets                 0.0               0.0                  0.0                   0.0
                            insecticide         18.5              74.7                 37.3                  50.8
                            diagnostics          0.0               0.0                  0.0                   0.0
                            treatment            0.0               0.0                  0.0                   0.0
                            personnel           57.1              22.6                 43.0                  31.8
                            training             0.0               1.0                  1.0                   1.4
                            overheads            0.0               0.0                  2.9                   0.8
                            IEC                  0.0               0.0                  0.0                   0.0
                            distribution         0.0               0.0                  0.0                   0.0
                            transport            2.3               0.0                  0.0                   0.0
                            storage             12.2               0.0                  0.0                   0.0
                            capital              3.0               0.0                  9.9                   6.3
                            study costs          0.0               0.0                  5.9                   8.9
                            other                6.8               1.8                  0.0                   0.0
                            user                 0.0               0.0                  0.0                   0.0
                            not costed           0.0               0.0                  0.0                   0.0
                            person protected    3.15              1.14                 6.23                  3.66




                                                     Kenya
                                          South Africa                   Mozambique           Mozambique
                            nets                0.00              0.00                 0.00                  0.00
                            insecticide         0.58              0.85                 2.32                  1.86
                            diagnostics         0.00              0.00                 0.00                  0.00
                            treatment           0.00              0.00                 0.00                  0.00
personnel      1.80           0.26           2.68            1.16
training       0.00           0.01           0.07            0.05
overheads      0.00           0.00           0.18            0.03
IEC            0.00           0.00           0.00            0.00
distribution   0.00           0.00           0.00            0.00
transport      0.07           0.00           0.00            0.00
storage        0.39           0.00           0.00            0.00
capital        0.10           0.00           0.62            0.23
study costs    0.00           0.00           0.37            0.32
other          0.21           0.02           0.00            0.00
user           0.00           0.00           0.00            0.00
not costed     0.00           0.00           0.00            0.00



       7.00




       6.00




       5.00




       4.00




       3.00




       2.00




       1.00




       0.00
               South Africa          Kenya          Mozambique
Economic costs
Breakdown %
insecticide personnel training       IEC       overheads capital         distributiontransport storage
     -          -          -               -       -          -                -          -         -

        18.5        57.1   -               -       -               3.0       -              2.3        12.2

        74.7        22.6       1.0         -       -          -              -          -          -

    -           -          -               -       -          -              -          -          -

    -           -          -               -       -          -              -          -          -

        37.3        43.0       1.0         -           2.9         9.9       -          -          -
        50.8        31.8       1.4         -           0.8         6.3       -          -          -

    -           -          -               -       -          -              -          -          -
    -           -          -               -       -          -              -          -          -




    0.00%
   39.60%
    0.00%
    0.00%
41.62%
 0.90%
 1.48%
 0.00%
 0.00%
 0.52%
 2.72%
 6.65%
 4.87%
 1.65%
 0.00%




                      not costed
                      user
                      other
                      study costs
                      capital
                      storage
                      transport
                      distribution
                      IEC
                      overheads
                      training
                      personnel
                      treatment
                      diagnostics
                      insecticide
                      nets




         Mozambique
                                             Cost per
study costsother         user       NA       house sprayed   person protected
     -         -                -        -            -          -

    -              6.8          -        -           -               3.15

    -              1.8          -        -           -               1.14

    -          -                -        -           -           -

    -          -                -        -           -           -

        5.9    -                -        -           -               6.23
        8.9    -                -        -           -               3.66

    -          -                -        -           -           -
    -          -                -        -           -           -
This sheet contains data from the sheet 'IRSdata'. All prices have been inflated
to 2009 US$.
               Study description

name                Currency                          cost
                               PerspectiveInflation factor of drugs     personnel    training
Ghana               2008 USD   Provider      1.00401                2.8         58.2        17.3
Ghana               2008 USD   Provider      1.00401              17.9          58.8         5.7
Ghana               2008 USD   Provider      1.00401              14.5          57.5        11.3
Ghana               2008 USD   Provider      1.00401          -               -           -
Ghana               2008 USD   Provider      1.00401          -               -           -
Ghana               2008 USD   Provider      1.00401          -               -           -

Ghana               2008 USD   Provider      1.00401                9.0                38.0        -
Ghana               2008 USD   Provider      1.00401                8.0                54.0        -
Ghana               2008 USD   Provider      1.00401                8.0                56.0        -
Ghana               2008 USD   Provider      1.00401                8.0                53.0        -

Tanzania            2006 USD Provider              1               14.2                16.6            39.6
Mozambique          2006 USD Provider              1               34.5                12.6            30.2

Tanzania                                       system
                    2005 USD Provider - health1.038                71.0                 7.2            17.3

Uganda              2002/3 USDProvider         1.038                8.8                52.4        -
Uganda              2002/3 USDProvider         1.038               13.6                44.5        -

Kenya               2006 USD Provider          1.038               60.4                 6.0        -

Africa              1995 USD   Provider      1.45309               38.5                27.7      33.8
Africa              1995 USD   Provider      1.45309               28.6                32.1      39.3
Africa              1995 USD   Provider      1.45309               35.2                33.8      31.0
Africa              1995 USD   Provider      1.45309               25.8                38.7      35.5
Africa              1995 USD   Provider      1.45309               21.6                59.5      19.0
Africa              1995 USD   Provider      1.45309               15.0                64.5      20.6

Mozambique          2007 USD Provider        1.06706              31.82            45.45           22.73




                    Africa (p) Africa (p) Africa (p) Africa (p)           Africa (p)          Africa (p)
nets                        0.0        0.0        0.0               0.0                 0.0           0.0
insecticide                 0.0        0.0        0.0               0.0                 0.0           0.0
diagnostics                 0.0        0.0        0.0               0.0                 0.0           0.0
treatment                  38.5       28.6       35.2              25.8                21.6          15.0
personnel                  27.7       32.1       33.8              38.7                59.5          64.5
training                   33.8       39.3       31.0              35.5                19.0          20.6
overheads                   0.0        0.0        0.0               0.0                 0.0           0.0
IEC                         0.0        0.0        0.0               0.0                 0.0           0.0
distribution                0.0        0.0        0.0               0.0                 0.0           0.0
transport                              0.0     0.0        0.0               0.0                 0.0          0.0
storage                                0.0     0.0        0.0               0.0                 0.0          0.0
capital                                0.0     0.0        0.0               0.0                 0.0          0.0
study costs                            0.0     0.0        0.0               0.0                 0.0          0.0
other                                  0.0     0.0        0.0               0.0                 0.0          0.0
user                                   0.0     0.0        0.0               0.0                 0.0          0.0
not costed                             0.0     0.0        0.0               0.0                 0.0          0.0
person treated (compliant)            1.89    1.64       2.06              1.82                3.36         3.11


                             Africa (p) Africa (p) Africa (p) Africa (p)          Africa (p)          Africa (p)
nets                                0.00       0.00       0.00             0.00                0.00          0.00
insecticide                         0.00       0.00       0.00             0.00                0.00          0.00
diagnostics                         0.00       0.00       0.00             0.00                0.00          0.00
treatment                           0.73       0.47       0.73             0.47                0.72          0.46
personnel                           0.52       0.53       0.70             0.70                2.00          2.01
training                            0.64       0.65       0.64             0.64                0.64          0.64
overheads                           0.00       0.00       0.00             0.00                0.00          0.00
IEC                                 0.00       0.00       0.00             0.00                0.00          0.00
distribution                        0.00       0.00       0.00             0.00                0.00          0.00
transport                           0.00       0.00       0.00             0.00                0.00          0.00
storage                             0.00       0.00       0.00             0.00                0.00          0.00
capital                             0.00       0.00       0.00             0.00                0.00          0.00
study costs                         0.00       0.00       0.00             0.00                0.00          0.00
other                               0.00       0.00       0.00             0.00                0.00          0.00
user                                0.00       0.00       0.00             0.00                0.00          0.00
not costed                          0.00       0.00       0.00             0.00                0.00          0.00



                                                                                          C: Unit financial c
                                   14.00



                                   12.00



                                   10.00
                        2009 USD




                                    8.00



                                    6.00



                                    4.00
                   4.00



                   2.00



                   0.00




                            Africa (p) [72]
               Africa (p) [72]                        Africa (p) [72] Africa (p) [72] Africa (p) [72]
                                         Africa (p) [72]
nets                  0.00         0.00         0.00               0.00          0.00        0.00
insecticide           0.00         0.00         0.00               0.00          0.00        0.00
diagnostics           0.00         0.00         0.00               0.00          0.00        0.00
treatment             0.73         0.47         0.73               0.47          0.72        0.46
personnel             0.52         0.53         0.70               0.70          2.00        2.01
training              0.64         0.65         0.64               0.64          0.64        0.64
overheads             0.00         0.00         0.00               0.00          0.00        0.00
IEC                   0.00         0.00         0.00               0.00          0.00        0.00
distribution          0.00         0.00         0.00               0.00          0.00        0.00
transport             0.00         0.00         0.00               0.00          0.00        0.00
storage               0.00         0.00         0.00               0.00          0.00        0.00
capital               0.00         0.00         0.00               0.00          0.00        0.00
study costs           0.00         0.00         0.00               0.00          0.00        0.00
other                 0.00         0.00         0.00               0.00          0.00        0.00
user                  0.00         0.00         0.00               0.00          0.00        0.00
not costed            0.00         0.00         0.00               0.00          0.00        0.00
                                                     Financial costs
                                Breakdown %
IEC               overheads capital   distributiontransport storage     study costsother          user
       -                  2.8    -          -             18.9     -         -         -                 -
       -                  1.1    -          -             16.5     -         -         -                 -
       -                  1.8    -          -             14.9     -         -         -                 -
       -               -         -          -           -          -         -         -                 -
       -               -         -          -           -          -         -         -                 -
       -               -         -          -           -          -         -         -                 -

      4.0              -          -          -          49.0        -       -          -                 -
      3.0              -          -          -          35.0        -       -          -                 -
      3.0              -          -          -          33.0        -       -          -                 -
      4.0              -          -          -          35.0        -       -          -                 -

           10.2        -          -              19.4    -          -       -          -                 -
            7.8        -          -              14.8    -          -       -          -                 -

            4.5        -          -          -           -          -       -               0.1          -

       -               -          -          -               38.8   -       -          -                 -
       -               -          -          -               41.9   -       -          -                 -

       -                   5.6        4.0    -               13.4   -       -              10.6          -

       -               -          -          -           -          -       -          -                 -
       -               -          -          -           -          -       -          -                 -
       -               -          -          -           -          -       -          -                 -
       -               -          -          -           -          -       -          -                 -
       -               -          -          -           -          -       -          -                 -
       -               -          -          -           -          -       -          -                 -

       -               -          -          -           -          -       -          -                 -




                               Kenya
Uganda (p) Uganda (p) Mozambique (p) (c) Ghana (c) Ghana (c) Ghana (c) Ghana (c) Ghana (c)
      0.0           0.0    0.0        0.0       0.0       0.0       0.0       0.0       0.0
      0.0           0.0    0.0        0.0       0.0       0.0       0.0       0.0       0.0
      0.0           0.0    0.0        0.0       0.0       0.0       0.0       0.0       0.0
      8.8          13.6   31.8       60.4       2.8     17.9      14.5        9.0       8.0
     52.4          44.5   45.5        6.0     58.2      58.8      57.5      38.0      54.0
      0.0           0.0   22.7        0.0     17.3        5.7     11.3        0.0       0.0
      0.0           0.0    0.0        5.6       2.8       1.1       1.8       0.0       0.0
      0.0           0.0    0.0        0.0       0.0       0.0       0.0       4.0       3.0
      0.0           0.0    0.0        0.0       0.0       0.0       0.0       0.0       0.0
           38.8        41.9       0.0     13.4      18.9      16.5      14.9      49.0      35.0
            0.0         0.0       0.0      0.0       0.0       0.0       0.0       0.0       0.0
            0.0         0.0       0.0      4.0       0.0       0.0       0.0       0.0       0.0
            0.0         0.0       0.0      0.0       0.0       0.0       0.0       0.0       0.0
            0.0         0.0       0.0     10.6       0.0       0.0       0.0       0.0       0.0
            0.0         0.0       0.0      0.0       0.0       0.0       0.0       0.0       0.0
            0.0         0.0       0.0      0.0       0.0       0.0       0.0       0.0       0.0
           2.43        2.66      0.47     1.25      4.96     11.80      7.35      3.24      3.84


                                     Kenya
      Uganda (p) Uganda (p) Mozambique (p) (c) Ghana (c) Ghana (c) Ghana (c) Ghana (c) Ghana (c)
           0.00          0.00   0.00       0.00     0.00      0.00      0.00      0.00      0.00
           0.00          0.00   0.00       0.00     0.00      0.00      0.00      0.00      0.00
           0.00          0.00   0.00       0.00     0.00      0.00      0.00      0.00      0.00
           0.21          0.36   0.15       0.75     0.14      2.11      1.07      0.29      0.31
           1.27          1.19   0.21       0.07     2.89      6.94      4.23      1.23      2.07
           0.00          0.00   0.11       0.00     0.86      0.67      0.83      0.00      0.00
           0.00          0.00   0.00       0.07     0.14      0.13      0.13      0.00      0.00
           0.00          0.00   0.00       0.00     0.00      0.00      0.00      0.13      0.12
           0.00          0.00   0.00       0.00     0.00      0.00      0.00      0.00      0.00
           0.94          1.12   0.00       0.17     0.93      1.95      1.10      1.59      1.34
           0.00          0.00   0.00       0.00     0.00      0.00      0.00      0.00      0.00
           0.00          0.00   0.00       0.05     0.00      0.00      0.00      0.00      0.00
           0.00          0.00   0.00       0.00     0.00      0.00      0.00      0.00      0.00
           0.00          0.00   0.00       0.13     0.00      0.00      0.00      0.00      0.00
           0.00          0.00   0.00       0.00     0.00      0.00      0.00      0.00      0.00
           0.00          0.00   0.00       0.00     0.00      0.00      0.00      0.00      0.00



Unit financial cost of IPT
           [73]         Mozambique (p) [74]
Uganda (p) Uganda (p) [73]
     0.00          0.00     0.00       0.0%   nets
     0.00          0.00     0.00       0.0%   insecticide
     0.00          0.00     0.00       0.0%   diagnostics
     0.21          0.36     0.15     22.1%    treatment
     1.27          1.19     0.21     46.9%    personnel
     0.00          0.00     0.11     20.3%    training
     0.00          0.00     0.00       0.0%   overheads
     0.00          0.00     0.00       0.0%   IEC
     0.00          0.00     0.00       0.0%   distribution
     0.94          1.12     0.00     10.6%    transport
     0.00          0.00     0.00       0.0%   storage
     0.00          0.00     0.00       0.0%   capital
     0.00          0.00     0.00       0.0%   study costs
     0.00          0.00     0.00       0.0%   other
     0.00          0.00     0.00       0.0%   user
     0.00          0.00     0.00       0.0%   not costed
                          Cost per                                                                                          Bre
NA                                 person treated (all) of drugs
          person treated (compliant)                cost       personnel training IEC                        overheads
     -                       4.96              4.21        1.7      73.8        11.5  -                            1.7
     -                      11.80             10.50      14.2       66.7         5.1  -                            0.9
     -                       7.35              6.47        9.9      70.2         8.5  -                            1.2
     -               -                     -               7.0      84.4      -       -                            6.5
     -               -                     -             47.1       47.8      -       -                            2.5
     -               -                     -             37.9       56.5      -       -                            4.1

     -                      3.24           -                6.0         56.0          -          3.0            2.0
     -                      3.84           -                6.0         65.0          -          3.0            2.0
     -                      3.52           -                6.0         66.0          -          2.0            3.0
     -                      4.22           -                6.0         64.0          -          2.0            3.0

     -                      0.07           -                     10.6        20.7         41.8        15.3        -
     -                      0.10           -                     24.6        17.4         35.2        12.9        -

     -                      0.19           -                     56.3        11.5         23.5         8.6        -

     -                      2.43           -                 -           -            -           -               -
     -                      2.66           -                 -           -            -           -               -

     -                      1.25           -                     38.4        40.2     -           -                   3.6

     -                      1.89           -                 -           -            -           -               -
     -                      1.64           -                 -           -            -           -               -
     -                      2.06           -                 -           -            -           -               -
     -                      1.82           -                 -           -            -           -               -
     -                      3.36           -                 -           -            -           -               -
     -                      3.11           -                 -           -            -           -               -

     -                      0.47           -                 -           -            -           -               -




Ghana (c) Ghana (c)                Tanzania (i)          Tanzania (i)Mozambique (i)
       0.0                   0.0                   0.0          0.0       0.0                                nets
       0.0                   0.0                   0.0          0.0       0.0                                insecticide
       0.0                   0.0                   0.0          0.0       0.0                                diagnostics
       8.0                   8.0                  71.0        14.2       34.5                                treatment
     56.0                   53.0                   7.2        16.6       12.6                                personnel
       0.0                   0.0                  17.3        39.6       30.2                                training
       0.0                   0.0                   0.0          0.0       0.0                                overheads
       3.0                   4.0                   4.5        10.2        7.8                                IEC
       0.0                   0.0                   0.0        19.4       14.8                                distribution
     33.0             35.0                   0.0         0.0        0.0               transport
      0.0              0.0                   0.0         0.0        0.0               storage
      0.0              0.0                   0.0         0.0        0.0               capital
      0.0              0.0                   0.0         0.0        0.0               study costs
      0.0              0.0                   0.1         0.0        0.0               other
      0.0              0.0                   0.0         0.0        0.0               user
      0.0              0.0                   0.0         0.0        0.0               not costed
     3.52             4.22                  0.18        0.08       0.10               person treated (complia


Ghana (c) Ghana (c)          Tanzania (i)          Tanzania (i)Mozambique (i)
     0.00             0.00                  0.00        0.00       0.00       0.00%   nets
     0.00             0.00                  0.00        0.00       0.00       0.00%   insecticide
     0.00             0.00                  0.00        0.00       0.00       0.00%   diagnostics
     0.28             0.34                  0.13        0.01       0.03    16.28%     treatment
     1.97             2.23                  0.01        0.01       0.01    51.37%     personnel
     0.00             0.00                  0.03        0.03       0.03    10.68%     training
     0.00             0.00                  0.00        0.00       0.00       0.78%   overheads
     0.11             0.17                  0.01        0.01       0.01       0.91%   IEC
     0.00             0.00                  0.00        0.02       0.01       0.05%   distribution
     1.16             1.48                  0.00        0.00       0.00    19.63%     transport
     0.00             0.00                  0.00        0.00       0.00       0.00%   storage
     0.00             0.00                  0.00        0.00       0.00       0.08%   capital
     0.00             0.00                  0.00        0.00       0.00       0.00%   study costs
     0.00             0.00                  0.00        0.00       0.00       0.22%   other
     0.00             0.00                  0.00        0.00       0.00       0.00%   user
     0.00             0.00                  0.00        0.00       0.00               not costed




                                                                                                       16.00


                                                                                                       14.00


                                                                                                       12.00


                                                                                                       10.00
                                                                                            2009 USD




                                                                                                        8.00
                                                                                                       2009 US
                                                                                                                 6.00


                                                                                                                 4.00


                                                                                                                 2.00


                                                                                                                 0.00




            Ghana (c) [76]
Kenya (c) [75]                      Ghana (c) [76]              Ghana (c) [77]
                                                     Ghana (c) [76]                   Ghana (c) [77]
                                                                           Ghana (c) [77]        Ghana (c) [77]
     0.00                    0.00               0.00      0.00       0.00       0.00       0.00       0.00
     0.00                    0.00               0.00      0.00       0.00       0.00       0.00       0.00
     0.00                    0.00               0.00      0.00       0.00       0.00       0.00       0.00
     0.75                    0.14               2.11      1.07       0.29       0.31       0.28       0.34
     0.07                    2.89               6.94      4.23       1.23       2.07       1.97       2.23
     0.00                    0.86               0.67      0.83       0.00       0.00       0.00       0.00
     0.07                    0.14               0.13      0.13       0.00       0.00       0.00       0.00
     0.00                    0.00               0.00      0.00       0.13       0.12       0.11       0.17
     0.00                    0.00               0.00      0.00       0.00       0.00       0.00       0.00
     0.17                    0.93               1.95      1.10       1.59       1.34       1.16       1.48
     0.00                    0.00               0.00      0.00       0.00       0.00       0.00       0.00
     0.05                    0.00               0.00      0.00       0.00       0.00       0.00       0.00
     0.00                    0.00               0.00      0.00       0.00       0.00       0.00       0.00
     0.13                    0.00               0.00      0.00       0.00       0.00       0.00       0.00
     0.00                    0.00               0.00      0.00       0.00       0.00       0.00       0.00
     0.00                    0.00               0.00      0.00       0.00       0.00       0.00       0.00
                               Economic costs
            Breakdown %                                                                                    Cost per
capital      distributiontransport storage    study costsother         user       NA       person treated (compliant)
     -             -           11.4     -          -         -                -        -                8.22
     -             -           13.1     -          -         -                -        -              14.85
     -             -           10.2     -          -         -                -        -              10.71
     -             -            2.2     -          -         -                -        -                1.87
     -             -            2.5     -          -         -                -        -                4.35
     -             -            1.9     -          -         -                -        -                2.70

     -            -          33.0       -         -          -                -        -               4.60
     -            -          24.0       -         -          -                -        -               5.29
     -            -          23.0       -         -          -                -        -               4.95
     -            -          25.0       -         -          -                -        -               5.67

     -                11.7    -         -         -          -                -        -               0.13
     -                 9.9    -         -         -          -                -        -               0.15

     -            -           -         -         -              0.1          -        -               0.24

     -            -           -         -         -          -                -        -           -
     -            -           -         -         -          -                -        -           -

          2.6     -               8.6   -         -              6.7          -        -               1.95

     -            -           -         -         -          -                -        -           -
     -            -           -         -         -          -                -        -           -
     -            -           -         -         -          -                -        -           -
     -            -           -         -         -          -                -        -           -
     -            -           -         -         -          -                -        -           -
     -            -           -         -         -          -                -        -           -

     -            -           -         -         -          -                -        -           -




Kenya (c) Ghana (c) Ghana (c) Ghana (c) Ghana (c) Ghana (c) Ghana (c) Ghana (c) Ghana (c)
       0.0       0.0       0.0       0.0       0.0       0.0       0.0       0.0                        0.0
       0.0       0.0       0.0       0.0       0.0       0.0       0.0       0.0                        0.0
       0.0       0.0       0.0       0.0       0.0       0.0       0.0       0.0                        0.0
     38.4        1.7     14.2        9.9       7.0     47.1      37.9        6.0                        6.0
     40.2      73.8      66.7      70.2      84.4      47.8      56.5      56.0                        65.0
       0.0     11.5        5.1       8.5       0.0       0.0       0.0       0.0                        0.0
       3.6       1.7       0.9       1.2       6.5       2.5       4.1       2.0                        2.0
       0.0       0.0       0.0       0.0       0.0       0.0       0.0       3.0                        3.0
       0.0       0.0       0.0       0.0       0.0       0.0       0.0       0.0                        0.0
         8.6   11.4      13.1      10.2       2.2       2.5       1.9       33.0            24.0
         0.0    0.0       0.0       0.0       0.0       0.0       0.0        0.0             0.0
         2.6    0.0       0.0       0.0       0.0       0.0       0.0        0.0             0.0
         0.0    0.0       0.0       0.0       0.0       0.0       0.0        0.0             0.0
         6.7    0.0       0.0       0.0       0.0       0.0       0.0        0.0             0.0
         0.0    0.0       0.0       0.0       0.0       0.0       0.0        0.0             0.0
         0.0    0.0       0.0       0.0       0.0       0.0       0.0        0.0             0.0
        1.95   8.22     14.85     10.71      1.87      4.35      2.70       4.60            5.29


Kenya (c) Ghana (c) Ghana (c) Ghana (c) Ghana (c) Ghana (c) Ghana (c) Ghana (c) Ghana (c)
     0.00      0.00      0.00      0.00      0.00      0.00      0.00      0.00             0.00
     0.00      0.00      0.00      0.00      0.00      0.00      0.00      0.00             0.00
     0.00      0.00      0.00      0.00      0.00      0.00      0.00      0.00             0.00
     0.75      0.14      2.11      1.06      0.13      2.05      1.02      0.28             0.32
     0.78      6.07      9.91      7.52      1.58      2.08      1.53      2.58             3.44
     0.00      0.94      0.75      0.91      0.00      0.00      0.00      0.00             0.00
     0.07      0.14      0.13      0.13      0.12      0.11      0.11      0.09             0.11
     0.00      0.00      0.00      0.00      0.00      0.00      0.00      0.14             0.16
     0.00      0.00      0.00      0.00      0.00      0.00      0.00      0.00             0.00
     0.17      0.94      1.95      1.09      0.04      0.11      0.05      1.52             1.27
     0.00      0.00      0.00      0.00      0.00      0.00      0.00      0.00             0.00
     0.05      0.00      0.00      0.00      0.00      0.00      0.00      0.00             0.00
     0.00      0.00      0.00      0.00      0.00      0.00      0.00      0.00             0.00
     0.13      0.00      0.00      0.00      0.00      0.00      0.00      0.00             0.00
     0.00      0.00      0.00      0.00      0.00      0.00      0.00      0.00             0.00
     0.00      0.00      0.00      0.00      0.00      0.00      0.00      0.00             0.00




                                          C: Unit financial cost of IPT
16.00


14.00


12.00


10.00


 8.00
            6.00


            4.00


            2.00


            0.00




Ghana (c) [77]                                   [46]        [78]
                                     Tanzania (i)Tanzania (i)Mozambique (i) [78]
                  0.0%   nets             0.00        0.00             0.00
                  0.0%   insecticide      0.00        0.00             0.00
                  0.0%   diagnostics      0.00        0.00             0.00
                 13.2%   treatment        0.13        0.01             0.03
                 53.9%   personnel        0.01        0.01             0.01
                  5.9%   training         0.03        0.03             0.03
                  1.2%   overheads        0.00        0.00             0.00
                  1.3%   IEC              0.01        0.01             0.01
                  0.0%   distribution     0.00        0.02             0.01
                 24.2%   transport        0.00        0.00             0.00
                  0.0%   storage          0.00        0.00             0.00
                  0.1%   capital          0.00        0.00             0.00
                  0.0%   study costs      0.00        0.00             0.00
                  0.3%   other            0.00        0.00             0.00
                  0.0%   user             0.00        0.00             0.00
                  0.0%   not costed       0.00        0.00             0.00
Cost per
  person treated (all)
                   6.98                         This sheet contains data from the sheet 'IPT data'. All prices have been inflated
                  13.21                         to 2009 US$.
                   9.49
            -
            -
            -

              -
              -
              -
              -

              -
              -

              -

              -
              -

              -

              -
              -
              -
              -
              -
              -

              -




  Ghana (c)               Ghana (c) Tanzania (i)Tanzania (i)Mozambique (i)
                   0.0           0.0       0.0         0.0       0.0
                   0.0           0.0       0.0         0.0       0.0
                   0.0           0.0       0.0         0.0       0.0
                   6.0           6.0     56.3        10.6       24.6
                  66.0         64.0      11.5        20.7       17.4
                   0.0           0.0     23.5        41.8       35.2
                   3.0           3.0       0.0         0.0       0.0
                   2.0           2.0       8.6       15.3       12.9
                   0.0           0.0       0.0       11.7        9.9
            23.0        25.0        0.0        0.0        0.0
             0.0         0.0        0.0        0.0        0.0
             0.0         0.0        0.0        0.0        0.0
             0.0         0.0        0.0        0.0        0.0
             0.0         0.0        0.1        0.0        0.0
             0.0         0.0        0.0        0.0        0.0
             0.0         0.0        0.0        0.0        0.0
            4.95        5.67       0.24       0.13       0.15


Ghana (c)          Ghana (c) Tanzania (i)Tanzania (i)Mozambique (i)
            0.00        0.00      0.00        0.00       0.00       0.00%
            0.00        0.00      0.00        0.00       0.00       0.00%
            0.00        0.00      0.00        0.00       0.00       0.00%
            0.30        0.34      0.14        0.01       0.04    13.21%
            3.27        3.63      0.03        0.03       0.03    64.62%
            0.00        0.00      0.06        0.05       0.05       4.22%
            0.15        0.17      0.00        0.00       0.00       2.02%
            0.10        0.11      0.02        0.02       0.02       0.87%
            0.00        0.00      0.00        0.02       0.01       0.05%
            1.14        1.42      0.00        0.00       0.00    14.74%
            0.00        0.00      0.00        0.00       0.00       0.00%
            0.00        0.00      0.00        0.00       0.00       0.08%
            0.00        0.00      0.00        0.00       0.00       0.00%
            0.00        0.00      0.00        0.00       0.00       0.20%
            0.00        0.00      0.00        0.00       0.00       0.00%
            0.00        0.00      0.00        0.00       0.00
mbique (i) [78]
                   0.0%
                   0.0%
                   0.0%
                  48.2%
                  10.8%
                  25.8%
                   0.0%
                   6.7%
                   8.4%
                   0.0%
                   0.0%
                   0.0%
                   0.0%
                   0.0%
                   0.0%
                   0.0%
data'. All prices have been inflated
            Study description

name        Currency PerspectiveInflation factor diagnosticstreatment personnel training
Zambia                 Provider                 1   94.5         5.5
            Chanda P, Hamainza B, Moonga HB, Chalwe V, Banda P, Pagnoni F. -         -
Zambia                 Provider                 1       80.6    19.4
            Chanda P, Hamainza B, Moonga HB, Chalwe V, Banda P, Pagnoni F. -         -

Ethiopia              Provider              1.067         0.0
            Lemma H, San Sebastian M, Löfgren C, Barnabas G.       100.0        -          -
Ethiopia              Provider              1.067         G.
            Lemma H, San Sebastian M, Löfgren C, Barnabas55.5       44.5        -          -
Ethiopia              Provider              1.067         G.
            Lemma H, San Sebastian M, Löfgren C, Barnabas72.1       27.9        -          -

Nigeria*               Society                    1       -         -
            Parikh R, Amole I, Tarpley M, Gbadero D, Davidson M, Vermund SH.    -          -
Nigeria*               Society                    1       -         -
            Parikh R, Amole I, Tarpley M, Gbadero D, Davidson M, Vermund SH.    -          -
Nigeria*               Society                    1       -         -
            Parikh R, Amole I, Tarpley M, Gbadero D, Davidson M, Vermund SH.    -          -
Nigeria*               Society                    1       -         -
            Parikh R, Amole I, Tarpley M, Gbadero D, Davidson M, Vermund SH.    -          -
Nigeria*               Society                    1       -         -
            Parikh R, Amole I, Tarpley M, Gbadero D, Davidson M, Vermund SH.    -          -
Nigeria*               Society                    1       -         -
            Parikh R, Amole I, Tarpley M, Gbadero D, Davidson M, Vermund SH.    -          -

Zambia      2005 USD    Provider          1.13865       -            -              83.4   -
Zambia      2005 USD    Provider          1.13865           13.5     -              64.3   -
Zambia      2005 USD    Provider          1.13865           32.7     -              51.8   -
Zambia      2005 USD    Provider          1.13865       -                34.5       54.6   -
Zambia      2005 USD    Provider          1.13865           11.8         12.9       56.0   -
Zambia      2005 USD    Provider          1.13865           26.1         20.1       41.4   -

Africa      2004 Euro                   1.4062711       -            -          -          -
Africa      2004 Euro                   1.4062711       -            -          -          -
Africa      2004 Euro                   1.4062711       -            -          -          -
Africa      2004 Euro                   1.4062711       -            -          -          -
Africa      2004 Euro                   1.4062711       -            -          -          -
Africa      2004 Euro                   1.4062711       -            -          -          -

Thailand    2000 Baht   Provider     0.032983228        -                 4.1       77.4       14.0
Thailand    2000 Baht   Provider     0.032983228            57.4          7.0       29.8        0.1
Thailand    2000 Baht   Provider     0.032983228            55.5          7.0       27.2        0.1
Thailand*   2000 Baht   Society      0.032983228        -                 3.1       58.4       10.6
Thailand*   2000 Baht   Society      0.032983228            56.6          6.9       29.4        0.1
Thailand*   2000 Baht   Society      0.032983228            54.1          6.8       26.5        0.1

Brazil      2006 USD Provider             1.10121       -            -              18.2       58.8
Brazil      2006 USD Provider             1.10121           83.2     -              10.2        0.8

Tanzania    2008 USD    Provider          1.00401            0.0         74.0   -          -
Tanzania    2008 USD    Provider          1.00401           21.5         35.1   -          -
Tanzania*   2008 USD    Society           1.00401            0.0         46.6   -          -
Tanzania*   2008 USD    Society           1.00401           16.6         27.0   -          -

Sri Lanka             Provider            1.2154       44.7 -            45.8       0.6
            Fernando SD, Karunaweera ND, Fernando WP, Attanayake N, Wickremasinghe AR.
Sri Lanka                     Provider            1.2154       99.1 -             0.9        -
                    Fernando SD, Karunaweera ND, Fernando WP, Attanayake N, Wickremasinghe AR.




                    Sri Lanka Sri Lanka Brazil             Brazil          Zambia    Zambia    Zambia
nets                       0.00      0.00           0.00         0.00           0.00      0.00      0.00
insecticide                0.00      0.00           0.00         0.00           0.00      0.00      0.00
diagnostics               44.70     99.10           0.00        83.23           0.00     13.49     32.70
treatment                  0.00      0.00           0.00         0.00           0.00      0.00      0.00
personnel                 45.80      0.90          18.21        10.20          83.40     64.28     51.79
training                   0.60      0.00          58.80         0.81           0.00      0.00      0.00
overheads                  6.10      0.00          13.61         0.45          12.80     12.72     13.63
IEC                        0.00      0.00           0.00         0.00           0.00      0.00      0.00
distribution               0.00      0.00           0.00         0.00           0.00      0.00      0.00
transport                  0.00      0.00           8.04         5.31           0.00      0.00      0.00
storage                    0.00      0.00           0.00         0.00           0.00      0.00      0.00
capital                    2.80      0.00           1.35         0.00           3.80      9.51      1.98
study costs                0.00      0.00           0.00         0.00           0.00      0.00      0.00
other                      0.00      0.00           0.00         0.00           0.00      0.00      0.00
user                       0.00      0.00           0.00         0.00           0.00      0.00      0.00
not costed                 0.00      0.00           0.00         0.00           0.00      0.00      0.00
patient diagnosed          0.34      4.64           7.48         5.66           3.07      9.34      5.35




                    Sri Lanka Sri Lanka Brazil             Brazil          Zambia    Zambia    Zambia
nets                       0.00      0.00           0.00            0.00        0.00      0.00      0.00
insecticide                0.00      0.00           0.00            0.00        0.00      0.00      0.00
diagnostics                0.15      4.60           0.00            4.71        0.00      1.26      1.75
treatment                  0.00      0.00           0.00            0.00        0.00      0.00      0.00
personnel                  0.16      0.04           1.36            0.58        2.56      6.00      2.77
training                   0.00      0.00           4.40            0.05        0.00      0.00      0.00
overheads                  0.02      0.00           1.02            0.03        0.39      1.19      0.73
IEC                        0.00      0.00           0.00            0.00        0.00      0.00      0.00
distribution               0.00      0.00           0.00            0.00        0.00      0.00      0.00
transport                  0.00      0.00           0.60            0.30        0.00      0.00      0.00
storage                    0.00      0.00           0.00            0.00        0.00      0.00      0.00
capital                    0.01      0.00           0.10            0.00        0.12      0.89      0.11
study costs                0.00      0.00           0.00            0.00        0.00      0.00      0.00
other                      0.00      0.00           0.00            0.00        0.00      0.00      0.00
user                       0.00      0.00           0.00            0.00        0.00      0.00      0.00
not costed                 0.00      0.00           0.00            0.00        0.00      0.00      0.00




                                D: Unit financial cost of diagnosis
                   D: Unit financial cost of diagnosis
           10.00


            9.00


            8.00


            7.00


            6.00
2009 USD


            5.00


            4.00


            3.00


            2.00


            1.00


            0.00
                                        Financial costs
                        Breakdown %
IEC       overheads capital   distributiontransport storage   study costsother          user
      -       -          -          -          -         -         -         -                 -
      -       -          -          -          -         -         -         -                 -

      -       -           -          -        -         -         -          -                 -
      -       -           -          -        -         -         -          -                 -
      -       -           -          -        -         -         -          -                 -

      -       -           -          -        -         -         -          -                 -
      -       -           -          -        -         -         -          -                 -
      -       -           -          -        -         -         -          -                 -
      -       -           -          -        -         -         -          -                 -
      -       -           -          -        -         -         -          -                 -
      -       -           -          -        -         -         -          -                 -

      -           12.8         3.8   -        -         -         -          -                 -
      -           12.7         9.5   -        -         -         -          -                 -
      -           13.6         2.0   -        -         -         -          -                 -
      -            8.4         2.5   -        -         -         -          -                 -
      -           11.1         8.3   -        -         -         -          -                 -
      -           10.9         1.6   -        -         -         -          -                 -

      -       -           -          -        -         -         -          -                 -
      -       -           -          -        -         -         -          -                 -
      -       -           -          -        -         -         -          -                 -
      -       -           -          -        -         -         -          -                 -
      -       -           -          -        -         -         -          -                 -
      -       -           -          -        -         -         -          -                 -

      -       -                0.6   -        -         -         -               3.9        -
      -       -           -          -        -         -         -               5.6        -
      -       -           -          -        -         -         -              10.2        -
      -       -                0.4   -        -         -         -               2.9       24.5
      -       -           -          -        -         -         -               5.5       1.4
      -       -           -          -        -         -         -              10.0       2.6

      -           13.6         1.3   -            8.0   -         -          -                 -
      -            0.4    -          -            5.3   -         -          -                 -

      -           25.5    -          -        -         -         -          -                 -
      -           43.6    -          -        -         -         -          -                 -
      -           16.1    -          -        -         -         -          -                     37.1
      -           33.6    -          -        -         -         -          -                     23.0

      -            6.1   2.8         -        -         -         -          -          -
             -    -            -         -        -        -       -   -   -




         Nigeria* Nigeria* Nigeria* Zambia    Zambia
               0.00     0.00     0.00    0.00      0.00                    nets
               0.00     0.00     0.00    0.00      0.00                    insecticide
               0.00     0.00     0.00   94.55     80.64                    diagnostics
               0.00     0.00     0.00    5.45     19.36                    treatment
               0.00     0.00     0.00    0.00      0.00                    personnel
               0.00     0.00     0.00    0.00      0.00                    training
               0.00     0.00     0.00    0.00      0.00                    overheads
               0.00     0.00     0.00    0.00      0.00                    IEC
               0.00     0.00     0.00    0.00      0.00                    distribution
               0.00     0.00     0.00    0.00      0.00                    transport
               0.00     0.00     0.00    0.00      0.00                    storage
               0.00     0.00     0.00    0.00      0.00                    capital
               0.00     0.00     0.00    0.00      0.00                    study costs
               0.00     0.00     0.00    0.00      0.00                    other
               0.00     0.00     0.00    0.00      0.00                    user
            100.00   100.00   100.00     0.00      0.00                    not costed
               3.74     3.74     3.74    3.99      5.33                    patient diagnosed and treated




         Nigeria* Nigeria* Nigeria* Zambia    Zambia
               0.00     0.00     0.00    0.00      0.00    0.00%           nets
               0.00     0.00     0.00    0.00      0.00    0.00%           insecticide
               0.00     0.00     0.00    3.77      4.30   45.44%           diagnostics
               0.00     0.00     0.00    0.22      1.03    2.76%           treatment
               0.00     0.00     0.00    0.00      0.00   29.81%           personnel
               0.00     0.00     0.00    0.00      0.00    9.83%           training
               0.00     0.00     0.00    0.00      0.00    7.47%           overheads
               0.00     0.00     0.00    0.00      0.00    0.00%           IEC
               0.00     0.00     0.00    0.00      0.00    0.00%           distribution
               0.00     0.00     0.00    0.00      0.00    1.99%           transport
               0.00     0.00     0.00    0.00      0.00    0.00%           storage
               0.00     0.00     0.00    0.00      0.00    2.70%           capital
               0.00     0.00     0.00    0.00      0.00    0.00%           study costs
               0.00     0.00     0.00    0.00      0.00    0.00%           other
               0.00     0.00     0.00    0.00      0.00    0.00%           user
               3.74     3.74     3.74    0.00      0.00                    not costed




gnosis                                                                            E: Unit finan
gnosis                      E: Unit finan
                    16.00



                    14.00



                    12.00



                    10.00




         2009 USD
                     8.00



                     6.00



                     4.00



                     2.00



                     0.00
                     Cost per                                                                  Break
NA                  patient    patient diagnosed and treatment distributiontransport storage
                                           treated   treated correctly
         patient diagnosed diagnosed and cost of drugs
     -         3.99       4.22      -           -         -          -          -         -
     -         5.33       6.61      -           -         -          -          -         -

     -       -          -          11.82      -          -         -          -          -
     -       -          -           4.97      -          -         -          -          -
     -       -          -           1.80      -          -         -          -          -

 100.0       -          -              4.49   -          -         -          -          -
 100.0       -          -              4.14   -          -         -          -          -
 100.0       -          -              4.63   -          -         -          -          -
 100.0           3.74   -              6.04   -          -         -          -          -
 100.0           3.74   -              4.84   -          -         -          -          -
 100.0           3.74   -              4.97   -          -         -          -          -

     -           3.07   -          -          -          -         -          -          -
     -           9.34   -          -          -          -         -          -          -
     -           5.35   -          -          -          -         -          -          -
     -       -           4.78       4.78      -          -         -          -          -
     -       -          10.70      10.02      -          -         -          -          -
     -       -           6.72       5.92      -          -         -          -          -

 100.0           0.76   14.06      14.06      -          -         -          -          -
 100.0       -          15.19      15.19      -          -         -          -          -
 100.0           0.76    7.03       7.03      -          -         -          -          -
 100.0       -           8.44       8.44      -          -         -          -          -
 100.0           0.76    4.64       4.64      -          -         -          -          -
 100.0       -           6.19       6.19      -          -         -          -          -

     -       -          10.05      -          -          -         -          -          -
     -       -           8.23      -          -          -         -          -          -
     -       -           8.96      -          -          -         -          -          -
     -       -          13.31      -          -          -         -          -          -
     -       -           8.34      -          -          -         -          -          -
     -       -           9.20      -          -          -         -          -          -

     -           7.48   -          -          -          -         -          -          -
     -           5.66   -          -          -          -         -          -          -

     -       -              2.32   -          -          -         -          -          -
     -       -              3.63   -          -          -         -          -          -
     -       -              3.68   -          -          -         -          -          -
     -       -              4.72   -          -          -         -          -          -

     -           0.34   -          -          -          -         -          -          -
     -         4.64     -         -        -         -         -        -         -




 Thailand Thailand Thailand Thailand* Thailand* Thailand* Zambia    Zambia    Zambia
       0.00     0.00     0.00     0.00      0.00      0.00     0.00      0.00      0.00
       0.00     0.00     0.00     0.00      0.00      0.00     0.00      0.00      0.00
       0.00    57.45    55.49     0.00     56.65     54.07     0.00     11.75     26.13
       4.13     7.00     6.97     3.12      6.90      6.80    34.53     12.86     20.08
      77.35    29.83    27.20    58.42     29.41     26.50    54.60     56.01     41.39
      14.04     0.11     0.10    10.60      0.11      0.10     0.00      0.00      0.00
       0.00     0.00     0.00     0.00      0.00      0.00     8.38     11.09     10.89
       0.00     0.00     0.00     0.00      0.00      0.00     0.00      0.00      0.00
       0.00     0.00     0.00     0.00      0.00      0.00     0.00      0.00      0.00
       0.00     0.00     0.00     0.00      0.00      0.00     0.00      0.00      0.00
       0.00     0.00     0.00     0.00      0.00      0.00     0.00      0.00      0.00
       0.59     0.00     0.00     0.45      0.00      0.00     2.48      8.29      1.59
       0.00     0.00     0.00     0.00      0.00      0.00     0.00      0.00      0.00
       3.89     5.61    10.24     2.93      5.53      9.97     0.00      0.00      0.00
       0.00     0.00     0.00    24.47      1.39      2.56     0.00      0.00      0.00
       0.00     0.00     0.00     0.00      0.00      0.00     0.00      0.00      0.00
      10.05     8.23     8.96    13.31      8.34      9.20     4.78     10.02      5.92




 Thailand Thailand Thailand Thailand* Thailand* Thailand* Zambia    Zambia    Zambia
       0.00     0.00     0.00     0.00      0.00      0.00     0.00      0.00      0.00
       0.00     0.00     0.00     0.00      0.00      0.00     0.00      0.00      0.00
       0.00     4.73     4.97     0.00      4.73      4.97     0.00      1.18      1.55
       0.41     0.58     0.63     0.41      0.58      0.63     1.65      1.29      1.19
       7.77     2.45     2.44     7.77      2.45      2.44     2.61      5.61      2.45
       1.41     0.01     0.01     1.41      0.01      0.01     0.00      0.00      0.00
       0.00     0.00     0.00     0.00      0.00      0.00     0.40      1.11      0.64
       0.00     0.00     0.00     0.00      0.00      0.00     0.00      0.00      0.00
       0.00     0.00     0.00     0.00      0.00      0.00     0.00      0.00      0.00
       0.00     0.00     0.00     0.00      0.00      0.00     0.00      0.00      0.00
       0.00     0.00     0.00     0.00      0.00      0.00     0.00      0.00      0.00
       0.06     0.00     0.00     0.06      0.00      0.00     0.12      0.83      0.09
       0.00     0.00     0.00     0.00      0.00      0.00     0.00      0.00      0.00
       0.39     0.46     0.92     0.39      0.46      0.92     0.00      0.00      0.00
       0.00     0.00     0.00     3.26      0.12      0.24     0.00      0.00      0.00
       0.00     0.00     0.00     0.00      0.00      0.00     0.00      0.00      0.00




E: Unit financial cost of diagnosis and treatment
E: Unit financial cost of diagnosis and treatment
                            Economic costs
              Breakdown %
personnel training IEC        overheads capital   study costsother   user       NA
    -          -        -         -          -         -         -          -        -
    -          -        -         -          -         -         -          -        -

    -        -         -          -          -        -          -          -        -
    -        -         -          -          -        -          -          -        -
    -        -         -          -          -        -          -          -        -

    -        -         -          -          -        -          -          -        -
    -        -         -          -          -        -          -          -        -
    -        -         -          -          -        -          -          -        -
    -        -         -          -          -        -          -          -        -
    -        -         -          -          -        -          -          -        -
    -        -         -          -          -        -          -          -        -

    -        -         -          -          -        -          -          -        -
    -        -         -          -          -        -          -          -        -
    -        -         -          -          -        -          -          -        -
    -        -         -          -          -        -          -          -        -
    -        -         -          -          -        -          -          -        -
    -        -         -          -          -        -          -          -        -

    -        -         -          -          -        -          -          -        -
    -        -         -          -          -        -          -          -        -
    -        -         -          -          -        -          -          -        -
    -        -         -          -          -        -          -          -        -
    -        -         -          -          -        -          -          -        -
    -        -         -          -          -        -          -          -        -

    -        -         -          -          -        -          -          -        -
    -        -         -          -          -        -          -          -        -
    -        -         -          -          -        -          -          -        -
    -        -         -          -          -        -          -          -        -
    -        -         -          -          -        -          -          -        -
    -        -         -          -          -        -          -          -        -

    -        -         -          -          -        -          -          -        -
    -        -         -          -          -        -          -          -        -

    -        -         -          -          -        -          -          -        -
    -        -         -          -          -        -          -          -        -
    -        -         -          -          -        -          -          -        -
    -        -         -          -          -        -          -          -        -

    -        -         -          -          -        -          -          -        -
            -            -            -               -               -               -              -        -         -




       Africa       Africa       Africa          Africa          Africa          Africa          Ethiopia Ethiopia Ethiopia
            0.00         0.00         0.00            0.00            0.00            0.00             0.00     0.00     0.00
            0.00         0.00         0.00            0.00            0.00            0.00             0.00     0.00     0.00
            0.00         0.00         0.00            0.00            0.00            0.00             0.00    55.52    72.08
            0.00         0.00         0.00            0.00            0.00            0.00           100.00    44.50    27.90
            0.00         0.00         0.00            0.00            0.00            0.00             0.00     0.00     0.00
            0.00         0.00         0.00            0.00            0.00            0.00             0.00     0.00     0.00
            0.00         0.00         0.00            0.00            0.00            0.00             0.00     0.00     0.00
            0.00         0.00         0.00            0.00            0.00            0.00             0.00     0.00     0.00
            0.00         0.00         0.00            0.00            0.00            0.00             0.00     0.00     0.00
            0.00         0.00         0.00            0.00            0.00            0.00             0.00     0.00     0.00
            0.00         0.00         0.00            0.00            0.00            0.00             0.00     0.00     0.00
            0.00         0.00         0.00            0.00            0.00            0.00             0.00     0.00     0.00
            0.00         0.00         0.00            0.00            0.00            0.00             0.00     0.00     0.00
            0.00         0.00         0.00            0.00            0.00            0.00             0.00     0.00     0.00
            0.00         0.00         0.00            0.00            0.00            0.00             0.00     0.00     0.00
          100.00       100.00       100.00          100.00          100.00          100.00             0.00     0.00     0.00
           14.06        15.19         7.03            8.44            4.64            6.19            11.82     4.97     1.80




       Africa       Africa       Africa          Africa          Africa          Africa          Ethiopia Ethiopia Ethiopia
             0.00         0.00            0.00            0.00            0.00            0.00         0.00     0.00     0.00
             0.00         0.00            0.00            0.00            0.00            0.00         0.00     0.00     0.00
             0.00         0.00            0.00            0.00            0.00            0.00         0.00     2.76     1.30
             0.00         0.00            0.00            0.00            0.00            0.00        11.82     2.21     0.50
             0.00         0.00            0.00            0.00            0.00            0.00         0.00     0.00     0.00
             0.00         0.00            0.00            0.00            0.00            0.00         0.00     0.00     0.00
             0.00         0.00            0.00            0.00            0.00            0.00         0.00     0.00     0.00
             0.00         0.00            0.00            0.00            0.00            0.00         0.00     0.00     0.00
             0.00         0.00            0.00            0.00            0.00            0.00         0.00     0.00     0.00
             0.00         0.00            0.00            0.00            0.00            0.00         0.00     0.00     0.00
             0.00         0.00            0.00            0.00            0.00            0.00         0.00     0.00     0.00
             0.00         0.00            0.00            0.00            0.00            0.00         0.00     0.00     0.00
             0.00         0.00            0.00            0.00            0.00            0.00         0.00     0.00     0.00
             0.00         0.00            0.00            0.00            0.00            0.00         0.00     0.00     0.00
             0.00         0.00            0.00            0.00            0.00            0.00         0.00     0.00     0.00
            14.06        15.19            7.03            8.44            4.64            6.19         0.00     0.00     0.00




ment
ment
            Cost per
           patient   patient diagnosed
patient diagnosed diagnosed and treatedand treated correctly   This sheet contains data from the sheet 'diagnostics da
     -          -         -                                    inflated to 2009 US$.
     -          -         -

    -          -          -
    -          -          -
    -          -          -

    -          -          -
    -          -          -
    -          -          -
    -          -          -
    -          -          -
    -          -          -

    -          -          -
    -          -          -
    -          -          -
    -          -          -
    -          -          -
    -          -          -

    -          -          -
    -          -          -
    -          -          -
    -          -          -
    -          -          -
    -          -          -

    -          -          -
    -          -          -
    -          -          -
    -          -          -
    -          -          -
    -          -          -

    -          -          -
    -          -          -

    -          -          -
    -          -          -
    -          -          -
    -          -          -

    -          -          -
    -        -        -




Tanzania Tanzania Tanzania* Tanzania* Nigeria* Nigeria* Nigeria* Nigeria* Nigeria*
     0.00     0.00     0.00      0.00       0.00     0.00     0.00     0.00     0.00
     0.00     0.00     0.00      0.00       0.00     0.00     0.00     0.00     0.00
     0.00    21.55     0.00     16.60       0.00     0.00     0.00     0.00     0.00
    74.03    35.08    46.59     27.02       0.00     0.00     0.00     0.00     0.00
     0.00     0.00     0.00      0.00       0.00     0.00     0.00     0.00     0.00
     0.00     0.00     0.00      0.00       0.00     0.00     0.00     0.00     0.00
    25.54    43.65    16.08     33.62       0.00     0.00     0.00     0.00     0.00
     0.00     0.00     0.00      0.00       0.00     0.00     0.00     0.00     0.00
     0.00     0.00     0.00      0.00       0.00     0.00     0.00     0.00     0.00
     0.00     0.00     0.00      0.00       0.00     0.00     0.00     0.00     0.00
     0.00     0.00     0.00      0.00       0.00     0.00     0.00     0.00     0.00
     0.00     0.00     0.00      0.00       0.00     0.00     0.00     0.00     0.00
     0.00     0.00     0.00      0.00       0.00     0.00     0.00     0.00     0.00
     0.00     0.00     0.00      0.00       0.00     0.00     0.00     0.00     0.00
     0.00     0.00    37.06     22.98       0.00     0.00     0.00     0.00     0.00
     0.00     0.00     0.00      0.00    100.00   100.00   100.00   100.00   100.00
     2.32     3.63     3.68      4.72       4.49     4.14     4.63     6.04     4.84




Tanzania Tanzania Tanzania* Tanzania* Nigeria* Nigeria* Nigeria* Nigeria* Nigeria*
     0.00     0.00     0.00      0.00       0.00     0.00     0.00     0.00     0.00
     0.00     0.00     0.00      0.00       0.00     0.00     0.00     0.00     0.00
     0.00     0.78     0.00      0.78       0.00     0.00     0.00     0.00     0.00
     1.72     1.28     1.72      1.28       0.00     0.00     0.00     0.00     0.00
     0.00     0.00     0.00      0.00       0.00     0.00     0.00     0.00     0.00
     0.00     0.00     0.00      0.00       0.00     0.00     0.00     0.00     0.00
     0.59     1.59     0.59      1.59       0.00     0.00     0.00     0.00     0.00
     0.00     0.00     0.00      0.00       0.00     0.00     0.00     0.00     0.00
     0.00     0.00     0.00      0.00       0.00     0.00     0.00     0.00     0.00
     0.00     0.00     0.00      0.00       0.00     0.00     0.00     0.00     0.00
     0.00     0.00     0.00      0.00       0.00     0.00     0.00     0.00     0.00
     0.00     0.00     0.00      0.00       0.00     0.00     0.00     0.00     0.00
     0.00     0.00     0.00      0.00       0.00     0.00     0.00     0.00     0.00
     0.00     0.00     0.00      0.00       0.00     0.00     0.00     0.00     0.00
     0.00     0.00     1.37      1.08       0.00     0.00     0.00     0.00     0.00
     0.00     0.00     0.00      0.00       4.49     4.14     4.63     6.04     4.84
ata from the sheet 'diagnostics data'. All prices have been
Nigeria* Zambia    Zambia
      0.00    0.00      0.00
      0.00    0.00      0.00
      0.00   94.55     80.64
      0.00    5.45     19.36
      0.00    0.00      0.00
      0.00    0.00      0.00
      0.00    0.00      0.00
      0.00    0.00      0.00
      0.00    0.00      0.00
      0.00    0.00      0.00
      0.00    0.00      0.00
      0.00    0.00      0.00
      0.00    0.00      0.00
      0.00    0.00      0.00
      0.00    0.00      0.00
   100.00     0.00      0.00
      4.97    4.22      6.61




Nigeria* Zambia    Zambia
      0.00    0.00      0.00    0.00%
      0.00    0.00      0.00    0.00%
      0.00    3.99      5.33   27.39%
      0.00    0.23      1.28   40.55%
      0.00    0.00      0.00   16.55%
      0.00    0.00      0.00    0.00%
      0.00    0.00      0.00   10.10%
      0.00    0.00      0.00    0.00%
      0.00    0.00      0.00    0.00%
      0.00    0.00      0.00    0.00%
      0.00    0.00      0.00    0.00%
      0.00    0.00      0.00    1.62%
      0.00    0.00      0.00    0.00%
      0.00    0.00      0.00    0.00%
      0.00    0.00      0.00    3.80%
      4.97    0.00      0.00
                    Study description
                                                                                                                  Break
name                                         inflation factor
            Currency PerspectivePeople covered           diagnosticstreatment personnel training
Tanzania                 Provider      2300            1                 -         -         -
            Lubell Y, Riewpaiboon A, Dondorp AM, von Seidlein- L, Mokuolu OA, Nansumba M, Gesase S, Kent A, Mtove G, Ola
Tanzania                 Provider      2300            1                 -         -         -
            Lubell Y, Riewpaiboon A, Dondorp AM, von Seidlein- L, Mokuolu OA, Nansumba M, Gesase S, Kent A, Mtove G, Ola
Tanzania                 Provider      2300            1                 -         -         -
            Lubell Y, Riewpaiboon A, Dondorp AM, von Seidlein- L, Mokuolu OA, Nansumba M, Gesase S, Kent A, Mtove G, Ola
Tanzania                 Provider      2300            1                 -         -         -
            Lubell Y, Riewpaiboon A, Dondorp AM, von Seidlein- L, Mokuolu OA, Nansumba M, Gesase S, Kent A, Mtove G, Ola
Uganda                   Provider      2300            1                 -         -         -
            Lubell Y, Riewpaiboon A, Dondorp AM, von Seidlein- L, Mokuolu OA, Nansumba M, Gesase S, Kent A, Mtove G, Ola
Uganda                   Provider      2300            1                 -         -         -
            Lubell Y, Riewpaiboon A, Dondorp AM, von Seidlein- L, Mokuolu OA, Nansumba M, Gesase S, Kent A, Mtove G, Ola
Nigeria                  Provider      2300            1                 -         -         -
            Lubell Y, Riewpaiboon A, Dondorp AM, von Seidlein- L, Mokuolu OA, Nansumba M, Gesase S, Kent A, Mtove G, Ola
Nigeria                  Provider      2300            1                 -         -         -
            Lubell Y, Riewpaiboon A, Dondorp AM, von Seidlein- L, Mokuolu OA, Nansumba M, Gesase S, Kent A, Mtove G, Ola
Africa                   Provider      2300            1                 -         -         -
            Lubell Y, Riewpaiboon A, Dondorp AM, von Seidlein- L, Mokuolu OA, Nansumba M, Gesase S, Kent A, Mtove G, Ola
Africa                   Provider      2300            1                 -         -         -
            Lubell Y, Riewpaiboon A, Dondorp AM, von Seidlein- L, Mokuolu OA, Nansumba M, Gesase S, Kent A, Mtove G, Ola

          Guinea* Societal              Karunajeewa HA, Davy C, Mueller I, Davis TM.
Papua New Davis WA, Clarke PM, Siba PM, 81     1.038     -         1.4            -           -
          Guinea* Societal            103      1.038     -        13.6            -
Papua New Davis WA, Clarke PM, Siba PM, Karunajeewa HA, Davy C, Mueller I, Davis TM.          -
          Guinea* Societal            100      1.038     -         8.4            -
Papua New Davis WA, Clarke PM, Siba PM, Karunajeewa HA, Davy C, Mueller I, Davis TM.          -
          Guinea* Societal            104      1.038     -         8.5            -
Papua New Davis WA, Clarke PM, Siba PM, Karunajeewa HA, Davy C, Mueller I, Davis TM.          -
          Guinea* Societal              Karunajeewa HA, Davy C, Mueller I, Davis TM.
Papua New Davis WA, Clarke PM, Siba PM, 46     1.038     -         1.7            -           -
          Guinea* Societal              Karunajeewa HA, Davy C, Mueller I, Davis TM.
Papua New Davis WA, Clarke PM, Siba PM, 39     1.038     -         9.6            -           -
          Guinea* Societal              Karunajeewa HA, Davy C, Mueller I, Davis TM.
Papua New Davis WA, Clarke PM, Siba PM, 36     1.038     -         6.6            -           -
          Guinea* Societal              Karunajeewa HA, Davy C, Mueller I, Davis TM.
Papua New Davis WA, Clarke PM, Siba PM, 33     1.038     -         6.0            -           -

Zambia      2005 USD Provider           55509      1.13865       57.9       18.1       11.4   -
Zambia      2005 USD Provider           55509      1.13865       68.7        2.9       13.6   -

Tanzania    2005 USD   Provider                    1.13865   -               0.8       78.2   -
Tanzania    2005 USD   Provider              270   1.13865   -               1.6       77.6   -
Tanzania    2005 USD   Provider              507   1.13865   -               2.5       76.8   -
Tanzania    2005 USD   Provider              515   1.13865   -               9.2       71.6   -
Tanzania    2005 USD   Provider              519   1.13865   -              15.3       66.8   -
Tanzania*   2005 USD   Society                     1.13865   -               0.2       19.2   -
Tanzania*   2005 USD   Society               270   1.13865   -               0.4       19.2   -
Tanzania*   2005 USD   Society               507   1.13865   -               1.1       35.2   -
Tanzania*   2005 USD   Society               515   1.13865   -               5.0       39.2   -
Tanzania*   2005 USD   Society               519   1.13865   -               9.3       40.7   -

India       1998?      Provider - hospital    76   0.02683   -               4.3       28.8   -
India       1998?      Provider - hospital    58   0.02683   -              20.6       23.9   -
India       1998?      Provider - hospital    65   0.02683   -               2.6       29.3   -
India*      1998?      Society                76   0.02683   -               2.3       15.7   -
India*      1998?      Society                58   0.02683   -              12.2       14.1   -
India*      1998?      Society                65   0.02683   -               1.4       16.0   -

Bangladesh2008 USD Provider - hospital222            1.038   -          -          -          -
India     2008 USD Provider - hospital 70            1.038   -          -          -          -
Indonesia 2008 USD Provider - hospital143            1.038   -          -          -          -
Myanmar 2008 USD       Provider - hospital295     1.038     -          -          -          -
Bangladesh2008 USD     Provider - hospital231     1.038     -          -          -          -
India     2008 USD     Provider - hospital 72     1.038     -          -          -          -
Indonesia 2008 USD     Provider - hospital146     1.038     -          -          -          -
Myanmar 2008 USD       Provider - hospital282     1.038     -          -          -          -

           2002 USD
South Africa           Provider       19929     1.21543     -          -          -          -
           2002 USD
South Africa           Provider        1025     1.21543     -          -          -          -
           2002 USD
South Africa           Provider        3261     1.21543     -          -          -          -
           2002 USD
South Africa           Provider         287     1.21543     -          -          -          -
           2002 USD
South Africa           Provider        1902     1.21543     -          -          -          -
           2002 USD
South Africa           Provider         108     1.21543     -          -          -          -

Tanzania   2003 USD Provider         212144     1.19629     -              72.8        7.6       2.1

           1997 USD Provider
South Africa                                    1.37234          4.5        3.8       70.4       0.8
           1997 USD Provider
South Africa                                    1.37234         15.9       20.7       37.6       2.7

Kenya      2005 USD Provider             211    1.13865         17.3        4.3   -          -
Kenya      2005 USD Provider             211    1.13865         25.8        5.2   -          -




                                                                Guinea* (u)Guinea* (u)Guinea* (u)
            India (s) India (s) India* (s) India* (s) Papua New Papua New Papua New Papua New Guinea* (u)
nets               0.00      0.00     0.00       0.00      0.00      0.00       0.00       0.00
insecticide        0.00      0.00     0.00       0.00      0.00      0.00       0.00       0.00
diagnostics        0.00      0.00     0.00       0.00      0.00      0.00       0.00       0.00
treatment          4.29    20.63      2.34      12.21      1.43     13.59       8.40       8.52
personnel        28.82     23.90     15.73      14.14      0.00      0.00       0.00       0.00
training           0.00      0.00     0.00       0.00      0.00      0.00       0.00       0.00
overheads        66.90     55.48     36.52      32.83     98.60     86.40      91.60      91.50
IEC                0.00      0.00     0.00       0.00      0.00      0.00       0.00       0.00
distribution       0.00      0.00     0.00       0.00      0.00      0.00       0.00       0.00
transport          0.00      0.00     0.00       0.00      0.00      0.00       0.00       0.00
storage            0.00      0.00     0.00       0.00      0.00      0.00       0.00       0.00
capital            0.00      0.00     0.00       0.00      0.00      0.00       0.00       0.00
study costs        0.00      0.00     0.00       0.00      0.00      0.00       0.00       0.00
other              0.00      0.00     0.00       0.00      0.00      0.00       0.00       0.00
user               0.00      0.00    45.51      40.82      0.00      0.00       0.00       0.00
not costed         0.00      0.00     0.00       0.00      0.00      0.00       0.00       0.00
patient treated 15.64      18.86     28.65      31.87      3.63      4.05       3.83       4.63


           India (s)   India (s)                                   Guinea* (u)Guinea* (u)Guinea* (u)
                                   India* (s) India* (s) Papua New Papua New Papua New Papua New Guinea* (u)
nets            0.00            0.00    0.00    0.00   0.00   0.00   0.00   0.00
insecticide     0.00            0.00    0.00    0.00   0.00   0.00   0.00   0.00
diagnostics     0.00            0.00    0.00    0.00   0.00   0.00   0.00   0.00
treatment       0.67            3.89    0.67    3.89   0.05   0.55   0.32   0.39
personnel       4.51            4.51    4.51    4.51   0.00   0.00   0.00   0.00
training        0.00            0.00    0.00    0.00   0.00   0.00   0.00   0.00
overheads      10.46           10.46   10.46   10.46   3.58   3.50   3.51   4.24
IEC             0.00            0.00    0.00    0.00   0.00   0.00   0.00   0.00
distribution    0.00            0.00    0.00    0.00   0.00   0.00   0.00   0.00
transport       0.00            0.00    0.00    0.00   0.00   0.00   0.00   0.00
storage         0.00            0.00    0.00    0.00   0.00   0.00   0.00   0.00
capital         0.00            0.00    0.00    0.00   0.00   0.00   0.00   0.00
study costs     0.00            0.00    0.00    0.00   0.00   0.00   0.00   0.00
other           0.00            0.00    0.00    0.00   0.00   0.00   0.00   0.00
user            0.00            0.00   13.04   13.01   0.00   0.00   0.00   0.00
not costed      0.00            0.00    0.00    0.00   0.00   0.00   0.00   0.00



                                                        F: Unit financial cost of treatm
                           160.00


                           140.00


                           120.00


                           100.00
                2009 USD




                            80.00


                            60.00


                            40.00


                            20.00


                             0.00
                               Financial costs
              Breakdown %                                                                              Cost per
IEC       overheads capital         transport storage   other   user              NA       patient treated
      -        -         -               -         -        -          -               -        -
      -        -         -               -         -        -          -               -        -
      -        -         -               -         -        -          -               -        -
      -        -         -               -         -        -          -               -        -
      -        -         -               -         -        -          -               -        -
      -        -         -               -         -        -          -               -        -
      -        -         -               -         -        -          -               -        -
      -        -         -               -         -        -          -               -        -
      -        -         -               -         -        -          -               -        -
      -        -         -               -         -        -          -               -        -

      -      98.6        -              -         -         -          -               -           3.63
      -      86.4        -              -         -         -          -               -           4.05
      -      91.6        -              -         -         -          -               -           3.83
      -      91.5        -              -         -         -          -               -           4.63
      -      98.3        -              -         -         -          -               -           4.18
      -      90.4        -              -         -         -          -               -           4.77
      -      93.4        -              -         -         -          -               -           4.08
      -      94.0        -              -         -         -          -               -           5.39

      -            7.4        5.2       -         -         -          -               -           8.36
      -            8.7        6.1       -         -         -          -               -           7.05

      -           11.2        9.8       -         -         -          -               -        5.80
      -           11.1        9.7       -         -         -          -               -        5.84
      -           11.0        9.7       -         -         -          -               -        5.90
      -           10.3        9.0       -         -         -          -               -        6.33
      -            9.6        8.4       -         -         -          -               -        6.79
      -            2.7        2.4       -         -         -              75.4        -       23.60
      -            2.7        2.4       -         -         -              75.3        -       23.65
      -            5.0        4.4       -         -         -              54.2        -       12.88
      -            5.6        4.9       -         -         -              45.2        -       11.56
      -            5.8        5.1       -         -         -              39.1        -       11.15

      -           66.9   -              -         -         -          -               -       15.64
      -           55.5   -              -         -         -          -               -       18.86
      -           68.1   -              -         -         -          -               -       -
      -           36.5   -              -         -         -              45.5        -       28.65
      -           32.8   -              -         -         -              40.8        -       31.87
      -           37.1   -              -         -         -              45.5        -       -

      -       -          -              -         -         -          -               -       -
      -       -          -              -         -         -          -               -       -
      -       -          -              -         -         -          -               -       -
    -         -          -         -          -         -         -          -         -
    -         -          -         -          -         -         -          -         -
    -         -          -         -          -         -         -          -         -
    -         -          -         -          -         -         -          -         -
    -         -          -         -          -         -         -          -         -

    -         -          -         -          -         -         -          -         -
    -         -          -         -          -         -         -          -         -
    -         -          -         -          -         -         -          -         -
    -         -          -         -          -         -         -          -         -
    -         -          -         -          -         -         -          -         -
    -         -          -         -          -         -         -          -         -

        7.5   -              3.0       5.0    -             1.9   -          -             2.36

    -             18.8   -             1.7    -         -         -          -        137.87
    -             23.4   -             0.7    -         -         -          -         28.54

    -             78.5   -         -          -         -         -          -        108.83
    -             69.0   -         -          -         -         -          -         71.07




          Guinea* (u)Guinea* (u)Guinea* (u)Guinea* (u)
                                                     South      Kenya
Papua New Papua New Papua New Papua New South Africa (s) Africa (s) (s) Kenya (s) Tanzania (u)
     0.00      0.00       0.00       0.00       0.00       0.00       0.00   0.00      0.00
     0.00      0.00       0.00       0.00       0.00       0.00       0.00   0.00      0.00
     0.00      0.00       0.00       0.00       4.53     15.91      17.25   25.79      0.00
     1.74      9.57       6.62       5.97       3.77     20.67        4.26   5.19     72.81
     0.00      0.00       0.00       0.00      70.40     37.58        0.00   0.00      7.65
     0.00      0.00       0.00       0.00       0.77       2.70       0.00   0.00      2.11
    98.30     90.40      93.40      94.00      18.80     23.40      78.50   69.02      0.00
     0.00      0.00       0.00       0.00       0.00       0.00       0.00   0.00      7.51
     0.00      0.00       0.00       0.00       0.00       0.00       0.00   0.00      0.00
     0.00      0.00       0.00       0.00       1.71       0.67       0.00   0.00      5.02
     0.00      0.00       0.00       0.00       0.00       0.00       0.00   0.00      0.00
     0.00      0.00       0.00       0.00       0.00       0.00       0.00   0.00      3.03
     0.00      0.00       0.00       0.00       0.00       0.00       0.00   0.00      0.00
     0.00      0.00       0.00       0.00       0.00       0.00       0.00   0.00      1.87
     0.00      0.00       0.00       0.00       0.00       0.00       0.00   0.00      0.00
     0.00      0.00       0.00       0.00       0.00       0.00       0.00   0.00      0.00
     4.18      4.77       4.08       5.39     137.87     28.54     108.83   71.07      2.36


          Guinea* (u)Guinea* (u)Guinea* (u)Guinea* (u)
                                                     South    Kenya
Papua New Papua New Papua New Papua New South Africa (s) Africa (s) (s) Kenya (s) Tanzania (u)
         0.00   0.00   0.00   0.00    0.00    0.00    0.00    0.00   0.00
         0.00   0.00   0.00   0.00    0.00    0.00    0.00    0.00   0.00
         0.00   0.00   0.00   0.00    6.24    4.54   18.78   18.33   0.00
         0.07   0.46   0.27   0.32    5.20    5.90    4.63    3.69   1.72
         0.00   0.00   0.00   0.00   97.06   10.73    0.00    0.00   0.18
         0.00   0.00   0.00   0.00    1.06    0.77    0.00    0.00   0.05
         4.11   4.32   3.81   5.06   25.92    6.68   85.43   49.05   0.00
         0.00   0.00   0.00   0.00    0.00    0.00    0.00    0.00   0.18
         0.00   0.00   0.00   0.00    0.00    0.00    0.00    0.00   0.00
         0.00   0.00   0.00   0.00    2.35    0.19    0.00    0.00   0.12
         0.00   0.00   0.00   0.00    0.00    0.00    0.00    0.00   0.00
         0.00   0.00   0.00   0.00    0.00    0.00    0.00    0.00   0.07
         0.00   0.00   0.00   0.00    0.00    0.00    0.00    0.00   0.00
         0.00   0.00   0.00   0.00    0.00    0.00    0.00    0.00   0.04
         0.00   0.00   0.00   0.00    0.00    0.00    0.00    0.00   0.00
         0.00   0.00   0.00   0.00    0.00    0.00    0.00    0.00   0.00



cial cost of treatment of uncomplicated/severe malaria
                                                                                              Economic costs
 Cost per                                                                     Breakdown %
             treatmentdiagnosticstreatment personnel training
per year forpatient diagnosed and treated correctly             IEC       overheads capital
     -           -          -            1.8      -       -           -         98.2     -
     -           -          -            4.1      -       -           -         95.9     -
     -           -          -            2.8      -       -           -         97.2     -
     -           -          -            6.4      -       -           -         93.6     -
     -           -          -            2.0      -       -           -         98.0     -
     -           -          -            6.2      -       -           -         93.8     -
     -           -          -            1.3      -       -           -         98.7     -
     -           -          -            3.2      -       -           -         96.8     -
     -           -          -            2.0      -       -           -         98.0     -
     -           -          -            4.9      -       -           -         95.1     -

    -          -          -         -          -          -           -       -          -
    -          -          -         -          -          -           -       -          -
    -          -          -         -          -          -           -       -          -
    -          -          -         -          -          -           -       -          -
    -          -          -         -          -          -           -       -          -
    -          -          -         -          -          -           -       -          -
    -          -          -         -          -          -           -       -          -
    -          -          -         -          -          -           -       -          -

    -          -          -         -          -          -           -       -          -
    -          -          -         -          -          -           -       -          -

    -          -          -         -          -          -           -       -          -
    -          -          -         -          -          -           -       -          -
    -          -          -         -          -          -           -       -          -
    -          -          -         -          -          -           -       -          -
    -          -          -         -          -          -           -       -          -
    -          -          -         -          -          -           -       -          -
    -          -          -         -          -          -           -       -          -
    -          -          -         -          -          -           -       -          -
    -          -          -         -          -          -           -       -          -
    -          -          -         -          -          -           -       -          -

    -          -          -         -          -          -           -       -          -
    -          -          -         -          -          -           -       -          -
    -          -          -         -          -          -           -       -          -
    -          -          -         -          -          -           -       -          -
    -          -          -         -          -          -           -       -          -
    -          -          -         -          -          -           -       -          -

    -          -          -             35.9        2.5   -           -           61.4   -
    -          -          -             30.7        2.0   -           -           67.3   -
    -          -          -             20.0       78.5   -           -            1.5   -
    -          -          -               48.3       48.0   -          -               3.7   -
    -          -          -               14.3       62.3   -          -              23.4   -
    -          -          -                9.1       75.5   -          -              15.4   -
    -          -          -                7.2       78.7   -          -              14.1   -
    -          -          -               18.5       48.8   -          -              32.7   -

    -          -              15.6        18.5   -          -          -          -               8.7
    -          -              52.7        12.2   -          -          -          -               4.0
    -          -               5.8         8.6   -          -          -          -               4.2
    -          -              39.9         1.3   -          -          -          -               3.3
    -          -               1.2         4.5   -          -          -          -              11.9
    -          -               5.2         3.1   -          -          -          -               9.6

        1.95   -          -           -          -          -          -          -          -

    -          -          -           -          -          -          -          -          -
    -          -          -           -          -          -          -          -          -

    -          -          -           -          -          -          -          -          -
    -          -          -           -          -          -          -          -          -




           Tanzania (u)
Tanzania (u)                     Tanzania (u)
                      Tanzania (u)                     Zambia (u) Zambia (u) Tanzania* (s)
                                            Tanzania (u)                                Tanzania* (s)
     0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00
     0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00
     0.00       0.00       0.00       0.00       0.00      57.90      68.66       0.00       0.00
     0.79       1.56       2.51       9.17      15.27      18.12       2.91       0.19       0.39
    78.19      77.58      76.83      71.58      66.78      11.44      13.57      19.20      19.16
     0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00
    11.20      11.11      11.00      10.25       9.56       7.36       8.72       2.75       2.74
     0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00
     0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00
     0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00
     0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00
     9.82       9.75       9.65       8.99       8.39       5.18       6.14       2.41       2.41
     0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00
     0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00
     0.00       0.00       0.00       0.00       0.00       0.00       0.00      75.45      75.30
     0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00       0.00
     5.80       5.84       5.90       6.33       6.79       8.36       7.05      23.60      23.65


           Tanzania (u)
Tanzania (u)                     Tanzania (u)
                      Tanzania (u)                     Zambia (u) Zambia (u) Tanzania* (s)
                                            Tanzania (u)                                Tanzania* (s)
0.00   0.00   0.00   0.00   0.00   0.00   0.00    0.00    0.00
0.00   0.00   0.00   0.00   0.00   0.00   0.00    0.00    0.00
0.00   0.00   0.00   0.00   0.00   4.84   4.84    0.00    0.00
0.05   0.09   0.15   0.58   1.04   1.51   0.20    0.05    0.09
4.53   4.53   4.53   4.53   4.53   0.96   0.96    4.53    4.53
0.00   0.00   0.00   0.00   0.00   0.00   0.00    0.00    0.00
0.65   0.65   0.65   0.65   0.65   0.61   0.61    0.65    0.65
0.00   0.00   0.00   0.00   0.00   0.00   0.00    0.00    0.00
0.00   0.00   0.00   0.00   0.00   0.00   0.00    0.00    0.00
0.00   0.00   0.00   0.00   0.00   0.00   0.00    0.00    0.00
0.00   0.00   0.00   0.00   0.00   0.00   0.00    0.00    0.00
0.57   0.57   0.57   0.57   0.57   0.43   0.43    0.57    0.57
0.00   0.00   0.00   0.00   0.00   0.00   0.00    0.00    0.00
0.00   0.00   0.00   0.00   0.00   0.00   0.00    0.00    0.00
0.00   0.00   0.00   0.00   0.00   0.00   0.00   17.81   17.81
0.00   0.00   0.00   0.00   0.00   0.00   0.00    0.00    0.00
         Economic costs
down %                                                                 Cost per
           transport storage   other   user       NA                  per        patient diagnosed and treated correctly
                                                           patient treatedyear for treatment
                -         -        -          -        -        65.50      -           -
                -         -        -          -        -        66.70      -           -
                -         -        -          -        -        55.60      -           -
                -         -        -          -        -        54.00      -           -
                -         -        -          -        -        58.60      -           -
                -         -        -          -        -        59.60      -           -
                -         -        -          -        -        86.20      -           -
                -         -        -          -        -       108.70      -           -
                -         -        -          -        -        63.50      -           -
                -         -        -          -        -        66.50      -           -

               -          -        -          -        -       -          -          -
               -          -        -          -        -       -          -          -
               -          -        -          -        -       -          -          -
               -          -        -          -        -       -          -          -
               -          -        -          -        -       -          -          -
               -          -        -          -        -       -          -          -
               -          -        -          -        -       -          -          -
               -          -        -          -        -       -          -          -

               -          -        -          -        -       -          -          -
               -          -        -          -        -       -          -          -

               -          -        -          -        -       -          -          -
               -          -        -          -        -       -          -          -
               -          -        -          -        -       -          -          -
               -          -        -          -        -       -          -          -
               -          -        -          -        -       -          -          -
               -          -        -          -        -       -          -          -
               -          -        -          -        -       -          -          -
               -          -        -          -        -       -          -          -
               -          -        -          -        -       -          -          -
               -          -        -          -        -       -          -          -

               -          -        -          -        -       -          -          -
               -          -        -          -        -       -          -          -
               -          -        -          -        -       -          -          -
               -          -        -          -        -       -          -          -
               -          -        -          -        -       -          -          -
               -          -        -          -        -       -          -          -

               -          -        -          -        -       45.67      -          -
               -          -        -          -        -       72.97      -          -
               -          -        -          -        -       69.55      -          -
    -           -          -          -   -    27.92       -           -
    -           -          -          -   -    36.33       -           -
    -           -          -          -   -    62.70       -           -
    -           -          -          -   -    66.22       -           -
    -           -          -          -   -    26.99       -           -

    -           -              57.2   -   -     9.14       -           -
    -           -              31.1   -   -    16.41       -           -
    -           -              81.5   -   -    28.55       -           -
    -           -              55.5   -   -    37.99       -           -
    -           -              82.4   -   -   210.88       -           -
    -           -              82.1   -   -   288.79       -           -

    -           -          -          -   -    -           -           -

    -           -          -          -   -    -           -           -
    -           -          -          -   -    -           -           -

    -           -          -          -   -    -           -           -
    -           -          -          -   -    -           -           -




           Tanzania* (s)
Tanzania* (s)         Tanzania* (s)                                           (s)
                                                                   BangladeshIndia (s)
     0.00       0.00       0.00                        nets               0.0        0.0
     0.00       0.00       0.00                        insecticide        0.0        0.0
     0.00       0.00       0.00                        diagnostics        0.0        0.0
     1.15       5.02       9.30                        treatment         35.9       30.7
    35.19      39.21      40.65                        personnel          2.5        2.0
     0.00       0.00       0.00                        training           0.0        0.0
     5.04       5.62       5.82                        overheads         61.4       67.3
     0.00       0.00       0.00                        IEC                0.0        0.0
     0.00       0.00       0.00                        distribution       0.0        0.0
     0.00       0.00       0.00                        transport          0.0        0.0
     0.00       0.00       0.00                        storage            0.0        0.0
     4.42       4.93       5.11                        capital            0.0        0.0
     0.00       0.00       0.00                        study costs        0.0        0.0
     0.00       0.00       0.00                        other              0.0        0.0
    54.20      45.22      39.12                        user               0.0        0.0
     0.00       0.00       0.00                        not costed         0.0        0.0
    12.88      11.56      11.15                        patient treated 45.67      72.97


           Tanzania* (s)
Tanzania* (s)         Tanzania* (s)                                          (s)
                                                                  BangladeshIndia (s)
0.00   0.00   0.00    0.00%   nets               0.00    0.00
0.00   0.00   0.00    0.00%   insecticide        0.00    0.00
0.00   0.00   0.00    9.48%   diagnostics        0.00    0.00
0.15   0.58   1.04    6.29%   treatment         16.40   22.42
4.53   4.53   4.53   28.52%   personnel          1.14    1.45
0.00   0.00   0.00    0.31%   training           0.00    0.00
0.65   0.65   0.65   40.96%   overheads         28.03   49.10
0.00   0.00   0.00    0.03%   IEC                0.00    0.00
0.00   0.00   0.00    0.00%   distribution       0.00    0.00
0.00   0.00   0.00    0.44%   transport          0.00    0.00
0.00   0.00   0.00    0.00%   storage            0.00    0.00
0.57   0.57   0.57    1.09%   capital            0.00    0.00
0.00   0.00   0.00    0.00%   study costs        0.00    0.00
0.00   0.00   0.00    0.01%   other              0.00    0.00
6.98   5.23   4.36   12.88%   user               0.00    0.00
0.00   0.00   0.00            not costed         0.00    0.00


                                       350.00



                                       300.00



                                       250.00



                                       200.00



                                       150.00



                                       100.00



                                        50.00



                                         0.00
gnosed and treated correctly   This sheet contains data from the sheet 'drug treatment data'. All prices have
                               been inflated to 2009 US$.
            Myanmar (s)
Indonesia (s)                    (s)                  Myanmar (s)
                      BangladeshIndia (s) Indonesia (s)                    South       Tanzania (s)
                                                                South Africa (s) Africa (s)
       0.0       0.0         0.0        0.0      0.0       0.0         0.0         0.0        0.0
       0.0       0.0         0.0        0.0      0.0       0.0         0.0         0.0        0.0
       0.0       0.0         0.0        0.0      0.0       0.0         1.2         5.2        0.0
     20.0       48.3        14.3        9.1      7.2      18.5         4.5         3.1        1.8
     78.5       48.0        62.3       75.5    78.7       48.8         0.0         0.0        0.0
       0.0       0.0         0.0        0.0      0.0       0.0         0.0         0.0        0.0
       1.5       3.7        23.4       15.4    14.1       32.7         0.0         0.0       98.2
       0.0       0.0         0.0        0.0      0.0       0.0         0.0         0.0        0.0
       0.0       0.0         0.0        0.0      0.0       0.0         0.0         0.0        0.0
       0.0       0.0         0.0        0.0      0.0       0.0         0.0         0.0        0.0
       0.0       0.0         0.0        0.0      0.0       0.0         0.0         0.0        0.0
       0.0       0.0         0.0        0.0      0.0       0.0        11.9         9.6        0.0
       0.0       0.0         0.0        0.0      0.0       0.0         0.0         0.0        0.0
       0.0       0.0         0.0        0.0      0.0       0.0        82.4        82.1        0.0
       0.0       0.0         0.0        0.0      0.0       0.0         0.0         0.0        0.0
       0.0       0.0         0.0        0.0      0.0       0.0         0.0         0.0        0.0
    69.55      27.92      36.33      62.70    66.22      26.99     210.88       288.79      65.50


            Myanmar (s)
Indonesia (s)                    (s)
                      BangladeshIndia (s)   Indonesia (s)
                                                        Myanmar (s)          South      Tanzania (s)
                                                                  South Africa (s) Africa (s)
 0.00    0.00    0.00    0.00    0.00    0.00     0.00     0.00    0.00
 0.00    0.00    0.00    0.00    0.00    0.00     0.00     0.00    0.00
 0.00    0.00    0.00    0.00    0.00    0.00     2.44    15.14    0.00
13.91   13.49    5.19    5.71    4.77    4.98     9.48     8.99    1.18
54.60   13.39   22.63   47.33   52.11   13.18     0.00     0.00    0.00
 0.00    0.00    0.00    0.00    0.00    0.00     0.00     0.00    0.00
 1.04    1.04    8.51    9.65    9.34    8.82     0.00     0.00   64.32
 0.00    0.00    0.00    0.00    0.00    0.00     0.00     0.00    0.00
 0.00    0.00    0.00    0.00    0.00    0.00     0.00     0.00    0.00
 0.00    0.00    0.00    0.00    0.00    0.00     0.00     0.00    0.00
 0.00    0.00    0.00    0.00    0.00    0.00     0.00     0.00    0.00
 0.00    0.00    0.00    0.00    0.00    0.00    25.15    27.59    0.00
 0.00    0.00    0.00    0.00    0.00    0.00     0.00     0.00    0.00
 0.00    0.00    0.00    0.00    0.00    0.00   173.81   237.06    0.00
 0.00    0.00    0.00    0.00    0.00    0.00     0.00     0.00    0.00
 0.00    0.00    0.00    0.00    0.00    0.00     0.00     0.00    0.00
rices have
Tanzania (s)Tanzania (s)Tanzania (s)Uganda (s) Uganda (s) Nigeria (s) Nigeria (s) Africa (s) Africa (s)
       0.0         0.0         0.0        0.0        0.0          0.0         0.0         0.0        0.0
       0.0         0.0         0.0        0.0        0.0          0.0         0.0         0.0        0.0
       0.0         0.0         0.0        0.0        0.0          0.0         0.0         0.0        0.0
       4.1         2.8         6.4        2.0        6.2          1.3         3.2         2.0        4.9
       0.0         0.0         0.0        0.0        0.0          0.0         0.0         0.0        0.0
       0.0         0.0         0.0        0.0        0.0          0.0         0.0         0.0        0.0
     95.9        97.2        93.6        98.0       93.8        98.7        96.8         98.0       95.1
       0.0         0.0         0.0        0.0        0.0          0.0         0.0         0.0        0.0
       0.0         0.0         0.0        0.0        0.0          0.0         0.0         0.0        0.0
       0.0         0.0         0.0        0.0        0.0          0.0         0.0         0.0        0.0
       0.0         0.0         0.0        0.0        0.0          0.0         0.0         0.0        0.0
       0.0         0.0         0.0        0.0        0.0          0.0         0.0         0.0        0.0
       0.0         0.0         0.0        0.0        0.0          0.0         0.0         0.0        0.0
       0.0         0.0         0.0        0.0        0.0          0.0         0.0         0.0        0.0
       0.0         0.0         0.0        0.0        0.0          0.0         0.0         0.0        0.0
       0.0         0.0         0.0        0.0        0.0          0.0         0.0         0.0        0.0
    66.70       55.60       54.00       58.60      59.60       86.20     108.70        63.50      66.50


Tanzania (s)Tanzania (s)Tanzania (s)Uganda (s) Uganda (s) Nigeria (s) Nigeria (s) Africa (s)   Africa (s)
 0.00    0.00    0.00    0.00    0.00    0.00     0.00    0.00    0.00
 0.00    0.00    0.00    0.00    0.00    0.00     0.00    0.00    0.00
 0.00    0.00    0.00    0.00    0.00    0.00     0.00    0.00    0.00
 2.73    1.56    3.46    1.17    3.70    1.12     3.48    1.27    3.26
 0.00    0.00    0.00    0.00    0.00    0.00     0.00    0.00    0.00
 0.00    0.00    0.00    0.00    0.00    0.00     0.00    0.00    0.00
63.97   54.04   50.54   57.43   55.90   85.08   105.22   62.23   63.24
 0.00    0.00    0.00    0.00    0.00    0.00     0.00    0.00    0.00
 0.00    0.00    0.00    0.00    0.00    0.00     0.00    0.00    0.00
 0.00    0.00    0.00    0.00    0.00    0.00     0.00    0.00    0.00
 0.00    0.00    0.00    0.00    0.00    0.00     0.00    0.00    0.00
 0.00    0.00    0.00    0.00    0.00    0.00     0.00    0.00    0.00
 0.00    0.00    0.00    0.00    0.00    0.00     0.00    0.00    0.00
 0.00    0.00    0.00    0.00    0.00    0.00     0.00    0.00    0.00
 0.00    0.00    0.00    0.00    0.00    0.00     0.00    0.00    0.00
 0.00    0.00    0.00    0.00    0.00    0.00     0.00    0.00    0.00
           South      South      South
South Africa (s) Africa (s) Africa (s) Africa (s)
       0.0        0.0        0.0        0.0
       0.0        0.0        0.0        0.0
      15.6       52.7        5.8       39.9
      18.5       12.2        8.6        1.3
       0.0        0.0        0.0        0.0
       0.0        0.0        0.0        0.0
       0.0        0.0        0.0        0.0
       0.0        0.0        0.0        0.0
       0.0        0.0        0.0        0.0
       0.0        0.0        0.0        0.0
       0.0        0.0        0.0        0.0
       8.7        4.0        4.2        3.3
       0.0        0.0        0.0        0.0
      57.2       31.1       81.5       55.5
       0.0        0.0        0.0        0.0
       0.0        0.0        0.0        0.0
      9.14      16.41      28.55      37.99


           South      South      South
South Africa (s) Africa (s) Africa (s) Africa (s)
0.00   0.00    0.00    0.00    0.00%
0.00   0.00    0.00    0.00    0.00%
1.42   8.64    1.65   15.17    2.64%
1.70   2.01    2.45    0.51    8.01%
0.00   0.00    0.00    0.00   12.22%
0.00   0.00    0.00    0.00    0.00%
0.00   0.00    0.00    0.00   46.15%
0.00   0.00    0.00    0.00    0.00%
0.00   0.00    0.00    0.00    0.00%
0.00   0.00    0.00    0.00    0.00%
0.00   0.00    0.00    0.00    0.00%
0.79   0.65    1.19    1.25    3.36%
0.00   0.00    0.00    0.00    0.00%
5.23   5.10   23.27   21.07   27.63%
0.00   0.00    0.00    0.00    0.00%
0.00   0.00    0.00    0.00

								
To top